

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
15 June 2006 (15.06.2006)

PCT

(10) International Publication Number
WO 2006/062716 A2

- (51) International Patent Classification: Not classified
- (21) International Application Number:
PCT/US2005/041664
- (22) International Filing Date:
18 November 2005 (18.11.2005)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/629,363 18 November 2004 (18.11.2004) US
60/649,479 2 February 2005 (02.02.2005) US
60/672,346 18 April 2005 (18.04.2005) US
- (71) Applicant (for all designated States except US): **YALE UNIVERSITY** [US/US]; Two Whitney Avenue, New Haven, CT 06511 (US).
- (72) Inventor; and
- (75) Inventor/Applicant (for US only): **HOH, Josephine** [US/US]; Apartment 506, 152 Temple Street, New Haven, CT 06510 (US).
- (74) Agent: **GRANAHAN, Patricia**; Fish & Neave IP Group, Ropes & Gray LLP, One International Place, Boston, MA 02110-2624 (US).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:
— without international search report and to be republished upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METHODS AND COMPOSITIONS FOR TREATING OCULAR DISORDERS

(57) Abstract: The present invention relates to identification of a human gene, Complement Factor H (CFH), associated with the occurrence for developing age related macular degeneration (AMD), which is useful for identifying or aiding in identifying individuals at risk for developing AMD, as well as for diagnosing or aiding in the diagnosis of AMD.



WO 2006/062716 A2

METHODS AND COMPOSITIONS FOR TREATING OCULAR DISORDERS

FUNDING

This invention was made with United States government support under grants NIH-K25HG000060 and NIH-R01EY015771, awarded by the National Institutes of Health.

- 5 The United States government has certain rights in the invention.

CROSS-REFERENCE TO RELATED APPLICATIONS

- This application claims the benefit of U.S. Provisional Application No. 60/629,363, filed November 18, 2004; U.S. Provisional Application No. 60/649,479, filed February 2, 2005; and U.S. Provisional Application No. 60/672,346, filed April 18, 2005. The
- 10 teachings of each of these referenced provisional applications are incorporated by reference herein in their entirety.

BACKGROUND OF THE INVENTION

- Age-related macular degeneration (AMD) is the leading cause of age-related blindness in the developed world. Its incidence is increasing as lifespan lengthens and the
- 15 elderly population expands (D.S. Friedman et al., Arch Ophthalmol 122, 564 (2004)). It is a chronic disease characterized by progressive destruction of the retina's central region (macula), causing central field visual loss (J. Tuo, C. M. Bojanowski, C. C. Chan, Prog Retin Eye Res 23, 229 (2004)). One key characteristic of AMD is the formation of extracellular deposits called drusen that are concentrated in and around the macula behind
- 20 the retina between the retina pigment epithelium (RPE) and choroid. To date, no therapy for this disease has proven to be broadly effective, especially in more advanced forms. Several risk factors have been linked to AMD, including age, smoking, and family history (AREDS Research Group, Ophthalmology 107, 2224 (2000)). Candidate gene association studies and genome-wide linkage scans have been performed to identify genetic risk
- 25 factors for AMD. A variety of candidate genes have been proposed based on their association with other retinal diseases or their known function. While some rare variants of some of these genes are associated with disease phenotype, no genetic differences have been observed that can account for a large proportion of the overall prevalence (J. Tuo, C.

M. Bojanowski, C. C. Chan, Prog Retin Eye Res 23, 229 (2004)). Additional information about genetic determinants of AMD is badly needed.

SUMMARY OF THE INVENTION

The present invention relates to identification of variations in a human gene correlated with a predisposition to AMD, which is useful in identifying or aiding in identifying individuals at risk for developing AMD, as well as for diagnosing or aiding in the diagnosis of AMD. It also relates to methods for identifying or aiding in identifying individuals at risk for developing AMD, methods for diagnosing or aiding in the diagnosis of AMD, polynucleotides (e.g., probes, primers) useful in the methods, diagnostic kits containing probes or primers, methods of treating an individual at risk for or suffering from AMD and compositions useful for treating an individual at risk for or suffering from AMD.

In one embodiment, the present invention provides polynucleotides useful for the detection or aiding in the detection of a CFH gene that is correlated with the occurrence of AMD in humans and, in specific embodiments, variations in the CFH gene that are correlated with AMD in humans. In another embodiment, the present invention provides methods and compositions useful for identifying or aiding in identifying individuals at risk for developing AMD. In a further embodiment, the methods and compositions of the invention may be used for the treatment of an individual suffering from AMD or at risk for developing AMD. The disclosure also provides diagnostic kits for detecting a variant CFH gene in a sample from an individual. Such kits are useful in identifying or aiding in identifying individuals at risk for developing AMD, as well as for diagnosing or aiding in the diagnosis of AMD in an individual.

In one embodiment, the invention provides an isolated polynucleotide for the detection of a variant CFH gene; the isolated polynucleotide comprises a nucleic acid molecule that specifically detects a variation in the CFH gene that is correlated with the occurrence of AMD in humans. Isolated polynucleotides are useful for detecting, in a sample from an individual, a variant CFH gene that is correlated with AMD in humans. The polynucleotides of the invention may further be used in allele-specific assays (e.g., allele-specific hybridization, primer extension, or ligation assays known in the art) to detect a variation in the CFH gene that is correlated with the occurrence of AMD. Allele-specific probes and primers are able to specifically hybridize to one or more alleles of a gene and

will not hybridize to other alleles of the same gene. For example, an allele-specific polynucleotide probe of the invention may hybridize to a variant CFH gene but will not hybridize to a wildtype CFH gene. In certain embodiments, the isolated polynucleotide is a probe that hybridizes, under stringent conditions, to a variation in the CFH gene that is correlated with the occurrence of AMD in humans. In particular embodiments, an isolated polynucleotide probe of the invention hybridizes, under stringent conditions, to a nucleic acid molecule comprising all or a portion of a CFH gene, or allelic variants thereof, wherein the nucleic acid molecule comprises a variation that is correlated with the occurrence of AMD in humans. In other embodiments, an isolated polynucleotide probe of the invention hybridizes, under stringent conditions, to a nucleic acid molecule comprising at least 10 contiguous nucleotides of a CFH gene, or allelic variants thereof, wherein the nucleic acid molecule comprises a variation that is correlated with the occurrence of AMD in humans. In further embodiments, the isolated polynucleotide is a primer that hybridizes, under stringent conditions, adjacent, upstream, or downstream to a variation in the CFH gene that is correlated with the occurrence of AMD in humans. In certain embodiments, an isolated polynucleotide primer of the invention is at least 10 nucleotides long and hybridizes to one side or another of a variation in the CFH gene that is correlated with the occurrence of AMD in humans. The subject polynucleotides may contain alterations, such as one or more nucleotide substitutions, additions or deletions, provided they hybridize to their target variant CFH gene with the same degree of specificity. As used herein, the term "isolated" when used in relation to a nucleic acid, refers to a nucleic acid sequence that is identified and separated from at least one contaminant nucleic acid with which it is ordinarily associated in its natural source. By contrast, non-isolated nucleic acids are nucleic acids such as DNA and RNA found in the state they exist in nature.

The polynucleotides described herein (e.g., a polynucleotide probe or a polynucleotide primer) may be DNA or RNA. The subject polynucleotide may be single-stranded or double-stranded. Polynucleotide probes and primers of the invention may be from about 5 nucleotides to about 3000 nucleotides. In some embodiments, the polynucleotide probes and primers of the invention are from about 8 nucleotides to about 500 nucleotides. In other embodiments, the polynucleotide probes and primers of the invention are from about 10 nucleotides to about 250 nucleotides. In certain embodiments, the subject polynucleotide probes and primers are about 20 nucleotides (e.g., 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides). In other embodiments, the

subject polynucleotide probes and primers are from about 50 to about 100 nucleotides (e.g., 45, 50, 55, 60, 65, 75, 85, or 100 nucleotides). The subject polynucleotides may comprise one or more non-natural or modified nucleotides. Non-natural or modified nucleotides include, without limitation, radioactively, fluorescently, or chemically labeled nucleotides.

5 In certain embodiments, the polynucleotide primer of the invention hybridizes upstream or downstream from a variation in the CFH gene that is correlated with the occurrence of AMD in humans. In one embodiment, the polynucleotide hybridizes vicinal to a variation in the CFH gene that is correlated with the occurrence of AMD in humans. For example, hybridization may occur in such a manner that fewer than 10 nucleotides
10 separate the variation and the end of the hybridized primer proximal to the variation. In another embodiment, hybridization occurs in such a manner that 1-3 nucleotides separate the variation and the end of the hybridized primer proximal to the variation. In certain other embodiments, the polynucleotide primer hybridizes immediately adjacent to the variation. In another embodiment, the polynucleotide primer of the invention hybridizes a
15 distance (e.g., at least 10 nucleotides) from a variation in the CFH gene that is correlated with the occurrence of AMD in humans. For example, hybridization may occur in such a manner that the end of the hybridized primer proximal to the variation is 10, 25, 50, 100, 250, 1000, 5000, or up to 10,000 nucleotides from the variation in the CFH gene. The invention described herein also relates to a pair of polynucleotide primers that specifically
20 detect a variation in the CFH gene that is correlated with the occurrence of AMD in humans, wherein the first polynucleotide primer hybridizes to one side of the variation and the second polynucleotide primer hybridizes to the other side of the variation. A pair of polynucleotide primers that hybridize to a region of DNA that comprises a variation in the CFH gene that is correlated with the occurrence of AMD in humans may hybridize to the
25 region in such a manner that the ends of the hybridized primers proximal to the variation are from about 20 to about 10,000 nucleotides apart. Alternatively, the pair of polynucleotide primers that hybridize to a region of DNA that comprises a variation in the CFH gene that is correlated with the occurrence of AMD in humans may hybridize to the
30 region in such a manner that the ends of the hybridized primers proximal to the variation are from about 100 to about 7,500 nucleotides apart, or from about 200 to about 5,000 nucleotides apart.

In another embodiment, the invention described herein provides three or more polynucleotide primers useful for distinguishing between two alleles of the CFH gene (for example, a wildtype allele and an allele that is correlated with the occurrence of AMD in humans). The first primer hybridizes to a nucleotide sequence that is common to both alleles, such as a non-allelic nucleotide sequence that is upstream or downstream of the variation in the CFH gene that is correlated with the occurrence of AMD. A second primer specifically hybridizes to a sequence that is unique to a first allele (e.g., a variation in the CFH gene that is correlated with the occurrence of AMD in humans). A third primer specifically hybridizes to a nucleotide sequence that is unique to the second allele (e.g., a wildtype CFH gene). The set of three primers result in the amplification of a region of DNA that is dependent on which CFH allele is present in the sample. For instance, one region of DNA is amplified if the CFH gene has a variation in the CFH gene that is correlated with the occurrence of AMD, and another region is amplified if a wildtype CFH gene is present in the sample. Alternatively, two primers out of the set may hybridize to a nucleotide sequence that is common to two alleles of the CFH gene, such as non-allelic nucleotide sequences that are upstream and downstream of a variation in the CFH gene that is correlated with the occurrence of AMD in humans, and a third primer specifically hybridizes to one of the two alleles of the CFH gene (such as a wildtype allele or an allele that is correlated with the occurrence of AMD in humans).

A variety of variations in the CFH gene that predispose an individual to AMD may be detected by the methods and compositions described herein. In a particular embodiment, the variation encodes an amino acid other than histidine at position 402 of the CFH protein. In a specific embodiment, the variation encodes tyrosine at position 402 of the CFH protein. In another embodiment, the variation encodes an amino acid other than valine at position 62 of the CFH protein. In a specific embodiment, the variation encodes isoleucine at position 62 of the CFH protein. In other embodiments, the methods and compositions described herein may be used to detect variations in the CFH gene that predispose an individual to AMD, such as those listed in Tables 4, 5 and 7. For example, other variant genes, such as those in which the variation is in a coding region (e.g., variations that encode: an amino acid other than serine, such as alanine, at position 58 of the CFH protein; an amino acid other than arginine, such as histidine, at position 127 of the CFH protein; an amino acid other than glutamine, such as lysine, at position 400 of the CFH protein; an amino acid other than valine, such as isoleucine, at position 609 of the

CFH protein; an amino acid other than serine, such as isoleucine, at position 890 of the CFH protein; an amino acid other than glutamic acid, such as aspartic acid, at position 936 of the CFH protein; an amino acid other than valine, such as leucine, at position 1007 of the CFH protein; an amino acid other than asparagine, such as tyrosine, at position 1050 of the CFH protein; an amino acid other than proline, such as glutamine, at position 1166 of the CFH protein; or an amino acid other than arginine, such as cysteine, at position 1210 of the CFH protein. See Tables 4, 5 and 7) can be detected using the methods and compositions described herein. Alternatively, variant genes in which the variation is in a noncoding region, such as those listed in Tables 4, 5 and 7, may detected using the methods and compositions described herein. As used herein, the term “variant CFH gene” refers to DNA that includes a variation in the CFH gene that is correlated with the occurrence of AMD. As used herein, the terms “wildtype CFH DNA” and “wildtype CFH gene” refer to DNA that does not include a variation in the CFH gene that is correlated with AMD.

The present invention also relates to a method of detecting, in a sample obtained from an individual, a variant CFH gene that is correlated with the occurrence of AMD in humans. Such a method may comprise: (a) combining the sample with a polynucleotide probe that hybridizes, under stringent conditions, to a variation in the CFH gene that is correlated with AMD in humans, but not to a wildtype CFH gene (wildtype CFH DNA is the term used above); and (b) determining whether hybridization occurs. The occurrence of hybridization indicates that a variant CFH gene that is correlated with age related macular degeneration is present in the sample. Samples used in the methods described herein may comprise cells from the eye, ear, nose, teeth, tongue, epidermis, epithelium, blood, tears, saliva, mucus, urinary tract, urine, muscle, cartilage, skin, or any other tissue or bodily fluid from which sufficient DNA or RNA can be obtained. Samples may be collected by a variety of means for collecting cells, such as for example, a buccal swab. The sample is processed, if necessary, to render the DNA or RNA that is present available for assaying in the methods described herein. For example, samples may be processed such that DNA from the sample is available for amplification or for hybridization to another polynucleotide. The processed samples may be crude lysates where available DNA or RNA is not purified from other cellular material, or may be purified to isolate available DNA or RNA. Samples may be processed by any means known in the art that renders DNA or RNA available for assaying in the methods described herein. Methods for

processing samples include, but are not limited to, mechanical, chemical, or molecular means of lysing and/or purifying cells and cell lysates. Processing methods may include, for example, chromatographic methods such as ion exchange (e.g., cation and anion), size exclusion, gel filtration, affinity, and hydrophobic interaction chromatography, or
5 ultrafiltration, electrophoresis, and immunoaffinity purification with antibodies specific for particular epitopes of the polypeptide.

In other embodiments, the invention provides a method of detecting, in a sample obtained from an individual, a variant CFH gene that is correlated with the occurrence of age related macular degeneration in humans, comprising: (a) combining the sample
10 (referred to as a test sample) with a polynucleotide probe that hybridizes, under stringent conditions, to a variation in the CFH gene that is correlated with the occurrence of AMD in humans, thereby producing a combination; (b) maintaining the combination produced in step (a) under stringent hybridization conditions; and (c) comparing hybridization that occurs in the combination with hybridization in a control. The occurrence of hybridization
15 in the combination but not in the control indicates that a variant CFH gene that correlates with AMD is present in the sample. In a further embodiment, the extent of hybridization is determined when comparing hybridization that occurs in the combination with hybridization in a control. The control is the same as the test sample and is treated the same as the test sample except that the polynucleotide probe is one that does not bind to a
20 variation in the CFH gene that is correlated with the occurrence of AMD in humans. Alternatively, the polynucleotide probe is one that binds only to a wildtype CFH gene. The control can be assayed serially or simultaneously with the combination described above. Alternatively, results from a control may be established in a reference assay previously or subsequent to the combination described above. The sample used in the control is typically
25 the same type of sample as the test sample and is treated the same as the test sample except that it is combined with a polynucleotide that does not hybridize to a variant CFH gene that is correlated with the occurrence of AMD in humans.

In another embodiment, the invention provides a method of detecting, in a sample obtained from an individual, a variant CFH gene that is correlated with the occurrence of
30 AMD in humans, comprising: (a) combining a first portion of the sample with a polynucleotide probe that hybridizes, under stringent conditions, to a variation in the CFH gene that is correlated with the occurrence of AMD in humans; (b) combining a second

portion of the sample with a polynucleotide probe that hybridizes, under stringent conditions, to a wildtype CFH gene; and (c) determining whether hybridization occurs. The occurrence of hybridization in the first portion, but not in the second portion, indicates that a variant CFH gene that is correlated with AMD is present in the sample.

5 In another embodiment, the invention provides a method of detecting, in a sample obtained from an individual, a variant CFH gene that is correlated with the occurrence of AMD in humans, comprising: (a) combining the sample with a pair of polynucleotide primers, wherein the first polynucleotide primer hybridizes to one side of DNA encoding amino acid 402 of the CFH protein and the second polynucleotide primer hybridizes to the
10 other side of DNA encoding amino acid 402 of the CFH protein; (b) amplifying DNA in the sample, thereby producing amplified DNA; (c) sequencing amplified DNA; and (d) detecting in the DNA the presence of a variation that encodes an amino acid other than histidine at position 402 of the CFH protein. The presence of the variation indicates that a variant CFH gene that is correlated with the occurrence of AMD in humans is detected in
15 the sample.

 In another embodiment, the invention provides a method of detecting, in a sample obtained from an individual, a variant CFH gene that is correlated with the occurrence of AMD in humans, comprising: (a) combining the sample with a pair of polynucleotide primers, wherein the first polynucleotide primer hybridizes to one side of DNA encoding
20 amino acid 62 of the CFH protein and the second polynucleotide primer hybridizes to the other side of DNA encoding amino acid 62 of the CFH protein; (b) amplifying DNA in the sample, thereby producing amplified DNA; (c) sequencing amplified DNA; and (d) detecting in the DNA the presence of a variation that encodes an amino acid other than histidine at position 62 of the CFH protein. The presence of the variation indicates that a
25 variant CFH gene that is correlated with the occurrence of AMD in humans is detected in the sample.

 Any method known in the art for amplifying nucleic acids may be used for the methods described herein. For example, DNA in a sample may be amplified using polymerase chain reaction (PCR), RT-PCR, quantitative PCR, real time PCR, Rapid
30 Amplified Polymorphic DNA Analysis, Rapid Amplification of cDNA Ends (RACE), or rolling circle amplification.

In other embodiments, the invention provides methods of identifying or aiding in identifying an individual at risk for developing AMD. In one specific embodiment, such a method comprises assaying a sample obtained from the individual for the presence of a variant CFH gene that is correlated with the occurrence of AMD in humans. The presence
5 of a variant CFH gene indicates that the individual is at risk for developing AMD.

In another embodiment, a method of identifying or aiding in identifying an individual at risk for developing AMD comprises: (a) combining a sample obtained from the individual with a polynucleotide probe that hybridizes, under stringent conditions, to a variation in the CFH gene that is correlated with AMD in humans, but does not hybridize
10 to a wildtype CFH gene; and (b) determining whether hybridization occurs. The occurrence of hybridization indicates that the individual is at risk for developing AMD.

In another embodiment, a method of identifying or aiding in identifying an individual at risk for developing AMD, comprises: (a) obtaining DNA from an individual; (b) sequencing a region of the DNA that comprises the nucleotides that encode amino acid
15 402 of the CFH protein; and (c) determining whether a variation that encodes an amino acid other than histidine at position 402 of the CFH protein is present in the DNA. The presence of the variation indicates that the individual is at risk for developing AMD.

In another embodiment, a method of identifying or aiding in identifying an individual at risk for developing AMD, comprises: (a) obtaining DNA from an individual;
20 (b) sequencing a region of the DNA that comprises the nucleotides that encode amino acid 62 of the CFH protein; and (c) determining whether a variation that encodes an amino acid other than valine at position 62 of the CFH protein is present in the DNA. The presence of the variation indicates that the individual is at risk for developing AMD.

In another embodiment, the invention provides a method of detecting, in a sample
25 obtained from an individual, a variant CFH polypeptide that is correlated with the occurrence of age related macular degeneration in humans. Such a method comprises: (a) combining the sample with an antibody that binds to a variant CFH polypeptide that is correlated with the occurrence of age related macular degeneration in humans; and (b) determining whether binding occurs. The occurrence of binding indicates that a variant
30 CFH polypeptide that is correlated with the occurrence of age related macular degeneration is present in the sample.

In another embodiment, the invention provides diagnostic kits useful for detecting a variant CFH gene in a sample from an individual. A diagnostic kit may comprise, for example: (a) at least one container means having disposed therein a polynucleotide probe that hybridizes, under stringent conditions, to a variation in the CFH gene that is correlated with the occurrence of AMD in humans; and (b) a label and/or instructions for the use of the diagnostic kit in the detection of a variant CFH gene in a sample.

In another embodiment, a diagnostic kit useful for detecting a variant CFH gene in a sample from an individual may comprise, for example: (a) at least one container means having disposed therein a polynucleotide primer that hybridizes, under stringent conditions, adjacent to one side of a variation in the CFH gene that is correlated with the occurrence of age related macular degeneration in humans; and (b) a label and/or instructions for the use of the diagnostic kit in the detection of CFH in a sample. Optionally, the diagnostic kit additionally comprises a second polynucleotide primer that hybridizes, under stringent conditions, to the other side of the variation in the CFH gene that is correlated with the occurrence of age related macular degeneration in humans.

The present invention also relates to compositions for treating a subject suffering from AMD. In a particular embodiment, a composition for treating a subject suffering from AMD comprises an effective amount of an isolated or recombinantly produced CFH polypeptide, or a fragment thereof, and a pharmaceutically acceptable carrier. In a particular embodiment, the CFH polypeptide, or the fragment thereof, inhibits the activation of C3. In another embodiment, the invention provides a method of treating a subject suffering from AMD, comprising administering to the subject an effective amount of an isolated or recombinantly produced CFH polypeptide, or a fragment thereof, and a pharmaceutically acceptable carrier.

In another embodiment, the invention provides a composition for treating a subject suffering from AMD, comprising an effective amount of an isolated or recombinantly produced nucleic acid molecule coding for a CFH polypeptide, or a fragment thereof, and a pharmaceutically acceptable carrier. As used herein, the term "effective amount" refers to the amount of an isolated or recombinantly produced CFH nucleic acid or polypeptide, or a composition comprising a CFH nucleic acid or polypeptide, that is in sufficient quantities to treat a subject or to treat the disorder itself. For example, an effective amount is sufficient to delay, slow, or prevent the onset or progression of AMD or related symptoms.

In other embodiments, the invention provides a method of treating a subject suffering from AMD, comprising administering to the subject an effective amount of an isolated or recombinantly produced nucleic acid molecule coding for a CFH polypeptide, or a fragment thereof, and a pharmaceutically acceptable carrier.

5 In another embodiment, the invention provides a composition for treating a subject suffering from or at risk for age related macular degeneration, comprising: (a) a nucleic acid molecule comprising an antisense sequence that hybridizes to a variant CFH gene or mRNA that is correlated with the occurrence of age related macular degeneration in humans; and (b) a pharmaceutically acceptable carrier. In certain embodiments,
10 hybridization of the antisense sequence to the variant CFH gene reduces the amount of RNA transcribed from the variant CFH gene. In certain other embodiments, hybridization of the antisense sequence to the variant CFH mRNA reduces the amount of protein translated from the variant CFH mRNA, and/or alters the splicing of the variant CFH mRNA. A nucleic acid molecule comprising an antisense sequence that hybridizes to a
15 variant CFH gene or mRNA may comprise one or more modified nucleotides or nucleosides that enhance in vivo stability, transport across the cell membrane, or hybridization to a variant CFH gene or mRNA. In other embodiments, the invention provides a method for treating a subject suffering from or at risk for age related macular degeneration, comprising administering to the subject an effective amount of a nucleic acid
20 molecule comprising an antisense sequence that hybridizes to a variant CFH gene or mRNA that is correlated with the occurrence of age related macular degeneration in humans, and a pharmaceutically acceptable carrier.

 In another embodiment, the invention provides a composition for treating a subject suffering from or at risk for age related macular degeneration, comprising: (a) a nucleic
25 acid molecule comprising a siRNA or miRNA sequence, or a precursor thereof, that hybridizes to a variant CFH gene or mRNA that is correlated with the occurrence of age related macular degeneration in humans; and (b) a pharmaceutically acceptable carrier. In certain embodiments, hybridization of a nucleic acid molecule comprising a siRNA or miRNA sequence, or a precursor thereof to the variant CFH gene reduces the amount of
30 RNA transcribed from the variant CFH gene. In other embodiments, hybridization of a nucleic acid molecule comprising a siRNA or miRNA sequence, or a precursor thereof to the variant CFH mRNA reduces the amount of protein translated from the variant CFH

mRNA, and/or alters the splicing of the variant CFH mRNA. A nucleic acid molecule comprising an antisense sequence that hybridizes to a variant CFH gene or mRNA may comprise one or more modified nucleotides or nucleosides that enhance in vivo stability, transport across the cell membrane, or hybridization to a variant CFH gene or mRNA. In other embodiments, the invention provides a method for treating a subject suffering from or at risk for age related macular degeneration, comprising administering to the subject an effective amount of a nucleic acid molecule comprising a siRNA or miRNA sequence, or a precursor thereof, that hybridizes to a variant CFH gene or mRNA that is correlated with the occurrence of age related macular degeneration in humans and a pharmaceutically acceptable carrier

In another embodiment, the invention provides a composition for treating a subject suffering from or at risk for age related macular degeneration, comprising: (a) an aptamer that binds to a variant CFH polypeptide that is correlated with the occurrence of age related macular degeneration in humans; and (b) a pharmaceutically acceptable carrier, wherein binding of the aptamer to the variant CFH polypeptide reduces the activity of the variant CFH polypeptide. In other embodiments, the invention provides a method for treating a subject suffering from or at risk for age related macular degeneration, comprising administering to the subject an effective amount of an aptamer that binds to a variant CFH polypeptide that is correlated with the occurrence of age related macular degeneration in humans and a pharmaceutically acceptable carrier.

In another embodiment, the invention provides a composition for treating a subject suffering from or at risk for age related macular degeneration, comprising: (a) a small molecule that binds to a variant CFH polypeptide that is correlated with the occurrence of age related macular degeneration in humans; and (b) a pharmaceutically acceptable carrier. In certain embodiments, binding of the small molecule to the variant CFH polypeptide reduces the activity of the variant CFH polypeptide. In another embodiment, the invention provides a method for treating a subject suffering from or at risk for age related macular degeneration, comprising administering to the subject an effective amount of a small molecule that binds to a variant CFH polypeptide that is correlated with the occurrence of age related macular degeneration in humans and a pharmaceutically acceptable carrier.

In another embodiment, the invention provides a composition for treating a subject suffering from or at risk for age related macular degeneration, comprising: (a) an antibody

that binds to a variant CFH polypeptide that is correlated with the occurrence of age related macular degeneration in humans; and (b) a pharmaceutically acceptable carrier. In certain embodiments, binding of the antibody to the variant CFH polypeptide reduces the activity of the variant CFH polypeptide. In another embodiment, the invention also provides a method for treating a subject suffering from or at risk for age related macular degeneration, comprising administering to the subject an effective amount of an antibody that binds to a variant CFH polypeptide that is correlated with the occurrence of age related macular degeneration in humans and a pharmaceutically acceptable carrier.

The methods and compositions described herein for treating a subject suffering from AMD may be used for the prophylactic treatment of individuals who have been diagnosed or predicted to be at risk for developing AMD. For instance, the composition is administered in an amount and dose that is sufficient to delay, slow, or prevent the onset of AMD or related symptoms. Alternatively, the methods and compositions described herein may be used for the therapeutic treatment of individuals who suffer from AMD. For example, the composition is administered in an amount and dose that is sufficient to delay or slow the progression of the condition, totally or partially, or in an amount and dose that is sufficient to reverse the condition.

As described herein for CFH, variations in CFH-like genes in humans (e.g., CFHL1, CFHL3, and CFHL4) are also useful for identifying or aiding in identifying individuals at risk for developing AMD. Variations in CFHL1, CFHL3, and CFHL4 may also be useful for diagnosing or aiding in the diagnosis of AMD, identifying or aiding in identifying individuals at risk for developing AMD, methods for diagnosing or aiding in the diagnosis of AMD, polynucleotides (e.g., probes, primers) useful in the methods, diagnostic kits containing probes or primers, methods of treating an individual at risk for or suffering from AMD and compositions useful for treating an individual at risk for or suffering from AMD. Examples of variations in CFHL1, CFHL3, and CFHL4 that may be correlated with the occurrence of AMD are found in Tables 8-10. Such variations, which can be in a coding or noncoding region of a CFHL gene (e.g., CFHL1, CFHL3, and CFHL4) can be useful in the methods and compositions described herein.

In one embodiment, the present invention provides polynucleotides useful for the detection or aiding in the detection of a CFHL gene (e.g., CFHL1, CFHL3, or CFHL4) that is correlated with the occurrence of AMD in humans and, in specific embodiments,

variations in a CFHL gene that are correlated with AMD in humans. The disclosure also provides diagnostic kits for detecting a variant CFHL gene in a sample from an individual. Such kits are useful in identifying or aiding in identifying individuals at risk for developing AMD, as well as for diagnosing or aiding in the diagnosis of AMD in an individual.

5 In another embodiment, the invention provides an isolated polynucleotide for the detection of a variant CFHL gene, such as CFHL1, CFHL3, or CFHL4, in a sample from an individual, comprising a nucleic acid molecule that specifically detects a variation in the CFHL gene that is correlated with the occurrence of age related macular degeneration in humans.

10 In another embodiment, the invention provides a polynucleotide primer that hybridizes, under stringent conditions, adjacent to a variation in a CFHL gene that is correlated with the occurrence of age related macular degeneration in humans. In certain embodiments, the invention provides a pair of polynucleotide primers that specifically detect a variation in a CFHL gene that is correlated with the occurrence of age related
15 macular degeneration in humans, wherein the first polynucleotide primer hybridizes to one side of the variation and the second polynucleotide primer hybridizes to the other side of the variation. The pair of polynucleotide primers may hybridize to a region of a CFHL gene in such a manner that the ends of the hybridized primers proximal to the variation are from about 100 to about 10,000 nucleotides apart.

20 The present invention also relates to a method of detecting, in a sample obtained from an individual, a variant CFHL gene that is correlated with the occurrence of AMD in humans. Such a method may comprise: (a) combining the sample with a polynucleotide probe that hybridizes, under stringent conditions, to a variation in the CFHL gene that is correlated with AMD in humans, but not to a wildtype CFHL gene; and (b) determining
25 whether hybridization occurs. The occurrence of hybridization indicates that a variant CFHL gene that is correlated with age related macular degeneration is present in the sample. As used herein, the term "wildtype CFHL gene" refers to a CFHL gene, such as CFHL1, CFHL3, or CFHL4, that is not correlated with the occurrence of AMD.

 In other embodiments, the invention provides a method of detecting, in a sample
30 obtained from an individual, a variant CFHL gene that is correlated with the occurrence of age related macular degeneration in humans, comprising: (a) combining the sample

(referred to as a test sample) with a polynucleotide probe that hybridizes, under stringent conditions, to a variation in the CFHL gene that is correlated with the occurrence of AMD in humans, thereby producing a combination; (b) maintaining the combination produced in step (a) under stringent hybridization conditions; and (c) comparing hybridization that occurs in the combination with hybridization in a control. The occurrence of hybridization in the combination but not in the control indicates that a variant CFHL gene that correlates with AMD is present in the sample. In a further embodiment, the extent of hybridization is determined when comparing hybridization that occurs in the combination with hybridization in a control. The control is the same as the test sample and is treated the same as the test sample except that the polynucleotide probe is one that does not bind to a variation in the CFHL gene that is correlated with the occurrence of AMD in humans. Alternatively, the polynucleotide probe is one that binds only to a wildtype CFHL gene.

In another embodiment, the invention provides a method of detecting, in a sample obtained from an individual, a variant CFHL gene that is correlated with the occurrence of AMD in humans, comprising: (a) combining a first portion of the sample with a polynucleotide probe that hybridizes, under stringent conditions, to a variation in the CFHL gene that is correlated with the occurrence of AMD in humans; (b) combining a second portion of the sample with a polynucleotide probe that hybridizes, under stringent conditions, to a wildtype CFHL gene; and (c) determining whether hybridization occurs. The occurrence of hybridization in the first portion, but not in the second portion, indicates that a variant CFHL gene that is correlated with AMD is present in the sample.

In other embodiments, the invention provides methods of identifying or aiding in identifying an individual at risk for developing AMD. In one specific embodiment, such a method comprises assaying DNA obtained from the individual for the presence of a variant CFHL gene that is correlated with the occurrence of AMD in humans. The presence of a variant CFHL gene indicates that the individual is at risk for developing AMD.

In another embodiment, a method of identifying or aiding in identifying an individual at risk for developing AMD comprises: (a) combining a sample obtained from the individual with a polynucleotide probe that hybridizes, under stringent conditions, to a variation in the CFHL gene that is correlated with AMD in humans, but does not hybridize to a wildtype CFHL gene; and (b) determining whether hybridization occurs. The occurrence of hybridization indicates that the individual is at risk for developing AMD.

In another embodiment, the invention provides diagnostic kits useful for detecting a variant CFHL gene in a sample from an individual. A diagnostic kit may comprise, for example: (a) at least one container means having disposed therein a polynucleotide probe that hybridizes, under stringent conditions, to a variation in the CFHL gene that is correlated with the occurrence of AMD in humans; and (b) a label and/or instructions for the use of the diagnostic kit in the detection of a variant CFHL gene in a sample.

In another embodiment, a diagnostic kit useful for detecting a variant CFHL gene in a sample from an individual may comprise, for example: (a) at least one container means having disposed therein a polynucleotide primer that hybridizes, under stringent conditions, adjacent to one side of a variation in the CFHL gene that is correlated with the occurrence of age related macular degeneration in humans; and (b) a label and/or instructions for the use of the diagnostic kit in the detection of CFHL in a sample. Optionally, the diagnostic kit additionally comprises a second polynucleotide primer that hybridizes, under stringent conditions, to the other side of the variation in the CFHL gene that is correlated with the occurrence of age related macular degeneration in humans.

The embodiments and practices of the present invention, other embodiments, and their features and characteristics, will be apparent from the description, figures and claims that follow, with all of the claims hereby being incorporated by this reference into this Summary.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1A-1B are graphs showing statistical data of a genome-wide association study of genes associated with AMD. Figure 1A shows p-values of the genome-wide association scan. $-\log_{10}(p)$ is plotted for each SNP in chromosomal order. The spacing between SNPs on the plot is uniform and does not reflect distances between SNPs on the chromosomes. The dotted horizontal line shows the cutoff for $p=0.05$ after Bonferroni correction. The vertical lines show chromosomal boundaries. Figure 1B shows variations in genotype frequencies between cases and controls.

Figures 2A-2D show data on SNPs that are associated with AMD. Figure 2A shows linkage disequilibrium (LD) across the CFH region, plotted as pairwise D' values. Figure 2B shows a schematic of the region in strong LD with the two associated SNPs in

the data. The vertical bars represent the approximate location of the SNPs available in the data set. The shaded region is the haplotype block found in the HapMap data. Figure 2C shows haplotype blocks in the HapMap CEU data cross the region. Darker shades indicate higher values of D' . Lighter shades indicate high D' with a low LOD score. The dark lines show the boundaries of haplotype blocks. Figure 2D shows a maximum parsimony cladogram derived from haplotypes across the 6-SNP region. The number by each line indicates which of the six SNPs varies along the branch. SNP 4 is rs380390 and SNP 6 is rs1329428, which are the two SNPs initially identified as associated with AMD.

Figures 3A-3C show immunofluorescent localization of CFH protein in human retina. Figure 3A shows human retina sections stained with anti-human CFH antibody. Figure 3B shows human retina sections stained with anti-human CFH antibody pre-incubated with CFH protein as negative control. The nuclei are identified by DAPI staining. The magnified view of the boxed area in Figure 3A is shown in Figure 3C. The fluorescent and DIC channels are collected from each image and presented as the left and right pictures, respectively, in each panel. The fluorescent pictures in Figure 3A and Figure 3B are merged images from CFH labeling and DAPI stained nuclei. The DIC picture in Figure 3C is a merged image of CFH labeling and the DIC channel. The black spots in DIC images correspond to melanin granules in RPE and choroids. The anti-CFH antibody primarily stains the choroids (Figure 3A), especially strong in the wall of vessels lumen and in area close to RPE (Figure 3C), and the immunoreactivity can be competed away with purified human CFH protein (Figure 3B). The fluorescent signal from RPE arises from the autofluorescence of lipofuscin which cannot be competed away by human factor H protein. GC: ganglion cells layer, INL: inner nuclear layer, ONL: outer nuclear layer, RPE: retinal pigment epithelium. Scale bar: 40 μm in Figures 3A and 3B, 20 μm in Figure 3C.

Figure 4A-4E show immunohistochemistry for activated complement C5b-9. Tissues from three patients are illustrated. Figures 4A and 4B show post-mortem fundus images from patients 1 and 2, respectively. The site illustrated histologically is indicated with an asterisk. Figure 4C shows tissue from patient 1 who is immunopositive for C5b-9 throughout Bruch's membrane and in intercapillary pillars (thin black arrows). Overlying retinal pigment epithelium is hypertrophic, and associated retina demonstrated marked photoreceptor loss. Complement deposition is also present within the elastica of a

choroidal artery (double headed black arrow), as well as within the walls of a choroidal vein (white arrow). Figure 4D shows C5b-9 deposition in Bruch's membrane, intercapillary pillars (arrows) and drusen (asterisk) in patient 2. The internal aspect of a choroidal vein is also immunopositive (white arrow). Figure 4E shows tissue from patient 5 3, an 86-year old with histologic evidence of early AMD. Activated complement deposition is noted throughout Bruch's membrane, in drusen (asterisks) and in the internal wall of a choroidal vein (white arrow). Scale bar: 20 μ m in Figures 4C and 4D), 15 μ m in Figure 4E.

Figure 5 shows the polypeptide sequence for human Complement Factor H
10 (GenBank Accession CAA68704).

DETAILED DESCRIPTION OF THE INVENTION

To provide an overall understanding of the invention, certain illustrative embodiments will now be described, including compositions and methods for identifying or aiding in identifying individuals at risk for developing AMD, as well as for diagnosing or aiding in the diagnosis of AMD. However, it will be understood by one of ordinary skill
15 in the art that the compositions and methods described herein may be adapted and modified as is appropriate for the application being addressed and that the compositions and methods described herein may be employed in other suitable applications, and that such other additions and modifications will not depart from the scope hereof.

20 1. Overview

The discovery that variations in the CFH gene are associated with AMD is useful for the early diagnosis and treatment of individuals predisposed to AMD. The determination of the genetic constitution of the CFH gene in an individual is useful in treating AMD at earlier stages, or even before an individual displays any symptoms of
25 AMD. Furthermore, diagnostic tests to genotype CFH may allow individuals to alter their behavior to minimize environmental risks to AMD (e.g., smoking). Accordingly, the present invention relates to the identification of a variant CFH gene correlated with a predisposition to AMD, which is useful in identifying or aiding in identifying individuals at risk for developing AMD, as well as for diagnosing or aiding in the diagnosis of AMD. It
30 also relates to methods for identifying or aiding in identifying individuals at risk for

developing AMD, methods for diagnosing or aiding in the diagnosis of AMD, polynucleotides (e.g., probes, primers) useful in the methods, diagnostic kits containing probes or primers, methods of treating an individual at risk for or suffering from AMD and compositions useful for treating an individual at risk for or suffering from AMD.

5 In accordance with the present invention, a common variation in the CFH gene has been shown to be strongly associated with AMD. The present invention relates to methods and compositions for detecting such variations that predispose a human to AMD. A CFH gene can either be the cDNA or the genomic form of the gene, which may include upstream and downstream regulatory sequences. The CFH polypeptide can be encoded by
10 a full length coding sequence or by any portion of the coding sequence so long as the desired activity or functional properties (e.g., enzymatic activity, ligand binding, signal transduction, etc.) of the full-length or fragment are retained. Examples of CFH nucleotide sequences include human nucleotide sequences (SEQ ID NOs: 1 or 2), a mouse nucleotide sequence (SEQ ID NO: 3), and a rat nucleotide sequence (SEQ ID NO: 4). Polynucleotide
15 probes and primers of the invention may hybridize to any contiguous portion of a CFH gene, such as those shown in SEQ ID NOs 1-4. Examples of CFH polypeptide sequences include human polypeptide sequences (SEQ ID NOs: 5 or 6 and Figure 5), a mouse polypeptide sequence (SEQ ID NO: 7), and a rat polypeptide sequence (SEQ ID NO: 8). The CFH gene may further include sequences located adjacent to the coding region on both
20 the 5' and 3' ends for a distance of about 1-2 kb on either end such that the gene corresponds to the length of the full-length mRNA. The sequences which are located 5' of the coding region and which are present on the mRNA are referred to as 5' non-translated sequences. The sequences which are located 3' or downstream of the coding region and which are present on the mRNA are referred to as 3' non-translated sequences.

25 The CFH gene is a member of the Regulator of Complement Activation (RCA) gene cluster and encodes a protein with twenty short consensus repeat (SCR) domains of 60 amino acids each. This protein is secreted into the bloodstream and has an essential role in the regulation of complement activation (Rodriguez de Cordoba et al., *Mol Immunol.* 41:355-67 (2004)). The complement system protects against infection and attacks diseased
30 and dysplastic cells and normally spares healthy cells. Cells involved in immune surveillance and response to disease are recruited to augment the lytic action of activated complement components. When C3 convertase is activated, it leads to the production of

C3a and C3b and then to the terminal C5b-9 complex. CFH on cells and in circulation regulates complement activity by inhibiting the activation of C3 to C3a and C3b, and by inactivating existing C3b. Variations in the CFH gene have previously been associated with hemolytic-uremic syndrome (HUS) and chronic hypocomplementemic nephropathy.

5 Alternate transcriptional splice variants, encoding different isoforms, have been characterized.

2. CFH polynucleotide probes and primers

In certain embodiments, the invention provides isolated and/or recombinant polynucleotides that specifically detect a variation in the CFH gene that is correlated with the occurrence of AMD. Polynucleotide probes of the invention hybridize to a variation (referred to as a variation of interest) in such a CFH gene, and the flanking sequence, in a specific manner and thus typically have a sequence which is fully or partially complementary to the sequence of the variation and the flanking region. Polynucleotide probes of the invention may hybridize to a segment of target DNA such that the variation aligns with a central position of the probe, or the variation may align with a terminal position of the probe. In one embodiment, an isolated polynucleotide probe of the invention hybridizes, under stringent conditions, to a nucleic acid molecule comprising a variant CFH gene, or a portion or allelic variant thereof, that is correlated with the occurrence of AMD in humans. In another embodiment, an isolated polynucleotide probe of the invention hybridizes, under stringent conditions, to a nucleic acid molecule comprising at least 10 contiguous nucleotides of a CFH gene, or an allelic variant thereof, wherein the nucleic acid molecule comprises a variation that is correlated with the occurrence of AMD in humans.

10
15
20

In certain embodiments, a polynucleotide probe of the invention is an allele-specific probe. The design and use of allele-specific probes for analyzing polymorphisms is described by e.g., Saiki et al., Nature 324:163-166 (1986); Dattagupta, EP 235726; and Saiki WO 89/11548. Allele-specific probes can be designed to hybridize to a segment of a target DNA from one individual but do not hybridize to the corresponding segment from another individual due to the presence of different polymorphic forms or variations in the respective segments from the two individuals. Hybridization conditions should be

25
30

sufficiently stringent such that there is a significant difference in hybridization intensity between alleles. In some embodiments, a probe hybridizes to only one of the alleles.

A variety of variations in the CFH gene that predispose an individual to AMD may be detected by the methods and polynucleotides described herein. For example, any
5 nucleotide polymorphism of a coding region, exon, exon-intron boundary, signal peptide, 5-prime untranslated region, promoter region, enhancer sequence, 3-prime untranslated region or intron that is associated with AMD can be detected. These polymorphisms include, but are not limited to, changes that: alter the amino acid sequence of the proteins encoded by the CFH gene, produce alternative splice products, create truncated products,
10 introduce a premature stop codon, introduce a cryptic exon, alter the degree or expression to a greater or lesser extent, alter tissue specificity of CFH expression, introduce changes in the tertiary structure of the proteins encoded by CFH, introduce changes in the binding affinity or specificity of the proteins expressed by CFH or alter the function of the proteins encoded by CFH. In a specific embodiment, the variation in the CFH gene encodes an
15 amino acid other than histidine (e.g., tyrosine) at position 402 of the CFH protein. In another specific embodiment, the variation in the CFH gene encodes an amino acid other than valine (e.g., isoleucine) at position 62 of the CFH protein. Other examples of variations in the CFH gene that may predispose an individual to AMD are found in Tables 4 and 5. For example, other variant genes, such as those in which the variation is in a
20 coding region (e.g., variations that encode: an amino acid other than serine, such as alanine, at position 58 of the CFH protein; an amino acid other than arginine, such as histidine, at position 127 of the CFH protein; an amino acid other than glutamine, such as lysine, at position 400 of the CFH protein; an amino acid other than valine, such as isoleucine, at position 609 of the CFH protein; an amino acid other than serine, such as
25 isoleucine, at position 890 of the CFH protein; an amino acid other than glutamic acid, such as aspartic acid, at position 936 of the CFH protein; an amino acid other than valine, such as leucine, at position 1007 of the CFH protein; an amino acid other than asparagine, such as tyrosine, at position 1050 of the CFH protein; an amino acid other than proline, such as glutamine, at position 1166 of the CFH protein; or an amino acid other than
30 arginine, such as cysteine, at position 1210 of the CFH protein. See Tables 4 and 5) can be detected using the methods and compositions described herein for other variants. Alternatively, variant genes in which the variation is in a noncoding region, such as those listed in Tables 4 and 5, may be detected using the methods and compositions described

herein. The subject polynucleotides are further understood to include polynucleotides that are variants of the polynucleotides described herein, provided that the variant polynucleotides maintain their ability to specifically detect a variation in the CFH gene that is correlated with the occurrence of AMD. Variant polynucleotides may include, for example, sequences that differ by one or more nucleotide substitutions, additions or deletions.

In certain embodiments, the isolated polynucleotide is a probe that hybridizes, under stringent conditions, to a variation in the CFH gene that is correlated with the occurrence of AMD in humans. As used herein, the term "hybridization" is used in reference to the pairing of complementary nucleic acids. The term "probe" refers to a polynucleotide that is capable of hybridizing to another nucleic acid of interest. The polynucleotide may be naturally occurring, as in a purified restriction digest, or it may be produced synthetically, recombinantly or by nucleic acid amplification (e.g., PCR amplification).

It is well known in the art how to perform hybridization experiments with nucleic acid molecules. The skilled artisan is familiar with the hybridization conditions required in the present invention and understands readily that appropriate stringency conditions which promote DNA hybridization can be varied. Such hybridization conditions are referred to in standard text books, such as Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory (2001); and Current Protocols in Molecular Biology, eds. Ausubel et al., John Wiley & Sons (1992). Particularly useful in methods of the present invention are polynucleotides which are capable of hybridizing to a variant CFH gene, or a region of a variant CFH gene, under stringent conditions. Under stringent conditions, a polynucleotide that hybridizes to a variant CFH gene does not hybridize to a wildtype CFH gene.

Nucleic acid hybridization is affected by such conditions as salt concentration, temperature, organic solvents, base composition, length of the complementary strands, and the number of nucleotide base mismatches between the hybridizing nucleic acids, as will readily be appreciated by those skilled in the art. Stringent temperature conditions will generally include temperatures in excess of 30°C, or may be in excess of 37°C or 45°C. Stringency increases with temperature. For example, temperatures greater than 45°C are highly stringent conditions. Stringent salt conditions will ordinarily be less than 1000 mM, or may be less than 500 mM or 200 mM. For example, one could perform the

hybridization at 6.0x sodium chloride/sodium citrate (SSC) at about 45 °C, followed by a wash of 2.0x SSC at 50 °C. For example, the salt concentration in the wash step can be selected from a low stringency of about 2.0x SSC at 50 °C to a high stringency of about 0.2x SSC at 50 °C. In addition, the temperature in the wash step can be increased from low stringency conditions at room temperature, about 22 °C, to high stringency conditions at about 65 °C. Both temperature and salt may be varied, or temperature or salt concentration may be held constant while the other variable is changed. Particularly useful in methods of the present invention are polynucleotides which are capable of hybridizing to a variant CFH gene, or a region of a variant CFH gene, under stringent conditions. It is understood, however, that the appropriate stringency conditions may be varied in the present invention to promote DNA hybridization. In certain embodiments, polynucleotides of the present invention hybridize to a variant CFH gene, or a region of a variant CFH gene, under highly stringent conditions. Under stringent conditions, a polynucleotide that hybridizes to a variation in the CFH gene does not hybridize to a wildtype CFH gene. In one embodiment, the invention provides nucleic acids which hybridize under low stringency conditions of 6.0x SSC at room temperature followed by a wash at 2.0x SSC at room temperature. The combination of parameters, however, is much more important than the measure of any single parameter. See, e.g., Wetmur and Davidson, 1968. Probe sequences may also hybridize specifically to duplex DNA under certain conditions to form triplex or higher order DNA complexes. The preparation of such probes and suitable hybridization conditions are well known in the art. One method for obtaining DNA encoding the biosynthetic constructs disclosed herein is by assembly of synthetic oligonucleotides produced in a conventional, automated, oligonucleotide synthesizer.

A polynucleotide probe or primer of the present invention may be labeled so that it is detectable in a variety of detection systems, including, but not limited, to enzyme (e.g., ELISA, as well as enzyme-based histochemical assays), fluorescent, radioactive, chemical, and luminescent systems. A polynucleotide probe or primer of the present invention may further include a quencher moiety that, when placed in proximity to a label (e.g., a fluorescent label), causes there to be little or no signal from the label. Detection of the label may be performed by direct or indirect means (e.g., via a biotin/avidin or a biotin/streptavidin linkage). It is not intended that the present invention be limited to any particular detection system or label.

In another embodiment, the isolated polynucleotide of the invention is a primer that hybridizes, under stringent conditions, adjacent, upstream, or downstream to a variation in the CFH gene that is correlated with the occurrence of AMD in humans. The isolated polynucleotide may hybridize, under stringent conditions, to a nucleic acid molecule comprising all or a portion of a variant CFH gene that is correlated with the occurrence of AMD in humans. Alternatively, the isolated polynucleotide primer may hybridize, under stringent conditions, to a nucleic acid molecule comprising at least 50 contiguous nucleotides of a variant CFH gene that is correlated with the occurrence of AMD in humans. For example, a polynucleotide primer of the invention can hybridize adjacent, upstream, or downstream to the region of the CFH gene that encodes amino acid 402 of the CFH protein. Alternatively, a polynucleotide primer of the invention can hybridize adjacent, upstream, or downstream to the region of the CFH gene that encodes amino acid 62 of the CFH protein.

As used herein, the term "primer" refers to a polynucleotide that is capable of acting as a point of initiation of nucleic acid synthesis when placed under conditions in which synthesis of a primer extension product that is complementary to a nucleic acid strand occurs (for example, in the presence of nucleotides, an inducing agent such as DNA polymerase, and suitable temperature, pH, and electrolyte concentration). Alternatively, the primer may be capable of ligating to a proximal nucleic acid when placed under conditions in which ligation of two unlinked nucleic acids occurs (for example, in the presence of a proximal nucleic acid, an inducing agent such as DNA ligase, and suitable temperature, pH, and electrolyte concentration). A polynucleotide primer of the invention may be naturally occurring, as in a purified restriction digest, or may be produced synthetically. The primer is preferably single stranded for maximum efficiency in amplification, but may alternatively be double stranded. If double stranded, the primer is first treated to separate its strands before being used. Preferably, the primer is an oligodeoxyribonucleotide. The exact lengths of the primers will depend on many factors, including temperature, source of primer and the use of the method. In certain embodiments, the polynucleotide primer of the invention is at least 10 nucleotides long and hybridizes to one side or another of a variation in the CFH gene that is correlated with the occurrence of AMD in humans. The subject polynucleotides may contain alterations, such as one or more nucleotide substitutions, additions or deletions, provided they hybridize to their target variant CFH gene with the same degree of specificity.

In one embodiment, the invention provides a pair of primers that specifically detect a variation in the CFH gene that is correlated with the occurrence of AMD. In such a case, the first primer hybridizes upstream from the variation and a second primer hybridizes downstream from the variation. It is understood that one of the primers hybridizes to one strand of a region of DNA that comprises a variation in the CFH gene that is correlated with the occurrence of AMD, and the second primer hybridizes to the complementary strand of a region of DNA that comprises a variation in the CFH gene that is correlated with the occurrence of AMD. As used herein, the term "region of DNA" refers to a sub-chromosomal length of DNA.

In another embodiment, the invention provides an allele-specific primer that hybridizes to a site on target DNA that overlaps a variation in the CFH gene that is correlated with the occurrence of AMD in humans. An allele-specific primer of the invention only primes amplification of an allelic form to which the primer exhibits perfect complementarity. This primer may be used, for example, in conjunction with a second primer which hybridizes at a distal site. Amplification can thus proceed from the two primers, resulting in a detectable product that indicates the presence of a variant CFH gene that is correlated with the occurrence of AMD in humans.

3. Detection assays

In certain embodiments, the invention relates to polynucleotides useful for detecting a variation in the CFH gene that is correlated with the occurrence of age related macular degeneration. Preferably, these polynucleotides are capable of hybridizing under stringent hybridization conditions to a region of DNA that comprises a variation in the CFH gene that is correlated with the occurrence of age related macular degeneration.

The polynucleotides of the invention may be used in any assay that permits detection of a variation in the CFH gene that is correlated with the occurrence of AMD. Such methods may encompass, for example, DNA sequencing, hybridization, ligation, or primer extension methods. Furthermore, any combination of these methods may be utilized in the invention.

In one embodiment, the presence of a variation in the CFH gene that is correlated with the occurrence of AMD is detected and/or determined by DNA sequencing. DNA sequence determination may be performed by standard methods such as dideoxy chain

termination technology and gel-electrophoresis, or by other methods such as by pyrosequencing (Biotage AB, Uppsala, Sweden). For example, DNA sequencing by dideoxy chain termination may be performed using unlabeled primers and labeled (e.g., fluorescent or radioactive) terminators. Alternatively, sequencing may be performed using
5 labeled primers and unlabeled terminators. The nucleic acid sequence of the DNA in the sample can be compared to the nucleic acid sequence of wildtype DNA to identify whether a variation in the CFH gene that is correlated with the occurrence of AMD is present.

In another embodiment, the presence of a variation in the CFH gene that is correlated with the occurrence of AMD is detected and/or determined by hybridization. In
10 one embodiment, a polynucleotide probe hybridizes to a variation in the CFH gene, and flanking nucleotides, that is correlated with AMD, but not to a wildtype CFH gene. The polynucleotide probe may comprise nucleotides that are fluorescently, radioactively, or chemically labeled to facilitate detection of hybridization. Hybridization may be performed and detected by standard methods known in the art, such as by Northern
15 blotting, Southern blotting, fluorescent in situ hybridization (FISH), or by hybridization to polynucleotides immobilized on a solid support, such as a DNA array or microarray. As used herein, the term "DNA array," and "microarray" refers to an ordered arrangement of hybridizable array elements. The array elements are arranged so that there are preferably at least one or more different array elements immobilized on a substrate surface. The
20 hybridization signal from each of the array elements is individually distinguishable. In a preferred embodiment, the array elements comprise polynucleotides, although the present invention could also be used with cDNA or other types of nucleic acid array elements.

In a specific embodiment, the polynucleotide probe is used to hybridize genomic DNA by FISH. FISH can be used, for example, in metaphase cells, to detect a deletion in
25 genomic DNA. Genomic DNA is denatured to separate the complimentary strands within the DNA double helix structure. The polynucleotide probe of the invention is then added to the denatured genomic DNA. If a variation in the CFH gene that is correlated with the occurrence of AMD is present, the probe will hybridize to the genomic DNA. The probe signal (e.g., fluorescence) can then be detected through a fluorescent microscope for the
30 presence of absence of signal. The absence of signal, therefore, indicates the absence of a variation in the CFH gene that is correlated with the occurrence of AMD. In another specific embodiment, a labeled polynucleotide probe is applied to immobilized

polynucleotides on a DNA array. Hybridization may be detected, for example, by measuring the intensity of the labeled probe remaining on the DNA array after washing. The polynucleotides of the invention may also be used in commercial assays, such as the Taqman assay (Applied Biosystems, Foster City, CA).

5 In another embodiment, the presence of a variation in the CFH gene that is correlated with the occurrence of AMD is detected and/or determined by primer extension with DNA polymerase. In one embodiment, a polynucleotide primer of the invention hybridizes immediately adjacent to the variation. A single base sequencing reaction using labeled dideoxynucleotide terminators may be used to detect the variation. The presence of
10 a variation will result in the incorporation of the labeled terminator, whereas the absence of a variation will not result in the incorporation of the terminator. In another embodiment, a polynucleotide primer of the invention hybridizes to a variation in the CFH gene that is correlated with the occurrence of AMD. The primer, or a portion thereof, will not hybridize to a wildtype CFH gene. The presence of a variation will result in primer
15 extension, whereas the absence of a variation will not result in primer extension. The primers and/or nucleotides may further include fluorescent, radioactive, or chemical probes. A primer labeled by primer extension may be detected by measuring the intensity of the extension product, such as by gel electrophoresis, mass spectrometry, or any other method for detecting fluorescent, radioactive, or chemical labels.

20 In another embodiment, the presence of a variation in the CFH gene that is correlated with the occurrence of AMD is detected and/or determined by ligation. In one embodiment, a polynucleotide primer of the invention hybridizes to a variation in the CFH gene that is correlated with the occurrence of AMD. The primer, or a portion thereof will not hybridize to a wildtype CFH gene. A second polynucleotide that hybridizes to a region
25 of the CFH gene immediately adjacent to the first primer is also provided. One, or both, of the polynucleotide primers may be fluorescently, radioactively, or chemically labeled. Ligation of the two polynucleotide primers will occur in the presence of DNA ligase if a variation in the CFH gene that is correlated with the occurrence of AMD is present. Ligation may be detected by gel electrophoresis, mass spectrometry, or by measuring the
30 intensity of fluorescent, radioactive, or chemical labels.

In another embodiment, the presence of a variation in the CFH gene that is correlated with the occurrence of AMD is detected and/or determined by single-base extension (SBE). For example, a fluorescently-labeled primer that is coupled with fluorescence resonance energy transfer (FRET) between the label of the added base and the label of the primer may be used. Typically, the method, such as that described by Chen et al., (PNAS 94:10756-61 (1997), incorporated herein by reference) uses a locus-specific polynucleotide primer labeled on the 5' terminus with 5-carboxyfluorescein (FAM). This labeled primer is designed so that the 3' end is immediately adjacent to the polymorphic site of interest. The labeled primer is hybridized to the locus, and single base extension of the labeled primer is performed with fluorescently labeled dideoxynucleotides (ddNTPs) in dye-terminator sequencing fashion, except that no deoxyribonucleotides are present. An increase in fluorescence of the added ddNTP in response to excitation at the wavelength of the labeled primer is used to infer the identity of the added nucleotide.

Methods of detecting a variation in the CFH gene that is correlated with the occurrence of AMD may include amplification of a region of DNA that comprises the variation. Any method of amplification may be used. In one specific embodiment, a region of DNA comprising the variation is amplified by using polymerase chain reaction (PCR). PCR was initially described by Mullis (See e.g., U.S. Pat. Nos. 4,683,195 4,683,202, and 4,965,188, herein incorporated by reference), which describes a method for increasing the concentration of a region of DNA, in a mixture of genomic DNA, without cloning or purification. Other PCR methods may also be used to nucleic acid amplification, including but not limited to RT-PCR, quantitative PCR, real time PCR, Rapid Amplified Polymorphic DNA Analysis, Rapid Amplification of cDNA Ends (RACE), or rolling circle amplification. For example, the polynucleotide primers of the invention are combined with a DNA mixture (or any polynucleotide sequence that can be amplified with the polynucleotide primers of the invention), wherein the DNA comprises the CFH gene. The mixture also includes the necessary amplification reagents (e.g., deoxyribonucleotide triphosphates, buffer, etc.) necessary for the thermal cycling reaction. According to standard PCR methods, the mixture undergoes a series of denaturation, primer annealing, and polymerase extension steps to amplify the region of DNA that comprises the variation in the CFH gene. The length of the amplified region of DNA is determined by the relative positions of the primers with respect to each other, and

therefore, this length is a controllable parameter. For example, hybridization of the primers may occur such that the ends of the primers proximal to the variation are separated by 1 to 10,000 base pairs (e.g., 10 base pairs (bp) 50 bp, 200 bp, 500 bp, 1,000 bp, 2,500 bp, 5,000 bp, or 10,000 bp).

5 Standard instrumentation known to those skilled in the art are used for the amplification and detection of amplified DNA. For example, a wide variety of instrumentation has been developed for carrying out nucleic acid amplifications, particularly PCR, e.g. Johnson et al, U.S. Pat. No. 5,038,852 (computer-controlled thermal
10 cycler); Wittwer et al, Nucleic Acids Research, 17: 4353-4357 (1989)(capillary tube PCR); Hallsby, U.S. Pat. No. 5,187,084 (air-based temperature control); Garner et al, Biotechniques, 14: 112-115 (1993)(high-throughput PCR in 864-well plates); Wilding et al, International application No. PCT/US93/04039 (PCR in micro-machined structures); Schnipelsky et al, European patent application No. 90301061.9 (publ. No. 0381501
15 A2)(disposable, single use PCR device), and the like. In certain embodiments, the invention described herein utilizes real-time PCR or other methods known in the art such as the Taqman assay.

 In certain embodiments, a variant CFH gene that is correlated with the occurrence of AMD in humans may be detected using single-strand conformation polymorphism analysis, which identifies base differences by alteration in electrophoretic migration of
20 single stranded PCR products, as described in Orita et al., Proc. Nat. Acad. Sci. 86, 2766-2770 (1989). Amplified PCR products can be generated as described above, and heated or otherwise denatured, to form single stranded amplification products. Single-stranded nucleic acids may refold or form secondary structures which are partially dependent on the base sequence. The different electrophoretic mobilities of single-stranded amplification
25 products can be related to base-sequence differences between alleles of target sequences.

 In one embodiment, the amplified DNA is analyzed in conjunction with one of the detection methods described herein, such as by DNA sequencing. The amplified DNA may alternatively be analyzed by hybridization with a labeled probe, hybridization to a DNA array or microarray, by incorporation of biotinylated primers followed by avidin-
30 enzyme conjugate detection, or by incorporation of ³²P-labeled deoxynucleotide triphosphates, such as dCTP or dATP, into the amplified segment. In a specific

embodiment, the amplified DNA is analyzed by determining the length of the amplified DNA by electrophoresis or chromatography. For example, the amplified DNA is analyzed by gel electrophoresis. Methods of gel electrophoresis are well known in the art. See for example, *Current Protocols in Molecular Biology*, eds. Ausubel et al., John Wiley & Sons: 5 1992. The amplified DNA can be visualized, for example, by fluorescent or radioactive means, or with other dyes or markers that intercalate DNA. The DNA may also be transferred to a solid support such as a nitrocellulose membrane and subjected to Southern Blotting following gel electrophoresis. In one embodiment, the DNA is exposed to ethidium bromide and visualized under ultra-violet light.

10 4. Therapeutic Nucleic Acids Encoding CFH Polypeptides

In certain embodiments, the invention provides isolated and/or recombinant nucleic acids encoding a CFH polypeptide, including functional variants, disclosed herein. For example, SEQ ID NOs: 1 or 2 are nucleic acid sequences that encode CFH and SEQ ID NOs: 5 or 6 and Figure 5 encode CFH polypeptides. The subject nucleic acids may be 15 single-stranded or double stranded. Such nucleic acids may be DNA or RNA molecules. These nucleic acids may be used, for example, in methods for making CFH polypeptides or as direct therapeutic agents (e.g., in a gene therapy approach).

The subject nucleic acids encoding CFH polypeptides are further understood to include nucleic acids that are variants of SEQ ID NOs: 1 or 2. Variant nucleotide 20 sequences include sequences that differ by one or more nucleotide substitutions, additions or deletions, such as allelic variants; and will, therefore, include coding sequences that differ from the nucleotide sequence of the coding sequence designated in SEQ ID NOs: 1 or 2. Coding sequences that differ from the nucleotide sequence of the coding sequence designated in SEQ ID NOs: 1 or 2 may be tested for their ability to inhibit the activation of 25 C3 to C3a and C3b, and by inactivating existing C3.

In certain embodiments, the invention provides isolated or recombinant nucleic acid sequences that are at least 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 1 or 2. One of ordinary skill in the art will appreciate that nucleic acid sequences complementary to SEQ ID NO: 1 or 2, and variants of SEQ ID NO: 1 or 2 are 30 also within the scope of this invention. In further embodiments, the nucleic acid sequences

of the invention can be isolated, recombinant, and/or fused with a heterologous nucleotide sequence, or in a DNA library.

In other embodiments, nucleic acids of the invention also include nucleic acids that hybridize under stringent conditions to the nucleotide sequence designated in SEQ ID NO: 1 or 2, complement sequence of SEQ ID NO: 1 or 2, or fragments thereof. As discussed above, one of ordinary skill in the art will understand readily that appropriate stringency conditions which promote DNA hybridization can be varied. For example, one could perform the hybridization at 6.0 x sodium chloride/sodium citrate (SSC) at about 45 °C, followed by a wash of 2.0 x SSC at 50 °C. For example, the salt concentration in the wash step can be selected from a low stringency of about 2.0 x SSC at 50 °C to a high stringency of about 0.2 x SSC at 50 °C. In addition, the temperature in the wash step can be increased from low stringency conditions at room temperature, about 22 °C, to high stringency conditions at about 65 °C. Both temperature and salt may be varied, or temperature or salt concentration may be held constant while the other variable is changed. In one embodiment, the invention provides nucleic acids which hybridize under low stringency conditions of 6 x SSC at room temperature followed by a wash at 2 x SSC at room temperature.

Isolated nucleic acids which differ from the nucleic acids as set forth in SEQ ID NO: 1 or 2 due to degeneracy in the genetic code are also within the scope of the invention. For example, a number of amino acids are designated by more than one triplet. Codons that specify the same amino acid, or synonyms (for example, CAU and CAC are synonyms for histidine) may result in "silent" variations which do not affect the amino acid sequence of the protein. However, it is expected that DNA sequence polymorphisms that do lead to changes in the amino acid sequences of the subject proteins will exist among mammalian cells. One skilled in the art will appreciate that these variations in one or more nucleotides (up to about 3-5% of the nucleotides) of the nucleic acids encoding a particular protein may exist among individuals of a given species due to natural allelic variation. Any and all such nucleotide variations and resulting amino acid polymorphisms are within the scope of this invention.

The nucleic acids and polypeptides of the invention may be produced using standard recombinant methods. For example, the recombinant nucleic acids of the invention may be operably linked to one or more regulatory nucleotide sequences in an

expression construct. Regulatory nucleotide sequences will generally be appropriate to the host cell used for expression. Numerous types of appropriate expression vectors and suitable regulatory sequences are known in the art for a variety of host cells. Typically, said one or more regulatory nucleotide sequences may include, but are not limited to, promoter sequences, leader or signal sequences, ribosomal binding sites, transcriptional start and termination sequences, translational start and termination sequences, and enhancer or activator sequences. Constitutive or inducible promoters as known in the art are contemplated by the invention. The promoters may be either naturally occurring promoters, or hybrid promoters that combine elements of more than one promoter. An expression construct may be present in a cell on an episome, such as a plasmid, or the expression construct may be inserted in a chromosome. The expression vector may also contain a selectable marker gene to allow the selection of transformed host cells. Selectable marker genes are well known in the art and will vary with the host cell used.

In certain embodiments of the invention, the subject nucleic acid is provided in an expression vector comprising a nucleotide sequence encoding a CFH polypeptide and operably linked to at least one regulatory sequence. Regulatory sequences are art-recognized and are selected to direct expression of the CFH polypeptide. Accordingly, the term regulatory sequence includes promoters, enhancers, termination sequences, preferred ribosome binding site sequences, preferred mRNA leader sequences, preferred protein processing sequences, preferred signal sequences for protein secretion, and other expression control elements. Examples of regulatory sequences are described in Goeddel; *Gene Expression Technology: Methods in Enzymology*, Academic Press, San Diego, CA (1990). For instance, any of a wide variety of expression control sequences that control the expression of a DNA sequence when operatively linked to it may be used in these vectors to express DNA sequences encoding a CFH polypeptide. Such useful expression control sequences, include, for example, the early and late promoters of SV40, tet promoter, adenovirus or cytomegalovirus immediate early promoter, RSV promoters, the lac system, the trp system, the TAC or TRC system, T7 promoter whose expression is directed by T7 RNA polymerase, the major operator and promoter regions of phage lambda, the control regions for fd coat protein, the promoter for 3-phosphoglycerate kinase or other glycolytic enzymes, the promoters of acid phosphatase, e.g., Pho5, the promoters of the yeast α -mating factors, the polyhedron promoter of the baculovirus system and other sequences known to control the expression of genes of prokaryotic or eukaryotic cells or their viruses,

and various combinations thereof. It should be understood that the design of the expression vector may depend on such factors as the choice of the host cell to be transformed and/or the type of protein desired to be expressed. Moreover, the vector's copy number, the ability to control that copy number and the expression of any other
5 protein encoded by the vector, such as antibiotic markers, should also be considered.

A recombinant nucleic acid of the invention can be produced by ligating the cloned gene, or a portion thereof, into a vector suitable for expression in either prokaryotic cells, eukaryotic cells (yeast, avian, insect or mammalian), or both. Expression vehicles for production of recombinant CFH polypeptides include plasmids and other vectors. For
10 instance, suitable vectors include plasmids of the types: pBR322-derived plasmids, pEMBL-derived plasmids, pEX-derived plasmids, pBTac-derived plasmids and pUC-derived plasmids for expression in prokaryotic cells, such as *E. coli*.

Some mammalian expression vectors contain both prokaryotic sequences to facilitate the propagation of the vector in bacteria, and one or more eukaryotic transcription
15 units that are expressed in eukaryotic cells. The pcDNAI/amp, pcDNAI/neo, pRc/CMV, pSV2gpt, pSV2neo, pSV2-dhfr, pTk2, pRSVneo, pMSG, pSVT7, pko-neo and pHyg derived vectors are examples of mammalian expression vectors suitable for transfection of eukaryotic cells. Some of these vectors are modified with sequences from bacterial plasmids, such as pBR322, to facilitate replication and drug resistance selection in both
20 prokaryotic and eukaryotic cells. Alternatively, derivatives of viruses such as the bovine papilloma virus (BPV-1), or Epstein-Barr virus (pHEBo, pREP-derived and p205) can be used for transient expression of proteins in eukaryotic cells. Examples of other viral (including retroviral) expression systems can be found below in the description of gene therapy delivery systems. The various methods employed in the preparation of the
25 plasmids and in transformation of host organisms are well known in the art. For other suitable expression systems for both prokaryotic and eukaryotic cells, as well as general recombinant procedures, see Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory (2001). In some instances, it may be desirable to express the recombinant polypeptide by the use of a baculovirus expression system. Examples of such
30 baculovirus expression systems include pVL-derived vectors (such as pVL1392, pVL1393 and pVL941), pAcUW-derived vectors (such as pAcUW1), and pBlueBac-derived vectors (such as the β -gal containing pBlueBac III).

In one embodiment, a vector will be designed for production of a subject CFH polypeptide in CHO cells, such as a Pcmv-Script vector (Stratagene, La Jolla, Calif.), pcDNA4 vectors (Invitrogen, Carlsbad, Calif.) and pCI-neo vectors (Promega, Madison, Wisc.). In other embodiments, the vector is designed for production of a subject CFH polypeptide in prokaryotic host cells (e.g., *E. coli* and *B. subtilis*), eukaryotic host cells such as, for example, yeast cells, insect cells, myeloma cells, fibroblast 3T3 cells, monkey kidney or COS cells, mink-lung epithelial cells, human foreskin fibroblast cells, human glioblastoma cells, and teratocarcinoma cells. Alternatively, the genes may be expressed in a cell-free system such as the rabbit reticulocyte lysate system.

As will be apparent, the subject gene constructs can be used to express the subject CFH polypeptide in cells propagated in culture, e.g., to produce proteins, including fusion proteins or variant proteins, for purification.

This invention also pertains to a host cell transfected with a recombinant gene including a coding sequence (e.g., SEQ ID NO: 1 or 2) for one or more of the subject CFH polypeptides. The host cell may be any prokaryotic or eukaryotic cell. For example, a CFH polypeptide of the invention may be expressed in bacterial cells such as *E. coli*, insect cells (e.g., using a baculovirus expression system), yeast, or mammalian cells. Other suitable host cells are known to those skilled in the art.

Accordingly, the present invention further pertains to methods of producing the subject CFH polypeptides. For example, a host cell transfected with an expression vector encoding a CFH polypeptide can be cultured under appropriate conditions to allow expression of the CFH polypeptide to occur. CFH polypeptides may be secreted and isolated from a mixture of cells and medium containing the CFH polypeptides. Alternatively, the polypeptide may be retained cytoplasmically or in a membrane fraction and the cells harvested, lysed and the protein isolated. A cell culture includes host cells, media and other byproducts. Suitable media for cell culture are well known in the art. The polypeptide can be isolated from cell culture medium, host cells, or both using techniques known in the art for purifying proteins, including ion-exchange chromatography, gel filtration chromatography, ultrafiltration, electrophoresis, and immunoaffinity purification with antibodies specific for particular epitopes of the polypeptide. In a particular embodiment, the CFH polypeptide is a fusion protein containing a domain which facilitates the purification of the CFH polypeptide.

In another embodiment, a fusion gene coding for a purification leader sequence, such as a poly-(His)/enterokinase cleavage site sequence at the N-terminus of the desired portion of the recombinant CFH polypeptide, can allow purification of the expressed fusion protein by affinity chromatography using a Ni²⁺ metal resin. The purification leader
5 sequence can then be subsequently removed by treatment with enterokinase to provide the purified polypeptide (e.g., see Hochuli et al., (1987) *J. Chromatography* 411:177; and Janknecht et al., *PNAS USA* 88:8972).

Techniques for making fusion genes are well known. Essentially, the joining of various DNA fragments coding for different polypeptide sequences is performed in
10 accordance with conventional techniques, employing blunt-ended or stagger-ended termini for ligation, restriction enzyme digestion to provide for appropriate termini, filling-in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid undesirable joining, and enzymatic ligation. In another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR
15 amplification of gene fragments can be carried out using anchor primers which give rise to complementary overhangs between two consecutive gene fragments which can subsequently be annealed to generate a chimeric gene sequence (see, for example, *Current Protocols in Molecular Biology*, eds. Ausubel et al., John Wiley & Sons: 1992).

5. Other therapeutic modalities

20 *Antisense polynucleotides*

In certain embodiments, the invention provides polynucleotides that comprise an antisense sequence that acts through an antisense mechanism for inhibiting expression of a variant CFH gene. Antisense technologies have been widely utilized to regulate gene expression (Buskirk et al., *Chem Biol* 11, 1157-63 (2004); and Weiss et al., *Cell Mol Life*
25 *Sci* 55, 334-58 (1999)). As used herein, "antisense" technology refers to administration or in situ generation of molecules or their derivatives which specifically hybridize (e.g., bind) under cellular conditions, with the target nucleic acid of interest (mRNA and/or genomic DNA) encoding one or more of the target proteins so as to inhibit expression of that protein, e.g., by inhibiting transcription and/or translation, such as by steric hinderance,
30 altering splicing, or inducing cleavage or other enzymatic inactivation of the transcript. The binding may be by conventional base pair complementarity, or, for example, in the

case of binding to DNA duplexes, through specific interactions in the major groove of the double helix. In general, "antisense" technology refers to the range of techniques generally employed in the art, and includes any therapy that relies on specific binding to nucleic acid sequences.

5 A polynucleotide that comprises an antisense sequence of the present invention can be delivered, for example, as a component of an expression plasmid which, when transcribed in the cell, produces a nucleic acid sequence that is complementary to at least a unique portion of the target nucleic acid. Alternatively, the polynucleotide that comprises an antisense sequence can be generated outside of the target cell, and which, when
10 introduced into the target cell causes inhibition of expression by hybridizing with the target nucleic acid. Polynucleotides of the invention may be modified so that they are resistant to endogenous nucleases, e.g. exonucleases and/or endonucleases, and are therefore stable in vivo. Examples of nucleic acid molecules for use in polynucleotides of the invention are phosphoramidate, phosphothioate and methylphosphonate analogs of DNA (see also U.S.
15 Pat. Nos. 5,176,996; 5,264,564; and 5,256,775). General approaches to constructing polynucleotides useful in antisense technology have been reviewed, for example, by van der krol et al. (1988) *Biotechniques* 6:958-976; and Stein et al. (1988) *Cancer Res* 48:2659-2668.

 Antisense approaches involve the design of polynucleotides (either DNA or RNA)
20 that are complementary to a target nucleic acid encoding a variant CFH gene. The antisense polynucleotide may bind to an mRNA transcript and prevent translation of a protein of interest. Absolute complementarity, although preferred, is not required. In the case of double-stranded antisense polynucleotides, a single strand of the duplex DNA may thus be tested, or triplex formation may be assayed. The ability to hybridize will depend
25 on both the degree of complementarity and the length of the antisense sequence. Generally, the longer the hybridizing nucleic acid, the more base mismatches with a target nucleic acid it may contain and still form a stable duplex (or triplex, as the case may be). One skilled in the art can ascertain a tolerable degree of mismatch by use of standard procedures to determine the melting point of the hybridized complex.

30 Antisense polynucleotides that are complementary to the 5' end of an mRNA target, e.g., the 5' untranslated sequence up to and including the AUG initiation codon, should work most efficiently at inhibiting translation of the mRNA. However, sequences

complementary to the 3' untranslated sequences of mRNAs have recently been shown to be effective at inhibiting translation of mRNAs as well (Wagner, R. 1994. *Nature* 372:333). Therefore, antisense polynucleotides complementary to either the 5' or 3' untranslated, non-coding regions of a variant CFH gene could be used in an antisense approach to inhibit translation of a variant CFH mRNA. Antisense polynucleotides complementary to the 5' untranslated region of an mRNA should include the complement of the AUG start codon. Antisense polynucleotides complementary to mRNA coding regions are less efficient inhibitors of translation but could also be used in accordance with the invention. Whether designed to hybridize to the 5', 3', or coding region of mRNA, antisense polynucleotides should be at least six nucleotides in length, and are preferably less than about 100 and more preferably less than about 50, 25, 17 or 10 nucleotides in length.

Regardless of the choice of target sequence, it is preferred that in vitro studies are first performed to quantitate the ability of the antisense polynucleotide to inhibit expression of a variant CFH gene. It is preferred that these studies utilize controls that distinguish between antisense gene inhibition and nonspecific biological effects of antisense polynucleotide. It is also preferred that these studies compare levels of the target RNA or protein with that of an internal control RNA or protein. Additionally, it is envisioned that results obtained using the antisense polynucleotide are compared with those obtained using a control antisense polynucleotide. It is preferred that the control antisense polynucleotide is of approximately the same length as the test antisense polynucleotide and that the nucleotide sequence of the control antisense polynucleotide differs from the antisense sequence of interest no more than is necessary to prevent specific hybridization to the target sequence.

Polynucleotides of the invention, including antisense polynucleotides, can be DNA or RNA or chimeric mixtures or derivatives or modified versions thereof, single-stranded or double-stranded. Polynucleotides of the invention can be modified at the base moiety, sugar moiety, or phosphate backbone, for example, to improve stability of the molecule, hybridization, etc. Polynucleotides of the invention may include other appended groups such as peptides (e.g., for targeting host cell receptors), or agents facilitating transport across the cell membrane (see, e.g., Letsinger et al., 1989, *Proc Natl Acad Sci. USA*

86:6553-6556; Lemaitre et al., 1987, *Proc Natl Acad Sci. USA* 84:648-652; PCT Publication No. W088/09810, published Dec. 15, 1988) or the blood- brain barrier (see, e.g., PCT Publication No. W089/10134, published Apr. 25, 1988), hybridization-triggered cleavage agents. (See, e.g., Krol et al., 1988, *BioTechniques* 6:958-976) or intercalating
 5 agents. (See, e.g., Zon, *Pharm. Res.* 5:539-549 (1988)). To this end, a polynucleotide of the invention may be conjugated to another molecule, e.g., a peptide, hybridization triggered cross-linking agent, transport agent, hybridization-triggered cleavage agent, etc.

Polynucleotides of the invention, including antisense polynucleotides, may comprise at least one modified base moiety which is selected from the group including but
 10 not limited to 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxytriethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5- carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6- isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine,
 15 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil; beta-D-mannosylqueosine, 5-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-
 20 oxyacetic acid methyl ester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine.

Polynucleotides of the invention may also comprise at least one modified sugar moiety selected from the group including but not limited to arabinose, 2-fluoroarabinose, xylulose, and hexose.

25 A polynucleotide of the invention can also contain a neutral peptide-like backbone. Such molecules are termed peptide nucleic acid (PNA)-oligomers and are described, e.g., in Perry-O'Keefe et al. (1996) *Proc. Natl. Acad. Sci. USA* 93:14670 and in Eglom et al. (1993) *Nature* 365:566. One advantage of PNA oligomers is their capability to bind to complementary DNA essentially independently from the ionic strength of the medium due
 30 to the neutral backbone of the DNA. In yet another embodiment, a polynucleotide of the invention comprises at least one modified phosphate backbone selected from the group consisting of a phosphorothioate, a phosphorodithioate, a phosphoramidothioate, a

phosphoramidate, a phosphordiamidate, a methylphosphonate, an alkyl phosphotriester, and a formacetal or analog thereof.

In a further embodiment, polynucleotides of the invention, including antisense polynucleotides are -anomeric oligonucleotides. An -anomeric oligonucleotide forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual -units, the strands run parallel to each other (Gautier et al., 1987, *Nucl. Acids Res.* 15:6625-6641). The oligonucleotide is a 2'-O-methylribonucleotide (Inoue et al., 1987, *Nucl. Acids Res.* 15:6131-6148), or a chimeric RNA-DNA analogue (Inoue et al., 1987, *FEBS Lett.* 215:327-330).

Polynucleotides of the invention, including antisense polynucleotides, may be synthesized by standard methods known in the art, e.g., by use of an automated DNA synthesizer (such as are commercially available from Biosearch, Applied Biosystems, etc.). As examples, phosphorothioate oligonucleotides may be synthesized by the method of Stein et al. *Nucl. Acids Res.* 16:3209 (1988)), methylphosphonate oligonucleotides can be prepared by use of controlled pore glass polymer supports (Sarin et al., *Proc. Natl. Acad. Sci. USA* 85:7448-7451 (1988)), etc.

While antisense sequences complementary to the coding region of an mRNA sequence can be used, those complementary to the transcribed untranslated region and to the region comprising the initiating methionine are most preferred.

Antisense polynucleotides can be delivered to cells that express target genes in vivo. A number of methods have been developed for delivering nucleic acids into cells; e.g., they can be injected directly into the tissue site, or modified nucleic acids, designed to target the desired cells (e.g., antisense polynucleotides linked to peptides or antibodies that specifically bind receptors or antigens expressed on the target cell surface) can be administered systematically.

However, it may be difficult to achieve intracellular concentrations of the antisense polynucleotides sufficient to attenuate the activity of a variant CFH gene or mRNA in certain instances. Therefore, another approach utilizes a recombinant DNA construct in which the antisense polynucleotide is placed under the control of a strong pol III or pol II promoter. The use of such a construct to transfect target cells in the patient will result in the transcription of sufficient amounts of antisense polynucleotides that will form

complementary base pairs with the variant CFH gene or mRNA and thereby attenuate the activity of CFH protein. For example, a vector can be introduced in vivo such that it is taken up by a cell and directs the transcription of an antisense polynucleotide that targets a variant CFH gene or mRNA. Such a vector can remain episomal or become
5 chromosomally integrated, as long as it can be transcribed to produce the desired antisense polynucleotide. Such vectors can be constructed by recombinant DNA technology methods standard in the art. Vectors can be plasmid, viral, or others known in the art, used for replication and expression in mammalian cells. A promoter may be operably linked to the sequence encoding the antisense polynucleotide. Expression of the sequence encoding
10 the antisense polynucleotide can be by any promoter known in the art to act in mammalian, preferably human cells. Such promoters can be inducible or constitutive. Such promoters include but are not limited to: the SV40 early promoter region (Bernoist and Chambon, *Nature* 290:304-310 (1981)), the promoter contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto et al., *Cell* 22:787-797 (1980)), the herpes thymidine kinase
15 promoter (Wagner et al., *Proc. Natl. Acad. Sci. USA* 78:1441-1445 (1981)), the regulatory sequences of the metallothioneine gene (Brinster et al, *Nature* 296:3942 (1982)), etc. Any type of plasmid, cosmid, YAC or viral vector can be used to prepare the recombinant DNA construct that can be introduced directly into the tissue site. Alternatively, viral vectors can be used which selectively infect the desired tissue, in which case administration may be
20 accomplished by another route (e.g., systematically).

RNAi constructs - siRNAs and miRNAs

RNA interference (RNAi) is a phenomenon describing double-stranded (ds)RNA-dependent gene specific posttranscriptional silencing. Initial attempts to harness this
25 phenomenon for experimental manipulation of mammalian cells were foiled by a robust and nonspecific antiviral defense mechanism activated in response to long dsRNA molecules. Gil et al. *Apoptosis* 2000, 5:107-114. The field was significantly advanced upon the demonstration that synthetic duplexes of 21 nucleotide RNAs could mediate gene specific RNAi in mammalian cells, without invoking generic antiviral defense
30 mechanisms. Elbashir et al. *Nature* 2001, 411:494-498; Caplen et al. *Proc Natl Acad Sci* 2001, 98:9742-9747. As a result, small-interfering RNAs (siRNAs) and micro RNAs (miRNAs) have become powerful tools to dissect gene function. The chemical synthesis of small RNAs is one avenue that has produced promising results. Numerous groups have

also sought the development of DNA-based vectors capable of generating such siRNA within cells. Several groups have recently attained this goal and published similar strategies that, in general, involve transcription of short hairpin (sh)RNAs that are efficiently processed to form siRNAs within cells. Paddison et al. PNAS 2002, 99:1443-1448; Paddison et al. Genes & Dev 2002, 16:948-958; Sui et al. PNAS 2002, 8:5515-5520; 5 and Brummelkamp et al. Science 2002, 296:550-553. These reports describe methods to generate siRNAs capable of specifically targeting numerous endogenously and exogenously expressed genes.

Accordingly, the present invention provides a polynucleotide comprising an RNAi 10 sequence that acts through an RNAi or miRNA mechanism to attenuate expression of a variant CFH gene. For instance, a polynucleotide of the invention may comprise a miRNA or siRNA sequence that attenuates or inhibits expression of a variant CFH gene. In one embodiment, the miRNA or siRNA sequence is between about 19 nucleotides and about 75 nucleotides in length, or preferably, between about 25 base pairs and about 35 base pairs in 15 length. In certain embodiments, the polynucleotide is a hairpin loop or stem-loop that may be processed by RNase enzymes (e.g., Drosha and Dicer).

An RNAi construct contains a nucleotide sequence that hybridizes under physiologic conditions of the cell to the nucleotide sequence of at least a portion of the mRNA transcript for a variant CFH gene. The double-stranded RNA need only be 20 sufficiently similar to natural RNA that it has the ability to mediate RNAi. The number of tolerated nucleotide mismatches between the target sequence and the RNAi construct sequence is no more than 1 in 5 basepairs, or 1 in 10 basepairs, or 1 in 20 basepairs, or 1 in 50 basepairs. It is primarily important that the RNAi construct is able to specifically target a variant CFH gene. Mismatches in the center of the siRNA duplex are most critical and 25 may essentially abolish cleavage of the target RNA. In contrast, nucleotides at the 3' end of the siRNA strand that is complementary to the target RNA do not significantly contribute to specificity of the target recognition.

Sequence identity may be optimized by sequence comparison and alignment algorithms known in the art (see Gribskov and Devereux, Sequence Analysis Primer, 30 Stockton Press, 1991, and references cited therein) and calculating the percent difference between the nucleotide sequences by, for example, the Smith-Waterman algorithm as implemented in the BESTFIT software program using default parameters (e.g., University

of Wisconsin Genetic Computing Group). Greater than 90% sequence identity, or even 100% sequence identity, between the inhibitory RNA and the portion of the target gene is preferred. Alternatively, the duplex region of the RNA may be defined functionally as a nucleotide sequence that is capable of hybridizing with a portion of the target gene transcript (e.g., 400 mM NaCl, 40mM PIPES pH 6.4, 1 mM EDTA, 50 °C or 70 °C hybridization for 12-16 hours; followed by washing).

Production of polynucleotides comprising RNAi sequences can be carried out by any of the methods for producing polynucleotides described herein. For example, polynucleotides comprising RNAi sequences can be produced by chemical synthetic methods or by recombinant nucleic acid techniques. Endogenous RNA polymerase of the treated cell may mediate transcription in vivo, or cloned RNA polymerase can be used for transcription in vitro. Polynucleotides of the invention, including wildtype or antisense polynucleotides, or those that modulate target gene activity by RNAi mechanisms, may include modifications to either the phosphate-sugar backbone or the nucleoside, e.g., to reduce susceptibility to cellular nucleases, improve bioavailability, improve formulation characteristics, and/or change other pharmacokinetic properties. For example, the phosphodiester linkages of natural RNA may be modified to include at least one of a nitrogen or sulfur heteroatom. Modifications in RNA structure may be tailored to allow specific genetic inhibition while avoiding a general response to dsRNA. Likewise, bases may be modified to block the activity of adenosine deaminase. Polynucleotides of the invention may be produced enzymatically or by partial/total organic synthesis, any modified ribonucleotide can be introduced by in vitro enzymatic or organic synthesis.

Methods of chemically modifying RNA molecules can be adapted for modifying RNAi constructs (see, for example, Heidenreich et al. (1997) *Nucleic Acids Res*, 25:776-780; Wilson et al. (1994) *J Mol Recog* 7:89-98; Chen et al. (1995) *Nucleic Acids Res* 23:2661-2668; Hirschbein et al. (1997) *Antisense Nucleic Acid Drug Dev* 7:55-61). Merely to illustrate, the backbone of an RNAi construct can be modified with phosphorothioates, phosphoramidate, phosphodithioates, chimeric methylphosphonate-phosphodiester, peptide nucleic acids, 5-propynyl-pyrimidine containing oligomers or sugar modifications (e.g., 2'-substituted ribonucleosides, a-configuration).

The double-stranded structure may be formed by a single self-complementary RNA strand or two complementary RNA strands. RNA duplex formation may be initiated either

inside or outside the cell. The RNA may be introduced in an amount which allows delivery of at least one copy per cell. Higher doses (e.g., at least 5, 10, 100, 500 or 1000 copies per cell) of double-stranded material may yield more effective inhibition, while lower doses may also be useful for specific applications. Inhibition is sequence-specific in that nucleotide sequences corresponding to the duplex region of the RNA are targeted for genetic inhibition.

In certain embodiments, the subject RNAi constructs are "siRNAs." These nucleic acids are between about 19-35 nucleotides in length, and even more preferably 21-23 nucleotides in length, e.g., corresponding in length to the fragments generated by nuclease "dicing" of longer double-stranded RNAs. The siRNAs are understood to recruit nuclease complexes and guide the complexes to the target mRNA by pairing to the specific sequences. As a result, the target mRNA is degraded by the nucleases in the protein complex or translation is inhibited. In a particular embodiment, the 21-23 nucleotides siRNA molecules comprise a 3' hydroxyl group.

In other embodiments, the subject RNAi constructs are "miRNAs." microRNAs (miRNAs) are small non-coding RNAs that direct post transcriptional regulation of gene expression through interaction with homologous mRNAs. miRNAs control the expression of genes by binding to complementary sites in target mRNAs from protein coding genes. miRNAs are similar to siRNAs. miRNAs are processed by nucleolytic cleavage from larger double-stranded precursor molecules. These precursor molecules are often hairpin structures of about 70 nucleotides in length, with 25 or more nucleotides that are base-paired in the hairpin. The RNase III-like enzymes Drosha and Dicer (which may also be used in siRNA processing) cleave the miRNA precursor to produce an miRNA. The processed miRNA is single-stranded and incorporates into a protein complex, termed RISC or miRNP. This RNA-protein complex targets a complementary mRNA. miRNAs inhibit translation or direct cleavage of target mRNAs. (Brennecke et al., *Genome Biology* 4:228 (2003); Kim et al., *Mol. Cells* 19:1-15 (2005).

In certain embodiments, miRNA and siRNA constructs can be generated by processing of longer double-stranded RNAs, for example, in the presence of the enzymes Dicer or Drosha. Dicer and Drosha are RNase III-like nucleases that specifically cleave dsRNA. Dicer has a distinctive structure which includes a helicase domain and dual RNase III motifs. Dicer also contains a region of homology to the

RDE1/QDE2/ARGONAUTE family, which have been genetically linked to RNAi in lower eukaryotes. Indeed, activation of, or overexpression of Dicer may be sufficient in many cases to permit RNA interference in otherwise non-receptive cells, such as cultured eukaryotic cells, or mammalian (non-oocytic) cells in culture or in whole organisms.

- 5 Methods and compositions employing Dicer, as well as other RNAi enzymes, are described in U.S. Pat. App. Publication No. 2004/0086884.

In one embodiment, the *Drosophila* in vitro system is used. In this embodiment, a polynucleotide comprising an RNAi sequence or an RNAi precursor is combined with a soluble extract derived from *Drosophila* embryo, thereby producing a combination. The
10 combination is maintained under conditions in which the dsRNA is processed to RNA molecules of about 21 to about 23 nucleotides.

The miRNA and siRNA molecules can be purified using a number of techniques known to those of skill in the art. For example, gel electrophoresis can be used to purify such molecules. Alternatively, non-denaturing methods, such as non-denaturing column
15 chromatography, can be used to purify the siRNA and miRNA molecules. In addition, chromatography (e.g., size exclusion chromatography), glycerol gradient centrifugation, affinity purification with antibody can be used to purify siRNAs and miRNAs.

In certain embodiments, at least one strand of the siRNA sequence of an effector domain has a 3' overhang from about 1 to about 6 nucleotides in length, or from 2 to 4
20 nucleotides in length. In other embodiments, the 3' overhangs are 1-3 nucleotides in length. In certain embodiments, one strand has a 3' overhang and the other strand is either blunt-ended or also has an overhang. The length of the overhangs may be the same or different for each strand. In order to further enhance the stability of the siRNA sequence, the 3' overhangs can be stabilized against degradation. In one embodiment, the RNA is
25 stabilized by including purine nucleotides, such as adenosine or guanosine nucleotides. Alternatively, substitution of pyrimidine nucleotides by modified analogues, e.g., substitution of uridine nucleotide 3' overhangs by 2'-deoxythymidine is tolerated and does not affect the efficiency of RNAi. The absence of a 2' hydroxyl significantly enhances the nuclease resistance of the overhang in tissue culture medium and may be beneficial in vivo.

30 In certain embodiments, a polynucleotide of the invention that comprises an RNAi sequence or an RNAi precursor is in the form of a hairpin structure (named as hairpin RNA). The hairpin RNAs can be synthesized exogenously or can be formed by

transcribing from RNA polymerase III promoters in vivo. Examples of making and using such hairpin RNAs for gene silencing in mammalian cells are described in, for example, Paddison et al., *Genes Dev*, 2002, 16:948-58; McCaffrey et al., *Nature*, 2002, 418:38-9; McManus et al., *RNA* 2002, 8:842-50; Yu et al., *Proc Natl Acad Sci USA*, 2002, 99:6047-52). Preferably, such hairpin RNAs are engineered in cells or in an animal to ensure continuous and stable suppression of a desired gene. It is known in the art that miRNAs and siRNAs can be produced by processing a hairpin RNA in the cell.

In yet other embodiments, a plasmid is used to deliver the double-stranded RNA, e.g., as a transcriptional product. After the coding sequence is transcribed, the complementary RNA transcripts base-pair to form the double-stranded RNA.

Aptamers and small molecules

The present invention also provides therapeutic aptamers that specifically bind to variant CFH polypeptides that are associated with AMD, thereby modulating activity of the variant CFH polypeptide. An "aptamer" may be a nucleic acid molecule, such as RNA or DNA that is capable of binding to a specific molecule with high affinity and specificity (Ellington et al., *Nature* 346, 818-22 (1990); and Tuerk et al., *Science* 249, 505-10 (1990)). An aptamer will most typically have been obtained by in vitro selection for binding of a target molecule. For example, an aptamer that specifically binds a variant CFH polypeptide can be obtained by in vitro selection for binding to a variant CFH polypeptide from a pool of polynucleotides. However, in vivo selection of an aptamer is also possible. Aptamers have specific binding regions which are capable of forming complexes with an intended target molecule in an environment wherein other substances in the same environment are not complexed to the nucleic acid. The specificity of the binding is defined in terms of the comparative dissociation constants (K_d) of the aptamer for its ligand (e.g., a variant CFH polypeptide) as compared to the dissociation constant of the aptamer for other materials in the environment or unrelated molecules in general. A ligand (e.g., a variant CFH polypeptide) is one which binds to the aptamer with greater affinity than to unrelated material. Typically, the K_d for the aptamer with respect to its ligand will be at least about 10-fold less than the K_d for the aptamer with unrelated material or accompanying material in the environment. Even more preferably, the K_d will be at least about 50-fold less, more preferably at least about 100-fold less, and most preferably at least about 200-fold less. An aptamer will typically be between about 10 and about 300

nucleotides in length. More commonly, an aptamer will be between about 30 and about 100 nucleotides in length.

Methods for selecting aptamers specific for a target of interest are known in the art. For example, organic molecules, nucleotides, amino acids, polypeptides, target features on
5 cell surfaces, ions, metals, salts, saccharides, have all been shown to be suitable for isolating aptamers that can specifically bind to the respective ligand. For instance, organic dyes such as Hoechst 33258 have been successfully used as target ligands for in vitro aptamer selections (Werstuck and Green, *Science* 282:296-298 (1998)). Other small organic molecules like dopamine, theophylline, sulforhodamine B, and cellobiose have
10 also been used as ligands in the isolation of aptamers. Aptamers have also been isolated for antibiotics such as kanamycin A, lividomycin, tobramycin, neomycin B, viomycin, chloramphenicol and streptomycin. For a review of aptamers that recognize small molecules, see Famulok, *Science* 9:324-9 (1999).

An aptamer of the invention can be comprised entirely of RNA. In other
15 embodiments of the invention, however, the aptamer can instead be comprised entirely of DNA, or partially of DNA, or partially of other nucleotide analogs. To specifically inhibit translation in vivo, RNA aptamers are preferred. Such RNA aptamers are preferably introduced into a cell as DNA that is transcribed into the RNA aptamer. Alternatively, an RNA aptamer itself can be introduced into a cell.

20 Aptamers are typically developed to bind particular ligands by employing known in vivo or in vitro (most typically, in vitro) selection techniques known as SELEX (Ellington et al., *Nature* 346, 818-22 (1990); and Tuerk et al., *Science* 249, 505-10 (1990)). Methods of making aptamers are also described in, for example, U.S. Pat. No. 5,582,981, PCT Publication No. WO 00/20040, U.S. Pat. No. 5,270,163, Lorsch and Szostak,
25 *Biochemistry*, 33:973 (1994), Mannironi et al., *Biochemistry* 36:9726 (1997), Blind, *Proc. Nat'l. Acad. Sci. USA* 96:3606-3610 (1999), Huizenga and Szostak, *Biochemistry*, 34:656-665 (1995), PCT Publication Nos. WO 99/54506, WO 99/27133, WO 97/42317 and U.S. Pat. No. 5,756,291.

Generally, in their most basic form, in vitro selection techniques for identifying
30 aptamers involve first preparing a large pool of DNA molecules of the desired length that contain at least some region that is randomized or mutagenized. For instance, a common oligonucleotide pool for aptamer selection might contain a region of 20-100 randomized

nucleotides flanked on both ends by an about 15-25 nucleotide long region of defined sequence useful for the binding of PCR primers. The oligonucleotide pool is amplified using standard PCR techniques, although any means that will allow faithful, efficient amplification of selected nucleic acid sequences can be employed. The DNA pool is then
5 in vitro transcribed to produce RNA transcripts. The RNA transcripts may then be subjected to affinity chromatography, although any protocol which will allow selection of nucleic acids based on their ability to bind specifically to another molecule (e.g., a protein or any target molecule) may be used. In the case of affinity chromatography, the transcripts are most typically passed through a column or contacted with magnetic beads or
10 the like on which the target ligand has been immobilized. RNA molecules in the pool which bind to the ligand are retained on the column or bead, while nonbinding sequences are washed away. The RNA molecules which bind the ligand are then reverse transcribed and amplified again by PCR (usually after elution). The selected pool sequences are then put through another round of the same type of selection. Typically, the pool sequences are
15 put through a total of about three to ten iterative rounds of the selection procedure. The cDNA is then amplified, cloned, and sequenced using standard procedures to identify the sequence of the RNA molecules which are capable of acting as aptamers for the target ligand. Once an aptamer sequence has been successfully identified, the aptamer may be further optimized by performing additional rounds of selection starting from a pool of
20 oligonucleotides comprising the mutagenized aptamer sequence. For use in the present invention, the aptamer is preferably selected for ligand binding in the presence of salt concentrations and temperatures which mimic normal physiological conditions.

The unique nature of the in vitro selection process allows for the isolation of a suitable aptamer that binds a desired ligand despite a complete dearth of prior knowledge
25 as to what type of structure might bind the desired ligand.

The association constant for the aptamer and associated ligand is preferably such that the ligand functions to bind to the aptamer and have the desired effect at the concentration of ligand obtained upon administration of the ligand. For in vivo use, for example, the association constant should be such that binding occurs well below the
30 concentration of ligand that can be achieved in the serum or other tissue. Preferably, the required ligand concentration for in vivo use is also below that which could have undesired effects on the organism.

The present invention also provides small molecules and antibodies that specifically bind to a variant CFH polypeptide that is associated with AMD, thereby inhibiting the activity of a variant CFH polypeptide. Examples of small molecules include, without limitation, drugs, metabolites, intermediates, cofactors, transition state analogs, ions, metals, toxins and natural and synthetic polymers (e.g., proteins, peptides, nucleic acids, polysaccharides, glycoproteins, hormones, receptors and cell surfaces such as cell walls and cell membranes).

Antibodies

Another aspect of the invention pertains to antibodies. In one embodiment, an antibody that is specifically reactive with a variant CFH polypeptide may be used to detect the presence of a variant CFH polypeptide or to inhibit activity of a variant CFH polypeptide. For example, by using immunogens derived from a variant CFH peptide, anti-protein/anti-peptide antisera or monoclonal antibodies can be made by standard protocols (see, for example, *Antibodies: A Laboratory Manual* ed. by Harlow and Lane (Cold Spring Harbor Press: 1988)). A mammal, such as a mouse, a hamster or rabbit can be immunized with an immunogenic form of the variant CFH peptide, an antigenic fragment which is capable of eliciting an antibody response, or a fusion protein. In a particular embodiment, the inoculated mouse does not express endogenous CFH, thus facilitating the isolation of antibodies that would otherwise be eliminated as anti-self antibodies. Techniques for conferring immunogenicity on a protein or peptide include conjugation to carriers or other techniques well known in the art. An immunogenic portion of a variant CFH peptide can be administered in the presence of adjuvant. The progress of immunization can be monitored by detection of antibody titers in plasma or serum. Standard ELISA or other immunoassays can be used with the immunogen as antigen to assess the levels of antibodies.

Following immunization of an animal with an antigenic preparation of a variant CFH polypeptide, antisera can be obtained and, if desired, polyclonal antibodies can be isolated from the serum. To produce monoclonal antibodies, antibody-producing cells (lymphocytes) can be harvested from an immunized animal and fused by standard somatic cell fusion procedures with immortalizing cells such as myeloma cells to yield hybridoma cells. Such techniques are well known in the art, and include, for example, the hybridoma

technique (originally developed by Kohler and Milstein, (1975) Nature, 256: 495-497), the human B cell hybridoma technique (Kozbar et al., (1983) Immunology Today, 4: 72), and the EBV-hybridoma technique to produce human monoclonal antibodies (Cole et al., (1985) Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc. pp. 77-96).

- 5 Hybridoma cells can be screened immunochemically for production of antibodies specifically reactive with a variant CFH polypeptide and monoclonal antibodies isolated from a culture comprising such hybridoma cells.

The term "antibody" as used herein is intended to include fragments thereof which are also specifically reactive with a variant CFH polypeptide. Antibodies can be
10 fragmented using conventional techniques and the fragments screened for utility in the same manner as described above for whole antibodies. For example, F(ab)₂ fragments can be generated by treating antibody with pepsin. The resulting F(ab)₂ fragment can be treated to reduce disulfide bridges to produce Fab fragments. The antibody of the present invention is further intended to include bispecific, single-chain, and chimeric and
15 humanized molecules having affinity for a variant CFH polypeptide conferred by at least one CDR region of the antibody. In preferred embodiments, the antibody further comprises a label attached thereto and able to be detected (e.g., the label can be a radioisotope, fluorescent compound, enzyme or enzyme co-factor).

In certain embodiments, an antibody of the invention is a monoclonal antibody, and
20 in certain embodiments, the invention makes available methods for generating novel antibodies that bind specifically to variant CFH polypeptides. For example, a method for generating a monoclonal antibody that binds specifically to a variant CFH polypeptide may comprise administering to a mouse an amount of an immunogenic composition comprising the CFH polypeptide effective to stimulate a detectable immune response, obtaining
25 antibody-producing cells (e.g., cells from the spleen) from the mouse and fusing the antibody-producing cells with myeloma cells to obtain antibody-producing hybridomas, and testing the antibody-producing hybridomas to identify a hybridoma that produces a monoclonal antibody that binds specifically to the variant CFH polypeptide. Once obtained, a hybridoma can be propagated in a cell culture, optionally in culture conditions
30 where the hybridoma-derived cells produce the monoclonal antibody that binds specifically to the CFH polypeptide. The monoclonal antibody may be purified from the cell culture.

The term “specifically reactive with” as used in reference to an antibody is intended to mean, as is generally understood in the art, that the antibody is sufficiently selective between the antigen of interest (e.g., a variant CFH polypeptide) and other antigens that are not of interest that the antibody is useful for, at minimum, detecting the presence of the antigen of interest in a particular type of biological sample. In certain methods employing the antibody, such as therapeutic applications, a higher degree of specificity in binding may be desirable. Monoclonal antibodies generally have a greater tendency (as compared to polyclonal antibodies) to discriminate effectively between the desired antigens and cross-reacting polypeptides. One characteristic that influences the specificity of an antibody:antigen interaction is the affinity of the antibody for the antigen. Although the desired specificity may be reached with a range of different affinities, generally preferred antibodies will have an affinity (a dissociation constant) of about 10^{-6} , 10^{-7} , 10^{-8} , 10^{-9} or less.

In addition, the techniques used to screen antibodies in order to identify a desirable antibody may influence the properties of the antibody obtained. For example, if an antibody is to be used for binding an antigen in solution, it may be desirable to test solution binding. A variety of different techniques are available for testing interaction between antibodies and antigens to identify particularly desirable antibodies. Such techniques include ELISAs, surface plasmon resonance binding assays (e.g., the Biacore binding assay, Bia-core AB, Uppsala, Sweden), sandwich assays (e.g., the paramagnetic bead system of IGEN International, Inc., Gaithersburg, Maryland), western blots, immunoprecipitation assays, and immunohistochemistry.

6. Screening Assays

In certain aspects, the present invention relates to the use of CFH polypeptides to identify compounds (agents) which are agonist or antagonists of CFH polypeptides. Compounds identified through this screening can be tested in cells of the eye, (e.g., epithelial and endothelial cells) as well as other tissues (e.g., muscle and/or neurons) to assess their ability to modulate CFH activity in vivo or in vitro. In certain aspects, compounds identified through this screening modulate the formation of drusen deposits. Optionally, these compounds can further be tested in animal models to assess their ability to modulate CFH activity in vivo.

There are numerous approaches to screening for therapeutic agents that target CFH polypeptides. In certain embodiments, high-throughput screening of compounds can be carried out to identify agents that affect activity of CFH polypeptides. A variety of assay formats will suffice and, in light of the present disclosure, those not expressly described
5 herein will nevertheless be comprehended by one of ordinary skill in the art. As described herein, the test compounds (agents) of the invention may be created by any combinatorial chemical method. Alternatively, the subject compounds may be naturally occurring biomolecules synthesized in vivo or in vitro. Compounds (agents) to be tested for their ability to act as modulators of CFH activity can be produced, for example, by bacteria,
10 yeast, plants or other organisms (e.g., natural products), produced chemically (e.g., small molecules, including peptidomimetics), or produced recombinantly. Test compounds contemplated by the present invention include non-peptidyl organic molecules, peptides, polypeptides, peptidomimetics, sugars, hormones, and nucleic acid molecules.

The test compounds of the invention can be provided as single, discrete entities, or
15 provided in libraries of greater complexity, such as made by combinatorial chemistry. These libraries can comprise, for example, alcohols, alkyl halides, amines, amides, esters, aldehydes, ethers and other classes of organic compounds. Presentation of test compounds to the test system can be in either an isolated form or as mixtures of compounds, especially in initial screening steps. Optionally, the compounds may be optionally derivatized with
20 other compounds and have derivatizing groups that facilitate isolation of the compounds. Non-limiting examples of derivatizing groups include biotin, fluorescein, digoxigenin, green fluorescent protein, isotopes, polyhistidine, magnetic beads, glutathione S transferase (GST), photoactivatable crosslinkers or any combinations thereof.

In many drug screening programs which test libraries of compounds and natural
25 extracts, high throughput assays are desirable in order to maximize the number of compounds surveyed in a given period of time. Assays which are performed in cell-free systems, such as may be derived with purified or semi-purified proteins, are often preferred as "primary" screens in that they can be generated to permit rapid development and relatively easy detection of an alteration in a molecular target which is mediated by a test
30 compound. Moreover, the effects of cellular toxicity or bioavailability of the test compound can be generally ignored in the in vitro system, the assay instead being focused primarily on the effect of the drug on the molecular target.

In certain embodiments, the subject compounds are identified by their ability to interact with a CFH polypeptide of the invention. The interaction between the compound and the CFH polypeptide may be covalent or non-covalent. For example, such interaction can be identified at the protein level using in vitro biochemical methods, including photo-crosslinking, radiolabeled ligand binding, and affinity chromatography (Jakoby WB et al., 1974, Methods in Enzymology 46:1). In certain cases, the compounds may be screened in a mechanism based assay, such as an assay to detect compounds which bind to a CFH polypeptide. This may include a solid phase or fluid phase binding event. Alternatively, the gene encoding a CFH polypeptide can be transfected with a reporter system (e.g., β -galactosidase, luciferase, or green fluorescent protein) into a cell and screened against the library preferably by a high throughput screening or with individual members of the library. Other mechanism based binding assays may be used, for example, binding assays which detect changes in free energy. Binding assays can be performed with the target fixed to a well, bead or chip or captured by an immobilized antibody or resolved by capillary electrophoresis. The bound compounds may be detected usually using colorimetric or fluorescence or surface plasmon resonance.

7. Pharmaceutical Compositions

The methods and compositions described herein for treating a subject suffering from AMD may be used for the prophylactic treatment of individuals who have been diagnosed or predicted to be at risk for developing AMD. In this case, the composition is administered in an amount and dose that is sufficient to delay, slow, or prevent the onset of AMD or related symptoms. Alternatively, the methods and compositions described herein may be used for the therapeutic treatment of individuals who suffer from AMD. In this case, the composition is administered in an amount and dose that is sufficient to delay or slow the progression of the condition, totally or partially, or in an amount and dose that is sufficient to reverse the condition to the point of eliminating the disorder. It is understood that an effective amount of a composition for treating a subject who has been diagnosed or predicted to be at risk for developing AMD is a dose or amount that is in sufficient quantities to treat a subject or to treat the disorder itself.

In certain embodiments, compounds of the present invention (e.g., an isolated or recombinantly produced nucleic acid molecule coding for a CFH polypeptide or an isolated or recombinantly produced CFH polypeptide) are formulated with a pharmaceutically

acceptable carrier. For example, a CFH polypeptide or a nucleic acid molecule coding for a CFH polypeptide can be administered alone or as a component of a pharmaceutical formulation (therapeutic composition). The subject compounds may be formulated for administration in any convenient way for use in human medicine.

5 In certain embodiments, the therapeutic methods of the invention include administering the composition topically, systemically, or locally. For example, therapeutic compositions of the invention may be formulated for administration by, for example, injection (e.g., intravenously, subcutaneously, or intramuscularly), inhalation or
10 insufflation (either through the mouth or the nose) or oral, buccal, sublingual, transdermal, nasal, or parenteral administration. The compositions described herein may be formulated as part of an implant or device. When administered, the therapeutic composition for use in this invention is in a pyrogen-free, physiologically acceptable form. Further, the composition may be encapsulated or injected in a viscous form for delivery to the site where the target cells are present, such as to the cells of the eye. Techniques and
15 formulations generally may be found in Remington's Pharmaceutical Sciences, Meade Publishing Co., Easton, PA. In addition to CFH polypeptides or nucleic acid molecules coding for CFH polypeptides, therapeutically useful agents may optionally be included in any of the compositions as described above. Furthermore, therapeutically useful agents may, alternatively or additionally, be administered simultaneously or sequentially with
20 CFH polypeptides or nucleic acid molecules coding for CFH polypeptides according to the methods of the invention.

 In certain embodiments, compositions of the invention can be administered orally, e.g., in the form of capsules, cachets, pills, tablets, lozenges (using a flavored basis, usually sucrose and acacia or tragacanth), powders, granules, or as a solution or a suspension in an
25 aqueous or non-aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion, or as an elixir or syrup, or as pastilles (using an inert base, such as gelatin and glycerin, or sucrose and acacia) and/or as mouth washes and the like, each containing a predetermined amount of an agent as an active ingredient. An agent may also be administered as a bolus, electuary or paste.

30 In solid dosage forms for oral administration (capsules, tablets, pills, dragees, powders, granules, and the like), one or more therapeutic compounds of the present invention may be mixed with one or more pharmaceutically acceptable carriers, such as

sodium citrate or dicalcium phosphate, and/or any of the following: (1) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and/or silicic acid; (2) binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose, and/or acacia; (3) humectants, such as glycerol; (4) disintegrating agents, such as agar-
5 agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; (5) solution retarding agents, such as paraffin; (6) absorption accelerators, such as quaternary ammonium compounds; (7) wetting agents, such as, for example, cetyl alcohol and glycerol monostearate; (8) absorbents, such as kaolin and bentonite clay; (9) lubricants, such a talc, calcium stearate, magnesium stearate, solid polyethylene glycols,
10 sodium lauryl sulfate, and mixtures thereof; and (10) coloring agents. In the case of capsules, tablets and pills, the pharmaceutical compositions may also comprise buffering agents. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugars, as well as high molecular weight polyethylene glycols and the like.

15 Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups, and elixirs. In addition to the active ingredient, the liquid dosage forms may contain inert diluents commonly used in the art, such as water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate,
20 propylene glycol, 1,3-butylene glycol, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof. Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming, and preservative agents.

25 Suspensions, in addition to the active compounds, may contain suspending agents such as ethoxylated isostearyl alcohols, polyoxyethylene sorbitol, and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.

Certain compositions disclosed herein may be administered topically, either to skin
30 or to mucosal membranes. The topical formulations may further include one or more of the wide variety of agents known to be effective as skin or stratum corneum penetration enhancers. Examples of these are 2-pyrrolidone, N-methyl-2-pyrrolidone,

dimethylacetamide, dimethylformamide, propylene glycol, methyl or isopropyl alcohol, dimethyl sulfoxide, and azone. Additional agents may further be included to make the formulation cosmetically acceptable. Examples of these are fats, waxes, oils, dyes, fragrances, preservatives, stabilizers, and surface active agents. Keratolytic agents such as those known in the art may also be included. Examples are salicylic acid and sulfur.

Dosage forms for the topical or transdermal administration include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches, and inhalants. The active compound may be mixed under sterile conditions with a pharmaceutically acceptable carrier, and with any preservatives, buffers, or propellants which may be required. The ointments, pastes, creams and gels may contain, in addition to a subject compound of the invention (e.g., an isolated or recombinantly produced nucleic acid molecule coding for a CFH polypeptide or an isolated or recombinantly produced CFH polypeptide), excipients, such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.

Powders and sprays can contain, in addition to a subject compound, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates, and polyamide powder, or mixtures of these substances. Sprays can additionally contain customary propellants, such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons, such as butane and propane.

It is understood that the dosage regimen will be determined for an individual, taking into consideration, for example, various factors which modify the action of the subject compounds of the invention (e.g., an isolated or recombinantly produced nucleic acid molecule coding for a CFH polypeptide or an isolated or recombinantly produced CFH polypeptide), the severity or stage of AMD, route of administration, and characteristics unique to the individual, such as age, weight, and size. A person of ordinary skill in the art is able to determine the required dosage to treat the subject. In one embodiment, the dosage can range from about 1.0 ng/kg to about 100 mg/kg body weight of the subject. Based upon the composition, the dose can be delivered continuously, or at periodic intervals. For example, on one or more separate occasions. Desired time intervals of multiple doses of a particular composition can be determined without undue experimentation by one skilled in the art. For example, the compound may be delivered

hourly, daily, weekly, monthly, yearly (e.g. in a time release form) or as a one time delivery.

In certain embodiments, pharmaceutical compositions suitable for parenteral administration may comprise a CFH polypeptide or a nucleic acid molecule coding for a CFH polypeptide in combination with one or more pharmaceutically acceptable sterile isotonic aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, or sterile powders which may be reconstituted into sterile injectable solutions or dispersions just prior to use, which may contain antioxidants, buffers, bacteriostats, solutes which render the formulation isotonic with the blood of the intended recipient or suspending or thickening agents. Examples of suitable aqueous and nonaqueous carriers which may be employed in the pharmaceutical compositions of the invention include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.

The compositions of the invention may also contain adjuvants, such as preservatives, wetting agents, emulsifying agents and dispersing agents. Prevention of the action of microorganisms may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents, such as sugars, sodium chloride, and the like into the compositions. In addition, prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents which delay absorption, such as aluminum monostearate and gelatin.

In certain embodiments, the present invention also provides gene therapy for the in vivo production of CFH polypeptides. Such therapy would achieve its therapeutic effect by introduction of CFH polynucleotide sequences into cells or tissues that are deficient for normal CFH function. Delivery of CFH polynucleotide sequences can be achieved using a recombinant expression vector such as a chimeric virus or a colloidal dispersion system. Targeted liposomes may also be used for the therapeutic delivery of CFH polynucleotide sequences.

Various viral vectors which can be utilized for gene therapy as taught herein include adenovirus, herpes virus, vaccinia, or an RNA virus such as a retrovirus. A retroviral vector may be a derivative of a murine or avian retrovirus. Examples of retroviral vectors in which a single foreign gene can be inserted include, but are not limited to: Moloney murine leukemia virus (MoMuLV), Harvey murine sarcoma virus (HaMuSV), murine mammary tumor virus (MuMTV), and Rous Sarcoma Virus (RSV). A number of additional retroviral vectors can incorporate multiple genes. All of these vectors can transfer or incorporate a gene for a selectable marker so that transduced cells can be identified and generated. Retroviral vectors can be made target-specific by attaching, for example, a sugar, a glycolipid, or a protein. Preferred targeting is accomplished by using an antibody. Those of skill in the art will recognize that specific polynucleotide sequences can be inserted into the retroviral genome or attached to a viral envelope to allow target specific delivery of the retroviral vector containing the CFH polynucleotide. In one preferred embodiment, the vector is targeted to cells or tissues of the eye.

Alternatively, tissue culture cells can be directly transfected with plasmids encoding the retroviral structural genes gag, pol and env, by conventional calcium phosphate transfection. These cells are then transfected with the vector plasmid containing the genes of interest. The resulting cells release the retroviral vector into the culture medium.

Another targeted delivery system for CFH polynucleotides is a colloidal dispersion system. Colloidal dispersion systems include macromolecule complexes, nanocapsules, microspheres, beads, and lipid-based systems including oil-in-water emulsions, micelles, mixed micelles, and liposomes. The preferred colloidal system of this invention is a liposome. Liposomes are artificial membrane vesicles which are useful as delivery vehicles in vitro and in vivo. RNA, DNA and intact virions can be encapsulated within the aqueous interior and be delivered to cells in a biologically active form (see e.g., Fraley, et al., Trends Biochem. Sci., 6:77, 1981). Methods for efficient gene transfer using a liposome vehicle, are known in the art, see e.g., Mannino, et al., Biotechniques, 6:682, 1988. The composition of the liposome is usually a combination of phospholipids, usually in combination with steroids, especially cholesterol. Other phospholipids or other lipids may also be used. The physical characteristics of liposomes depend on pH, ionic strength, and the presence of divalent cations.

Examples of lipids useful in liposome production include phosphatidyl compounds, such as phosphatidylglycerol, phosphatidylcholine, phosphatidylserine, phosphatidylethanolamine, sphingolipids, cerebroside, and gangliosides. Illustrative phospholipids include egg phosphatidylcholine, dipalmitoylphosphatidylcholine, and distearoylphosphatidylcholine. The targeting of liposomes is also possible based on, for example, organ-specificity, cell-specificity, and organelle-specificity and is known in the art.

Moreover, the pharmaceutical preparation can consist essentially of the gene delivery system in an acceptable diluent, or can comprise a slow release matrix in which the gene delivery vehicle is imbedded. Alternatively, where the complete gene delivery system can be produced intact from recombinant cells, e.g. retroviral packages, the pharmaceutical preparation can comprise one or more cells which produce the gene delivery system. In the case of the latter, methods of introducing the viral packaging cells may be provided by, for example, rechargeable or biodegradable devices. Various slow release polymeric devices have been developed and tested in vivo in recent years for the controlled delivery of drugs, including proteinaceous biopharmaceuticals, and can be adapted for release of viral particles through the manipulation of the polymer composition and form. A variety of biocompatible polymers (including hydrogels), including both biodegradable and non-degradable polymers, can be used to form an implant for the sustained release of the viral particles by cells implanted at a particular target site. Such embodiments of the present invention can be used for the delivery of an exogenously purified virus, which has been incorporated in the polymeric device, or for the delivery of viral particles produced by a cell encapsulated in the polymeric device.

A person of ordinary skill in the art is able to determine the required amount to treat the subject. It is understood that the dosage regimen will be determined for an individual, taking into consideration, for example, various factors which modify the action of the subject compounds of the invention, the severity or stage of AMD, route of administration, and characteristics unique to the individual, such as age, weight, and size. A person of ordinary skill in the art is able to determine the required dosage to treat the subject. In one embodiment, the dosage can range from about 1.0 ng/kg to about 100 mg/kg body weight of the subject. The dose can be delivered continuously, or at periodic intervals. For example, on one or more separate occasions. Desired time intervals of multiple doses of a

particular composition can be determined without undue experimentation by one skilled in the art. For example, the compound may be delivered hourly, daily, weekly, monthly, yearly (e.g. in a time release form) or as a one time delivery. As used herein, the term “subject” means any individual animal capable of becoming afflicted with AMD. The
5 subjects include, but are not limited to, human beings, primates, horses, birds, cows, pigs, dogs, cats, mice, rats, guinea pigs, ferrets, and rabbits. In the preferred embodiment, the subject is a human being.

Samples used in the methods described herein may comprise cells from the eye, ear, nose, teeth, tongue, epidermis, epithelium, blood, tears, saliva, mucus, urinary tract,
10 urine, muscle, cartilage, skin, or any other tissue or bodily fluid from which sufficient DNA or RNA can be obtained.

The sample should be sufficiently processed to render the DNA or RNA that is present available for assaying in the methods described herein. For example, samples may be processed such that DNA from the sample is available for amplification or for
15 hybridization to another polynucleotide. The processed samples may be crude lysates where available DNA or RNA is not purified from other cellular material. Alternatively, samples may be processed to isolate the available DNA or RNA from one or more contaminants that are present in its natural source. Samples may be processed by any means known in the art that renders DNA or RNA available for assaying in the methods
20 described herein. Methods for processing samples may include, without limitation, mechanical, chemical, or molecular means of lysing and/or purifying cells and cell lysates. Processing methods may include, for example, ion-exchange chromatography, size exclusion chromatography, affinity chromatography, hydrophobic interaction chromatography, gel filtration chromatography, ultrafiltration, electrophoresis, and
25 immunoaffinity purification with antibodies specific for particular epitopes of the polypeptide

8. Kits

Also provided herein are kits, e.g., kits for therapeutic purposes or kits for detecting a variant CFH gene in a sample from an individual. In one embodiment, a kit comprises at
30 least one container means having disposed therein a premeasured dose of a polynucleotide probe that hybridizes, under stringent conditions, to a variation in the CFH gene that is correlated with the occurrence of AMD in humans. In another embodiment, a kit

comprises at least one container means having disposed therein a premeasured dose of a polynucleotide primer that hybridizes, under stringent conditions, adjacent to one side of a variation in the CFH gene that is correlated with the occurrence of AMD in humans. In a further embodiment, a second polynucleotide primer that hybridizes, under stringent
5 conditions, to the other side of a variation in the CFH gene that is correlated with the occurrence of AMD in humans is provided in a premeasured dose. Kits further comprise a label and/or instructions for the use of the therapeutic or diagnostic kit in the detection of CFH in a sample. Kits may also include packaging material such as, but not limited to, ice, dry ice, styrofoam, foam, plastic, cellophane, shrink wrap, bubble wrap, paper, cardboard,
10 starch peanuts, twist ties, metal clips, metal cans, drierite, glass, and rubber (see products available from www.papermart.com for examples of packaging material).

The practice of the present methods will employ, unless otherwise indicated, conventional techniques of cell biology, cell culture, molecular biology, transgenic biology, microbiology, recombinant DNA, and immunology, which are within the skill of
15 the art. Such techniques are explained fully in the literature. See, for example, *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory (2001); *DNA Cloning*, Volumes I and II (D. N. Glover ed., 1985); *Oligonucleotide Synthesis* (M. J. Gait ed., 1984); Mullis et al. U.S. Patent No: 4,683,195; *Nucleic Acid Hybridization* (B. D. Hames & S. J. Higgins eds. 1984); *Transcription And Translation* (B. D. Hames & S. J. Higgins
20 eds. 1984); *Culture Of Animal Cells* (R. I. Freshney, Alan R. Liss, Inc., 1987); *Immobilized Cells And Enzymes* (IRL Press, 1986); B. Perbal, *A Practical Guide To Molecular Cloning* (1984); the treatise, *Methods In Enzymology* (Academic Press, Inc., N.Y.); *Gene Transfer Vectors For Mammalian Cells* (J. H. Miller and M. P. Calos eds., 1987, Cold Spring Harbor Laboratory); *Methods In Enzymology*, Vols. 154 and 155 (Wu
25 et al. eds.), *Immunochemical Methods In Cell And Molecular Biology* (Mayer and Walker, eds., Academic Press, London, 1987); *Handbook Of Experimental Immunology*, Volumes I-IV (D. M. Weir and C. C. Blackwell, eds., 1986); *Manipulating the Mouse Embryo*, (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1986).

EXAMPLES

30 The following examples are for illustrative purposes and are not intended to be limiting in any way.

EXAMPLE 1: Whole genome SNP association for genes correlated with AMD.

Described herein is a whole-genome case-control association study for genes involved in AMD. Two crucial factors were used in designing this experiment; clearly defined phenotypes were chosen for cases and controls. The definition of a case was based on both a quantitative photographic assessment of the presence of at least some large drusen combined with photographic evidence of sight-threatening AMD (geographic atrophy or neovascular AMD). The definition of a control was based on the study participant having either no drusen or only a few small drusen. Data was analyzed using a statistically conservative approach to correct for the large number of SNPs tested, thereby guaranteeing that the actual probability of a false positive is no greater than the reported p-values.

A subset of individuals who participated in the Age-Related Eye Disease Study (AREDS) (AREDS Research Group, Arch Ophthalmol 119, 1417, (2001)) were used in the association study. From the AREDS sample, 96 case subjects were identified who, at their most recent study visit, had either uniocular choroidal neovascularization (50 cases) or geographic atrophy either central or non-central to the macula (46 cases). The fellow eye of these case subjects was required to have at least one large drusen ($>125 \mu\text{m}$ in diameter), and total drusen area equivalent to a circle of at least $1061 \mu\text{m}$ in diameter. The group of study participants who had both large drusen and sight-threatening AMD was selected because there can be many precursors to the development of either choroidal neovascularization or geographic atrophy. Controls were 50 individuals from the AREDS sample who had few or no drusen ($<63 \mu\text{m}$ in diameter in each eye) for the duration of their participation in AREDS. All individuals identified themselves as "White, not of Hispanic origin." To the extent possible, the proportions of gender and smoking status were kept the same in cases and controls. Controls were purposely chosen to be older than the cases to increase the probability that they will remain without AMD (Table 1).

Table 1. Summary of sample phenotypes.

	Cases (n=96)	Controls (n=50)
Males (%)	44	54
Never smoked (%)	36	52
Formerly smoked (%)	58	48

Currently smoke (%)	5	0
Mean age ($\pm$ s.d.) (years)	79 $\pm$ 5.2	82 $\pm$ 2.2
Age range (years)	65-89	78-87
One eye with neovascular AMD, other eye with at least one large drusen (%)	52	0
One eye with geographic atrophy AMD, other eye with at least one large drusen (%)	48	0
Both eyes with few or no drusen (%)	0	100

EXAMPLE 2: Genotyping and SNP identification of individuals in study population

Each individual was genotyped using the Affymetrix GeneChip Mapping 100K Set of microarrays (H. Matsuzaki et al., Nat Methods 1, 109 (2004)). This mapping assay
 5 consists of two chips (XbaI and HindIII) with approximately 50,000 SNPs each that are used for each individual. About 250 ng of genomic DNA was digested with two restriction enzymes XbaI and HindIII and processed according to the Affymetrix protocol (H. Matsuzaki et al., Nat Methods 1, 109 (2004)). The images were analyzed using GDAS
 10 software (Affymetrix). For the data obtained from each chip, two internal quality control measures were used: the call rate always exceeded 95% and heterozygosity on the X chromosome correctly identified the gender of the individual. Thirty-one identical SNPs were placed on both chips and checked that they yielded the same genotype for the same individual to ensure that no samples were confused.

15 Three experiments were performed to test the reproducibility of this system. First, 4 samples were processed twice with the Xba chips. Next, 2 replicates of a reference DNA positive control provided by Affymetrix were run on Xba chips alongside the samples. Finally, results for 3 individuals were compared with genotyping using the Affymetrix 10K SNP platform to test the accuracy of this assay (H. Matsuzaki et al., Genome Res 14, 414
 20 (2004)).

An assessment of the percentage of the individuals producing a genotype call for each SNP was made in order to examine the genotyping quality for each individual SNP. A SNP with a call rate of 100% means every individual is successfully assigned a genotype for this SNP and there is no missing data. Call rates were required to be at least 85% to
 25 remove SNPs for which genotyping was consistently problematic. SNPs which are

monomorphic in the data were also removed, since these SNPs are uninformative. SNPs in which genotype frequencies deviated from the Hardy-Weinberg equilibrium expectation (HWD $\chi^2 > 25$, $P = 0.05$, 1df, after Bonferroni correction) were removed as being likely to contain genotyping errors rather than real disequilibrium. SNPs for which no homozygotes
5 were observed in the entire sample were also likely due to errors and removed. Altogether, of the 116,204 SNPs genotyped, 105,980 SNPs with a call rate of at least 85%, both alleles observed, at least one homozygote observed, and a HWD $\chi^2 \leq 25$ were found and considered. Of these, the 103,611 SNPs that lie on the 22 autosomal chromosomes were analyzed. A summary of genotyping quality can be found in Table 2.

Table 2. Genotyping quality control and informativeness.

Per-chip data quality	
Median call rate per chip	99.1%
Minimum call rate per chip	95.6%
Chips for which gender matches	292 (100%)
Per-individual data quality	
Median call rate per individual	99.1%
Minimum call rate per individual	96.7%
Average number of matches for common SNPs between two chips	30.7/31
Minimum number of matches for common SNPs between two chips*	28/31
Reproducibility	
Xba Repeat concordance (4 replicates)	99.886%
Xba Positive control concordance (2 replicates)	99.870%
10K concordance (3 replicates)	99.767%
Call rate (per-SNP)	
Total number of SNPs	116204
SNPs with 100% call rate	81456
SNPs with call rate between 85% and 100%	33262
SNPs with call rate less than 85%	1486
Locus Polymorphism	
Number of SNPs with no polymorphism observed	8538
Number of SNPs with minor allele frequency < 0.01	3604
Number of SNPs with only heterozygotes observed	19
Number of polymorphic SNPs with no heterozygotes observed	71
Hardy-Weinberg Equilibrium	
Number of SNPs significantly out of equilibrium	231

*For the most part, when SNPs do not match it is due to one of the SNPs not being called. In only 3 out of 4485 comparisons is a mismatch observed, which is equivalent to 99.93% concordance.

EXAMPLE 3: Statistical analysis of SNP association with disease status

Allelic association with disease status was tested for each SNP. A 2x2 contingency table of allele frequencies was constructed. The Pearson χ^2 value and a P-value were calculated, based on the central χ^2 distribution under the null hypothesis of no association with 1 degree of freedom. This nominal P-value was corrected for multiple testing by applying the Bonferroni correction, in which only SNPs with a p-value less than $0.05/103,611 = 4.8 \times 10^{-7}$ were considered. This produced a Bonferroni-corrected P-value. This correction is known to be conservative and thus may "overcorrect" the raw p-values (L. M. McIntyre, E. R. Martin, K. L. Simonsen, N. L. Kaplan, *Genet Epidemiol* 19, 18 (2000)). While this technique may overlook real associations, it adjusts for the large number of multiple comparisons and yields p-values that do not underestimate the false positive rate.

Two methods of genomic control were used to look for population stratification, GC and GCF (B. Devlin, S. A. Bacanu, K. Roeder, *Nat Genet* 36, 1129 (2004)). In the first method, the median χ^2 value was taken for allelic association with a number of SNPs assumed to be unassociated with the disease (null SNPs). The test statistic $\chi^2_{(1)}$ values were divided by this median, and tested for significance using the χ^2 distribution. Alternatively, for the GCF method, the mean rather than the median of the null χ^2 statistics was used; significance of the quotient was tested using the F(1,L) distribution, where L is the number of null SNPs used (B. Devlin, S. A. Bacanu, K. Roeder, *Nat Genet* 36, 1129 (2004)). Two different sets of unassociated SNPs were used: all the SNPs successfully genotyped except the two significant (see below) ones, and the set of 31 SNPs that are in common between the two chips used in the assay (see Example 2 above).

The candidate region was defined by looking for adjacent SNPs in which all four gametes were observed (R. R. Hudson, N. L. Kaplan, *Genetics* 111, 147 (1985)) and bounding the region there. To look at linkage disequilibrium between SNPs in the candidate region, haplotype frequencies in the region were inferred using PHASE version 2.1 (M. Stephens, P. Donnelly, *Am J Hum Genet* 73, 1162 (2003); M. Stephens, N. J. Smith, P. Donnelly, *Am J Hum Genet* 68, 978 (2001)). Based on the inferred haplotype frequencies across the entire region, pairwise linkage disequilibrium was calculated by first computing the two-locus haplotype frequencies implied by the overall haplotype

frequencies. The measure of linkage disequilibrium, D' , was then calculated using standard equations (D. L. Hartl, A. G. Clark, Principles of Population Genetics (Sinauer Associates, Sunderland, MA, ed. Third, 1997)) and plotted using the program GOLD (G. R. Abecasis, W. O. Cookson, Bioinformatics 16, 182 (2000)).

5 To define the smaller haplotype blocks within the 4-gamete region, the HapMap data website was used (<http://www.hapmap.org>). Genotypes for SNPs in the region between SNPs rs10494744 and rs10484502 were downloaded. Genotypes for the CEU population (CEPH Utah population of northern and western European ancestry) were downloaded and visualized using Haploview version 3.0. Haplotype blocks were then
10 defined using the method and parameters of Gabriel et al (S. B. Gabriel et al., Science 296, 2225 (2002)).

Haplotypes across the narrower region defined by the HapMap block were also inferred using PHASE version 2.1. Haplotypes with an estimated frequency of at least 1% were considered for further analysis. Phylogenetic trees were built using the maximum
15 parsimony of PHYLIP 3.62 ("dnaphars" program). The odds ratio in a nested cladistic framework was calculated for the haplotypes (P. Armitage, G. Berry, Statistical Methods in Medical Research (Blackwell Scientific Publications, Oxford, ed. Second, 1987); A. R. Templeton, E. Boerwinkle, C. F. Sing, Genetics 117, 343 (1987)).

Odds ratios, confidence intervals, and population attributable risk were calculated
20 as described in P. Armitage, G. Berry, Statistical Methods in Medical Research (Blackwell Scientific Publications, Oxford, ed. Second, 1987). The population frequency of the alleles of interest (see Example 4 below) is relatively high, 23% for and 41% for homozygous rs380390 and rs1329428, respectively. Therefore, the odds ratios necessarily calculated from the case control design study used here will over-estimate (without changing the
25 significance levels) the equivalent relative risk estimate needed to calculate lifetime risk. A prospective cohort study design will provide valid estimates of lifetime risk in persons who have and have not inherited the alleles.

EXAMPLE 4: Polymorphisms in the Complement Factor H gene are associated with AMD

Of the autosomal SNPs, only two, rs380390 and rs10272438, are significantly associated with disease status (Bonferroni corrected $p=0.0043$ and $p=0.0080$, respectively; Figure 1A). One criticism of case-control association studies such as this one is that population stratification can result in false positive results. If the cases and controls are drawn from populations of different ancestry, with different allele frequencies, it is possible to detect these population differences instead of loci associated with the disease. All individuals in this study self-identify their ethnicity as non-Hispanic white and all of the case and control individuals are drawn from the same AREDS population. There was some differential recruiting of cases from office practices and recruiting of controls from radio and newspaper advertising (AREDS Research Group, Ophthalmology 107, 2224 (2000)). Finding two SNPs out of >100,000 implied no genetic stratification, but genomic control methods were used to control for this possibility (B. Devlin, S. A. Bacanu, K. Roeder, Nat Genet 36, 1129 (2004)). It was consistently found that the significance of the tests was not inflated and that, therefore, these two SNPs are significantly associated with disease.

SNP rs380390 was successfully genotyped in all individuals. In 21 individuals, no genotype was determined for SNP rs10272438, and it appears to be excessively out of Hardy-Weinberg equilibrium ($HWE\chi^2=36$), indicating possible genotyping errors. Missing genotypes were determined by resequencing. After including these additional genotypes, the association was no longer significant after Bonferroni correction. Furthermore, the SNP with the third lowest p -value, rs1329428 (Bonferroni corrected $p=0.14$), is located 1.8 kb away from rs380390 on the same chromosome. The genotype frequencies at these two neighboring loci clearly vary between the case and control populations (Figure 1B). Homozygotes for the C allele of rs380390 and the C allele at rs1329248 clearly have an increased risk of developing AMD (Table 1). The risk conferred by these genotypes accounts for approximately 45% (rs380390) to 61% (rs1329248) of the cases observed in the population (Table 3). Therefore, we decided to focus on these two SNPs as marking our most promising locus.

Table 3. Risk ratios and population attributable risks for various genotypes and haplotypes.

	rs380390 (C/G)	rs1329428 (C/T)
Risk allele	C	C
Allelic Association χ^2 nominal p-value	4.1e-08	1.4e-06
Odds ratio (dominant) (95% CI)	4.6 (2.0-11)	4.7 (1.0-22)
PAR (95% CI)	70% (42%-84%)	80% (0%-96%)
Frequency in HapMap CEU	0.70	0.82
Odds ratio (recessive) (95% CI)	7.4 (2.9-19)	6.2 (2.9-13)
PAR (95% CI)	46% (31%-57%)	61% (43%-73%)
Frequency in HapMap CEU	0.23	0.41

Dominant and recessive refer to the risk factor consisting of having at least one copy (dominant) or two copies (recessive) of the risk allele. PAR is the population attributable risk. The dominant odds ratio and PAR compare likelihood of AMD in individuals with one copy of the risk allele versus individuals with no copy of the risk allele. The recessive odds ratio and PAR compare likelihood of AMD in individuals with two copies of the risk allele versus individuals with no more than one copy of the risk allele. The population frequencies for the risk genotypes are taken from the CEU HapMap population (CEPH collection of Utah residents of northern and western European ancestry).

rs380390 and rs1329248 lie in an intron of the gene for complement factor H (CFH). As both of these SNPs are noncoding and neither appears to alter a conserved sequence, these two SNPs may be in linkage disequilibrium with a corresponding functional mutation. To circumscribe the region in which the functional mutation may lie, the linkage disequilibrium throughout this region was analyzed (Figure 2A). The two associated SNPs lie in a region of high linkage disequilibrium that is around 500 kb long. As this region is longer than other typically observed blocks of high linkage disequilibrium (S. B Gabriel et al., Science 296, 2225 (2002)) and there are long stretches in this region where there are no SNPs in our dataset (Figure 2B), other data sources with denser SNP coverage were used to narrow down the region.

Data from the International HapMap project was used to analyze patterns of linkage disequilibrium in a population of residents of Utah with ancestry from northern and western Europe (the CEPH sample) (The International HapMap Consortium, Nature 426, 789 (2003)). In the 500 kb region of interest, there are 152 SNPs in the HapMap data set. Using a standard definition of linkage disequilibrium blocks (S. B Gabriel et al., Science

296, 2225 (2002)), it was found that the two associated SNPs lie in a block that is 41 kb long and entirely contained within the CFH gene (Figure 2C).

There are six SNPs from the present study's data set in this 41 kb region. These SNPs form four predominant haplotypes with a frequency greater than 1% (Table 4).

- 5 Combined, these four haplotypes represent 99% of the chromosomes in this study. Reconstructing inferred haplotypes and building a phylogenetic tree allowed assessment of the evolutionary relationship between haplotypes (Figure 2D). Using inferred haplotypes for each individual, the odds ratio of disease in a nested clastic framework under both dominant and recessive models were computed (A. R. Templeton, E. Boerwinkle, C. F. Sing, Genetics 117, 343 (1987)). The highest risk is conferred by haplotype N1, which is the only haplotype containing the risk allele at SNP rs380390.

Table 4. Haplotypes in the haplotype block that harbors the putative disease variant.

Name	rs2019727	rs10489456	rs3753396	rs380390	rs2284664	rs1329428	Frequency
N1	A	C	T	C	C	G	0.59
N1	A	C	T	G	C	G	0.0068
N3	A	C	T	G	T	A	0.12
N4	A	T	C	G	C	G	0.15
N5	T	C	T	G	C	A	0.12
N6	T	C	T	G	C	G	0.0071

- 15 Haplotype frequencies are estimated using the program PHASE (M. Stephens, P. Donnelly, Am J Hum Genet 73, 1162 (2003); M. Stephens, N. J. Smith, P. Donnelly, Am J Hum Genet 68, 978 (2001)). The SNPs used to construct the haplotypes are the SNPs from the mapping microarrays found in the 41 kb haplotype block defined by the HapMap data. Frequencies are the estimated frequency of each haplotype in the combined case and control population. The two SNPs that show association in the initial analysis are indicated in boldface.

- 20 Having at least one copy of this haplotype increases the risk for AMD 4.6-fold (95% CI 2.0-11). Having two copies of this haplotype increases the risk for AMD 7.4-fold (95% CI 3.0-19). Therefore, functionally relevant mutation should be found in the context of haplotype N1. This mutation will occur somewhere in the CFH gene, as the 41kb haplotype block is entirely within CFH.

EXAMPLE 5: Resequencing confirms that variations in CFH are correlated with AMD

To identify the functional mutation underlying susceptibility to AMD, 96 individuals (66 cases and 30 controls) were chosen for exonic resequencing, including the exon/intron junctions. Most of these individuals were selected either because SNP rs380390 was homozygous (representing opposite risk groups) or SNP rs10272438 was not successfully genotyped (the same plates were used to re-sequence this SNP for genotyping). Three additional individuals were randomly selected to get a total of 96 for a full plate. Primer design, PCR amplification, bi-directional sequencing of PCR products, and mutation analyses were performed by Genaissance (New Haven, CT).

All CFH exons were sequenced, including those outside of the 41kb block, as well as the region of SNP rs380390 as a control. Priority was given to sequencing homozygotes at SNP rs380390 to make it easier to determine haplotypes. SNP rs380390 was successfully resequenced in 93 individuals; the genotype derived from resequencing matched the original genotype in all cases. A total of 50 polymorphisms were identified; 17 of these have a minor allele frequency of at least 5% (**Table 5**). Of these 17, three represent non-synonymous mutations. If these SNPs are ranked based on the allelic association χ^2 measure, SNP rs1061170 is the most associated among the non-synonymous SNPs. This SNP represents a mutation between tyrosine and histidine. This SNP is located in exon 9 of CFH, only 2 kb upstream of the 41 kb haplotype block. Adding this SNP to the haplotype analysis reveals that 97% of the chromosomes with the highest-risk haplotype (N1) also have the risk allele (His).

Table 5. New polymorphisms identified through resequencing.

Region	Position	Change	Type	MAF	AA Change	rs Number
promoter	120992	A/G	noncoding	0.005263		
promoter	120865	A/G	noncoding	0.010526		
promoter	120546	C/T	noncoding	0.242105		rs3753394
promoter	120410	T/C	noncoding	0.005263		
promoter	120294	A/G	noncoding	0.005263		
intron 1	99391	C/T	noncoding	0.117021		rs511397
exon 2	99242	T/G	nonsynonomous	0.005319	Ser 58 Ala	
exon 2	99230	G/A	nonsynonomous	0.117021	Val 62 Ile	rs800292
intron 2	99114	G/A	noncoding	0.005319		
intron 3	98283	T/C	noncoding	0.005263		

intron 3	98188	T/G	noncoding	0.005263		
exon 4	96315	G/A	nonsynonymous	0.005263	Arg 127 His	
exon 7	87139	A/C	synonymous	0.415789		rs1061147
intron 7	83059	T/C	noncoding	0.005263		
intron 7	82966	G/T	noncoding	0.410526		rs482934
intron 7	82957	A/G	noncoding	0.005263		
exon 9	82232	C/A	nonsynonymous	0.005208	Gln 400 Lys	
exon 9	82226	C/T	nonsynonymous	0.414894	His 402 Tyr	rs1061170
intron 9	58652	T/C	noncoding	0.005319		
exon 10	58516	G/A	synonymous	0.22043		rs2274700
intron 10	58319	A/G	noncoding	0.005319		rs203678
intron 10	58260	C/G	noncoding	0.005319		
intron 10	56838	G/T	noncoding	0.367021		rs203674
exon 12	47084	G/A	nonsynonymous	0.005263	Val 609 Ile	
intron 12	46992	T/G	noncoding	0.005208		
exon 13	45721	A/G	synonymous	0.143617		rs3753396
exon 15	43875	A/G	synonymous	0.005376		
intron 15	40549	A/G	noncoding	0.215054		rs7514261
intron 15	40445	C/T	noncoding	0.021277		
intron 15	40412	G/C	noncoding	0.365591		rs380390
intron 15	40335	G/C	noncoding	0.005319		rs380060
intron 15	40179	C/T	noncoding	0.215054		rs7540032
intron 15	35577	T/G	noncoding	0.005208		rs435628
intron 15	35537	C/A	noncoding	0.357895		rs375046
intron 16	35263	C/T	noncoding	0.005263		rs428060
exon 17	34821	C/T	synonymous	0.026316		
exon 17	34786	G/T	nonsynonymous	0.005263	Ser 890 Ile	rs515299
intron 17	31825	A/C	noncoding	0.005319		
exon 18	31689	G/T	nonsynonymous	0.154255	Glu 936 Asp	rs1065489
intron 18	30673	T/G	noncoding	0.005556		rs385892
intron 18	30547	T/C	noncoding	0.111702		rs16840522
intron 18	30546	A/G	noncoding	0.005319		rs385543
exon 19	30396	G/T	nonsynonymous	0.005319	Val 1007 Leu	rs534399
intron 19	28886	T/C	noncoding	0.154255		rs513699
exon 20	28877	C/T	synonymous	0.154255		rs513729
exon 20	28867	A/T	nonsynonymous	0.015957	Asn 1050 Tyr	
intron 20	28592	A/G	noncoding	0.012987		

intron 20	26589	G/C	noncoding	0.005618		
exon 22	25219	C/A	nonsynonymous	0.005556	Pro 1166 Gln	
exon 22	25088	C/T	nonsynonymous	0.005618	Arg 1210 Cys	

Location of each polymorphism refers to the position on GenBank accession AL049744.8 (SEQ ID NO: 9), or the complementary DNA strand of GenBank accession AL049744.8. MAF is minor allele frequency.

Other data support the finding that mutations in CFH are correlated with AMD.

The gene for CFH is located on chromosome 1q31, a region that had been previously identified by six independent linkage scans to be involved in AMD (J. Majewski et al., Am J Hum Genet 73, 540 (2003); J. M. Seddon, S. L. Santangelo, K. Book, S. Chong, J. Cote, Am J Hum Genet 73, 780 (2003); D. E. Weeks et al., Am J Hum Genet 75, 174 (2004); G. R. Abecasis et al., Am J Hum Genet 74, 482 (2004); S. K. Iyengar et al., Am J Hum Genet 74, 20 (2004); and D. W. Schultz et al., Hum Mol Genet 12, 3315 (2003)). In one of these linkage studies, using a single large pedigree the authors concluded that mutations in a different gene in this region (HEMICENTIN-1), was responsible for AMD (D. W. Schultz et al., Hum Mol Genet 12, 3315 (2003)). This conclusion was based on the observation that of all the polymorphisms tested, only the HEMICENTIN-1 mutation perfectly cosegregated with disease status. Mutations in HEMICENTIN-1, however, have not been found to be generally associated with AMD in three separate, independent population-based association studies (G. R. Abecasis et al., Am J Hum Genet 74, 482 (2004); M. Hayashi et al., Ophthalmic Genet 25, 111 (2004); and G. J. McKay et al., Mol Vis 10, 682 (2004)). Mutations in CFH, as disclosed herein, are therefore more likely to be the cause of linkage signals observed at chromosome 1q31.

Example 6: Immunolocalization of C5b-9 complex in the eyes of patients suffering from AMD

Various components of the complement cascade, including the terminal C5b-9 complex, have been identified as components of drusen in the eyes of patients with AMD (L. V. Johnson, W. P. Leitner, M. K. Staples, D. H. Anderson, Exp Eye Res 73, 887 (2001); R. F. Mullins, S. R. Russell, D. H. Anderson, G. S. Hageman, FASEB J 14, 835 (2000)). The eyes of four patients with AMD were examined to look for the presence of C5b-9 (Figure 4). Post-mortem retinas from four donors were examined. Three were obtained through the Foundation Fighting Blindness (FFB) eye donor program. All of these had a clinical diagnosis of dry AMD. One pair of eyes embedded in paraffin was

obtained from an 86 year old Caucasian female through the autopsy service of the Yale School of Medicine. No clinical history was available. Histologically, these retinas have multiple large or coalescing drusen with minimal RPE and photoreceptor loss consistent with a diagnosis of early AMD. Approval for research on human post mortem donor eyes was obtained from the Yale School of Medicine.

Upon enucleation, eyes were fixed in 4% paraformaldehyde, 0.5% glutaraldehyde in 0.1 M phosphate buffer for several days. The fixed eyes were transferred to 2% paraformaldehyde for storage. Six 0.5 cm circular punches were taken from each of the AMD donor eyes. Three of these were selected from the central retina at the junction of atrophic and more normal retina, and the remaining three from peripheral retina. Retinal plugs were embedded in paraffin and sections cut at 5µm.

Following deparaffinization and rehydration, antigen retrieval was performed by boiling sections in a microwave oven for 10 minutes in 10 mM sodium citrate (pH 6.0). Sections were allowed to cool for 20 minutes, prior to a 5-minute endogenous peroxidase block in 5% H₂O₂. Immunohistochemistry was performed using a mouse monoclonal antibody against human activated complement C5b-9 (Quidel Corporation, San Diego, CA, catalogue #A239). Primary antibody was applied at a concentration of 1:250 in 1X PBS. Biotinylated goat anti-mouse (cat # BA9200) secondary antibody (Vector, Burlingame, CA) was used at a concentration of 1:200. Nickel enhanced diaminobenzidine (DAB; cat # SK4100; Vector) was used to visualize bound antibody. Negative controls were obtained by omission of the primary antibody. Images were obtained with a Zeiss Axioplan microscope equipped with differential interference contrast lenses and a Zeiss Axiocam digital camera.

Immunofluorescence Microscopy for CFH

Donor eyes were embedded in optimal cutting temperature compound (OCT; Miles Laboratory, Elkhart, IN), snap frozen, and stored at -70°C. Frozen retina sections were cut at 8 to 10 µm and placed on slides (Superfrost/Plus; Fisher Scientific, Fair Lawn, NJ). All human eyes were obtained with the informed consent of the donors, and the research with human eyes was performed in accordance with the tenets of the Declaration of Helsinki and the Institutional Review Board (IRB).

For immunofluorescence labeling, frozen sections of human retina were fixed in 4% paraformaldehyde in phosphate buffer saline (PBS) for 10 minutes. The tissue sections were blocked for 30 minutes with 5% normal donkey serum (Jackson ImmunoResearch, West Grove, PA), diluted in IC buffer (PBS, containing 0.2% Tween-20, 0.1% sodium azide), and incubated for 1 hour at room temperature with a goat anti-human Factor H antibody (Quidel, Santa Clara, CA) diluted 1:200 in staining buffer (IC buffer plus 1% normal donkey serum). Sections were washed repeatedly in IC buffer and incubated for 1 hour with the nuclear dye 4',6'-diamino-2 phenylindole (DAPI; 1 µg/mL) and Alexa-488 Donkey anti-goat antibodies (Molecular Probes, Eugene, OR) diluted 1:250 in staining buffer. After repeated washing with IC buffer, sections were covered in mounting medium (Gel Mount; Biomedex, Foster City, CA) and coverslipped. For the control, the same concentration of anti-human factor H antibody was preincubated for 1 hour with purified human factor H protein (Calbiochem, La Jolla, CA) at the ratio of 3 µg for 1 µl of antibodies. The pretreated antibodies were then used to stain tissue sections as just described. Specimens were analyzed on a laser scanning confocal microscope (model SP2; Leica Microsystems, Exton, PA) equipped with Nomarski optics. Immunolabeled and negative control sections were imaged under identical scanning conditions. Images were processed with Photoshop (Adobe Systems, San Jose, CA).

In all patients, deposition of activated complement C5b-9 was noted in Bruch's membrane. Immunostaining frequently extended to include the intercapillary pillars, and was strongly present within drusen. Staining was rarely noted in the stroma vascularis. However, when it was present, it was invariably located in the inner (toward the retina) walls of choroidal veins, and in severe cases, arteries. No immunostaining for C5b-9 was noted in the retina or elsewhere in sections. The negative control failed to exhibit any staining. These and other biochemical analyses of the composition of drusen may indicate that AMD results from an aberrant inflammatory process in which inappropriate complement activation plays a role (G. S. Hageman et al., *Prog Retin Eye Res* 20, 705 (2001)). This is supported by a mouse model of AMD in which complement components are found in the drusen (J. Ambati et al., *Nat Med* 9, 1390 (2003)).

Moreover, both age and smoking, two significant risk factors for AMD, influence plasma levels of complement factor H (J. Esparza-Gordillo et al., *Immunogenetics* 56, 77 (2004)). CFH sequences have also been observed in an EST library derived from human

RPE and choroid (G. Wistow et al., Mol Vis 8, 205 (2002)). Immunofluorescence experiments confirm that CFH is present in this region of the eye (Figure 3). The fluorescent images and their corresponding DIC images obtained from two different areas of human retina sections show strong staining in choroid vessels and area close to RPE (likely to be underneath the Bruch's membrane) (Figure 3). This finding is consistent with the observation that the RPE and choroid produce mRNA for several complement components found in drusen (R. F. Mullins, S. R. Russell, D. H. Anderson, G. S. Hageman, FASEB J 14, 835 (2000)). Drusen of similar composition to that found in AMD are found in the eyes of patients with membranoproliferative glomerulonephritis type II (MPGNII), a kidney disease (R. F. Mullins, N. Aptsiauri, G. S. Hageman, Eye 15, 390 (2001)); factor H deficiency can cause MPGNII (S. R. D Cordoba, J. Esparza-Gordillo, E. G. d. Jorge, M. Lopez-Trascasa, P. Sanchez-Corral, Mol Immunol 41, 355 (2004)). Our immunostaining experiments (Figures 3 and 4) suggest a pathogenesis of AMD in which loss, impairment, or deficiency of factor H results in complement deposition in choroidal capillaries (more severe) and choroidal vessels (less severe) with subsequent leakage of plasma proteins in to Bruch's membrane. Finally, nutritional supplementation with zinc at 80 mg/day decreases the risk of AMD; biochemical studies have shown that factor H function is sensitive to zinc concentration (AREDS Research Group, Arch Ophthalmol 119, 1417, (2001); A. M. Blom, L. Kask, B. Ramesh, A. Hillarp, Arch Biochem Biophys 418, 108 (2003)).

The present invention provides among other things polynucleotides useful for identifying or aiding in identifying individuals at risk for developing AMD, as well as for diagnosing or aiding in the diagnosis of AMD. While specific embodiments of the subject invention have been discussed, the above specification is illustrative and not restrictive. Many variations of the invention will become apparent to those skilled in the art upon review of this specification. The full scope of the invention should be determined by reference to the claims, along with their full scope of equivalents, and the specification, along with such variations.

All publications and patents mentioned herein are hereby incorporated by reference in their entirety as if each individual publication or patent was specifically and individually indicated to be incorporated by reference. In case of conflict, the present application, including any definitions herein, will control.

Also incorporated by reference in their entirety are any polynucleotide and polypeptide sequences which reference an accession number correlating to an entry in a public database, such as those maintained by The Institute for Genomic Research (TIGR) (www.tigr.org) and/or the National Center for Biotechnology Information (NCBI)

5 (www.ncbi.nlm.nih.gov).

Table 6. Primer sequences used in resequencing.

Region	Forward primer sequence	Reverse primer sequence
promoter	AGAATCGTGGTCTCTGTGTGTGG	AGCAGCTGGTGATATCCTCTGG
promoter	TCAAATGAGAGTGAGCCAGTTGC	CTGTTCAACACGTCCAGTTCTCC
exon 1	GTGGGAGTGCAGTGAGAAATTGG	AACTCAACAATGTCAAAAGCC
exon 2	GATAGACCTGTGACTGTCTAGGC	GGCAATAGTGATATAATTCAGGC
exon 3	ACCTCAGCCTCCCAAAGTGC	TGCATACTGTTTTCCCACTCTCC
exon 4	AAGGAGGAGGAGAAGGAGGAAGG	CAGGCTGCATTTCGTTTTTGG
exon 5	CCACTCCCATAGAAAAGAATCAGG	ACTTCTTTGCACCAGTCTCTTCC
exon 6	GATAAATCATTTATTAAGCGG	GAACCTTGAACACAGAAAATGC
exon 7	GGATGACTTTGGAGAAGAAGG	TATGAGTTTCGGCAACTTCG
exon 8	TCATCTTCATTAACAAAGACC	AGATCTATTTTGGTCACTTTGC
exon 9	CTTTGTAGTAACTTTAGTTCCG	TTATACACAGTTGAAAAACC
exon 10	GGCAACTCTGAGCTTATTTTCC	AGAGTAGGAAAAGCCTGAATGG
exon 11	CATAGATTATTTTGTACGG	CAAACTCCCTTCTTTTCCC
exon 12	ATCTGATGCCCTCTGTATGACC	ATTCAGTACTCAATACATGTCC
exon 13	CACCATCTTGATTGTTTAGG	GAATCTCCATAGTAATAAGG
exon 14	CAATGTGTTGATGGAGAGTGG	ATTGAATTATAAGCAATATGC
exon 15	CATTTCAGCGACAGAATACAGG	GTGTGTGTGTGTGTGTGTGC
intron 15	AAGGCAGGAAAGTGTCTTATGC	GTCAAATTACTGAAAATCACC
exon 16	AACTGTTACACAGCTGAAAAG	GTGGTGATTGATTAATGTGC
exon 17	GGTGGAGGAATATATCTTTGC	ATAGAATAGATTCAATCATGC
exon 18	CGATAGACAGACAGACACCAGAAGG	CAGCTATAATTTCCCACAGCAGTCC
exon 19	GTGTAATCTCAATTGCTACGGCTACC	CAAGTAGCTGGGACTTCAGATGC
exon 20	TAGTTTCATGTCTTTTCCTC	GAATTTTAAGCACCATCAGTC
exon 21	CCAGGACTCATTTCTTTACC	CTTTCTGACAGAAATATTTGG
exon 22	TGATGTTTCTACATAGTTGG	GGAGTAAAACAATACATAAAAAATG

Table 7. Variations in CFH identified through resequencing that may be correlated with the occurrence of AMD. Each variation is shown in the context of its surrounding DNA sequence. Location of each variation refers to the position on GenBank accession AL049744.8, or the complementary DNA strand of GenBank Accession AL049744.8.

Region	Position	Common/Common	Common/Rare	Rare/Rare	Log HW P-value	Change	Sequence Context
promoter	120992	94	1	0	0	A/G	GTAAGGGGTTTCTCGGAGTAAT [A/G] ATGTTCAAGTGTCTTGACCTGGTGG
promoter	120865	94	0	1	-2.2764618	A/G	ACAAAAGTTTAAATAATCAGCAATTC [A/G] ATTTGTGTGATTTTGGATTATAAA
promoter	120546	57	30	8	-0.7719879	C/T	AGGGTTTATGAATCCAGAGGATAT [C/T] ACCAGCTGCTGATTTGCACATACCA
promoter	120410	94	1	0	0	T/C	GAGTGCAGTGAGAAITGGGTTTAAAC [T/C] TCTGGCAATTCCTGGGCTTGTGGCTT
promoter	120294	94	1	0	0	A/G	TTTGACGCAAGTCTTCTGCACT [A/G] ATCAAAATTCCTGGAAAGGAGAAC
intron 1	99391	72	22	0	0.4512837	C/T	TAAATATACTGTACATTTAAATAGA [C/T] ACTTTATGCACTTATTTGTTTAA
exon 2	99242	93	1	0	0	T/G Ser 58 Ala	CTATAAATGCCGCCCTGGATATAGA [T/G Ser 58 Ala] CTCCTGGAAATGTAATAATGGTATG
exon 2	99230	72	22	0	0.4512837	G/A Val 62 Ile	CCTGGATATAGATCTCTTGGAAAT [G/A Val 62 Ile] TAAATAATGGTATGCAAGGAGAGA
intron 2	99114	93	1	0	0	G/A	GAAAACTAGGTGTAAATAACTTAA [G/A] ATTTAATATTGTAGCAATTAATGCT
intron 2	98485	75	20	0	0.2285278	-T/T/0	CATACTAATTCATAACTTTT [T/T/0] CGTTTAGAAAGGCCCTGTGGACAT
intron 3	98283	94	1	0	0	T/C	ATATAITTTAAGGTTATATATTT [T/C] TCTATGAGCAATTTAAAAAGTAATA
intron 3	98188	94	1	0	0	T/G	GGATACCATATATCTCTTAAACAT [T/G] GAAAAATTTAAATGAAGTATAACTT
exon 4	96315	94	1	0	0	G/A Arg 127 His	CAATTGCTAGGTGAGATTAATACC [G/A Arg 127 His] TGAATGTGACACAGATGGAGCC
intron 4	96211	94	1	0	0	-T/T/0	AATAAATATCTAAGATTAAAAAAA [-T/T/0] GTCTTACATTAATAATCTTAAAGT
exon 7	87139	46	19	30	-7.9849797	A/C (C) Ala 307 Ala	ATCTGCACCCGGGAAATACAGC [A/C (C) Ala 307 Ala] AAAATGCACAAAGTACTGGCTGGATAC
intron 7	83071	94	1	0	0	-ATGAGATATAGAA/0	AGACCTTCTTGTTACATATCTCAGT [-ATGAGATATAGAA/0] CATCTGAGTTCTATCATTTGTTTG
intron 7	83059	94	1	0	0	T/C	TTACATATCTCAGTCATCTGAGTTC [T/C] ATCATTTGTTTGGACCTAGAAACCC
intron 7	82966	48	16	31	-10.039955	G/T	TGATAAAAAATTTATCTCTAATAGA [G/T] TGTATTACAGTAAAAATTTCTTTA
intron 7	82957	94	1	0	0	A/G	TTTATCTCTAATATGAGTGTATT [A/G] CAGTAAAAATTTCTTTATACITTTT
exon 9	82232	95	1	0	0	C/A Gln 400 Lys	TCCTTATTGGAAAAATGGATATAAT [C/A Gln 400 Lys] AAAATCATGGAAAGAAAGTTGTACA
exon 9	82226	46	18	30	-8.6058781	C/T His 402 Tyr	TTTGGAAAAATGGATATAATCAAAAT [C/T His 402 Tyr] ATGGAAGAAAGTTTGTACAGGGTAA
intron 9	58652	93	1	0	0	T/C	TATATTACATATTACTTAAATCTT [T/C] ATAAAAATGTTATTGATCATATGCTT
exon 10	58516	59	27	7	-0.8677698	G/A Ala 473 Ala	ATACATATGCTTTAAAAAGAAAAAGC [G/A Ala 473 Ala] AAAATATCAATGCAAACTAGGATATG
intron 10	58319	93	1	0	0	A/G	TGGGGCTGATATATAATTTTCATTTGA [A/G] AAGATAAGAAAAAAAACCTGCAGG
intron 10	58260	93	1	0	0	C/G	AGACATCAATTTTCTTCTTTTCA [C/G] ATTAATTACTCAGATAATTAGTCTGT
intron 10	56838	54	11	29	-13.007209	G/T	TTTGTACGGTACCTATTATTAGTA [G/T] ATCTAAATCAATAAGCTTTTCTTTC
exon 12	47084	94	1	0	0	G/A Val 609 Ile	ATTTACAAATAGTTGGACCTAATCC [G/A Val 609 Ile] TTCAGTGTACCACCTTGGATTGTC
intron 12	46992	95	1	0	0	T/G	ATTGCTGAAATAAGAAATTAGAACTT [T/G] GAAATACCAACTTTTCTTATTAAT
exon 13	45721	71	19	4	-1.0457792	A/G Gln 672 Gln	TAAATGAAGGGACCTAATAAAATTC [A/G Gln 672 Gln] TGTGTTGATGGAGATGGACAACCTT

exon 15	43875	92	1	0	0	A/G Gly 783 Gly	CTAACAATAAGGTACAGATGTAGAGG [A/G Gly 783 Gly] AAAGAAGGATGGATACACACAGTCT
intron 15	40549	60	26	7	-0.9218916	G/A	AACTAGAAATTAATCCCTGGCAGIT [G/A] TTTCCTTCAGAAATTTTGAGTATAT
intron 15	40445	90	4	0	0	C/T	CTGTGGAAATTCATTTTATGTAA [C/T] CATCACATTTTCATGGCTTTTTC
intron 15	40412	54	10	29	-13.609694	G/C	TTTCATGGCTTTTTCATAACTT [G/C] GTCTATAACTTTTGATAATTGATT
intron 15	40335	93	1	0	0	G/C	TCATTAACCTTATTTGATTTCCITT [G/C] AGATTCTGGGTGGGTTCCTATT
intron 15	40179	60	26	7	-0.9218916	C/T	CCACATGGTAGTATCCCATCTGGAT [C/T] TTAAGCTATCTTCACCTTTTATTTAT
intron 15	35577	95	1	0	0	T/G	CATATAAATATTTTTCATCAAAAA [T/G] TCTAAATTTTAAATTTTATTTTTT
intron 15	35537	55	12	28	-12.229741	C/A	TTTTATTTTATTTTATTATAA [C/A] ATTAATTATATTTTAAATATTTTTT
intron 16	35263	94	1	0	0	C/T	ATGAGGTTAAATATCTCTGTGTGCTT [C/T] GTGTAAACAAGAGAGAAGTCTTTTC
exon 17	34821	90	5	0	0	C/T His 878 His	GTTCACAACCACCTCAGATAGAAC [C/T His 878 His] GGAAACCAATTAATTCACAGGTCTT
exon 17	34786	94	1	0	0	G/T Ser 890 Ile	AATTCAATCCAGGCTTCACAAAGAA [G/T Ser 890 Ile] TTAATGCACATGGGACTAAATTGAGT
intron 17	31825	93	1	0	0	A/C	ATTGTGTTACTTCTCTGTGTGTC [A/C] TAGTAGCTCTCTGTATTGTTATTTT
exon 18	31689	70	19	5	-1.4115003	G/T Gln 936 Asp	GCCTTCCTTGTAATCTCCACCTGA [G/T Gln 936 Asp] ATTTCTCATGGTGTGTAGCTCA
intron 18	30673	89	1	0	0	T/G	GCTACGGCTACCAATATTTCTTCAG [T/G] CTCTAATATCATTTTCTATCTTTGTA
intron 18	30547	78	11	5	-2.9065654	T/C	TGTTGTACAGTATTCATTGATTCTA [T/C] ATATCGCTATTTTAGAATCCATTAC
intron 18	30546	93	1	0	0	A/G	GTGTACAGTATTCATTGATTCTAT [A/G] TATCGCTATTTTAGAATCCATTACA
exon 19	30396	93	1	0	0	G/T Val 1007 Leu	CATACCCATGGGAGAGAAAGGAT [G/T Val 1007 Leu] TGTATAAGGGGGGTGAGCAAGTGAC
intron 19	28886	65	29	0	0.9350138	T/C	GGTGGAAACCACTCTCTTTTCTTA [T/C] TCAGACACCTCTCTGTGTGAATCCGC
exon 20	28877	65	29	0	0.9350138	C/T Thr 1046 Thr	ACTTCTTTTCTTCTATTCAGACAC [C/T Thr 1046 Thr] TCCGTGTGAATCCGCCACAGTAC
exon 20	28867	91	3	0	0	A/T Asn 1050 Tyr	TTTCTATTCAGACACCTCTGTGTG [A/T Asn 1050 Tyr] ATCCGCCACAGTACAAAATGCTTA
intron 20	28592	75	2	0	0	A/G	AATAGATTTTTCAAATGCAATAAA [A/G] TGACTGATGGTGTGTTAAAAATTCAT
intron 20	26589	88	1	0	0	G/C	TGATATTATATACAGTGTGTGTT [G/C] CGTTGCCCTTATTGAACTTGTATT
exon 22	25219	89	1	0	0	C/A Pro 1166 Gln	GTTTACTGTTTTTATTTTCAGATC [C/A Pro 1166 Gln] GTGTGTAATATCCCGAGAAATTATG
exon 22	25088	88	1	0	0	C/T Arg 1210 Cys	TAAACGGGGATATCGTCTTTCATCA [C/T Arg 1210 Cys] GTTCTCACACATTGCGAACACATG

Table 8. Variations in CFHL1 that may be correlated with the occurrence of AMD. Each variation is shown in the context of its surrounding DNA sequence. Location of each variation refers to the position on GenBank Accession AL049741.7, or the complementary DNA strand of GenBank Accession AL049741.7.

Region	Position	Common/Common	Rare/Rare	Log HW P-value	Change	Sequence Context
promoter	24634	49	9	22	-10.77769145	A/G
promoter	24630	57	24	2	0	C/G
promoter	24620	50	9	24	-11.7118554	T/C
promoter	24607	49	8	22	-11.37722688	T/G
promoter	24558	74	2	0	0	G/T
promoter	24543	49	6	20	-11.82719892	-C/()
promoter	24482	68	19	5	-1.372873106	C/T
promoter	24445	74	19	0	0.229044145	G/A
promoter	24426	68	20	5	-1.259964884	C/T
promoter	24412	74	19	0	0.229044145	C/T
promoter	24404	74	12	1	-0.363372133	C/T
promoter	24303	80	14	0	0	T/G
promoter	24182	74	19	1	0	C/T
promoter	24141	92	1	0	0	C/T
exon 1	23873	93	1	0	0	C/G
exon 1	23857	93	1	0	0	C/A
intron 1	23622	77	12	5	-2.667405836	C/G
intron 1	23583	78	13	0	0	A/G
intron 1	18334	71	0	20	-20.66376969	-T/()
intron 1	18264	73	0	19	-20.20008135	C/T
intron 2	17916	74	10	7	-4.384231059	G/A
intron 2	16939	65	17	8	-2.859665125	C/T
intron 2	16934	60	11	20	-10.15791403	A/G
intron 2	16837	89	1	0	0	T/G
intron 3	16599	60	11	19	-9.704247488	G/A
intron 3	16543	59	11	20	-10.05211275	T/A
intron 4	13227	85	5	0	0	T/C
exon 5	13128	89	1	0	0	T/C Pro 211 Pro
exon 5	13092	66	17	7	-2.450785359	G/A Pro 223 Pro
exon 6	11741	59	11	20	-10.05211275	G/T Arg 302 Arg
exon 6	11705	19	11	60	-9.704247488	T/A (a) Arg 314 Arg
exon 6	11593	19	11	60	-9.704247488	A/C

Table 9. Variations in CFHL3 that may be correlated with the occurrence of AMD. Each variation is shown in the context of its surrounding DNA sequence. Location of each variation refers to the position on GenBank Accession AL049741.8, or the complementary DNA strand of GenBank Accession AL049741.8.

Region	Position	Common/Common	Rare/Rare	Log HW P-value	Change	Sequence Context
promoter	3779	86	2	0	A/G	ATTTTGACCAATTTGTGGGGGGGG [A/G] AAAAAACCTTGCCATGCCAAACAGC
promoter	4364	63	17	-3.220465172	T/G	AATCCACAGATGATGTGAAACCAC [T/G] AACTGGAAATTATGGAAGCATTTTGT
promoter	4465	64	17	-3.26153442	A/C	TCATGGTAGTGCACCTTAAATTCAGA [A/C] CCACACTTGGTAACTAATAATGAAA
promoter	4502	64	17	-3.699998612	C/A	AACTAAATGAAAGATTTCAAACC [C/A] CAAACAGGGGAACCTGAAACTTTTGT
exon 1	4607	88	1	0	G/C Gly 18 Ala	ACCTTGTTGGGTTTCCTGTGCTAATG [G/C Gly 18 Ala] ACAAGGTAAGTTAAAGAGATCTAA
intron 2	9382	79	2	-1.435387193	T/C	ATGTTTATGCGATCTTATTTAAATA [T/C] GGTAACAATAATTTTAATATACTTT
intron 4	19710	56	15	-2.935633472	-T/()	TCCCCACATATAAAGTATTTT [T/()] CAGATTCCTCAGAAAAAGTGTGGGC
exon 5	19820	56	14	-4.079180573	C/T Pro 241 Ser	GTCAAGAGTCGAGTACCAATGCCAG [C/T Pro 241 Ser] CCTACTATGAACCTTCAGGGTCTTAA
exon 5	19885	58	14	-3.249405761	A/T Pro 262 Pro	GTAATGGAGAGTGGTGGGAACCAACC [A/T Pro 262 Pro] AGATGCATACGTAAGTTCTTAAAAAT
intron 5	19917	58	14	-3.249405761	T/A	ATACGTAAGTTCTTAAAAATCTAGA [T/A] CCTGAGAAAAATCAGAGTAATAAGTT
intron 5	19928	79	1	0	T/C	CTTAAAAATCTAGATCCTCGAGAAAA [T/C] CAGAGTAATAAGTTTGATATTGCT
intron 5	20057	78	0	-2.195899652	G/A	CAGATCTTAATATATAAGTGTATAA [G/A] CTGTGAAAAATTCATGTAAACAATG
intron 5	22921	69	1	0	G/T	TATTTATCTCTAACTACTACTATTAG [G/T] ATGCAATTTTATTTGCTCATGAAAAA
exon 6	23027	69	1	0	TA/- ? 280 ?	GAAGAAAAACATGAATAAAAAATAACA [TA/- ? 280 ?] AAGTTAAAAAGGAAGATGACAGAA
exon 6	23203	66	3	-1.147796072	G/A	ATAAGGCAGCATTTGTACCCCTAAAT [G/A] TATGTCCAACTCCACITTTCCACT
exon 6	23322	68	0	-5.252863221	A/G	AAAGAAAAATTAATAATAAGTTTCA [A/G] TTTGCAACTTAATAATATATCTCAAAA

Table 10. Variations in CFHL4 that may be correlated with the occurrence of AMD. Each variation is shown in the context of its surrounding DNA sequence in Chromosome 7:32512024-33512123.

Region	Position	Common/Common	Rare/Rare	Log HW P-value	Change	Sequence Context
promoter	7013	93	1	0	C/T	GTTTATTTTCAACGTGATGTCAACA [C/T] GGCTCCTATCTTTCATTTCTCTCC
promoter	7369	91	4	0	C/G	AATAGTGCAGAAAGCCTTTCATTC [C/G] TGATTTAAAAACTCTCTTTACTTAAA
promoter	7577	91	5	0	C/A	CTGAACCTTTGATATTTACTAAGTGA [C/A] CTTAAAGCCCTAGCTTTTGTGGTAGT
promoter	7585	95	1	0	C/G	TGATATTTACTAAGTGCACCTTAAAG [C/G] CCTAGCTTTTGTGGTAGTGCACTTAA
exon 2	22144	94	2	0	T/C Asp 76 Asp	*GGGATTACATTCACCTGCACACAAGA [T/C Asp 76 Asp] GGGTGGTGGCAACAGTCCCATGCC
exon 3	32436	94	1	0	T/C Ile 132 Ile	CAGATGGAAATTCCTCAGGTTCAAT [T/C Ile 132 Ile] ACATGTTTGCAAAAATGGATGGTCAG
intron 5	37640	88	4	-2.226371993	T/G	GCTAAAGTCAGTATGTAGCACAAAAT [T/G] AATACTATTAACTATTGGATTAT
intron 5	37701	69	18	-1.933221388	G/A	TATTTATCTCTAAACTACTCATTTAG [G/A] ATGCAATTTTATTTGCTCATGAAAGG
exon 6	37884	74	19	-0.208237586	G/A Gly 306 Glu	ACCAATTGAATTATGTGTAATAATTGG [G/A Gly 306 Glu] ATATAATGCGAATACATCAGTTCTA

Claims

We claim:

1. An isolated polynucleotide for the detection of a variant CFH gene, in a sample from an individual, comprising a nucleic acid molecule that specifically detects a variation in the CFH gene that is correlated with the occurrence of age related macular degeneration in humans.
2. The polynucleotide of claim 1, wherein the polynucleotide is a probe that hybridizes, under stringent conditions, to a variation in the CFH gene that is correlated with the occurrence of age related macular degeneration in humans.
3. The probe of claim 2, wherein the variation encodes an amino acid other than histidine at position 402 of the CFH protein.
4. The probe of claim 3, wherein the variation encodes tyrosine at position 402 of the CFH protein.
5. The probe of claim 2, wherein the probe is a DNA probe.
6. The probe of claim 5, wherein the probe is from about 8 nucleotides to about 500 nucleotides.
7. The probe of claim 5, wherein the probe is from about 10 nucleotides to about 250 nucleotides.
8. The probe of claim 5, wherein the probe comprises one or more non-natural or modified nucleotides.
9. The probe of claim 8, wherein the one or more non-natural or modified nucleotides are radioactive, fluorescently, or chemically labeled nucleotides.
10. A polynucleotide primer that hybridizes, under stringent conditions, adjacent to a variation in the CFH gene that is correlated with the occurrence of age related macular degeneration in humans.
11. The polynucleotide primer of claim 10, which hybridizes immediately adjacent to a variation in the CFH gene that is correlated with the occurrence of age related macular degeneration in humans.
12. A pair of polynucleotide primers that specifically detect a variation in the CFH gene that is correlated with the occurrence of age related macular degeneration in humans,

wherein the first polynucleotide primer hybridizes to one side of the variation and the second polynucleotide primer hybridizes to the other side of the variation.

13. A pair of polynucleotide primers that hybridize to a region of DNA that comprises a variation in the CFH gene that is correlated with the occurrence of age related macular degeneration in humans, wherein the polynucleotide primers hybridize to the region in such a manner that the ends of the hybridized primers proximal to the variation are from about 20 to about 10,000 nucleotides apart.

14. The pair of polynucleotide primers of claim 12, wherein the variation encodes an amino acid other than histidine at position 402 of the CFH protein.

15. The pair of polynucleotide primers of claim 14, wherein the variation encodes tyrosine at position 402 of the CFH protein.

16. The pair of polynucleotide primers of claim 12, wherein the primers are DNA primers.

17. The pair of polynucleotide primers of claim 16, wherein the primers are each from about 8 nucleotides to about 500 nucleotides.

18. The pair of polynucleotide primers of claim 16, wherein the primers are each from about 10 nucleotides to about 250 nucleotides.

19. The pair of polynucleotide primers of claim 16, wherein the primers comprise one or more non-natural or modified nucleotides.

20. The pair of polynucleotide primers of claim 19, wherein the one or more non-natural or modified nucleotides are radioactive or fluorescently labeled nucleotides.

21. A method of detecting, in a sample obtained from an individual, a variant CFH gene that is correlated with the occurrence of age related macular degeneration in humans, comprising:

- (a) combining the sample with a polynucleotide probe that hybridizes, under stringent conditions, to a variation in the CFH gene that is correlated with the occurrence of age related macular degeneration in humans, but not to a wildtype CFH gene; and
 - (b) determining whether hybridization occurs,
- wherein the occurrence of hybridization indicates that a variant CFH gene

that is correlated with the occurrence of age related macular degeneration is present in the sample.

22. A method of detecting, in a sample obtained from an individual, a variant CFH gene that is correlated with the occurrence of age related macular degeneration in humans, comprising:

- (a) combining the sample with a polynucleotide probe that hybridizes, under stringent conditions, to a variation in the CFH gene that is correlated with the occurrence of age related macular degeneration in humans, thereby producing a combination;
- 10 (b) maintaining the combination produced in step (a) under stringent hybridization conditions; and
- (c) comparing hybridization that occurs in the combination with hybridization in a control, wherein the control is a polynucleotide probe that does not bind to a variation in the CFH gene that is correlated with the occurrence of age related macular degeneration in humans or binds only to a wildtype CFH gene, and the sample is the same type of sample as in (a) and is treated the same as the sample in (a), and
- 15 wherein the occurrence of hybridization in the combination but not in the control indicates that a variant CFH gene that correlates with age related macular degeneration is present in the sample.
- 20

23. The method of claim 22, wherein the extent of hybridization is determined in step (c).

24. A method of detecting, in a sample obtained from an individual, a variant CFH gene that is correlated with the occurrence of age related macular degeneration in humans, comprising:

- (a) combining a first portion of the sample with a polynucleotide probe that hybridizes, under stringent conditions, to a variation in the CFH gene that is correlated with the occurrence of age related macular degeneration in humans;
- 30 (b) combining a second portion of the sample with a polynucleotide probe that hybridizes, under stringent conditions, to a wildtype CFH gene; and

(c) determining whether hybridization occurs,
wherein the occurrence of hybridization in the first portion but not in the
second portion indicates that a variant CFH gene that is correlated with the
occurrence of age related macular degeneration is present in the sample.

5 25. The method of claim 21, wherein the variation encodes an amino acid other
than histidine at position 402 of the CFH protein.

 26. The method of claim 25, wherein the variation encodes tyrosine at position 402
of the CFH protein.

 27. The method of claim 21, wherein the sample comprises cells obtained from the
10 eye, ear, nose, teeth, tongue, epidermis, epithelium, blood, tears, saliva, mucus, urinary
tract, urine, muscle, cartilage, skin, or any other tissue or bodily fluid.

 28. The method of claim 21, wherein the polynucleotide probe is a DNA probe.

 29. The method of claim 21, wherein the polynucleotide probe is from about 8
nucleotides to about 500 nucleotides.

15 30. A method of detecting, in a sample obtained from an individual, a variant CFH
gene that is correlated with the occurrence of age related macular degeneration in humans,
comprising:

 (a) combining the sample with a pair of polynucleotide primers, wherein the
20 first polynucleotide primer hybridizes to one side of DNA encoding amino
acid 402 of the CFH protein and the second polynucleotide primer
hybridizes to the other side of DNA encoding amino acid 402 of the CFH
protein;

 (b) amplifying DNA in the sample, thereby producing amplified DNA;

 (c) sequencing amplified DNA; and

25 (d) detecting in the DNA the presence of a variation that encodes an amino
acid other than histidine at position 402 of the CFH protein,
wherein the presence of the variation indicates that a variant CFH gene that
is correlated with the occurrence of age related macular degeneration in
humans is detected in the sample.

31. A method of identifying or aiding in identifying an individual at risk for developing age related macular degeneration, comprising assaying a sample obtained from the individual for the presence of a variant CFH gene that is correlated with the occurrence of age related macular degeneration in humans, wherein the presence of a variant CFH
5 gene indicates that the individual is at risk for developing age related macular degeneration.

32. A method of identifying or aiding in identifying an individual at risk for developing age related macular degeneration, comprising:

- 10 (a) combining a sample obtained from the individual with a polynucleotide probe that hybridizes, under stringent conditions, to a variation in the CFH gene that is correlated with the occurrence of age related macular degeneration in humans, but does not hybridize to a wildtype CFH gene; and
- 15 (b) determining whether hybridization occurs, wherein the occurrence of hybridization indicates that the individual is at risk for developing age related macular degeneration.

33. A method of identifying or aiding in identifying an individual at risk for developing age related macular degeneration, comprising:

- 20 (a) obtaining DNA from an individual;
- (b) sequencing a region of the DNA that comprises the nucleotides that encode amino acid 402 of the CFH protein; and
- 25 (c) determining whether a variation that encodes an amino acid other than histidine at position 402 of the CFH protein is present in the DNA, wherein the presence of the variation indicates that the individual is at risk for developing age related macular degeneration.

34. A diagnostic kit for detecting a variant CFH gene in a sample from an individual, comprising:

- 30 (a) at least one container means having disposed therein a polynucleotide probe that hybridizes, under stringent conditions, to a variation in the CFH gene that is correlated with the occurrence of age related macular degeneration in humans; and

(b) a label and/or instructions for the use of the diagnostic kit in the detection of a variant CFH gene in a sample.

35. A diagnostic kit for detecting a variant CFH gene in a sample from an individual, comprising:

- 5 (a) at least one container means having disposed therein a polynucleotide primer that hybridizes, under stringent conditions, adjacent to one side of a variation in the CFH gene that is correlated with the occurrence of age related macular degeneration in humans; and
- 10 (b) a label and/or instructions for the use of the diagnostic kit in the detection of CFH in a sample.

36. The diagnostic kit of claim 35, additionally comprising a second polynucleotide primer that hybridizes, under stringent conditions, to the other side of the variation in the CFH gene that is correlated with the occurrence of age related macular degeneration in humans.

15 37. A composition for treating a subject suffering from age related macular degeneration, comprising:

- (a) an effective amount of an isolated or recombinantly produced wildtype CFH polypeptide, or a fragment thereof; and
- (b) a pharmaceutically acceptable carrier.

20 38. The composition of claim 37, wherein the CFH polypeptide or the fragment thereof inhibits the activation of C3.

39. A method of treating a subject suffering from age related macular degeneration, comprising administering to the subject an effective amount of the composition of claim 37.

25 40. A composition for treating a subject suffering from age related macular degeneration, comprising:

- (a) an effective amount of an isolated or recombinantly produced nucleic acid molecule coding for a CFH polypeptide, or a fragment thereof; and
- (b) a pharmaceutically acceptable carrier.

41. A method of treating a subject suffering from age related macular degeneration, comprising administering to the subject an effective amount of the composition of claim 40.

42. A method of detecting, in a sample obtained from an individual, a variant CFH polypeptide that is correlated with the occurrence of age related macular degeneration in humans, comprising:

(a) combining the sample with an antibody that binds to a variant CFH polypeptide that is correlated with the occurrence of age related macular degeneration in humans; and

(b) determining whether binding occurs, wherein the occurrence of binding indicates that a variant CFH polypeptide that is correlated with the occurrence of age related macular degeneration is present in the sample.

43. A composition for treating a subject suffering from or at risk for age related macular degeneration, comprising:

(a) a nucleic acid molecule comprising an antisense sequence that hybridizes to a variant CFH gene or mRNA that is correlated with the occurrence of age related macular degeneration in humans; and

(b) a pharmaceutically acceptable carrier.

44. The composition of claim 43, wherein hybridization of the antisense sequence to the variant CFH gene reduces the amount of RNA transcribed from the variant CFH gene.

45. The composition of claim 43, wherein hybridization of the antisense sequence to the variant CFH mRNA reduces the amount of protein translated from the variant CFH mRNA, and/or alters the splicing of the variant CFH mRNA.

46. The composition of claim 43, wherein said nucleic acid molecule includes one or more modified nucleotides or nucleosides that enhance in vivo stability, transport across the cell membrane, or hybridization to a variant CFH gene or mRNA.

47. A method for treating a subject suffering from or at risk for age related macular degeneration, comprising administering to the subject an effective amount of the composition of claim 43.

48. A composition for treating a subject suffering from or at risk for age related macular degeneration, comprising:

- 5 (a) a nucleic acid molecule comprising a siRNA or miRNA sequence, or a precursor thereof, that hybridizes to a variant CFH gene or mRNA that is correlated with the occurrence of age related macular degeneration in humans; and
- (b) a pharmaceutically acceptable carrier.

49. The composition of claim 48, wherein hybridization of the siRNA or miRNA sequence to the variant CFH gene reduces the amount of RNA transcribed from the variant CFH gene.

10

50. The composition of claim 48, wherein hybridization of the siRNA or miRNA sequence to the variant CFH mRNA reduces the amount of protein translated from the variant CFH mRNA, and/or alters the splicing of the variant CFH mRNA.

51. The composition of claim 48, wherein said nucleic acid molecule includes one or more modified nucleotides or nucleosides that enhance in vivo stability, transport across the cell membrane, or hybridization to a variant CFH gene or mRNA.

15

52. A method for treating a subject suffering from or at risk for age related macular degeneration, comprising administering to the subject an effective amount of the composition of claim 48.

20 53. A composition for treating a subject suffering from or at risk for age related macular degeneration, comprising:

- (a) an aptamer that binds to a variant CFH polypeptide that is correlated with the occurrence of age related macular degeneration in humans; and
- (b) a pharmaceutically acceptable carrier,
- 25 wherein binding of the aptamer to the variant CFH polypeptide reduces the activity of the variant CFH polypeptide.

54. A method for treating a subject suffering from or at risk for age related macular degeneration, comprising administering to the subject an effective amount of the composition of claim 53.

55. A composition for treating a subject suffering from or at risk for age related macular degeneration, comprising:

- 5 (a) a small molecule that binds to a variant CFH polypeptide that is correlated with the occurrence of age related macular degeneration in humans; and
- (b) a pharmaceutically acceptable carrier,

wherein binding of the small molecule to the variant CFH polypeptide reduces the activity of the variant CFH polypeptide.

10 56. A method for treating a subject suffering from or at risk for age related macular degeneration, comprising administering to the subject an effective amount of the composition of claim 55.

57. A composition for treating a subject suffering from or at risk for age related macular degeneration, comprising:

- 15 (a) an antibody that binds to a variant CFH polypeptide that is correlated with the occurrence of age related macular degeneration in humans; and
- (b) a pharmaceutically acceptable carrier,

wherein binding of the antibody to the variant CFH polypeptide reduces the activity of the variant CFH polypeptide.

20 58. A method for treating a subject suffering from or at risk for age related macular degeneration, comprising administering to the subject an effective amount of the composition of claim 57.




FIG. 1A




FIG. 1B




FIG. 2A




FIG. 2B




FIG. 2C




FIG. 2D






FIG. 3A

FIG. 3B





FIG. 3C

FIG. 4



Polypeptide Sequence for Homo sapiens Complement Factor H (GenBank Accession CAA68704)

1	mrllaklcl	mlwaicvaed	cnelpprint	eiltgswsdq	typegtaiy	kcrpgyrslg
61	nvimvcrkge	wvalnplrkc	qkrpcghpgd	tpfgtftltg	gnvfeygvka	vytcnogyql
121	lgeinyrecd	tdgwtndipl	cevvkclpvt	apengkiyss	amepdreyhf	gqavrfvcns
181	gykiegdeem	hcsddgfwsk	ekpkcveisc	kspdvingsp	isqiliyken	erfqykcnmq
241	yeysergdav	ctesgwrplp	sceekscdnp	yipngdyspl	rikhrtgdei	tyqcrngfyp
301	atrgntakct	stgwipaprc	tlkpcdypdi	khgglyhenm	rrpyfpvavg	kyysyyccdeh
361	fetpsgsywd	hihtqdgws	pavpclrkcy	fpylengynq	nhgrkfvqgk	sidvachpgy
421	alpkaqtvtc	cmengwsptp	rcirvktcsk	ssidiengfi	sesqytyalk	ekakyqcklg
481	yvtadgetsq	sircgkdgws	aqptcikscd	ipvfmmartk	ndftwfklnl	tl dyechdgy
541	esntgsttgs	ivcgyngwsd	lpicyerece	lpkidvhlvp	drkkdgykvg	evlkfscckpg
601	ftivgpnsvq	cyhfglspdl	pickceqvqc	gpppellngn	vkektkeeyg	hsevveyycn
661	prflmkgnpk	iqcvdgewtt	lpvciveest	cgdipelehq	waqlssppyy	ygdsvfefncs
721	esftmighrs	itcihgvtq	lpqcvaiddl	kkckssnlil	leehlknkke	fdhnsninyr
781	crgkegwih	vcingrwdpe	vncsmaqiql	cppppqipns	hnmттllyr	dgekvsvlcq
841	enyliegeee	itckdgrwqs	iplcvekipc	sqppqiehg	inssrsqes	yahgtklst
901	ceggfrisee	nettcymgkw	ssppqceglp	cksppeiishg	vvahmsdsyq	ygeevtykcf
961	egfgldgpai	akclgekwh	ppsciktddl	slpsfenaip	ngekkdvka	geqvttytcat
1021	yykmdgasnv	tcinsrwtgr	ptcrdtscvn	pptvqnayiv	srqmskypsg	ervryqcrsp
1081	yemfgdeevm	clngnwtepp	qckdstgkcg	pppidngdi	tsfplsvyap	assveyqcqn
1141	lyqlegnkri	tcrnngwsep	pkclhpcvis	reimenynia	lrwtakqkly	srtgesvefv
1201	ckrgyrlssr	shtlrrttcwd	gkleyptcak	r		

FIG. 5

1/64

SEQUENCE LISTING

<110> Yale University
Hoh, Josephine

<120> METHODS AND COMPOSITIONS FOR TREATING OCULAR DISORDERS

<130> YU-PWO-038

<150> US 60/629,363

<151> 2004-11-18

<150> US 60/649,479

<151> 2005-02-02

<150> US 60/672,346

<151> 2005-04-18

<160> 59

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 4004

<212> DNA

<213> Homo sapiens

<400> 1

ccttttgcag	caagttcttt	cctgcactaa	tcacaattct	tggaagagga	gaactggacg	60
ttgtgaacag	agttagctgg	taaatgtcct	cttaaaagat	ccaaaaaatg	agacttctag	120
caaagattat	ttgccttatg	ttatgggcta	tttgtgtagc	agaagattgc	aatgaacttc	180
ctccaagaag	aaatacagaa	attctgacag	gttcctggtc	tgaccxaaaca	tatccagaag	240
gcacccaggc	tatctataaa	tgccgccttg	gatatagatc	tcttggaat	gtaataatgg	300
tatgcaggaa	gggagaatgg	gttgctctta	atccattaag	gaaatgtcag	aaaaggccct	360
gtggacatcc	tgagatact	ccttttggtg	cttttaccct	tacaggagga	aatgtgtttg	420
aatatggtgt	aaaagctgtg	tatacatgta	atgaggggta	tcaattgcta	ggtgagatta	480
attaccgtga	atgtgacaca	gatggatgga	ccaatgatat	tcctatatgt	gaagttgtga	540
agtgtttacc	agtgacagca	ccagagaatg	gaaaaattgt	cagtagtgca	atggaaccag	600
atcggaata	ccattttgga	caagcagtac	ggtttgtatg	taactcaggc	tacaagattg	660
aaggagatga	agaaatgcat	tgttcagacg	atggtttttg	gagtaaagag	aaaccaaagt	720
gtgtggaaat	ttcatgcaaa	tccccagatg	ttataaatgg	atctcctata	tctcagaaga	780
ttattttata	ggagaatgaa	cgatttcaat	ataaatgtaa	catgggttat	gaatacagtg	840
aaagaggaga	tgctgtatgc	actgaatctg	gatggcgctc	gttgccctca	tgtgaagaaa	900
aatcatgtga	taatccttat	attccaaatg	gtgactactc	acctttaagg	attaacacac	960
gaactggaga	tgaaatcacg	taccagtgtg	gaaatggttt	ttatcctgca	acccggggaa	1020
atacagcaaa	atgcacaagt	actggctgga	tacctgctcc	gagatgtacc	ttgaaacctt	1080
gtgattatcc	agacattaaa	catggaggtc	tatatcatga	gaatatgcgt	agaccatact	1140
ttccagtagc	tgtaggaaaa	tattactcct	attactgtga	tgaacatttt	gagactccgt	1200
caggaagtta	ctgggatcac	attcattgca	cacaagatgg	atggtcgcca	gcagtaccat	1260
gcctcagaaa	atgttatttt	ccttatttgg	aaaaatggata	taatcaaaat	catggaagaa	1320
agtttgtaca	gggtaaatct	atagacgttg	cctgccatcc	tggctacgct	cttccaaaag	1380
cgcagaccac	agttacatgt	atggagaatg	gctgggtctc	tactcccaga	tgcattccgtg	1440
tcaaaacatg	ttccaaatca	agtatagata	ttgagaatgg	gtttattttct	gaatctcagt	1500
atacatatgc	cttaaaagaa	aaagcgaat	atcaatgcaa	actaggatat	gtaacagcag	1560
atgggtgaaac	atcaggatca	attacatgtg	ggaaagatgg	atggtcagct	caacccacgt	1620
gcattaaatc	tttgtgatatc	ccagtatttt	tgaatgccag	aactaaaaat	gacttcacat	1680
ggtttaagct	gaatgacaca	ttggactatg	aatgccatga	tggttatgaa	agcaatactg	1740
gaagcaccac	tggttccata	gtgtgtggtt	acaatgggtt	gtctgattta	cccatatggt	1800
atgaaagaga	atgcgaactt	cctaaaatag	atgtacactt	agttcctgat	cgaagaaaag	1860
accagtataa	agttggagag	gtgttgaaat	tctcctgcaa	accaggattt	acaatagttg	1920

2/64

gacctaat	cgttcagt	taccacttt	gattgtct	tgacctcca	atatgtaa	1980
agcaagtaca	atcatgtg	ccacctcct	aactcctca	tggaatgt	aaggaaaaa	2040
cgaaagaaga	atatggac	agtgaagt	tggaatatta	ttgcaatc	agatttcta	2100
tgaagggacc	taataaa	caatgtgt	atggagagt	gacaacttt	ccagtgtgt	2160
ttgtggagga	gagtacct	ggagatata	ctgaacttg	acatggctg	gcccagctt	2220
cttcccctcc	ttattact	ggagattcag	tggaattcaa	ttgctcagaa	tcattttaca	2280
tgattggaca	cagatcaat	acgtgtatt	atggagtat	gacccaact	ccccagtgt	2340
tggaataga	taaactta	aagtgc aa	catcaaat	aattatact	gaggaacatt	2400
taaaaaaca	gaaggaat	gatcataat	ctaacata	gtacagatg	agaggaaaa	2460
aaggatggat	acacacag	tgcataaat	gaagatgg	tccagaagt	aactgctca	2520
tggcacaa	acaattat	ccacctcc	ctcagatt	caattctc	aatatgaca	2580
ccacactg	ttatcggg	ggagaaaa	tatctgtt	ttgccaaga	aattatctaa	2640
ttcaggaag	agaagaa	acatgcaa	atggaagat	gcagtcaata	ccactctgt	2700
ttgaaaaa	tccatgtt	caaccac	agatagaac	cggaaacc	aattcatcca	2760
ggtcttcac	agaaagtt	gcacatgg	ctaaattg	ttatacttg	gaggggtgg	2820
tcaggatata	tgaagaaa	gaaacaac	gctacatgg	aaaatggag	tctccacct	2880
agtgtgaag	ccttccttg	aaatctcc	ctgagatt	tcatgggt	gtagctcaca	2940
tgctcagac	ttatcagta	ggagaaga	ttacgtaca	atgttttg	ggttttgg	3000
ttgatgggg	tgcaattg	aaatgctt	gagaaaa	gtctcacc	ccatcatg	3060
taaaaacag	ttgtctcag	ttacctag	ttgaaaa	catacccat	ggagagaga	3120
aggatgtgt	taaggcgg	gagcaagt	cttacact	tgcaacata	tacaaaa	3180
atggagccag	taatgtaac	tgcattaata	gcagatgg	aggaaggcca	acatgcag	3240
acacctcct	tgtgaatcc	cccacagt	aaaatgct	tatagtgt	agacagat	3300
gtaaatatcc	atctgggtg	agagtacgt	atcaatgt	gagccctt	gaaatgttt	3360
gggatgaaga	agtgtgtgt	ttaaatgg	actggacg	accacctca	tgcaagatt	3420
ctacaggaaa	atgtggggc	cctccacct	ttgacaat	ggacattact	tcattccc	3480
tgctcagtata	tgctccag	tcatcagtt	agtaccaat	ccagaact	tatcaact	3540
agggttaacaa	gcgaataac	tgtagaaat	gacaatgg	agaaccacca	aatgcttac	3600
atccgtgtgt	aatatccc	gaaattat	aaaattata	catagcatta	aggtggac	3660
ccaaacagaa	gctttatt	agaacaggt	aatcagtt	atgtgtgt	aaacgggg	3720
atcgtctttt	atcacgtt	cacacatt	gaacaacat	ttgggatgg	aaactggag	3780
atccaacttg	tgcaaaa	tagaatca	cataaagt	acaccttt	tcagaact	3840
agtattaaat	cagttctca	tttcatttt	tatgtatt	tttactc	tttattcata	3900
cgtaaaat	tggattaat	tgtgaaa	taattata	ctgagacc	tggctctct	3960
cttaaaagca	ccatattaaa	tcctggaaa	ctaaaaaaa	aaaa		4004

<210> 2

<211> 1702

<212> DNA

<213> Homo sapiens

<400> 2

ccttttgcag	caagttct	cctgcactaa	tcacaatt	tggaagagga	gaactggacg	60
ttgtgaacag	agttagct	taaatgtc	cttaaaag	ccaaaaat	agacttctag	120
caaagattat	ttgccttat	ttatgggcta	tttgtgtag	agaagattg	aatgaacttc	180
ctccaagaag	aaatacagaa	attctgacag	gttctgtgc	tgaccaaaca	tatccagaag	240
gcacccaggc	tatctataaa	tgccgcctg	gatatagat	tcttggaat	gtaataatgg	300
tatgcaggaa	gggagaat	gttgctctta	atccattaag	gaaatgtcag	aaaaggccct	360
gtggacatcc	tgagatact	ccttttggt	cttttacc	tacaggagga	aatgtgtttg	420
aatatgggtg	aaaagctgt	tatacatgta	atgaggggt	tcaattgcta	ggtgagatta	480
attaccgtga	atgtgacaca	gatggatgga	ccaatgatat	tcctatatgt	gaagttgtga	540
agtgtttacc	agtgcagaca	ccagagaat	gaaaaatt	cagtagtgca	atggaaccag	600
atcggaata	ccattttgga	caagcagta	ggtttgtat	taactcaggc	tacaagattg	660
aaggagatga	agaaatgc	tggtcagac	atgggtttt	gagtaaagag	aaaccaaagt	720
gtgtggaat	ttcatgcaaa	tccccagat	ttataaat	atctcctata	tctcagaaga	780
ttattttata	ggagaatgaa	cgatttcaat	ataaatgtaa	catgggttat	gaatacagtg	840
aaagaggaga	tgctgtatgc	actgaatctg	gatggcgtcc	gttgccctca	tgtgaagaaa	900
aatcatgtga	taatccttat	attccaaat	gtgactact	acctttaagg	attaacacac	960
gaactggaga	tgaaatcacg	taccagtgt	gaaatggttt	ttatcctgca	acccggggaa	1020
atacagcaaa	atgcacaagt	actggctgga	tacctgtcc	gagatgtacc	ttgaaacctt	1080
gtgattatcc	agacattaaa	catggaggtc	tatatcatga	gaatatgcgt	agaccatact	1140
ttccagtagc	tgtaggaaaa	tattactcct	attactgtga	tgaacatttt	gagactccgt	1200

3/64

caggaagtta	ctgggatcac	attcattgca	cacaagatgg	atgggtcgcca	gcagtaccat	1260
gcctcagaaa	atgttatctt	ccttatcttg	aaaatggata	taatcaaat	catggaagaa	1320
agtttgtaca	gggtaaatct	atagacgttg	cctgccatcc	tggctacgct	cttccaaaag	1380
cgcagaccac	agttacatgt	atggagaatg	gctgggtctcc	tactcccaga	tgcatccgtg	1440
tcagctttac	cctctgaact	tctgatcgaa	ggtcatccct	ctccagcttg	agtggatcaa	1500
agatgacaag	ggccaatgga	accaagtttg	agtcttgcca	ggtcaatact	tgggtcctga	1560
gtatggtgac	tagtatctgt	tttggttatgt	gtgtattatt	ccagccagaa	tgggaaatgc	1620
taattcagct	cctccaggca	gccaatggg	gctgggtggct	ttgagattat	taaactcttt	1680
ctctgctgca	aaaaaaaaaa	aa				1702

<210> 3

<211> 4252

<212> DNA

<213> Mus musculus

<400> 3

aagtctttcc	ctgctgtgac	cacagttcat	agcagagagg	aactggatgg	tacagcacag	60
atcttctctt	gagtcagttg	gtcccagaaa	gatccaaatt	atgagactgt	cagcaagaat	120
tatttggtct	atattatgga	ctgtttgtgc	agcagaagat	tgtaaagggtc	ctcctccaag	180
agaaaattca	gaaattctct	caggctcgtg	gtcagaacaa	ctatatccag	aaggcaccac	240
ggctacctac	aaatgccgcc	ctggataccg	aacacttggc	actattgtaa	aagtatgcaa	300
gaatggaaaa	tgggtggcgt	ctaaccatc	caggatatgt	cggaaaaagc	cttgtgggca	360
tcccggagac	acaccctttg	ggtcctttag	gctggcagtt	ggatctcaat	ttgagtttgg	420
tgcaaaagggt	ttttatacct	gtgatgatgg	gtatcaacta	ttaggtgaaa	ttgattaccg	480
tgaatgtggt	gcagatggct	ggatcaatga	tattccacta	tgtgaagttg	tgaagtgtct	540
acctgtgaca	gaactcgaga	atggaagaat	tgtgagtggt	gcagcagaaa	cagaccagga	600
atactatctt	ggacaggtgg	tgcggtttga	atgcaattca	ggcttcaaga	ttgaaggaca	660
taaggaaatt	cattgtctcag	aaaatggcct	ttggagcaat	gaaaagccac	gatgtgtgga	720
aattctctgc	acaccaccgc	gagtggaaaa	tggagatggg	ataaatgtga	aaccagttta	780
caaggagaat	gaaagatacc	actataagtg	taagcatggg	tatgtgcccc	aagaaagagg	840
ggatgccgct	tgcacaggct	ctggatggag	ttctcagcct	ttctgtgaag	aaaagagatg	900
ctcacctcct	tatatcttaa	atggtatcta	cacacctcac	aggattatac	acagaagtga	960
tgatgaaatc	agatatgaat	gtaattatgg	cttctatcct	gtaactggat	caactgtttc	1020
aaagtgtaca	cccactggct	ggatccctgt	tccaagatgt	accttgaaac	catgtgaatt	1080
tccacaattc	aaatatggac	gtctgtatta	tgaagagagc	ctgagaccca	acttcccagt	1140
atctatagga	aataagtaca	gctataagtg	tgacaacggg	ttttcaccac	cttctgggta	1200
ttcctgggac	taccttcgtt	gcacagcaca	aggggtgggag	cctgaagtcc	catgcgtgac	1260
gaaatgtgtt	ttccattatg	tggagaatga	agactctgca	tactgggaaa	aagtatatgt	1320
gcagggtcag	tctttaaaag	tccagtgtta	caatggctat	agtcttcaaa	atgggtcaaga	1380
cacaatgaca	tgtacagaga	atggctggct	ccctcctccc	aaatgcatcc	gtatcaagac	1440
atgttcagca	tcagatatat	acattgacaa	tggatttctt	tctgaatctt	cttctatata	1500
tgctctaaat	agagaaacat	cctatagatg	taagcagggg	tatgtgacaa	atactggaga	1560
aatatcagga	tcaataactt	gccttcaaaa	tggatgggtca	cctcaaccct	catgcattaa	1620
gtcttgtgat	atgcctgtat	ttgagaattc	tataactaag	aatactagga	catgggttaa	1680
gctcaatgac	aaattagact	atgaatgtct	cggtggattt	gaaaatgaat	ataaacatac	1740
caaaggctct	ataacatgta	cttattatgg	atgggtctgat	acaccctcat	gttatgaaag	1800
agaatgcagt	gttccactc	tagaccgaaa	actagtcgtt	tccccagaa	aagaaaaata	1860
cagagttgga	gatttgtttg	aattctcctg	ccattcagga	cacagagttg	ggccagattc	1920
agtgcaatgc	taccactttg	gatgggtctcc	tgggttccct	acatgtaaaag	gtcaagtagc	1980
atcatgtgca	ccacctcttg	aaattcttaa	tggggaaatt	aatggagcaa	aaaaagttga	2040
atacagccat	ggtgaagtgg	tgaatatatga	ttgcaaacct	agattcctac	tgaagggacc	2100
caataaaatc	cagtgtgttg	atgggaattg	gacaaccttg	cctgtatgta	ttgaggagga	2160
gagaacatgt	ggagacattc	ctgaacttga	acatggctct	gccaaagtgt	ctgttctctc	2220
ctaccaccat	ggagattcag	tggagttcat	tttgtgaagaa	aacttcacaa	tgattggaca	2280
tgggtcagtt	tcttgcatga	gtggaaaatg	gaccagctt	cctaaatgtg	ttgcaacaga	2340
ccaactggag	aagtgtagag	tgctgaagtc	aactggcata	gaagcaataa	aaccaaaatt	2400
gactgaattt	acgcataact	ccaccatgga	ttacaaatgt	agagacaagc	aggagtacga	2460
acgctcaatc	tgtatcaatg	gaaaatggga	tcctgaacca	aactgtacaa	gcaaaacatc	2520
ctgccctcct	ccaccgcaga	ttccaaatac	ccaagtgatt	gaaaccaccg	tgaataactt	2580
ggatggagaa	aaattatctg	ttcttttgcca	agacaattac	ctaactcagg	actcagaaga	2640
aatggtgtgc	aaagatggaa	ggtggcagtc	attacctcgc	tgcatgtgaa	aaattccatg	2700
ttcccagccc	cctacaatag	aacatggatc	tattaattta	cccagatctt	cagaagaaag	2760

4/64

gagagattcc	attgagtcga	gcagtcacga	acatggaact	acattcagct	atgtctgtga	2820
tgatgggttc	aggatacctg	aagaaaatag	gataacctgc	tacatgggaa	aatggagcac	2880
tccacctcgc	tgtgttgga	ttccttgtgg	acctccacct	tcaattcctc	ttggtactgt	2940
ttctcttgag	ctagagagtt	accaacatgg	ggaagagggt	acataccatt	gttctacagg	3000
ctttggaatt	gatggaccag	catttattat	atgcgaaggga	ggaaagtggg	ctgacccacc	3060
aaaatgcata	aaaacggatt	gtgacgtttt	accacaggtt	aaaaatgcca	taataagagg	3120
aaagagcaaa	aaatcatata	ggacaggaga	acaagtgcga	ttcagatgtc	aatctcctta	3180
tcaaataaat	ggctcagaca	ctgtgacatg	tgtaaatagt	cgggtggattg	gacagccagt	3240
atgcaaagat	aattcctgtg	tggatccacc	acatgtgcca	aatgctacta	tagtaacaag	3300
gaccaagaat	aaatatctac	atggtgacag	agtacgttat	gaatgtaata	aacctttgga	3360
actatgtggg	caagtggaa	tgatgtgtga	aaatgggata	tggacagaaa	aaccaaagtg	3420
ccgagactca	acagggaaat	gtgggcctcc	tccacctatt	gacaatggag	acatcacctc	3480
cttgtcatta	ccagtatatg	aaccattatc	atcagttgaa	tatcaatgcc	agaagtatta	3540
tctccttaag	ggaaagaaga	caataacatg	tacaaatgga	aagtgggtctg	agccaccaac	3600
atgcttacat	gcatgtgtaa	taccagaaaa	cattatggaa	tcacacaata	taattctcaa	3660
atggagacac	actgaaaaga	tttattccca	ttcaggggag	gatattgaat	ttggatgtaa	3720
atattggatat	tataaagcaa	gagattcacc	gccatttcgt	acaaagtgcg	ttaatggcac	3780
catcaattat	cccacttgtg	tataaaatca	taatacatctt	attagttgat	tttattgttt	3840
agaaaggcac	atgcatgtga	ctaataact	ttcaatttgc	attgaagtat	tgtttaactc	3900
atgtcttctc	ataaatataa	acatttttgt	tatatggtga	ttactttgta	actttaaaaa	3960
ctattgccaa	aatgcaaaa	cagtaattca	aaactcctaa	tctaaaaatat	gatattgtcca	4020
aggacaaact	atttcaatca	agaaagtaga	tgtaagttct	tcaacatctg	tttctattca	4080
gaactttctc	agattttcct	ggataccttt	tgatgtaagg	tcctgattta	cagtggataa	4140
aggatatatt	gactgattct	tcaaattaat	atgatttccc	aaagcatgta	acaaccaaac	4200
tatcatatat	tatatgacta	atgcatacaa	ttaattacta	tataatactt	tc	4252

<210> 4

<211> 4250

<212> DNA

<213> Rattus norvegicus

<400> 4

acagcacata	cttctcttcg	agtcaactgc	tcccagatag	atccaagaca	tgagactgtc	60
agcaagaatt	atttggtcta	tattatggac	tgtttgtgta	gcagaagatt	gtaaagggtcc	120
tcctccaaga	gaaaattcag	aaattctctc	aggttcgtgg	tctgaacaac	tatattcaga	180
aggcactcag	gcaacctaca	aatgccgccc	tggataccga	acacttggta	ctattgtaaa	240
agtatgcaag	aatggagaat	gggtaccttc	taacccatca	aggatatgtc	ggaaaaggcc	300
atgtgggcat	cccgagaca	caccctttgg	gtcctttagg	ctggcagttg	gatctgaatt	360
tgaatttggg	gcaaagggtg	tttatacatg	tgatgaagg	taccaactct	taggtgaaat	420
tgattaccgt	gaatgtgatg	cagatgggtg	gaccaatgat	attccaatat	gtgaagttgt	480
gaagtgcctg	ccagtgcacg	aactggagaa	tggagaat	gtgagtgggtg	cagccgaacc	540
agaccaggaa	tattattttg	gacaggtggg	acgctttgaa	tgcaactccg	gcttcaagat	600
tgaaggacag	aaagaaatgc	actgctcaga	aaatggcctc	tggagcaatg	aaaagccaca	660
gtgtgtggaa	atttcttgcc	tgccaccacg	agttgaaaat	ggagatggta	tatatctgaa	720
accagtttac	aaggagaatg	aaagattcca	atataaatgt	aagcaagggtt	ttgtgtacaa	780
agaaagaggg	gatgctgtct	gcacgggttc	tggatggaat	cctcagcctt	cctgtgaaga	840
aatgacatgt	ttgactccat	atattccaaa	tggatcttac	acacctcaca	ggattaaaca	900
cagaattgat	gatgaaatca	gatattgaatg	taaaaatggc	ttctatcctg	caacccgatc	960
acctgtttca	aagtgtacaa	ttactggctg	gatccctgct	ccaagatgta	gcttgaaacc	1020
ttgtgatatt	ccacaattca	aacatggacg	tctgtattat	gaagaaagcc	ggagacccta	1080
cttcccagta	cctataggaa	aggagtacag	ctattactgt	gacaacgggt	ttacaacgcc	1140
ttcacagtca	tactgggact	accttcgttg	cacagtaaat	gggtgggagc	ctgaagttcc	1200
atgcctcagg	caatgtatct	tccattatgt	ggaatatgga	gaatctttat	actggcaagg	1260
aagatatata	gagggtcagt	ctgcaaaaag	ccagtgtcac	agtggctata	gtcttccaaa	1320
tggtcaagat	acaatattat	gtacagaaaa	tggctgggtc	cctcctccca	aatgcgtccg	1380
tatcaagact	tggtcagtat	cagatataga	aattgaaaat	gggttttttt	ctgaatctga	1440
ttatacatat	gctctaaata	gaaaaacacg	gtatagatgt	aaacagggat	atgtaacaaa	1500
taccggagaa	atatcaggaa	taattacttg	tcttcaagat	ggatgggtcac	ctcgaccctc	1560
atgcattaag	tcttgtgata	tgcctgtatt	tgagaatgct	atgactaaga	ataataacac	1620
atgggtttaaa	ctcaatgaca	aattagacta	tgaatgtcac	attggatatg	aaaaatgaata	1680
taaacatacc	aaaggctcta	taacatgtac	ttatgatgga	tggctagta	caccctcctg	1740
ttatgaaaga	gaatgcagca	ttcccctggt	acaccaagac	ttagttgttt	ttcccagaga	1800

5/64

```

agtaaaatac aaagttggag attcgttgag tttctcttgc cgttcaggac acagagttgg 1860
agcagattta gtgcaatgct accacttttg atgggtcccct aatttcccaa cgtgtgaagg 1920
ccaagtaaaa tcatgtgacc aacctcttga aatcccgaat ggggaaataa agggaaacaaa 1980
aaaagttgaa tacagccatg gtgacgtggt ggaatatgat tgcaaaccta gatttctact 2040
gaagggaccc aataaaaatcc agtgtgttga cgggaagtgg acaaccttgc cgatatgcgt 2100
tgagtatgag agaacatgtg gagaccttcc tgcacttgag catggctctg tccagttatc 2160
tgtccctccc taccaccacg gagattcagt ggagttcact tgtgcagaaa ccttcacaat 2220
gattgggcat gcagtagttt tctgcattag tgggaagggtgg accgagcttc ctcaatgtgt 2280
tgcaacagat caactggaga agtgtaaagc cccgaagtca actggcatag atgcaattca 2340
tccaaataag aatgaattta atcataactt tagtgtgagt tacagatgta gacaaaagca 2400
ggagtatgaa cattcaatct gcatcaatgg aagatgggat cctgaaccaa actgtacaag 2460
aaatgagaaa agattctgcc ctccctcccc acagattcca aatgccccaa tgattgaaac 2520
cacagtgaag tacttggatg gagagaaagt atctgttctt tgccaagatg gttacctaac 2580
tcagggccca gaagaaatgg tgtgtaaaca tgggaagggtgg cagtcgttac cagctcgttac 2640
ggaaaaaatt ccattgtccc agccccctaa aattgaacat ggatctatta agtcgcccag 2700
gtcctcagaa gagagagatt taattgagtc cagcagttat gaacacggaa ctacattcag 2760
ctatgtctgt gatgatggat tcaggatata tgaagaaaat agggtaacct gcaacatggg 2820
aaaatggagc tctctgcctc gttgtgttgg aataccttgt ggacccccac cttcaattcc 2880
tcttggattt gtttctcatg aactagaaaag ttaccaatat ggagaggagg ttacatacaa 2940
ttgttctgaa ggctttggaa ttgatggacc agcatttatt aaatgtgtag gaggacagtg 3000
gtctgaacca cccaaatgca taaaaactga ttgtgacaac ttgccacat ttgaaattgc 3060
caaaccgaca gaaaagaaaa aaaaatcata caggtcagga gaacaagtga cattcagatg 3120
tccacctccg tatcgaatgg atggctctga cattgtcaca tgtgttaata cgaagtggat 3180
tggacagccg gtatgcaaag ataattcctg tgtgaatcca ccacatgtgc caaatgctac 3240
tatactaaca aggcacaaga ctaaatatcc atctggtgac aaagtacgtt atgactgtaa 3300
taaacctttt gaattatttg gggaagtggga agtgatgtgc caaaacggga tttggacaga 3360
accaccgaaa tgcaaagatt caacagggaa atgtgggcct cctccacctt ttgacaatgg 3420
agacatcacc tccttgtcat taccagtata tgcaccatta tcatcagttg aatatcaatg 3480
ccagaactat tatctactta agggaaataa gatagtaaca tgtagaaatg gaaagtgggtc 3540
tcagccacca acctgcttac atgcatgtgt gataccagaa gatattatgg aaaaacataa 3600
tatagtcttc agatggaggg aaaaatgcaaa gatttattcc caatcagggg agaatattga 3660
attcatgtgt aaacctggat atagaaaatt cagaggatca cctccgtttc gtacaaagtg 3720
cattgagggt cacatcaatt atcccacttg tgtataaaat cgctatacaa ttattagtaa 3780
accttatgga tgaacctttg tttagaaatg cacatgtata ttactaatac agtttgaatt 3840
tacatttgaa atattgttta gctcatttct tctaataagt atataaactt tttttatatg 3900
gtgggttaatc agtaacttta cagactgttg ccacaaagca agaacattgc attcaaaact 3960
cctaatacaa aatatgatat gtccaaggac aaactatgtc taagcaagaa aataaatggt 4020
agttcttcaa tgtctgtttt tattcaggat ttttcagatt ttcttggata ccttttgttg 4080
ttaggttctg attcacagtg agtggaagac acactgactc tgacttcaaa ttagtattac 4140
ttgccaatac ataacaacca aactatcata atatcacaaa tgtatacagc taattactgt 4200
gtcctacctt tgtatcaata aagaaatcta agaaagttct tgcttatgaa 4250

```

<210> 5

<211> 1231

<212> PRT

<213> Homo sapiens

<400> 5

```

Met Arg Leu Leu Ala Lys Ile Ile Cys Leu Met Leu Trp Ala Ile Cys
 1          5          10          15
Val Ala Glu Asp Cys Asn Glu Leu Pro Pro Arg Arg Asn Thr Glu Ile
          20          25          30
Leu Thr Gly Ser Trp Ser Asp Gln Thr Tyr Pro Glu Gly Thr Gln Ala
          35          40          45
Ile Tyr Lys Cys Arg Pro Gly Tyr Arg Ser Leu Gly Asn Val Ile Met
          50          55          60
Val Cys Arg Lys Gly Glu Trp Val Ala Leu Asn Pro Leu Arg Lys Cys
          65          70          75          80
Gln Lys Arg Pro Cys Gly His Pro Gly Asp Thr Pro Phe Gly Thr Phe
          85          90          95
Thr Leu Thr Gly Gly Asn Val Phe Glu Tyr Gly Val Lys Ala Val Tyr
          100          105          110

```

6/64

Thr	Cys	Asn	Glu	Gly	Tyr	Gln	Leu	Leu	Gly	Glu	Ile	Asn	Tyr	Arg	Glu
		115					120					125			
Cys	Asp	Thr	Asp	Gly	Trp	Thr	Asn	Asp	Ile	Pro	Ile	Cys	Glu	Val	Val
	130					135					140				
Lys	Cys	Leu	Pro	Val	Thr	Ala	Pro	Glu	Asn	Gly	Lys	Ile	Val	Ser	Ser
145					150					155					160
Ala	Met	Glu	Pro	Asp	Arg	Glu	Tyr	His	Phe	Gly	Gln	Ala	Val	Arg	Phe
				165					170					175	
Val	Cys	Asn	Ser	Gly	Tyr	Lys	Ile	Glu	Gly	Asp	Glu	Glu	Met	His	Cys
		180						185					190		
Ser	Asp	Asp	Gly	Phe	Trp	Ser	Lys	Glu	Lys	Pro	Lys	Cys	Val	Glu	Ile
	195					200						205			
Ser	Cys	Lys	Ser	Pro	Asp	Val	Ile	Asn	Gly	Ser	Pro	Ile	Ser	Gln	Lys
	210					215					220				
Ile	Ile	Tyr	Lys	Glu	Asn	Glu	Arg	Phe	Gln	Tyr	Lys	Cys	Asn	Met	Gly
225					230					235					240
Tyr	Glu	Tyr	Ser	Glu	Arg	Gly	Asp	Ala	Val	Cys	Thr	Glu	Ser	Gly	Trp
				245					250					255	
Arg	Pro	Leu	Pro	Ser	Cys	Glu	Glu	Lys	Ser	Cys	Asp	Asn	Pro	Tyr	Ile
		260						265					270		
Pro	Asn	Gly	Asp	Tyr	Ser	Pro	Leu	Arg	Ile	Lys	His	Arg	Thr	Gly	Asp
	275						280					285			
Glu	Ile	Thr	Tyr	Gln	Cys	Arg	Asn	Gly	Phe	Tyr	Pro	Ala	Thr	Arg	Gly
	290					295					300				
Asn	Thr	Ala	Lys	Cys	Thr	Ser	Thr	Gly	Trp	Ile	Pro	Ala	Pro	Arg	Cys
305					310					315					320
Thr	Leu	Lys	Pro	Cys	Asp	Tyr	Pro	Asp	Ile	Lys	His	Gly	Gly	Leu	Tyr
				325					330					335	
His	Glu	Asn	Met	Arg	Arg	Pro	Tyr	Phe	Pro	Val	Ala	Val	Gly	Lys	Tyr
		340						345					350		
Tyr	Ser	Tyr	Tyr	Cys	Asp	Glu	His	Phe	Glu	Thr	Pro	Ser	Gly	Ser	Tyr
		355					360					365			
Trp	Asp	His	Ile	His	Cys	Thr	Gln	Asp	Gly	Trp	Ser	Pro	Ala	Val	Pro
	370					375					380				
Cys	Leu	Arg	Lys	Cys	Tyr	Phe	Pro	Tyr	Leu	Glu	Asn	Gly	Tyr	Asn	Gln
385					390					395					400
Asn	His	Gly	Arg	Lys	Phe	Val	Gln	Gly	Lys	Ser	Ile	Asp	Val	Ala	Cys
				405					410					415	
His	Pro	Gly	Tyr	Ala	Leu	Pro	Lys	Ala	Gln	Thr	Thr	Val	Thr	Cys	Met
			420					425					430		
Glu	Asn	Gly	Trp	Ser	Pro	Thr	Pro	Arg	Cys	Ile	Arg	Val	Lys	Thr	Cys
		435				440						445			
Ser	Lys	Ser	Ser	Ile	Asp	Ile	Glu	Asn	Gly	Phe	Ile	Ser	Glu	Ser	Gln
	450					455					460				
Tyr	Thr	Tyr	Ala	Leu	Lys	Glu	Lys	Ala	Lys	Tyr	Gln	Cys	Lys	Leu	Gly
465					470					475					480
Tyr	Val	Thr	Ala	Asp	Gly	Glu	Thr	Ser	Gly	Ser	Ile	Thr	Cys	Gly	Lys
				485					490					495	
Asp	Gly	Trp	Ser	Ala	Gln	Pro	Thr	Cys	Ile	Lys	Ser	Cys	Asp	Ile	Pro
			500					505					510		
Val	Phe	Met	Asn	Ala	Arg	Thr	Lys	Asn	Asp	Phe	Thr	Trp	Phe	Lys	Leu
		515					520					525			
Asn	Asp	Thr	Leu	Asp	Tyr	Glu	Cys	His	Asp	Gly	Tyr	Glu	Ser	Asn	Thr
		530				535					540				
Gly	Ser	Thr	Thr	Gly	Ser	Ile	Val	Cys	Gly	Tyr	Asn	Gly	Trp	Ser	Asp
545					550					555					560
Leu	Pro	Ile	Cys	Tyr	Glu	Arg	Glu	Cys	Glu	Leu	Pro	Lys	Ile	Asp	Val
				565					570					575	
His	Leu	Val	Pro	Asp	Arg	Lys	Lys	Asp	Gln	Tyr	Lys	Val	Gly	Glu	Val
			580					585					590		
Leu	Lys	Phe	Ser	Cys	Lys	Pro	Gly	Phe	Thr	Ile	Val	Gly	Pro	Asn	Ser
		595					600					605			

7/64

Val	Gln	Cys	Tyr	His	Phe	Gly	Leu	Ser	Pro	Asp	Leu	Pro	Ile	Cys	Lys
610						615					620				
Glu	Gln	Val	Gln	Ser	Cys	Gly	Pro	Pro	Pro	Glu	Leu	Leu	Asn	Gly	Asn
625					630					635					640
Val	Lys	Glu	Lys	Thr	Lys	Glu	Glu	Tyr	Gly	His	Ser	Glu	Val	Val	Glu
				645					650					655	
Tyr	Tyr	Cys	Asn	Pro	Arg	Phe	Leu	Met	Lys	Gly	Pro	Asn	Lys	Ile	Gln
			660					665					670		
Cys	Val	Asp	Gly	Glu	Trp	Thr	Thr	Leu	Pro	Val	Cys	Ile	Val	Glu	Glu
		675					680					685			
Ser	Thr	Cys	Gly	Asp	Ile	Pro	Glu	Leu	Glu	His	Gly	Trp	Ala	Gln	Leu
	690					695					700				
Ser	Ser	Pro	Pro	Tyr	Tyr	Tyr	Gly	Asp	Ser	Val	Glu	Phe	Asn	Cys	Ser
705					710					715					720
Glu	Ser	Phe	Thr	Met	Ile	Gly	His	Arg	Ser	Ile	Thr	Cys	Ile	His	Gly
				725					730					735	
Val	Trp	Thr	Gln	Leu	Pro	Gln	Cys	Val	Ala	Ile	Asp	Lys	Leu	Lys	Lys
			740				745						750		
Cys	Lys	Ser	Ser	Asn	Leu	Ile	Ile	Leu	Glu	Glu	His	Leu	Lys	Asn	Lys
		755					760					765			
Lys	Glu	Phe	Asp	His	Asn	Ser	Asn	Ile	Arg	Tyr	Arg	Cys	Arg	Gly	Lys
	770					775					780				
Glu	Gly	Trp	Ile	His	Thr	Val	Cys	Ile	Asn	Gly	Arg	Trp	Asp	Pro	Glu
785					790					795					800
Val	Asn	Cys	Ser	Met	Ala	Gln	Ile	Gln	Leu	Cys	Pro	Pro	Pro	Pro	Gln
				805					810						815
Ile	Pro	Asn	Ser	His	Asn	Met	Thr	Thr	Thr	Leu	Asn	Tyr	Arg	Asp	Gly
		820					825						830		
Glu	Lys	Val	Ser	Val	Leu	Cys	Gln	Glu	Asn	Tyr	Leu	Ile	Gln	Glu	Gly
		835					840					845			
Glu	Glu	Ile	Thr	Cys	Lys	Asp	Gly	Arg	Trp	Gln	Ser	Ile	Pro	Leu	Cys
	850					855					860				
Val	Glu	Lys	Ile	Pro	Cys	Ser	Gln	Pro	Pro	Gln	Ile	Glu	His	Gly	Thr
865					870					875					880
Ile	Asn	Ser	Ser	Arg	Ser	Ser	Gln	Glu	Ser	Tyr	Ala	His	Gly	Thr	Lys
				885					890					895	
Leu	Ser	Tyr	Thr	Cys	Glu	Gly	Gly	Phe	Arg	Ile	Ser	Glu	Glu	Asn	Glu
			900					905					910		
Thr	Thr	Cys	Tyr	Met	Gly	Lys	Trp	Ser	Ser	Pro	Pro	Gln	Cys	Glu	Gly
		915					920					925			
Leu	Pro	Cys	Lys	Ser	Pro	Pro	Glu	Ile	Ser	His	Gly	Val	Val	Ala	His
	930					935					940				
Met	Ser	Asp	Ser	Tyr	Gln	Tyr	Gly	Glu	Glu	Val	Thr	Tyr	Lys	Cys	Phe
945					950					955					960
Glu	Gly	Phe	Gly	Ile	Asp	Gly	Pro	Ala	Ile	Ala	Lys	Cys	Leu	Gly	Glu
				965					970					975	
Lys	Trp	Ser	His	Pro	Pro	Ser	Cys	Ile	Lys	Thr	Asp	Cys	Leu	Ser	Leu
			980					985					990		
Pro	Ser	Phe	Glu	Asn	Ala	Ile	Pro	Met	Gly	Glu	Lys	Lys	Asp	Val	Tyr
		995					1000					1005			
Lys	Ala	Gly	Glu	Gln	Val	Thr	Tyr	Thr	Cys	Ala	Thr	Tyr	Tyr	Lys	Met
	1010					1015					1020				
Asp	Gly	Ala	Ser	Asn	Val	Thr	Cys	Ile	Asn	Ser	Arg	Trp	Thr	Gly	Arg
1025					1030					1035					1040
Pro	Thr	Cys	Arg	Asp	Thr	Ser	Cys	Val	Asn	Pro	Pro	Thr	Val	Gln	Asn
				1045					1050					1055	
Ala	Tyr	Ile	Val	Ser	Arg	Gln	Met	Ser	Lys	Tyr	Pro	Ser	Gly	Glu	Arg
			1060					1065					1070		
Val	Arg	Tyr	Gln	Cys	Arg	Ser	Pro	Tyr	Glu	Met	Phe	Gly	Asp	Glu	Glu
	1075						1080					1085			
Val	Met	Cys	Leu	Asn	Gly	Asn	Trp	Thr	Glu	Pro	Pro	Gln	Cys	Lys	Asp
	1090					1095					1100				

8/64

Ser Thr Gly Lys Cys Gly Pro Pro Pro Pro Ile Asp Asn Gly Asp Ile
 1105 1110 1115 1120
 Thr Ser Phe Pro Leu Ser Val Tyr Ala Pro Ala Ser Ser Val Glu Tyr
 1125 1130 1135
 Gln Cys Gln Asn Leu Tyr Gln Leu Glu Gly Asn Lys Arg Ile Thr Cys
 1140 1145 1150
 Arg Asn Gly Gln Trp Ser Glu Pro Pro Lys Cys Leu His Pro Cys Val
 1155 1160 1165
 Ile Ser Arg Glu Ile Met Glu Asn Tyr Asn Ile Ala Leu Arg Trp Thr
 1170 1175 1180
 Ala Lys Gln Lys Leu Tyr Ser Arg Thr Gly Glu Ser Val Glu Phe Val
 1185 1190 1195 1200
 Cys Lys Arg Gly Tyr Arg Leu Ser Ser Arg Ser His Thr Leu Arg Thr
 1205 1210 1215
 Thr Cys Trp Asp Gly Lys Leu Glu Tyr Pro Thr Cys Ala Lys Arg
 1220 1225 1230

<210> 6

<211> 449

<212> PRT

<213> Homo sapiens

<400> 6

Met Arg Leu Leu Ala Lys Ile Ile Cys Leu Met Leu Trp Ala Ile Cys
 1 5 10 15
 Val Ala Glu Asp Cys Asn Glu Leu Pro Pro Arg Arg Asn Thr Glu Ile
 20 25 30
 Leu Thr Gly Ser Trp Ser Asp Gln Thr Tyr Pro Glu Gly Thr Gln Ala
 35 40 45
 Ile Tyr Lys Cys Arg Pro Gly Tyr Arg Ser Leu Gly Asn Val Ile Met
 50 55 60
 Val Cys Arg Lys Gly Glu Trp Val Ala Leu Asn Pro Leu Arg Lys Cys
 65 70 75 80
 Gln Lys Arg Pro Cys Gly His Pro Gly Asp Thr Pro Phe Gly Thr Phe
 85 90 95
 Thr Leu Thr Gly Glu Asn Val Phe Glu Tyr Gly Val Lys Ala Val Tyr
 100 105 110
 Thr Cys Asn Glu Gly Tyr Gln Leu Leu Gly Glu Ile Asn Tyr Arg Glu
 115 120 125
 Cys Asp Thr Asp Gly Trp Thr Asn Asp Ile Pro Ile Cys Glu Val Val
 130 135 140
 Lys Cys Leu Pro Val Thr Ala Pro Glu Asn Gly Lys Ile Val Ser Ser
 145 150 155 160
 Ala Met Glu Pro Asp Arg Glu Tyr His Phe Gly Gln Ala Val Arg Phe
 165 170 175
 Val Cys Asn Ser Gly Tyr Lys Ile Glu Gly Asp Glu Glu Met His Cys
 180 185 190
 Ser Asp Asp Gly Phe Trp Ser Lys Glu Lys Pro Lys Cys Val Glu Ile
 195 200 205
 Ser Cys Lys Ser Pro Asp Val Ile Asn Gly Ser Pro Ile Ser Gln Lys
 210 215 220
 Ile Ile Tyr Lys Glu Asn Glu Arg Phe Gln Tyr Lys Cys Asn Met Gly
 225 230 235 240
 Tyr Glu Tyr Ser Glu Arg Gly Asp Ala Val Cys Thr Glu Ser Gly Trp
 245 250 255
 Arg Pro Leu Pro Ser Cys Glu Glu Lys Ser Cys Asp Asn Pro Tyr Ile
 260 265 270
 Pro Asn Gly Asp Tyr Ser Pro Leu Arg Ile Lys His Arg Thr Gly Asp
 275 280 285
 Glu Ile Thr Tyr Gln Cys Arg Asn Gly Phe Tyr Pro Ala Thr Arg Gly
 290 295 300

9/64

```

Asn Thr Ala Lys Cys Thr Ser Thr Gly Trp Ile Pro Ala Pro Arg Cys
305          310          315          320
Thr Leu Lys Pro Cys Asp Tyr Pro Asp Ile Lys His Gly Gly Leu Tyr
          325          330          335
His Glu Asn Met Arg Arg Pro Tyr Phe Pro Val Ala Val Gly Lys Tyr
          340          345          350
Tyr Ser Tyr Tyr Cys Asp Glu His Phe Glu Thr Pro Ser Gly Ser Tyr
          355          360          365
Trp Asp His Ile His Cys Thr Gln Asp Gly Trp Ser Pro Ala Val Pro
          370          375          380
Cys Leu Arg Lys Cys Tyr Phe Pro Tyr Leu Glu Asn Gly Tyr Asn Gln
385          390          395          400
Asn His Gly Arg Lys Phe Val Gln Gly Lys Ser Ile Asp Val Ala Cys
          405          410          415
His Pro Gly Tyr Ala Leu Pro Lys Ala Gln Thr Thr Val Thr Cys Met
          420          425          430
Glu Asn Gly Trp Ser Pro Thr Pro Arg Cys Ile Arg Val Ser Phe Thr
          435          440          445
Leu

```

```

<210> 7
<211> 1234
<212> PRT
<213> Mus musculus

```

```

<400> 7
Met Arg Leu Ser Ala Arg Ile Ile Trp Leu Ile Leu Trp Thr Val Cys
1          5          10          15
Ala Ala Glu Asp Cys Lys Gly Pro Pro Pro Arg Glu Asn Ser Glu Ile
20          25          30
Leu Ser Gly Ser Trp Ser Glu Gln Leu Tyr Pro Glu Gly Thr Gln Ala
35          40          45
Thr Tyr Lys Cys Arg Pro Gly Tyr Arg Thr Leu Gly Thr Ile Val Lys
50          55          60
Val Cys Lys Asn Gly Lys Trp Val Ala Ser Asn Pro Ser Arg Ile Cys
65          70          75          80
Arg Lys Lys Pro Cys Gly His Pro Gly Asp Thr Pro Phe Gly Ser Phe
85          90          95
Arg Leu Ala Val Gly Ser Gln Phe Glu Phe Gly Ala Lys Val Val Tyr
100          105          110
Thr Cys Asp Asp Gly Tyr Gln Leu Leu Gly Glu Ile Asp Tyr Arg Glu
115          120          125
Cys Gly Ala Asp Gly Trp Ile Asn Asp Ile Pro Leu Cys Glu Val Val
130          135          140
Lys Cys Leu Pro Val Thr Glu Leu Glu Asn Gly Arg Ile Val Ser Gly
145          150          155          160
Ala Ala Glu Thr Asp Gln Glu Tyr Tyr Phe Gly Gln Val Val Arg Phe
165          170          175
Glu Cys Asn Ser Gly Phe Lys Ile Glu Gly His Lys Glu Ile His Cys
180          185          190
Ser Glu Asn Gly Leu Trp Ser Asn Glu Lys Pro Arg Cys Val Glu Ile
195          200          205
Leu Cys Thr Pro Pro Arg Val Glu Asn Gly Asp Gly Ile Asn Val Lys
210          215          220
Pro Val Tyr Lys Glu Asn Glu Arg Tyr His Tyr Lys Cys Lys His Gly
225          230          235          240
Tyr Val Pro Lys Glu Arg Gly Asp Ala Val Cys Thr Gly Ser Gly Trp
245          250          255
Ser Ser Gln Pro Phe Cys Glu Glu Lys Arg Cys Ser Pro Pro Tyr Ile
260          265          270

```


10/64

Leu	Asn	Gly	Ile	Tyr	Thr	Pro	His	Arg	Ile	Ile	His	Arg	Ser	Asp	Asp
		275					280					285			
Glu	Ile	Arg	Tyr	Glu	Cys	Asn	Tyr	Gly	Phe	Tyr	Pro	Val	Thr	Gly	Ser
		290					295				300				
Thr	Val	Ser	Lys	Cys	Thr	Pro	Thr	Gly	Trp	Ile	Pro	Val	Pro	Arg	Cys
305					310					315					320
Thr	Leu	Lys	Pro	Cys	Glu	Phe	Pro	Gln	Phe	Lys	Tyr	Gly	Arg	Leu	Tyr
				325					330					335	
Tyr	Glu	Glu	Ser	Leu	Arg	Pro	Asn	Phe	Pro	Val	Ser	Ile	Gly	Asn	Lys
			340					345					350		
Tyr	Ser	Tyr	Lys	Cys	Asp	Asn	Gly	Phe	Ser	Pro	Pro	Ser	Gly	Tyr	Ser
		355					360					365			
Trp	Asp	Tyr	Leu	Arg	Cys	Thr	Ala	Gln	Gly	Trp	Glu	Pro	Glu	Val	Pro
370						375					380				
Cys	Val	Arg	Lys	Cys	Val	Phe	His	Tyr	Val	Glu	Asn	Gly	Asp	Ser	Ala
385					390					395					400
Tyr	Trp	Glu	Lys	Val	Tyr	Val	Gln	Gly	Gln	Ser	Leu	Lys	Val	Gln	Cys
			405						410					415	
Tyr	Asn	Gly	Tyr	Ser	Leu	Gln	Asn	Gly	Gln	Asp	Thr	Met	Thr	Cys	Thr
			420					425					430		
Glu	Asn	Gly	Trp	Ser	Pro	Pro	Pro	Lys	Cys	Ile	Arg	Ile	Lys	Thr	Cys
		435					440					445			
Ser	Ala	Ser	Asp	Ile	His	Ile	Asp	Asn	Gly	Phe	Leu	Ser	Glu	Ser	Ser
		450					455				460				
Ser	Ile	Tyr	Ala	Leu	Asn	Arg	Glu	Thr	Ser	Tyr	Arg	Cys	Lys	Gln	Gly
465					470					475					480
Tyr	Val	Thr	Asn	Thr	Gly	Glu	Ile	Ser	Gly	Ser	Ile	Thr	Cys	Leu	Gln
				485					490					495	
Asn	Gly	Trp	Ser	Pro	Gln	Pro	Ser	Cys	Ile	Lys	Ser	Cys	Asp	Met	Pro
			500					505					510		
Val	Phe	Glu	Asn	Ser	Ile	Thr	Lys	Asn	Thr	Arg	Thr	Trp	Phe	Lys	Leu
		515					520					525			
Asn	Asp	Lys	Leu	Asp	Tyr	Glu	Cys	Leu	Val	Gly	Phe	Glu	Asn	Glu	Tyr
		530					535				540				
Lys	His	Thr	Lys	Gly	Ser	Ile	Thr	Cys	Thr	Tyr	Tyr	Gly	Trp	Ser	Asp
545					550					555					560
Thr	Pro	Ser	Cys	Tyr	Glu	Arg	Glu	Cys	Ser	Val	Pro	Thr	Leu	Asp	Arg
				565					570					575	
Lys	Leu	Val	Val	Ser	Pro	Arg	Lys	Glu	Lys	Tyr	Arg	Val	Gly	Asp	Leu
			580					585					590		
Leu	Glu	Phe	Ser	Cys	His	Ser	Gly	His	Arg	Val	Gly	Pro	Asp	Ser	Val
		595					600					605			
Gln	Cys	Tyr	His	Phe	Gly	Trp	Ser	Pro	Gly	Phe	Pro	Thr	Cys	Lys	Gly
		610				615					620				
Gln	Val	Ala	Ser	Cys	Ala	Pro	Pro	Leu	Glu	Ile	Leu	Asn	Gly	Glu	Ile
625					630					635					640
Asn	Gly	Ala	Lys	Lys	Val	Glu	Tyr	Ser	His	Gly	Glu	Val	Val	Lys	Tyr
				645					650					655	
Asp	Cys	Lys	Pro	Arg	Phe	Leu	Leu	Lys	Gly	Pro	Asn	Lys	Ile	Gln	Cys
			660					665					670		
Val	Asp	Gly	Asn	Trp	Thr	Thr	Leu	Pro	Val	Cys	Ile	Glu	Glu	Glu	Arg
		675					680					685			
Thr	Cys	Gly	Asp	Ile	Pro	Glu	Leu	Glu	His	Gly	Ser	Ala	Lys	Cys	Ser
		690					695				700				
Val	Pro	Pro	Tyr	His	His	Gly	Asp	Ser	Val	Glu	Phe	Ile	Cys	Glu	Glu
705					710					715					720
Asn	Phe	Thr	Met	Ile	Gly	His	Gly	Ser	Val	Ser	Cys	Ile	Ser	Gly	Lys
				725					730					735	
Trp	Thr	Gln	Leu	Pro	Lys	Cys	Val	Ala	Thr	Asp	Gln	Leu	Glu	Lys	Cys
			740					745					750		
Arg	Val	Leu	Lys	Ser	Thr	Gly	Ile	Glu	Ala	Ile	Lys	Pro	Lys	Leu	Thr
		755					760					765			

11/64

Glu Phe Thr His Asn Ser Thr Met Asp Tyr Lys Cys Arg Asp Lys Gln
 770 775 780
 Glu Tyr Glu Arg Ser Ile Cys Ile Asn Gly Lys Trp Asp Pro Glu Pro
 785 790 795 800
 Asn Cys Thr Ser Lys Thr Ser Cys Pro Pro Pro Gln Ile Pro Asn
 805 810 815
 Thr Gln Val Ile Glu Thr Thr Val Lys Tyr Leu Asp Gly Glu Lys Leu
 820 825 830
 Ser Val Leu Cys Gln Asp Asn Tyr Leu Thr Gln Asp Ser Glu Glu Met
 835 840 845
 Val Cys Lys Asp Gly Arg Trp Gln Ser Leu Pro Arg Cys Ile Glu Lys
 850 855 860
 Ile Pro Cys Ser Gln Pro Pro Thr Ile Glu His Gly Ser Ile Asn Leu
 865 870 875 880
 Pro Arg Ser Ser Glu Glu Arg Arg Asp Ser Ile Glu Ser Ser Ser His
 885 890 895
 Glu His Gly Thr Thr Phe Ser Tyr Val Cys Asp Asp Gly Phe Arg Ile
 900 905 910
 Pro Glu Glu Asn Arg Ile Thr Cys Tyr Met Gly Lys Trp Ser Thr Pro
 915 920 925
 Pro Arg Cys Val Gly Leu Pro Cys Gly Pro Pro Pro Ser Ile Pro Leu
 930 935 940
 Gly Thr Val Ser Leu Glu Leu Glu Ser Tyr Gln His Gly Glu Glu Val
 945 950 955 960
 Thr Tyr His Cys Ser Thr Gly Phe Gly Ile Asp Gly Pro Ala Phe Ile
 965 970 975
 Ile Cys Glu Gly Gly Lys Trp Ser Asp Pro Pro Lys Cys Ile Lys Thr
 980 985 990
 Asp Cys Asp Val Leu Pro Thr Val Lys Asn Ala Ile Ile Arg Gly Lys
 995 1000 1005
 Ser Lys Lys Ser Tyr Arg Thr Gly Glu Gln Val Thr Phe Arg Cys Gln
 1010 1015 1020
 Ser Pro Tyr Gln Met Asn Gly Ser Asp Thr Val Thr Cys Val Asn Ser
 1025 1030 1035 1040
 Arg Trp Ile Gly Gln Pro Val Cys Lys Asp Asn Ser Cys Val Asp Pro
 1045 1050 1055
 Pro His Val Pro Asn Ala Thr Ile Val Thr Arg Thr Lys Asn Lys Tyr
 1060 1065 1070
 Leu His Gly Asp Arg Val Arg Tyr Glu Cys Asn Lys Pro Leu Glu Leu
 1075 1080 1085
 Phe Gly Gln Val Glu Val Met Cys Glu Asn Gly Ile Trp Thr Glu Lys
 1090 1095 1100
 Pro Lys Cys Arg Asp Ser Thr Gly Lys Cys Gly Pro Pro Pro Pro Ile
 1105 1110 1115 1120
 Asp Asn Gly Asp Ile Thr Ser Leu Ser Leu Pro Val Tyr Glu Pro Leu
 1125 1130 1135
 Ser Ser Val Glu Tyr Gln Cys Gln Lys Tyr Tyr Leu Leu Lys Gly Lys
 1140 1145 1150
 Lys Thr Ile Thr Cys Thr Asn Gly Lys Trp Ser Glu Pro Pro Thr Cys
 1155 1160 1165
 Leu His Ala Cys Val Ile Pro Glu Asn Ile Met Glu Ser His Asn Ile
 1170 1175 1180
 Ile Leu Lys Trp Arg His Thr Glu Lys Ile Tyr Ser His Ser Gly Glu
 1185 1190 1195 1200
 Asp Ile Glu Phe Gly Cys Lys Tyr Gly Tyr Tyr Lys Ala Arg Asp Ser
 1205 1210 1215
 Pro Pro Phe Arg Thr Lys Cys Ile Asn Gly Thr Ile Asn Tyr Pro Thr
 1220 1225 1230
 Cys Val

12/64

<210> 8
 <211> 1235
 <212> PRT
 <213> Rattus norvegicus

<400> 8
 Met Arg Leu Ser Ala Arg Ile Ile Trp Leu Ile Leu Trp Thr Val Cys
 1 5 10 15
 Val Ala Glu Asp Cys Lys Gly Pro Pro Arg Glu Asn Ser Glu Ile
 20 25 30
 Leu Ser Gly Ser Trp Ser Glu Gln Leu Tyr Ser Glu Gly Thr Gln Ala
 35 40 45
 Thr Tyr Lys Cys Arg Pro Gly Tyr Arg Thr Leu Gly Thr Ile Val Lys
 50 55 60
 Val Cys Lys Asn Gly Glu Trp Val Pro Ser Asn Pro Ser Arg Ile Cys
 65 70 75 80
 Arg Lys Arg Pro Cys Gly His Pro Gly Asp Thr Pro Phe Gly Ser Phe
 85 90 95
 Arg Leu Ala Val Gly Ser Glu Phe Glu Phe Gly Ala Lys Val Val Tyr
 100 105 110
 Thr Cys Asp Glu Gly Tyr Gln Leu Leu Gly Glu Ile Asp Tyr Arg Glu
 115 120 125
 Cys Asp Ala Asp Gly Trp Thr Asn Asp Ile Pro Ile Cys Glu Val Val
 130 135 140
 Lys Cys Leu Pro Val Thr Glu Leu Glu Asn Gly Arg Ile Val Ser Gly
 145 150 155 160
 Ala Ala Glu Pro Asp Gln Glu Tyr Tyr Phe Gly Gln Val Val Arg Phe
 165 170 175
 Glu Cys Asn Ser Gly Phe Lys Ile Glu Gly Gln Lys Glu Met His Cys
 180 185 190
 Ser Glu Asn Gly Leu Trp Ser Asn Glu Lys Pro Gln Cys Val Glu Ile
 195 200 205
 Ser Cys Leu Pro Pro Arg Val Glu Asn Gly Asp Gly Ile Tyr Leu Lys
 210 215 220
 Pro Val Tyr Lys Glu Asn Glu Arg Phe Gln Tyr Lys Cys Lys Gln Gly
 225 230 235 240
 Phe Val Tyr Lys Glu Arg Gly Asp Ala Val Cys Thr Gly Ser Gly Trp
 245 250 255
 Asn Pro Gln Pro Ser Cys Glu Glu Met Thr Cys Leu Thr Pro Tyr Ile
 260 265 270
 Pro Asn Gly Ile Tyr Thr Pro His Arg Ile Lys His Arg Ile Asp Asp
 275 280 285
 Glu Ile Arg Tyr Glu Cys Lys Asn Gly Phe Tyr Pro Ala Thr Arg Ser
 290 295 300
 Pro Val Ser Lys Cys Thr Ile Thr Gly Trp Ile Pro Ala Pro Arg Cys
 305 310 315 320
 Ser Leu Lys Pro Cys Asp Phe Pro Gln Phe Lys His Gly Arg Leu Tyr
 325 330 335
 Tyr Glu Glu Ser Arg Arg Pro Tyr Phe Pro Val Pro Ile Gly Lys Glu
 340 345 350
 Tyr Ser Tyr Tyr Cys Asp Asn Gly Phe Thr Thr Pro Ser Gln Ser Tyr
 355 360 365
 Trp Asp Tyr Leu Arg Cys Thr Val Asn Gly Trp Glu Pro Glu Val Pro
 370 375 380
 Cys Leu Arg Gln Cys Ile Phe His Tyr Val Glu Tyr Gly Glu Ser Leu
 385 390 395 400
 Tyr Trp Gln Arg Arg Tyr Ile Glu Gly Gln Ser Ala Lys Val Gln Cys
 405 410 415
 His Ser Gly Tyr Ser Leu Pro Asn Gly Gln Asp Thr Ile Leu Cys Thr
 420 425 430
 Glu Asn Gly Trp Ser Pro Pro Pro Lys Cys Val Arg Ile Lys Thr Cys
 435 440 445

13/64

Ser	Val	Ser	Asp	Ile	Glu	Ile	Glu	Asn	Gly	Phe	Phe	Ser	Glu	Ser	Asp
450						455					460				
Tyr	Thr	Tyr	Ala	Leu	Asn	Arg	Lys	Thr	Arg	Tyr	Arg	Cys	Lys	Gln	Gly
465					470					475					480
Tyr	Val	Thr	Asn	Thr	Gly	Glu	Ile	Ser	Gly	Ile	Ile	Thr	Cys	Leu	Gln
				485					490					495	
Asp	Gly	Trp	Ser	Pro	Arg	Pro	Ser	Cys	Ile	Lys	Ser	Cys	Asp	Met	Pro
			500					505					510		
Val	Phe	Glu	Asn	Ala	Met	Thr	Lys	Asn	Asn	Asn	Thr	Trp	Phe	Lys	Leu
		515					520					525			
Asn	Asp	Lys	Leu	Asp	Tyr	Glu	Cys	His	Ile	Gly	Tyr	Glu	Asn	Glu	Tyr
		530				535					540				
Lys	His	Thr	Lys	Gly	Ser	Ile	Thr	Cys	Thr	Tyr	Asp	Gly	Trp	Ser	Ser
545					550					555					560
Thr	Pro	Ser	Cys	Tyr	Glu	Arg	Glu	Cys	Ser	Ile	Pro	Leu	Leu	His	Gln
				565					570					575	
Asp	Leu	Val	Val	Phe	Pro	Arg	Glu	Val	Lys	Tyr	Lys	Val	Gly	Asp	Ser
			580					585					590		
Leu	Ser	Phe	Ser	Cys	Arg	Ser	Gly	His	Arg	Val	Gly	Ala	Asp	Leu	Val
		595					600					605			
Gln	Cys	Tyr	His	Phe	Gly	Trp	Ser	Pro	Asn	Phe	Pro	Thr	Cys	Glu	Gly
		610				615					620				
Gln	Val	Lys	Ser	Cys	Asp	Gln	Pro	Leu	Glu	Ile	Pro	Asn	Gly	Glu	Ile
625					630					635					640
Lys	Gly	Thr	Lys	Lys	Val	Glu	Tyr	Ser	His	Gly	Asp	Val	Val	Glu	Tyr
				645					650					655	
Asp	Cys	Lys	Pro	Arg	Phe	Leu	Leu	Lys	Gly	Pro	Asn	Lys	Ile	Gln	Cys
			660					665					670		
Val	Asp	Gly	Lys	Trp	Thr	Thr	Leu	Pro	Ile	Cys	Val	Glu	Tyr	Glu	Arg
		675					680					685			
Thr	Cys	Gly	Asp	Leu	Pro	Ala	Leu	Glu	His	Gly	Ser	Val	Gln	Leu	Ser
		690				695					700				
Val	Pro	Pro	Tyr	His	His	Gly	Asp	Ser	Val	Glu	Phe	Thr	Cys	Ala	Glu
705					710					715					720
Thr	Phe	Thr	Met	Ile	Gly	His	Ala	Val	Val	Phe	Cys	Ile	Ser	Gly	Arg
				725					730					735	
Trp	Thr	Glu	Leu	Pro	Gln	Cys	Val	Ala	Thr	Asp	Gln	Leu	Glu	Lys	Cys
			740					745					750		
Lys	Ala	Pro	Lys	Ser	Thr	Gly	Ile	Asp	Ala	Ile	His	Pro	Asn	Lys	Asn
			755				760					765			
Glu	Phe	Asn	His	Asn	Phe	Ser	Val	Ser	Tyr	Arg	Cys	Arg	Gln	Lys	Gln
		770				775					780				
Glu	Tyr	Glu	His	Ser	Ile	Cys	Ile	Asn	Gly	Arg	Trp	Asp	Pro	Glu	Pro
785					790					795					800
Asn	Cys	Thr	Arg	Asn	Glu	Lys	Arg	Phe	Cys	Pro	Pro	Pro	Pro	Gln	Ile
				805					810					815	
Pro	Asn	Ala	Gln	Val	Ile	Glu	Thr	Thr	Val	Lys	Tyr	Leu	Asp	Gly	Glu
			820					825					830		
Lys	Val	Ser	Val	Leu	Cys	Gln	Asp	Gly	Tyr	Leu	Thr	Gln	Gly	Pro	Glu
			835				840					845			
Glu	Met	Val	Cys	Lys	His	Gly	Arg	Trp	Gln	Ser	Leu	Pro	Arg	Cys	Thr
		850				855					860				
Glu	Lys	Ile	Pro	Cys	Ser	Gln	Pro	Pro	Lys	Ile	Glu	His	Gly	Ser	Ile
865					870					875					880
Lys	Ser	Pro	Arg	Ser	Ser	Glu	Glu	Arg	Asp	Leu	Ile	Glu	Ser	Ser	Ser
				885					890					895	
Tyr	Glu	His	Gly	Thr	Thr	Phe	Ser	Tyr	Val	Cys	Asp	Asp	Gly	Phe	Arg
			900					905					910		
Ile	Ser	Glu	Glu	Asn	Arg	Val	Thr	Cys	Asn	Met	Gly	Lys	Trp	Ser	Ser
		915					920					925			
Leu	Pro	Arg	Cys	Val	Gly	Ile	Pro	Cys	Gly	Pro	Pro	Pro	Ser	Ile	Pro
					935						940				

14/64

Leu Gly Ile Val Ser His Glu Leu Glu Ser Tyr Gln Tyr Gly Glu Glu
 945 950 955 960
 Val Thr Tyr Asn Cys Ser Glu Gly Phe Gly Ile Asp Gly Pro Ala Phe
 965 970 975
 Ile Lys Cys Val Gly Gly Gln Trp Ser Glu Pro Pro Lys Cys Ile Lys
 980 985 990
 Thr Asp Cys Asp Asn Leu Pro Thr Phe Glu Ile Ala Lys Pro Thr Glu
 995 1000 1005
 Lys Lys Lys Lys Ser Tyr Arg Ser Gly Glu Gln Val Thr Phe Arg Cys
 1010 1015 1020
 Pro Pro Pro Tyr Arg Met Asp Gly Ser Asp Ile Val Thr Cys Val Asn
 1025 1030 1035 1040
 Thr Lys Trp Ile Gly Gln Pro Val Cys Lys Asp Asn Ser Cys Val Asn
 1045 1050 1055
 Pro Pro His Val Pro Asn Ala Thr Ile Leu Thr Arg His Lys Thr Lys
 1060 1065 1070
 Tyr Pro Ser Gly Asp Lys Val Arg Tyr Asp Cys Asn Lys Pro Phe Glu
 1075 1080 1085
 Leu Phe Gly Glu Val Glu Val Met Cys Gln Asn Gly Ile Trp Thr Glu
 1090 1095 1100
 Pro Pro Lys Cys Lys Asp Ser Thr Gly Lys Cys Gly Pro Pro Pro Pro
 1105 1110 1115 1120
 Ile Asp Asn Gly Asp Ile Thr Ser Leu Ser Leu Pro Val Tyr Ala Pro
 1125 1130 1135
 Leu Ser Ser Val Glu Tyr Gln Cys Gln Asn Tyr Tyr Leu Leu Lys Gly
 1140 1145 1150
 Asn Lys Ile Val Thr Cys Arg Asn Gly Lys Trp Ser Gln Pro Pro Thr
 1155 1160 1165
 Cys Leu His Ala Cys Val Ile Pro Glu Asp Ile Met Glu Lys His Asn
 1170 1175 1180
 Ile Val Leu Arg Trp Arg Glu Asn Ala Lys Ile Tyr Ser Gln Ser Gly
 1185 1190 1195 1200
 Glu Asn Ile Glu Phe Met Cys Lys Pro Gly Tyr Arg Lys Phe Arg Gly
 1205 1210 1215
 Ser Pro Pro Phe Arg Thr Lys Cys Ile Glu Gly His Ile Asn Tyr Pro
 1220 1225 1230
 Thr Cys Val
 1235

<210> 9

<211> 150626

<212> DNA

<213> Homo sapiens

<400> 9

```

gatcataatg gtatacaaca attaacatca gaataaaact tggaaaacttt acaaacactt 60
ggaaattaaa caacatgtac attttaaacc aatggctcaa tgaaggaact aaaaaaatt 120
tggaaagttt ttgagacaaa tgacaatgga agcacagcat actataatag atgagataca 180
gcaaaaccag ttctaagagg aaatthttata acaataaatg ccttatcaaa aagaataaat 240
ctctcaaaata aacaaccaaa cattgcacct taaggagcta aaaattttaag aacaacatta 300
ctaaaaacaa gtcgaaaaag aaataataaa gatcagagca gaaacaaaca acgcagagac 360
taaagttaag tatgacaaaa tcagtaaagc aaagatttta aaaaaaattg acaaacattt 420
tcttagacta agaaaaataa gggagacgat ccaataaat aaatcagag agggaaagg 480
agacattaca tctggttcta cagaaacaca aaggatcata aaaactataa ggaacaattg 540
tttgccaata aattggtata cctggaagaa atggacaaat ttttggacac atacaacata 600
ccaagattga attaggaata aatagaaatc taaacagaca aataatgagt aagttgatta 660
aatcagtaat aaaattcacc catcaaaaaa gcccaaaacc tggtatcgtc actgctgaat 720
tctaccaaatt attaaaaaaa aaaaaactca gagtaatttt tctcaaacta tgccaaaagc 780
aaagaaaatg gaatttttcc aacttattgt agcatgccag cattgccctg ataccaaaac 840
caaacaagga aacaacacaa aaagaaaact acaggctgat gtccctggtg aacagaggtg 900
ttaaaattct taataaaaata cacaaaaaag tgaattttctg ttcctttggt tgttttgttt 960

```

tgagaagagg	tctctctctg	tcagcccggt	tggaacgcag	gggtgccatc	ctggctggct	1020
ctatcctcga	cctcttgggc	tcaagcaatc	ctttcacctc	atcctccaga	gtagctggga	1080
ctataggcct	gggtcaacac	accagctaa	ctcaaaagct	aactgcagtt	tttaaaaata	1140
gagtataatt	aaaacaagg	ttgtatgtac	aatgttgaat	catacaactt	aaaacgtgga	1200
gggctcagaa	gagatcaact	cttctacccc	caccccgac	atagggcaat	atccgtatag	1260
gtcacacttt	tagaaaatca	cttgacctct	gattcgatgt	tggataatac	tgttacctgc	1320
ttcactgact	gtgacagtcc	tcatcaaaag	ctaacttact	ccccctcata	aatgttttga	1380
aatatctcaa	gacagtcatt	ataatgctat	aactctatct	ttttgcatgc	ttcttatgct	1440
ataatttctt	taactcttca	actatctata	tattctcttc	tatgccatga	tagttggaaa	1500
ccaatcattt	taaaacgtgg	taggctaagt	acggatatatt	attacagaca	tgatatttgg	1560
tgggcaaacc	acacagttga	gagtactttg	ttgacactga	aaaacatcat	ttcctcatga	1620
agcctgaaag	agatagatgt	tctcctcagt	accaccattg	tctattaata	ttagggttat	1680
taatgaaaat	cttcattttc	ctccacttaa	tttactttta	aagctaaata	caaatgttgt	1740
ttccactaag	taaatctgcc	aacaaaaaaa	taaaaattct	tttttgactt	gaatgcctca	1800
tgaatgattt	atctgttctt	aacagataaaa	taaaaagac	tttttttttt	ttttgagaca	1860
gaatcttgct	cagttgcccc	ggctggagtg	cagtgactcg	atctccgctc	actgcaagct	1920
ctgcctcctg	gattcacgca	ataatccgcg	ctcagcctcc	cgagttagctg	ggactacaga	1980
cgcccgccac	cacgcccaga	taattttttt	tgtatatttt	ttagtagaga	cggggtttcg	2040
ccctgttagc	caggatggtc	ttgatctcct	gacctcgtga	tccgcccctc	tcggcctccc	2100
aaagtgctgg	gattacaggt	gtgagccact	gtgcccggcc	aaaaagacat	ttttgaagga	2160
agttaaaaat	ttaattaaaa	acatgtttgt	gatttctttt	gctttgaaga	ttagttctct	2220
tgagataaat	ggtatagagt	aatattcttt	gaatgtatat	gtgaatttca	gtatagacat	2280
aggtttgctg	taatagctat	tttcgctgag	tcagctataa	aaatattcca	tgctctattt	2340
gttcataata	tagtaattat	tgacagaaca	ttttttgggg	gaaattcatg	tcaatcattc	2400
tcattacctc	tctcaataat	aactgaactt	ctgcaattgt	ggtgttccct	ttcactcaat	2460
ttttttctgt	caaaacgaac	aaacaaacag	gcgcaaaaaa	accctggcaa	taacctttga	2520
taaacatcgt	ctctcaacca	ttttcttctg	agattgcagc	aatcataact	agtttctctga	2580
tcctgacctc	tcatctttgt	aatctatttc	cctgtgtata	aattaatgac	ctttcatctg	2640
gtcattttat	ttctccactt	aaaatcttta	atggatctca	agtcagctaa	caggacaaga	2700
acctcatttc	actttctcta	cttctactaa	catagtatgg	tctcttcagc	aattctggag	2760
gttttatcag	cattaattta	aactgagctt	atctacaact	ataccaagtt	aagctcaagc	2820
tgccagttca	gggtgcacgc	attagcaatg	attgtttttt	ggaaaagaga	gacaagaaat	2880
atgactgtaa	cataaaaaat	ctgatatgta	gcaaatatc	tccagatata	aaacattttg	2940
tttagttttg	tggcattttg	tttgtagcg	atggcatgca	ttcttaccat	agttagaatt	3000
catgtgtcag	ataagatata	ttattgacat	aaaaaataag	tgcatagacg	aatgtacaaa	3060
tatgtatata	ttottacatt	ctataggtat	gtatacctat	agaatgttga	acaacatcac	3120
aatttaaata	gcataatcatt	tatgtttact	ctataattat	ggaacaagtg	atagaaaata	3180
gtatttatcat	tactatttgt	atgaaaactt	aagaatataa	ttaaataaaa	gttaagtttg	3240
aatcatcata	aaccagagag	aactagaaag	acgctagtgg	cacaacagct	ttagtgtgca	3300
gatgagaaga	ctaagttcag	agaagtgaca	tctttacttt	gaggggaagc	tttgctagtt	3360
acagaactgg	atccagaggc	ttgttgggcg	acgcatgaca	ccttctctga	cccagtcctt	3420
caagcatgga	tgcacagttt	tctgctgagt	gtctcctccg	tattggaaaa	tcgaaacttc	3480
ccggccctgt	gtaacctcct	gagatactct	tacattttct	tatgattgca	ggatatttag	3540
tccgaggtag	aaagggacat	aaactaaagg	aaatcattta	aatctttctt	tttttcttca	3600
tttttatttt	tatttttaat	agtcttgctg	tgtctccaaa	gctagagtgc	agtggcacta	3660
tattggctca	cgtoaacctc	tgtctcccg	gttcaagtga	ttctcctgcc	tcagtctcct	3720
gtgaagctgg	aattacaggt	gtgtgccg	acatccagct	atttttttta	acttttagta	3780
gagacagcat	ttcatcatgt	tggccaactc	ctggcctcaa	gtgatctgcg	cgccttggcc	3840
ctcgaaagtg	ctgggattaa	tgtgtgagcc	atcctgctcg	gccaaaaatt	atttttctta	3900
gtcaacgata	atttcgaaac	tgaagtga	ttttcatgg	ttaggtttgt	ttctaaaaat	3960
cgttcttccc	actaaaaggc	actggaattt	catagagaaa	ttattgaaac	ttagtctgta	4020
gtaggaaaaag	tcaaggaaaag	tatgggtctt	tatgttatgc	caaagcttaa	tgggggcaca	4080
tgaatatata	acagaagcca	tcttcttagt	gagatgtgaa	acaaatttca	gcattcccaa	4140
gaagtacaat	ggcaattaac	tgtaatgcat	ttggtactgt	aatgatcagt	ttaaaaggga	4200
tttaaaagca	accctgctct	acaatgttaa	ttgtcactct	tgacactttg	ttatggcaac	4260
tctagtagat	gaatataaaa	tttatacaat	tctgaaagga	tattcataat	taaaaaataat	4320
gttattgaca	acctattttt	aaataagtat	aaataactta	tgacttgatg	gaagaaataa	4380
tggccaatac	aaattcaatg	aacattataa	taggttacaa	ttacaaattt	tctgtcaagt	4440
ttgtctttca	aatagcgtgg	tttccaaaag	aattggtgtg	ccgattttat	tgttcagaac	4500
tgaatatatca	actaccatta	aaaaaatttt	attagcataa	gcaattcaca	aagtatgtcc	4560
ttcattaatg	atatgaaaaa	tctttcttag	atttgattta	ctagattctg	aatatagatg	4620
aatacagata	tatatacaca	taaagtattc	aacaagacaa	aaatcagcag	gaaaatacac	4680

ccaagatgta	attaccaa	tctgatga	agcctctaaa	atctgtgtgg	tggtacata	4740
tatatatata	tattcttgag	taaaaagtaa	aaaattat	ttagttatta	atgttctttt	4800
aataaattgt	gtaaatatca	tggtattcat	ctgctagagc	taccataaca	aagtaccact	4860
gatttcatag	aaatttattt	tctcacagtt	ctggaggcta	atagtttgag	atagagctgt	4920
caacaggatt	ggattcttct	gagacctctt	cctttgcctt	gtaaatgggt	gtattctttc	4980
tatgccttgc	gtgatctttc	tctatatggg	gtgttcttat	tttctcttcc	tatatagaca	5040
ccagttatac	tgagtagga	cccacctgaa	tcattggcct	ttaacttaat	tacatcttta	5100
agcactcctt	ctccaaatgc	agtcacattc	tcaggtattg	ggaatttgga	ctttaacaaa	5160
tgaatttttg	cgggatgcaa	ttgagccaat	gctactgaat	acacaaagat	gtttctctct	5220
aaccaagact	ttgaaagtaa	cccaatgagt	tactttctcc	tttgagaaat	ataggtgcga	5280
cccaaattta	caagacattt	tgctcaagtt	tactcttaca	aagagttcat	tggaggagac	5340
aagttttcaa	ctggaatata	agataaggaa	gaatttgtca	tcattctttt	ctatagtgt	5400
tttaagaaag	taagtaagaa	agtatagtgc	atatgtcttt	ctaattccag	tcatttcaga	5460
atggtactac	ttttcttctt	ttcattctac	tttaatctat	ttaatcttta	tttgaaaaaa	5520
atgtacctgt	atcagttcag	ttaacaaaag	aaataacagg	agaatttcc	tttttttcca	5580
ttttagcaca	gatcaagttt	gattttgcac	aacaaataaa	actagcaa	catgtgatag	5640
ataatactgt	aaaacctaaa	gctctttacc	tagaatcaaa	taaagtggca	tagctttgag	5700
aagagaggct	gagggaaaag	atactctcat	aaattgataa	ttggatttcc	agtattacc	5760
tccactacat	ttgttgaaat	attatgaagt	tttgataat	tacaaaattt	gtattcttca	5820
ttaatggcca	caaacctttg	attgtccatg	acatttgacc	catgtgggtc	cactgcta	5880
gttacgatata	agttctttta	tatgcaaggc	ctgcattcaa	aaaggtagtt	aatatagaaa	5940
atatatgact	gttgaggaga	aaacaaatca	gtgaacaata	acataaagct	ataaaaaata	6000
attatgtatt	tatttattga	acatttgcta	gtgagctcag	aaatgcaaaa	tttctgtca	6060
tttaaaagta	agttaagcat	atagtctact	ttttgattat	attcatgttg	tgatttacat	6120
gttggtgattt	acatgtttgt	aatcttggtg	aaatattaag	ttcatattaa	tgtaattca	6180
ttttagcagc	tttcttaagg	tattatagaa	ataaaagaaa	ctgcagaatt	taaaatgtat	6240
tatttgatgt	tttgatata	gaatctataa	aaaatcacca	tctgtaagat	tatgaaaata	6300
tcagtcactc	cccttgcat	acaaataaga	aacttctgaa	catttttaagg	ttagaatctg	6360
tctagtgaca	tgtttccctac	ttaaagtttc	atgagtatat	tcacatatct	ccataatcaa	6420
tattaaatgt	cttttacact	gtagaactta	taaaacaaag	aaaatattat	tattgtttta	6480
agttaaaaatg	agataatatt	tcataaaatt	aatttctggt	atagtcttac	aaaatattgct	6540
atttctacta	gcataatgaa	taaatcctct	ttggttcata	aaaaattgta	gacatggaga	6600
cataggaagc	tagatattac	atgaagttac	atttaagatg	ggagctgagt	gttttagatct	6660
ctttcaattt	accttgctca	ttagcatagg	aaaccacaa	ggtagaatg	acattaatta	6720
gtaacaacat	gttagatatt	ctcagtagta	tagtaatgca	aaagtttcag	ttgtactgtt	6780
tgagatttga	aatctttcat	tattagttac	caagggtgat	tccgaatttg	aggaaactac	6840
cacgaagcta	ggcctttaag	gtcacttagt	aaatatcaaa	gttcagagag	ttttgcaaaa	6900
tgcttcaata	attccagtta	gtggtttcac	aaccatctgt	ggaattgatt	cctgaaatg	6960
tacttgtaaa	atattattta	gggacagtaa	tgactgaat	ccaaaagtaa	tataaaacat	7020
taattttattt	tatctctcat	tttttgagta	aagagagtat	caataaagg	aacgaaaggc	7080
ttctgcaact	actggaagaa	ctgagggaa	aaaggtcata	aatgctattt	ccagaaaatt	7140
ccgaagttca	ggaatcttag	tgatgcccc	ctaattatcc	attgtactgc	agtggatgtt	7200
tcttaggaaa	acttccagaa	gcaaggaaag	ctactgttgg	tgatctcagc	tgctaccagc	7260
agctgctacc	agataatgcc	ttgcctttca	ccttggtccaa	gttttcttta	ggtacatctc	7320
atgggggaat	ctaagggaga	agcaagctaa	aatacaaaata	cagctacaaa	tacaaatata	7380
agctaaaaat	aaaatagctt	gtaaaataca	aatacaaaat	aaaataaaaa	ttcctaatac	7440
agatcgtatt	aggaataaat	agaaaatcaa	aacaaacaaa	taatgagtaa	gttgattaaa	7500
tcagtaataa	aattcaccta	tcaaaaaagc	ccaacgcctg	ttatcttcac	tgctgaattc	7560
aaccaaacag	tataaaaaac	tggtagtatt	ttttttcaaa	ctatgcataa	aataaagatg	7620
agcagacata	cacaaaccaa	tagatgtaac	atatcacaat	aacagaatca	acaaaactat	7680
atgatcattt	tcatagaagt	actaaaaaca	tttgagaaac	tttgacattt	cttcatgata	7740
aagagtctcc	acaaattagg	cagagcagag	ccagatgggtg	gaataggaga	caccaaccat	7800
tccccttcaa	agataccaag	ttaacaacta	tgtacacaga	aaaaaaaaaa	aacaccttca	7860
taaaaatgaa	acattatcag	attagcactc	attagtacatg	gttttaactt	catatccctg	7920
aaagaggcac	gtaagagata	ggtcagacaa	tcttgagtca	ctgacactac	cctttcccct	7980
ctccccacac	ttgcagctgt	gccatgatgt	acagagcctt	gctctaggca	ctgagggagg	8040
gagaacatag	caattgtgag	gcattgaaca	aaatgctgtg	ctgttagagc	agaaaggaaa	8100
gccaaaccaa	actcagctaa	ccccttccca	tgaggggagt	atttaaacca	atgctagcca	8160
tgacgggtatt	gctgaccgca	ggggtctgaa	atcaagttcc	cacaaatctt	gccacctagg	8220
gctacctacc	atgcattgtg	tctctaaata	aactagaaag	acagtctagg	acataaggac	8280
tgcacacata	tgtgagtcct	agtgtgaac	taggtcaga	gactatggac	tgggggaaga	8340
cacagaatat	tcagagacac	caactgcacc	agctgaggca	gccaagagca	tgctggcatc	8400

acccaacccc	taaccccagg	cttcacattt	cacagctcca	aaagaaaccc	cttccttctg	8460
cttgaggaga	ggagaggga	gaacggggaa	gactttgtct	tacatcttgg	atatcagctc	8520
agacaaagca	ggatagggca	actgtcaaag	gaatgaggcc	cctgctttaa	gccctagctc	8580
ccagatgaca	tttcttgaca	taccctgaac	caaaagggaa	cccaatgccc	tgaaggaaat	8640
gatgcagtc	tggcagcatt	cacccagcct	aactgaagag	cccttgggcc	tcaataacct	8700
gcagtgatac	ccagatacta	tgttgagggc	cttaggtgag	cctctgagac	ttgctggctt	8760
caggtaccag	catggccaca	ggggatagag	aaccacctgg	gctcccagg	tccccagttc	8820
ctggacttga	ctgggtgggtg	gcatttttgg	acataccatg	gaccagatgg	gagcccagtt	8880
cccagaaggg	tgaatcctag	gctagccagc	attcaccaca	aactgactta	ggagcaccta	8940
aaccttaagg	gaacatcagc	agttgtctgg	cagtactcct	catggcctgg	agtgggtgta	9000
gaccataggg	tgaggctcct	ctgactttgg	aaaggggagg	gaacagtgg	gaggattttt	9060
ttttattatt	atactttaag	gtttagggta	catgtgcaca	acgtgaaggt	tagttacctt	9120
tgtatacatg	tgccatgttg	gtgtgctgaa	ccagtaact	cgtcatttaa	cattaggtat	9180
atctccaaat	gctatccctc	ccccctcccc	ccaccccacc	ccacaacatt	ttaacttgca	9240
atatgactgc	cagcccagat	acagtaccat	ataacatcaa	gcagacatct	aaggtttttg	9300
aaactgggtc	cctggaaacc	accctgggtc	aggggcccct	atcactctga	attctctcag	9360
atcatgtgca	agacatcaa	tagagtacc	ccagaagtct	gcaagaacca	ctgcattggg	9420
gggattttga	cacctgttaa	agaagttaca	gcttaggtca	caacacccaa	gtcctttcaa	9480
acatgtggaa	catcttgcca	agaaggatgg	ttacaattaa	gccagacag	tgaagaaaac	9540
aataaatacc	taactcttca	gtgccagac	acagaagaat	atctgctagc	attaacgcca	9600
tccaggaaaa	cccgcacctc	ccaaatgaac	taaacaagc	accagggaac	aatcctagag	9660
aaactgagtt	atgtcacctt	tcaaacaacg	aattcaaaat	agttttgttg	aagaaactca	9720
aagaaaaatca	agataacaca	gagaaggaat	ctgaaactct	atcagataaa	tgaaacaaag	9780
agattgaaat	aattttaaaa	aatcaagcag	agattctgga	gccgaaacat	gcaattgaca	9840
tactgaagaa	gatattacac	gtgctattct	ttaatagcag	aatagatcaa	gcagaagaaa	9900
gaattgttga	gcttgaagac	aagctatgtg	aaaatacaca	gtcagaggag	acaaaaaat	9960
aaagaattaa	aaacaatgaa	gtatgcctac	aggatctaaa	aaataacctc	caaaaaagca	10020
atctaagagt	attcacctta	aggaagaagt	agagaacgag	ataggagtag	aaagtttatt	10080
caaattggata	atcacaaaga	acttcccaaa	cctagagaat	gatatctata	tcagggtacta	10140
gaaggttata	ggatgccaa	cagattttaac	ccaaagaaga	ctacctcaac	tcatttataa	10200
atcaaattct	cataaggtcaa	ggataaagag	actattctaa	aatcagtaag	aacaaagaaa	10260
taaataacat	acaatggagc	accaatacat	ctggtagcag	gctttttaga	ggaatcctta	10320
caggagtgat	atgacacatg	ctgacagaaa	aataacgttt	atcctagagt	agaatatctg	10380
gtgaaaatat	cccttaaaca	taaagaagaa	ataaagacat	tctcagataa	gcaaaagggtg	10440
aggaatttta	ttatgccaga	cctgtcctac	aagaaatgct	aaagggataa	tttcaatcaa	10500
aaaattaaat	tcatagaaca	taatcacctg	aagacacaaa	tctcactggg	aatagtaagt	10560
acatagaaaa	atacagaata	ttaaaacact	gcaactgggt	tgtgtaagct	aatatcctta	10620
gtagaaagac	ttaaataatga	actaatgaaa	actaattcact	acagattttc	aagacatagt	10680
ctgtacaata	agataaaaaat	agaaacaaca	aaaagtttga	aagcagaagg	gaaaattaa	10740
gtggagagta	tttatgagtt	ttctttggct	tgtttgttta	tgcaaacagt	gttaagttgt	10800
tttctgggta	taagatagta	tttgcaatcc	ttatggcaag	ttgaaacaaa	aaattaaaga	10860
atctggaaat	taaagaatat	gcccctgaat	gcacagtggg	tcaatgaaga	aattaaaata	10920
ttttgtgaaa	caaatagata	tggaaacaca	aaacctatgg	gatatagcag	ttttagtacc	10980
aagagaaaaa	tttatagcta	taagtgacta	cataaaaaag	aaaggaaaaa	cttcaaataa	11040
acaatttggg	gatttatgtt	aaagaactag	aaaaggaagg	gcaatccaaa	tccaaaatta	11100
ttagaagaaa	ataataataa	aatatcacag	cagataaaact	tgaaattgaa	atgaataaaa	11160
tacaaagatc	aatgaaacat	aagttgttat	tttaaaatat	taaacatgct	gatcaacctt	11220
tatccagact	aagagaaaaa	gagtgagaat	tcaataaat	aaaatcagaa	atgaaaagga	11280
aacattacat	ctgatcctgg	agaaattcaa	agaatcatta	ttggccacta	tgtggaatga	11340
tattccaata	aattggaaaa	tctagaagaa	atggacaaa	tcctagacac	ataaaaccta	11400
ctaagattga	agcagaaaga	aatccaaaa	ctgaacagat	caattattaa	tacaagtaat	11460
gagatcaaag	ccagaataaa	aagtctcata	gtaaagaaaa	gctcaggaca	tattggcttc	11520
actgttgaat	tctccctaac	atttaaagaa	gaactagtac	caattctact	cttaactattt	11580
tgaaaaatag	aggaggagga	ggagcaataa	cttccaatgt	gaggctaata	ttaccctgaa	11640
aagaaaaatca	gacaaagaca	cattaaaaaa	agaatactac	aggtcaatat	ctctgacaaa	11700
tgtaattgta	aaaatttctc	acaaaagaat	agcaaacaaa	tttaacagca	tactagaaag	11760
atcattcaac	atgaccaa	gggattttat	cttgagatgc	aaagatggct	caacatatac	11820
aactcaatca	atgtaataca	tcataccaac	acaatgaagg	atataaacca	catgattatt	11880
tcaattgatt	ccaaaaaggc	atttgataaa	attcaaaatc	cttcatgata	aaacactaaa	11940
gaaaactgaa	gatagaagga	acacacccaa	acataatcaa	agctgcattt	gacagacaca	12000
cagctactct	caaactgaat	ggagaaagtc	tgaaataatt	tcctcaaagt	actggaaacat	12060
gacaaggata	cccacttcac	cactgttatt	caacataata	ctggaagtcc	tggtctacagc	12120

agttagacaa	gagagggata	taaaggtatc	caaactgaaa	agaaagaagc	caaattatct	12180
ttgtttgcag	atggtataag	tttttttcga	taaacgtaag	gtaatcacca	gaaaactatt	12240
agaactgata	aacaaatcca	gtaaaggtgc	aagatataat	atcaacataa	aaaaccagta	12300
gcattttgtat	atgttgacag	caaacaatct	gaaaaaaatc	ctaaaggtaa	tcccattttac	12360
agtaaccaca	gataaaaaata	aataattaga	tattaaccaa	agaagtcaaa	gatctctata	12420
agaaaaacag	taaaacacta	aaaatagaag	ttgaagagga	caccaaaaaat	aaaaaagata	12480
tttcatgatac	atggactgga	aggatcaata	ttgtttataat	gtccatacta	cccaaggcaa	12540
tctacagatt	caagaaatca	ctatgaaaat	accagggaca	ttcttcacag	taatagagaa	12600
aaacaatcct	aaaatttttct	tggtaccaca	aaagctaaag	gtaccccaaaa	tagctaaagc	12660
tatcctaagc	aataaaaaaca	aaactgaagg	aataacatta	cctgacttca	aattatacta	12720
cagagttgta	gtaactaaaa	cagcatagta	ctggcataaa	aacagacata	cagtctaata	12780
gaacagaata	gagaacacag	aaacaaaattt	acacatctac	agtgaatgca	tttttgacaa	12840
agggacgttg	tggaaaagac	agtctcttca	attaacggtt	ctaggaaaac	tggatttttc	12900
tatgcagaag	aatgaaacta	gacctctatg	tttcaccata	tccaaaaaatc	aaatcaaatg	12960
gataaagact	taagtctaag	acctcaaat	atgaaaacttc	taccagaaaa	cattgggggaa	13020
aactctcaag	actttgttct	gggcaaaaat	ttcttcagca	ataactcaca	agcacaggca	13080
agcaaaagc	aaatggacaa	atgagatcac	atcaagttaa	aaatgttctg	cacagcaaag	13140
gacacaatga	acaaagtga	gaaataacac	tgagtgggac	aaaatatgtc	aaactaccca	13200
tctgacaagg	gattaataac	cagaataatt	aaagagctca	aacaactcta	tcagaaatca	13260
tctaataatc	agatcaaaaa	agggcaaaaag	atctgaatat	agatttctta	aaaggatata	13320
ttcaaatgga	aaacagacat	gtgaaaagat	gatcaacata	actgatcatc	agagaaatgc	13380
aaatcagaac	tacagtgaga	tatcatctca	ctccagtga	aatggccttat	atggaaaaga	13440
gagaaaaata	cagatgctaa	tgaggatgtg	gagaatagg	aaatcttgta	cactgttggg	13500
gggaatgtaa	attaatacaa	ccactatgga	gaacagtttg	gagggttctt	agaaaactaa	13560
aaattgagct	accttatgat	ccagccatcc	taatgctgtg	tatacaacag	cagtgtacgg	13620
aaatcagtg	atggaagcgg	tatctgcaca	cctatgtttg	ttgcctcact	gtatacaata	13680
gctacgattt	ggaagccacc	aaagtgtcca	tcaacagatg	aatgaataaa	taaaatgtgg	13740
cacacataca	caatggagta	ctactttgcc	ataataaaga	atgagatcca	atcatttgca	13800
acaacatgga	tggaactgga	gatcattatt	ttaagtga	ttagccaggc	acagaaatc	13860
aaacctcaca	tgttctcact	tatctgtggc	atctaaaaat	caaaacaatt	gaactcttgg	13920
acatagaag	ttgaaggatg	gttactagag	actgtgaagg	gtggtatagg	gctagagggg	13980
agatggggat	ggtcaatgtg	tacgaaaaaa	aatagaaaaa	ataaataagt	ccatctattt	14040
gacagcaca	tcgggttggt	atagtcaatg	ataacttact	tgtacatttt	aaaataaact	14100
atacagtatt	attggatggg	tggaactcaa	aggaaagata	cttgaggggca	tgtatacccc	14160
attccccatg	atgtgctcat	ttcacattgt	atgcctgtat	caaaacattc	taagtactcc	14220
atcaatacat	acacctactg	tacacctatg	atgtgcacag	gaaaatttta	aaacatatgt	14280
atagaagaaa	agtaccccaa	taccataaat	agcatatatg	acaaacccat	aggtaacttt	14340
tatatccatg	ggctgtcatc	acaatgtgtt	attggcattg	accagagtag	aataaaacac	14400
tactagatat	gtaaagaagc	agaaaaatcg	gcccatattt	agaagaaaaa	gatctatcaa	14460
taatgctaaa	gacaaaccat	atagtaaata	tagtaaaata	agcaaaacct	cctccataac	14520
tttaaaataa	ctgcaaaaaca	taagacaaaa	atcttcagga	aaatatatac	gtaaatgttg	14580
aagagaggtg	gaatttcagt	tgaataatga	cacttagcca	agtataacag	gttactgaaa	14640
acattttcag	ttataatgaa	attttaactc	atctgtaagt	agtgttcgta	aaaactttat	14700
aaaagtattg	taatttttta	aactattgtt	agtattttta	agatggttgt	ttttgaaatt	14760
ctataaaaaa	ataatctttt	tgaaaaata	tttatttttc	caagtgtccc	aaccttttgc	14820
aacatctgtg	attggtcaga	aatatggatg	ataataaact	ttaaaataca	gcacaagggtg	14880
ttttcaaagt	tctttgcata	aatataatc	agaaattact	gaccaaggac	cttagtgaag	14940
aacaccagga	atccactaat	attgttaagt	gtgctattta	caaaaaaaga	gtcagcccct	15000
tcattaatta	cttttttaag	tatagcatag	caaaaaacct	tgactatcca	aaatgacaca	15060
caaaagtaag	taggttcctc	agcgggttatt	taggagttta	tatgacttta	tgtattagtt	15120
gatagtattt	taattttttc	aatattcagt	gaatacaaa	tgaaataccc	aaactgaaac	15180
atgcttcata	ctttttatct	tttttacata	aaatttctcc	tatggaataa	ttttagattt	15240
acataaaaagt	tgtaaagagt	attcagataa	ggcttttgg	aatctgaaaa	tcaataaaac	15300
aaagattaga	tttattacat	gaatgtcaaa	tgaacttatt	ttttgtaaga	taagcatact	15360
tacaaaagac	atttagcttc	tctttctgta	gtagttagaa	aggctaggct	taaataatatt	15420
aatagaata	tatgtactca	gcaatattga	aatatataat	attatcacta	ttattattat	15480
tattattaag	tgtgaacacc	atgctgtgaa	atagatagta	aatgtatttc	ctctagtcta	15540
actgaaaatt	tatacccttt	gaccaacacc	tcctagaaac	accgccatcc	cttcagcttc	15600
tggttaaccac	cactctactc	tcaccttctg	taaatttgaa	tttcttagat	tccacatatc	15660
aataagatca	tgcaggattt	ttctttgtgt	tgacttttatt	ttagatagca	taatgtccac	15720
tagattcatc	cacgttttcc	ctatttgacaa	aatgttcttc	tttttagttt	gtatagtatt	15780
ctactgtgta	tctataccac	atattctctt	tttgtaaaaca	ttttcattta	ttttttattg	15840

gcaaataaaa	ttgcatatat	ttattatgta	aaacatat	tggtgaaata	tgtatacatt	15900
agatagtggc	taaatcaagc	taataaatat	atgctttcct	tcacatactt	ctcattttttg	15960
tgtgtggtga	gactgcttaa	aatctacact	aagtagtttt	caagaataca	acataattatt	16020
gttaactaaa	gtcaccatat	tttacaacgg	attgcatgta	taagtgcaat	catgtgggtt	16080
tgtctgtctt	attccaccta	acttaatgtc	ctccctgttt	attctatggt	cttgaaaaatg	16140
caggatttcc	ttttttcaaa	gctgaatagt	attacattgt	gtatatagac	cacatttttct	16200
ttatctattc	atctgtaatg	gatacttaag	ttgattccat	attttggcta	ttataaataa	16260
tgctgtaatg	aagatgggaa	tgcatagataac	tctttgacat	actgattcct	ttttcttttgt	16320
acatatattc	agtagtagga	ttactggatt	gattatatgt	tctgcttttc	attttttgaca	16380
aactctatag	tattttccat	aatggctata	ctaataataca	tttccatcaa	caatgtgcaa	16440
gtgtgtcctt	ttctccacat	gtttgataac	acttgatggt	tttttgtatt	gttgataata	16500
atacttggtg	gccattggta	cgtcttcttt	tgagaaatgt	ccattcaggt	acattgccta	16560
tttttaaatt	ggttaattcc	tttttattag	ccattgaggt	gagttcctta	tatatatttga	16620
atattaacgc	tttatcagat	atatggcttg	caaataattt	tccaactcat	gagttgtctc	16680
ttcactctgg	gcattgtttt	ctttgctgtg	cagaagcttt	ttagtttgat	gtataacaat	16740
gtgtgtattt	ttccttttgt	tgccatgtct	tggggaacca	atccaagaaa	tcatagccca	16800
gaccaatgtc	atgtattttt	ttctctttta	ttttcctcta	gcagttttat	agtttcaagc	16860
tttaccatgtc	agtcttacat	atattctgag	tagttttatg	tagtgtgaaa	cagtggatca	16920
attacattct	tctatgtgtg	aatatccgat	tttcccagca	agatgtattg	aagagactat	16980
tattttccct	atgtgagttc	ttgtcatctt	tattgaaaat	atattgaatt	ctattctgtt	17040
ttattgggtg	cttgtttttat	gccaatgtca	tgctatcgtg	cctataatag	cattatatca	17100
taattcaaaa	ttttagaagt	taatgcctcc	agctttgttc	tttttaataca	aaattacttt	17160
gaccttcggg	atctcttgtc	atttcataca	tatttttgaa	ctgtttttca	ttttctgtgtg	17220
aaaaatgaca	ttagaatttt	gatggggact	gcattgaatc	cttacatctt	tttgtgtaat	17280
atgaacattt	tatccatatt	aaatcttgca	gtccctgaac	atgggctatt	tttctgttta	17340
tgtgtgtctt	cttcaatttg	tttcatcaat	attgtattgt	ttaaaatata	tagatttttg	17400
agatccttgg	ttaaattttac	tcctaatttt	attttttggg	gttatcagaa	aaggaataga	17460
tcttttaaatt	tcttttttcag	acagttttat	gttagtata	aagaaagaaa	aaagcaaat	17520
ctaagcatga	agaacacaag	tgaaaattaa	tatacaactc	tatggattcg	gtaatagggt	17580
gaaccagaga	taagaagtat	ttaaatcatt	tttgaagaaga	agattcacac	tcagagtcac	17640
ctatctaggg	gcaaaataaa	cacaaagaaa	ttttaatttt	cacttagtag	tttaactact	17700
aatagcaacg	tttcattaca	cttttgacat	tttcatgaat	gagtcagtaa	agacaaatga	17760
gagaagaata	tattttaatga	gcataaacat	atagttagat	agaataaata	agatctagta	17820
tttgatagca	caacagggtg	actatagtca	aaagtaattt	attgcacatt	ttaaaataag	17880
agggataaatt	ggattgtttg	taacacaaaag	aaagtataaa	tgctagagat	gatgaatacc	17940
tcattttacc	tgatgtgatt	attacacctt	gtatgcctgt	atcaaaatat	tttatgtacc	18000
tcatacatag	atagacgtac	catatactca	caaaaatgaa	aacatgtata	tactaaagt	18060
gtttttcacag	atgtattatt	aaatttgaat	tgtaaaatcc	agtgagaaca	acaaactttt	18120
atatttttatt	tatatattcaa	agattttacc	acaaaaaatc	cctgaaaata	attatatattc	18180
caaagtattg	gacattccca	tctattacca	atacttcatg	gttcttgagt	tctaaatttt	18240
attctgcttt	aaaaataatc	agactttcta	ggaaagggtg	atgattttga	atgttgggca	18300
gaggaaatat	aaagtgaact	tagaacatgt	tatgctgaaa	aaaaaagaga	gaaatactca	18360
gataaaatta	gggcacatga	gaagcaatga	ggagccaggt	tccagagata	tccagattga	18420
ataaatcaaa	atacacgact	ccaagggtgat	acaaacaact	acaacaaaca	aaaaaccttt	18480
ctgttttttac	aaaaagacat	atttatattt	caaaacctag	aagtaatat	ttgggtccatt	18540
aaacttccatt	tttactgatt	aatgtaatca	atttttttcac	ccctataaaa	gtatcattgg	18600
caaatacaaaa	tttttatatt	cacgttatatac	aacatattat	tttgatatac	ataacatttt	18660
ataatgatta	tcataatgaa	gctaatacaaa	tatccaatat	ctcaccttgt	taccttttgt	18720
atgaatgaca	tcagaacact	taagaactat	tgtcttttgta	atttcaaata	tataatata	18780
tattaataaac	tatagtcata	atgcttttaca	ctaggtctcc	agaaattatt	tgtcttaaaa	18840
cttgatatcct	ctgactgaca	tctctctatt	tctcccactg	tgcaaccctt	ggtaactata	18900
cttctactct	ccatatctat	gagctcagggt	gtttttttaga	ttccaaatat	aaatgacatc	18960
atgcagcatt	tgtctgtttt	acttccactta	cttaatatct	gccatgttta	19020	
tcaatgttgt	taaaaaagac	agattttgcct	tcttttttaaa	aatgtattcc	19080	
actgtatata	tgacaccacat	tttcttttatt	caatcatctt	ataagtttgt	19140	
tccatatcat	agctattgtg	aacaatcctg	caaaaaacat	atattttctta	19200	
gacatactga	ttttgttttc	tttgtttata	caccacagaag	gagtcatgct	19260	
atagttctat	gtttaatat	ttgaggaacc	tccatataggt	ggctgttaaca	19320	
atctacattc	ccaccataaa	tgtacaagtgt	tttccctttt	aaccaacact	19380	
tgtcatggag	cttcagttaa	attatttgaa	aattttatggg	caaaagaaat	19440	
cagccattta	gaaacagata	actcatttta	ggcagaggca	aaggatgaag	19500	
cccacagcgg	cagactagcc	acactaattt	gtgagaaaaa	ctcacatctg	19560	

gattaaagat	gactgatgac	taagagcaga	atcaatagtc	aacaccataa	ttagttcatc	19620
ttacaaattc	tgatgggaaa	atcaatgtta	tagcaaaaatt	tccattcagt	gagacccaag	19680
accattgcac	ccagatgagg	tgtagtagac	aagagaagag	tgttttgttt	ttgagactga	19740
gtctggctcc	gttgcccagg	ctggagtgtc	gtggggcaat	ctcagttcac	tggaagctcc	19800
gcctgccggg	ttcaggccat	tctcctgcct	cagcctcccc	agtagctggg	actacaggcg	19860
cccaccacct	cgcccgcaga	ttttttttta	tttttagtag	agacgggggt	tcaccgtgtt	19920
agccaggata	gtctcgatct	cctgacctcg	tgatcctcac	gcttcggcct	cccaaagtgc	19980
tgggattaca	ggcgtgagcc	acggcgcccc	gccagcaagg	gaatagtttt	taacggaaaag	20040
tgtattaaac	aagtgggaat	aagaacctga	aacatttctt	caaagatttg	taacaagagc	20100
tgaaacatga	gtttatcagt	atgatcctga	atacaaaaaca	taatcaaagc	aatggcatac	20160
caaaggtgga	agtgggtccaa	tgaaagcaaa	agcaggccag	tcaggagaaa	acatcatggc	20220
aacagtttat	gagatggcca	aggcatttta	ctagttagtg	tctggaaggc	caaagagaaa	20280
catttgcttc	ttaagagaat	gttttgagaa	agttttcaaa	gcttttagcag	aaaaatgccc	20340
aggaaaactt	catcagagag	tcctcctcca	ccagaacaat	gctcctgctc	attcctctca	20400
acagacaaaa	acaattttgt	gagaattttt	atgggaaatc	tttgagcatt	cctacattaa	20460
agtcttggtt	tgcccttctcc	tgacttcttt	cttttgcccta	attttaaaaa	atcttataaa	20520
gggtaccctt	tgtttcagtt	aattatgtga	aaaagactgc	ttaacatgga	tatagtcca	20580
gaaccatcga	gtcttttaggg	atggactaaa	tggcttgat	cactgttttc	aaaagtgtgt	20640
tgaacttgat	ggagcttatg	ttaagaaata	aagtgtagtt	ttaaaatttt	cttattttta	20700
ttcaattttc	catgaatatt	tggaagtgcc	tttatatatg	catgatttta	tttcggagct	20760
tttaattctg	tctatgtatc	ttttttgtat	caggactaaa	ctgttctgat	tattatagat	20820
ttgtagtgtg	atttgaaacc	agagagcatg	atagtgtgct	gtctcttctc	tttttgcctt	20880
gtaagactgc	tttagctatt	tggtgtctct	tgctctatat	taatttttaga	attttttttc	20940
catttctgcg	aaagatgtgt	ttagaatatt	gacaatattg	catggaatct	ggagttttag	21000
gtattgaaga	caattttata	atattgattc	ttttgatcct	tgaagacagg	acatcttttc	21060
atttatttgt	gttttcttca	atttctttca	tcaatatttc	atagttttca	gagtacagaa	21120
ctctcatctc	cttgctttga	tttagtctca	agtattttat	tatttttgat	gctattgtaa	21180
attagatgtt	tgttttcaat	ttcttatttc	aatagcttgc	tgttagtgtg	tagaaatgta	21240
actggctctg	tctgtagatc	ttgtaccctg	caactttact	gaattgggtg	ttacttttag	21300
caaagtttgg	tgaagtcctt	gggtttttcca	tgtatataat	gagatcatgg	catctgcaaa	21360
cagagacaac	tgttttcttt	tccaatttcc	atgcctaaca	gctctagcca	ggatttccag	21420
cactatgttg	aacataagtg	gtgagagcga	gcctccttgt	tttttttttt	ttttctgata	21480
atagacaaaa	atgtttcaac	ttttcactct	tgagtataat	gttaaagtgt	agcctgtgat	21540
atgtagcctt	tattgtcttg	gggtaatttc	ttttatggct	aatttggtga	gactttttat	21600
catgaaagga	tgttgatttt	gttaaagtct	ttttctgtat	ctattgagat	gaatatacaa	21660
tttttgcttt	tcattctttt	aattcggtgt	ggaacagtaa	ttgattgggtg	tatatatact	21720
atctttacat	cccagatata	cattactttt	cattatggcg	aatgattcct	ttaatgtgtt	21780
gtcttcactt	tggaagtatt	ttgttgagca	tttttgcctc	tatattcatg	aagaatattg	21840
acctataatt	gttttttgta	gtgtccatgt	gtggctttgg	tgtcagtatg	atttttgacc	21900
tcatataata	aaactgagag	ttcactctta	aatttttgac	agaatttgag	aaggattagt	21960
gttgattott	taaatgtttg	gtaggattcc	atccatcatg	aagccatgag	ttttttttgt	22020
tttggtttgt	ttttttgatg	agagactttt	tattacttgt	tcatttttct	tactcattac	22080
tgttctgtat	taatttttgta	tttcattatg	tttcagtaat	cgtggtaggt	tgtagatgtc	22140
tatgaatata	tttgttttcca	ttaggttatc	caacagttat	atggtggcat	ataactgttc	22200
atagcggctt	cttctggttt	tttgtatttc	tgtgctatca	gttacaatgt	ttcctgtttc	22260
atttctaaat	ttaattgttt	cttctctctt	tttttagttca	gctaaagggt	tgtcaatctt	22320
gtttataatt	tcaaaagcca	acttctagtt	ttgtggatcc	tctattattt	ttccagtctg	22380
ttttatttat	ttctgttctg	tacctacta	tttttttctt	tccagtagct	ttgggttaat	22440
ttttttcttc	attttctagt	ttcctgagat	acaaagttac	ttgctttatt	aggatcttca	22500
tggagtcaat	catatctcta	aacatccctt	tatactgctt	ttggtgcata	ccatatgttt	22560
tttagaatgt	tgtttttcca	tttttgtttt	tctcaagata	tttttaaat	tccctttgaa	22620
ttctctcaat	gccccattgg	ttgttccgga	tcatgttgtt	taatttccat	gtatttgtga	22680
atttcttaac	atttcttctg	ctattgtttt	ctagtttcat	atgacaatgt	taaaaaaatt	22740
tatgtaattt	caatcttttt	aaaatttttt	aagacttgtt	ttgtggcccc	acatatgatc	22800
tataattggag	attatacctt	gtgtgcttga	gaagaatgtt	tattctactg	ttgtcaaagt	22860
gaatgttcta	tataggctctg	ataggctccat	ttggctctaat	atagagttca	agtcctaatgt	22920
ttttattgat	ttctgtatag	actgtctatc	cattgttgaa	tgtgggttat	tgaagtcccc	22980
tactattact	gcatttttgt	ctatttcttc	cttttagatgt	attaatgctt	gctttataag	23040
tttcattgct	cccatgttga	gtgcatacat	atttgcaata	gttataatct	atttgtgaat	23100
tgactccttt	gtataatgac	cttccttgtt	tctttttaca	gatttgactt	aaaaattcaat	23160
tttagttaat	gttagtatag	ccccctgtct	ttcttttgtt	ttccatttac	atggaacata	23220
tttgtttatc	cctatgctgt	gctatgggtg	gcatagtagt	accctttcaa	aatatgtgtg	23280

ttacgtcctc	atcactatgg	tgatagtatc	aggaagtaag	gacttttttag	gtgattaggt	23340
catgaggatt	ccacccta	acattggatt	agtcttttta	caaagaagag	tcatgggaact	23400
cccttgcccc	ttccacattg	taaggacata	gtaggaaggc	accatagtgg	gaaggcacca	23460
aaacagggag	caagccctta	caagacatca	aatcagttgg	tatcttaagc	tggaaaatct	23520
cagcctctaa	aactgtatga	aataaatttc	tattttttat	aaactagcca	gtttatggta	23580
atttctttata	gtgggtcaaa	tgtactaaaa	caatttagga	ataaacgtat	attcccaa	23640
gttaacatta	ctatcaacat	aagttgctaa	ttataacaaa	tgctcttttag	atttttgaaa	23700
tctggctttc	ctcaactcaa	gcaattttatc	taaatcagga	tcactaacia	ggagacagcc	23760
tgagtatata	agccacctga	ttttataacag	taagaagtaa	taagggtatca	ttaaataata	23820
tttggtgtgt	attattgata	tctttatttt	tcacataatg	gcttcacctc	ctttatgagt	23880
ttaaaatgtt	cctaatacaaa	aatgattttta	cctaactagt	gctgattaaa	agaatgaat	23940
ataaaaatta	catttcagaa	ccttactatt	gaaattttcca	aaactcttct	actccaaaaa	24000
tacttaagag	gctatttgat	gttaagatca	ttactgatga	aatctttatc	attctcaaca	24060
tgcaccgcct	tgcttggttag	acatcattat	tttaaaataa	attgtgcttt	tgtttccaaa	24120
gtgatataatg	ttaaaggtag	aaaaatcaga	ggataccgat	atatacaaaa	gaattaaacc	24180
ctaactttta	cccctagtat	ctctaaatc	acacacacac	acacgcacac	actcacatac	24240
atatacatgt	atacacacac	acacacacac	acacacacac	ttatctatag	ttttgaattt	24300
cctggcaatg	ttttttctat	aaacattaaa	tcagggcaaa	agtatcatgt	ttctatgttt	24360
gcaagtgaatg	gcatgcaagt	gagcatgtta	taactgatac	tgtgttttta	ttttttgtat	24420
gtttatgttg	taatatattat	ataccctatt	acgtttttaac	tcctctttat	gattagtttg	24480
cattatcacg	tgtgctagat	tgacatcttg	tagaagtatc	tacatttcat	cagttttggt	24540
gcatttatgt	attgatataca	cttttggtgc	atttatgtat	tgataaatag	taattactta	24600
tatctcatta	ccaacatgag	ttaagacttg	acttggtttt	tacatctttg	taaagtgata	24660
taattttgaa	atcagagaca	atgatatgct	ttccattttc	tgtaaaacag	tgagcctcag	24720
aagctgtgga	gaaagctttg	ggagatttaa	gagtgatgaa	cagaaataaa	gtctgaaaaa	24780
ttgctgtctaa	tttcttgcca	caaacatttt	atgaactgga	cacaaccgtt	agttttccag	24840
gatttaatat	ggtgctttta	agaagagagc	caccggtctc	agcttataat	tacattttca	24900
caaattaatc	caaaattttta	cgtatgaata	aaaaggagta	aaacaatata	taaaaaatga	24960
aattgagaac	tgattttaata	ctaaagttct	gaataaagggt	gtgcacttta	tgattgatcc	25020
tatctttttg	cacaagttgg	atactccagt	ttcccatccc	aacatgttgt	tcgcaatgtg	25080
tgagaacgtg	atgaagacg	atatcccgt	ttacacacaa	attcaactga	ttcacctgtt	25140
ctcgaataaa	gcttctgttt	ggctgtccac	cttaatgcta	tgttataaatt	ttccataaatt	25200
tctcgggata	ttacacacgg	atctgaaaaat	aaaaaacagt	aaacataaaa	cattaagtag	25260
tatgcaaatc	ttcatagact	ttcagggtttt	caagtagaat	gttatatgat	ggttcaggaa	25320
ttattttctca	aaacactatc	caaaccaact	atgtagaaac	atcatattga	tttgaataaa	25380
cttagaatgg	taatcgatgt	gaaaatgagg	ttcgatgttt	aatgtatgag	aattaggggt	25440
gtattatcaa	tgattcatta	catcagttgt	caatttttagga	tccttgctgt	ttagaactta	25500
tcattgctgc	ttttgattaa	gatattgggtc	aaagagtaca	aactttcagc	tataaatatga	25560
ataagaactt	ggaatcaaac	atagagatct	agtgatattt	agagctaata	atattgtatt	25620
gtttatttga	aaattggtta	gaaagcagat	tttaagtgtc	ctcaccacaa	acacacacac	25680
acatactcac	acaccacact	acaccacatg	ctaagcatag	gtgatgaaga	atgtgcta	25740
taatttggtg	taatctttgt	agcataaata	tatcaaaaaca	acatattgtc	aaacatcaaa	25800
atataattttt	atttggtcaac	taaatgcttt	aaaataaaat	ataaatataa	agagaaaaat	25860
tacttttttt	gttggttttta	ttgagacgga	gtctcgcttt	gtcaccacag	ctggagtga	25920
gtggcgcgaa	ctcggtctac	tgcaacctgc	gctcccgagg	ttccctgcct	ttccctgcct	25980
cagactcccg	actagctggg	actacaggtg	cccgtcacca	tgccggttat	tattattatt	26040
ttgtattttt	agtagagacg	gggtttcacc	gtgttagcca	ggatgggtct	caatctcctg	26100
acctcgtgat	ctgcccgcct	cagcctccca	aagtgtctgg	attacaggtg	tgagccaccg	26160
caccagagccc	taaagagaaa	aattttctaaa	ctttactttc	tgacagaaat	atttggtagg	26220
caagcattca	gcagaatggt	tgttcaataa	tctgtgagta	ttttgttaca	aacagtga	26280
tatcagactc	atcacagaga	tttttccagc	cacgtgaata	ttaaagtact	tacgtaagca	26340
ttttggtggt	tctgaccatt	gtccattttct	acatgttatt	cgcttggtac	cctcaagttg	26400
atacaagttc	tggtcattggt	actcaactga	tgaagctgga	gcatatactg	acaacgggaa	26460
tgaagtaatg	tcccattgtg	caataggtgg	agggggccca	cattttcctg	tagaatctaa	26520
aaaacatcat	ttcatcactt	gatttggtgt	gagagcaaat	caaaatacaa	gttcaataa	26580
ggcaaacgca	aacacagcac	tgtatataat	atcaacagtt	ttgtgatttc	tggtgaaaga	26640
aatgagtcct	ggaagaaatt	ttaacccttt	aaactgaaag	taatatattt	aagttctttt	26700
ctccgtactg	aaagaacaca	taaaacatta	acaaatattg	ctgcttatgg	tagaccagga	26760
ttaagaaatg	tctttccgaa	tgaatacatg	ctaaacatag	aaaactatga	caaaggaagt	26820
ttcttatttc	atattcgaaa	aatcccatag	gaattataaa	atggaaaagt	atgacaaaaa	26880
ttttttaaaa	acactgaata	tacttaataa	tacatgggga	gctgacagac	aaataaatcc	26940
atgaacttga	acatacagca	atataaatta	cccactctga	aaataaactg	aaaacaaaaa	27000

actgaactga	gacattcaga	aaaatacaac	aacaaataat	gccgatgcag	aaaaagaaga	27060
gaaaggatat	tgggctggaa	aatgaataa	ataaaatgat	gcctgaaaac	ttcccatttt	27120
gaccataagg	tataaactta	tatttaagaa	gctgagtga	ctccaaagag	gataaaaaca	27180
ttggaattta	taccaatata	cattaaata	aaactacttt	aaaaaaagaa	aaaaatacct	27240
tgaaagcaac	tagacaaaaa	ctatgctttt	cctcgagggg	atcaacaatt	caaatgatgc	27300
tgagtttttc	atctataacc	atgtggcacg	gttttcaagt	gttcaaagaa	ctgtcaactc	27360
caaatttgat	atccagtgac	acgatctttt	acaagtaagg	ggatcaatac	agacattctc	27420
agagaaaggg	ataccaaggg	aatttgcctc	cagtagacct	atgcctaaag	attaactaaa	27480
ggaattcttc	aaattaaaat	aaaacagata	aaagaaagag	cttgagactt	taggatcctg	27540
aaaaaataga	aaaatagaat	ggataaacag	aggagtcaat	ataacaggat	atctttttcc	27600
tcataagttt	tttcaattat	gttcgatatt	tgaagcaagt	gagtttaata	tggagctcaa	27660
tgtatgcaga	gaaaatacta	gtggcattta	tacttacaac	gtggagagtg	taaatggatc	27720
tacatgaaag	taagggtttc	atattccagt	tgtagattta	aatgtcagtg	ccagtagaca	27780
gtaatatatt	attacatata	tagtattagc	tagagcaaca	acttttttaa	aggaggagaa	27840
aagctataca	aagagataga	atggaaaaca	atacatatga	atcgaaatta	atctccttaa	27900
taatttccct	acagggaaatg	gaggaatagg	gaaataggac	tgaaacccag	aggaacagg	27960
cagaaacaaa	taaacgacag	agatttaagt	cctatatatc	aataattatt	ttaagtgtaa	28020
atggtccaag	tgcaccagtt	aacaggccat	gaaaggatga	atggatatgt	aaacatgacc	28080
caactatatg	ctgtctacaa	aaactcactt	caataataaa	cataggtaga	gtctaagtaa	28140
aatagtga	aaaaaaat	agaaaaacat	taatttttaa	acataaaggt	gagtaagata	28200
caatttccct	ttttgggttc	ccttattttc	tctctttata	ttagaatgac	ccaggactat	28260
gtgctcggac	ttctttttat	aaatacagtc	agtcacacac	ctttaaatat	aatccatata	28320
ctgaagatgc	ccacatttat	atcacagtc	atgatctctc	ttcaactgcc	tattccatat	28380
cttagaatgc	acatcactta	tggctgtcaa	atgcacataa	tgtatctttt	attacacgta	28440
ttcttgagaa	ggaactaagt	gttgtaatgc	ttaaaaagta	ttgtttttca	ggttccaact	28500
ctcaatttgg	tcgaatcttt	ctggaaaata	atatacccta	ttacttgtgt	tctgttcaca	28560
ggaagaattg	aattttaagc	accatcagtc	attttatttg	catttgaaaa	atctattaat	28620
aaaaatgact	tcattttgtt	taaatacaaca	tattttaacc	ctgctatact	ccccaaaat	28680
gttaaaagaa	atataatact	ctacctttgc	attgaggtgg	ttccgtccag	tttccattta	28740
aacacatcac	ttcttcatcc	ccaaacattt	cataagggct	cctacattga	taacgtactc	28800
tctcaccaga	tggatattta	ctcatctgtc	tcgacactat	ataagcattt	tgtactgtgg	28860
gcggttcac	acaggaggtg	tctgaataga	aaaaaaagaa	gtggttccac	ctagtgttca	28920
ttttgagtag	caaatacaact	gataacagtt	acaaatatat	ttcaagacga	atttaaaata	28980
agtagacaat	ctcatcaaat	attttgttga	ttttaataaa	tttaaatgta	atattgagga	29040
aaagacatga	aactattttt	tgtaagggtac	aagcggtgat	gtttttaaat	tcttcttcat	29100
ccttcgctag	aacactgata	gacctttatt	tttcccttct	ggaagccagt	gtaaacgaaa	29160
gttttccctg	atatctctct	ttgagtttga	gtaaacaaat	attaccagtt	ctatttattt	29220
aacattaatt	tataaaatgc	aaaaagtcag	cataaataga	ttatgtgata	ccagattttt	29280
gtttgcaact	atcctgctta	tacatttttag	cctcttaaaa	ataaaactca	ataggcattt	29340
tcttagcgaa	taagcaaaga	attaaaaaca	catttttgaaa	attacccaag	ttaaaaggag	29400
gaagaatgg	taatcaaagg	atccaaattg	gagatgtgga	aaaatttttt	taaaaagcct	29460
ataataataa	aaataacctc	agataattta	attgccaatg	attaaggata	ttatgctgaa	29520
caatgcaaaa	ttcatcgag	agtttcatat	ccatgtgtag	tgaatagact	atagcaatgc	29580
ttctcactcg	gaagtgtaaa	tagaattccc	tggaggtgtt	ggtaaaacag	tttcaggggt	29640
ttactttgag	acttttgatt	ctggatgtct	agaatgagct	tacggaattt	tattttcatt	29700
tcaaacaact	tccaagaaga	tgtatgtcct	accggtttag	cgaccacact	ttgagaacta	29760
ttgagctaag	attaatcatc	aaatactcag	ttocatcttt	ttatttttag	gcatacgact	29820
actttgtcct	gccgtaaaaa	cttaatttat	gtccatttta	atgatgttag	agacaattct	29880
atattttatt	cccaaaacac	tctatataaa	taaattgtac	ttatatattt	atttatttca	29940
ggtttattta	tttttttgag	acggaatctc	actctgtcac	cctgggtgga	gtgcagtggc	30000
acgatcttgg	cccacttcaa	tcttcatctc	cctgggtcaa	gcgattctcc	tgccctcagtc	30060
tcccaagtag	ctgggacttc	agatgcattg	caccatgccc	cactattttt	ttgtattttt	30120
agtagagacg	ggttttcacc	atggttgcca	ggctgggtct	gaactcctga	cctcaagtga	30180
tccgccacc	tccgctccc	aaagtgcctg	gattacaggc	gccagccact	gggctgggccc	30240
cacacattat	ataaataaat	tttgaaaatt	caccaaagta	cctctgcattg	ttggccttcc	30300
tgtccatctg	ctattaatgc	atggttacatt	actggctcca	tccattttgt	aatatgttgc	30360
acaagtgtaa	gtcacttgct	caccgcctt	atacacatcc	ttcttctctc	ccatgggtat	30420
ggcattttca	aagctaggta	aactgagaca	atctgtttct	gaaataggaa	aaatatgtat	30480
ttgttccgca	aatcttttaa	aatagggttac	atacaataca	tgtaatggat	tctaaaatag	30540
cgatatatag	aatcaatgaa	tactgtacaa	catttttctt	ataacttgag	aaaatatatt	30600
agccattttg	tcttaattac	attaaattct	tctaaatcta	ttaaaaatac	aagatagaaa	30660
tgatattaga	agactgaaga	aatattggta	gccgtagcaa	ttgagattac	acattttttt	30720

gttcacatta	tttttgtcca	tacttgccac	ctgatatggt	taggccttgt	gtcctcaccc	30780
aaatctcatc	ttgaataata	atctccaggt	gttgagagag	agacctggtg	ggaagtgatt	30840
ggatcatggt	ggcagtttcc	cacatgctgt	tctcacgatg	gtgagtgagt	tctcacaaga	30900
tatgatgatt	taataactgt	ttagaagttc	ctccttcact	cactcctctc	tctcctgcc	30960
ccttgtgaag	aaggtgcctg	cttccccctc	agcggtaatg	gtaagtttca	tgacacctcc	31020
tcagtcatga	ggaactgtga	tcaattaaaa	ttttttcttt	tataaattac	ccagtctcag	31080
gaaggtcttt	acagcagtg	gaaaacggaa	taatacacca	cctatatattg	gtgtgcattt	31140
ccaaattttt	tgcttctatc	aaatgtgaaa	tacttataat	gatttttttaa	aatattttcag	31200
aaaatgtact	tataggcaga	ttgttgataa	actgacagaa	gattgaataa	tgtggagatt	31260
gatgagtaga	ggcagctgtg	ccctaagaac	agagatgaga	agtctgagaa	tatacatcag	31320
aggatgctta	aagttcacac	aagatgatgt	gaaaatgaac	taatttggct	tataatgtca	31380
aatgttttaa	ttactacagc	tataattttc	cacagcagtc	cagaatattc	aagaaaacct	31440
tatgaatttc	tagagtccct	gtttactttc	ttattggtac	cacttacact	ttgaatgaag	31500
aatattttatc	atacatataa	taaaattcaa	tgaccatac	ttatgcatga	tggagggtga	31560
gaccattttt	ctcctaagca	ttttgcaatt	gcaggcccat	caattccaaa	accttcaaaa	31620
catttgtacg	taacttcttc	tccatactga	taactgtctg	acatgtgagc	tacaacacca	31680
tgagaaatct	caggtggaga	tttacaagga	aggcctaaaa	aaaaaagaat	gaattcaggt	31740
ttcactaact	cataaattta	attttatatg	cctgttttaa	tattaagtag	ttttatttga	31800
aaataaacia	tacaggagct	actatgacat	cacagagaag	taacacaaat	gtttcctaaa	31860
actagccttc	tggtgtctgt	ctgtctatcg	gactgtcacc	aactgaagaa	ggacttgaaa	31920
ctaaaaatag	caatacatth	cagaaagaga	tcacttatgc	ctggtaaaca	atgcctctgt	31980
aaacttacta	gtgataataa	gatacacatt	gagagttaac	gattccaggt	aaaacataat	32040
atattgttagg	aaataagaag	gggcatttgt	ggaagaatgt	ttaaaacata	cccaaactctc	32100
gtggcaaagc	aaacatgaca	acttgacaga	caggttttagc	tgtgtcccca	cccaaactctc	32160
atcgtgaatt	gcaattgcc	taactctcac	gtgttgtgga	tgggacctgg	tgggagaaaa	32220
ttgaatcatg	agggcgattt	ttcctctgct	gctgttctca	tgatactgag	tgagttctcc	32280
tgagatctga	tggttttata	aggagctttt	ctgtctttgc	tttgcaactc	tccttctctgt	32340
catcatgtga	agaaggacat	gtttgtctac	ccttccacca	gggtttgtaag	tttcttgagg	32400
cctcccagcc	atgtggaatt	gtgagtcaat	tacacctctt	tcctttataa	attatgcagt	32460
cttggttagt	tctttatagc	agcatgataa	cagataataa	cagtaaatgt	gtactgcaga	32520
gagtaggggt	ctgctgtaaa	gataaccaaa	aatgtggaag	cagcttttga	actggataac	32580
aggcagggtg	tagaacattt	tggaggggtc	agaagaagac	aggagaatgt	taaaatgttt	32640
ggaacttctt	agggagttgg	acggctcaga	agacaagatg	tgggaaagtt	tggcacttcc	32700
tagaggcttg	ttgaatggct	ttgacccaaa	tactcacagt	gatattggaca	atgaagtcca	32760
ggatgggggtg	gtcacagatg	aagatgaggt	gaggaacttg	tttgaaactg	gagtaaagggt	32820
cactoctgct	atgcaaagag	actggtggca	tattgccctg	ccttagagat	ctgtggaact	32880
ttgaacttga	gagagatgat	ttagggtatc	tggcagaata	aacttctaag	tggcaaagag	32940
ctcaaagagga	agcagagcat	aaaagtttgg	aaaatgtgca	gcttgtaaat	gcaatagaaa	33000
ataaaacttc	attttctgg	ggagaaattc	aagcctgctg	cagaaatttg	caaaaataat	33060
aaggagccaa	agttaatcac	caagacaatg	gggaatatat	ctccggggca	tgtcagaggc	33120
cttcatgaca	ccccaccca	tcacaggccc	agaagcccag	gagggaaaaa	tggtttgatg	33180
gacctggatc	aggtccctgc	tgtctatg	agcctcagga	ctgtatccca	gctgcttcag	33240
ctccagctgt	ggctaaaagg	ggccaacaaa	cagcttggtc	cattgcctca	aagggtgaaa	33300
ccccaagcct	tggtggatta	catgtagtct	tgggcctgtg	ggtgcacaca	agtcagaagt	33360
tgaggtttgg	gaacctacaa	ctaggttgca	gaggatata	gaaaataacct	ggatgtccag	33420
gcagaagttt	gctgcagggg	ggagccca	tggagaacct	ctgctaggcc	attgaggaaa	33480
ggaaatgtgg	ggtcagagcc	ctcacataga	gtccccactg	aggcactgcc	ttgtggagct	33540
gtgagaacag	gaccacaatc	attgaagccc	cagaatggta	gatccatcaa	tagcttgcac	33600
tatgttctctg	gaaaagccac	agacactcaa	tgccagccca	tgaaagcaac	caggaggggg	33660
acaaagccac	atctgcacaa	ggctgtggga	gcccattctc	tgcatcagca	tgacctgaat	33720
gtgagacatg	gagtcaaaagg	agataatctt	ggaaatttaa	ggtttaatat	ctgccctatt	33780
aaatttcaga	cttccatcaa	gcataatagcc	actttgtttc	agccatttcc	cccccttttg	33840
aatggaagca	tttaccaca	ccctgtaccc	ccattgtgtc	taggaaataa	ccaacttgct	33900
tttgattttt	caggctcata	agcagagagg	acttgccctg	tctcagatga	gactttggat	33960
atgaactttt	gagttaatgc	tggaaataagt	taagattttg	aggactgttg	ggaaggcatg	34020
atttgtttt	gaattgtgag	gacatagact	tgggataggc	catggtggaa	tgataggatt	34080
tgactgtatc	tccaacaaa	taacaatttg	aattgtactt	cccataatct	ccatgttttg	34140
tgggagggac	tcagtaggaa	gtagttagaat	aatgggggca	gttatcccca	tgcttctgtt	34200
ctcaggatag	tgagtgtgtt	ttcatgagat	ctaattggtt	tataagggcc	ttttcccttt	34260
ggtcagaact	tctccttctt	gtcttcatgc	gtttgtctct	ccctccacca	tgattgtgaag	34320
tttcctaaga	cctcctcagc	catgcagaac	agtgcagcaa	ttaaaccttt	ttttgtatgt	34380
ataaattatc	cagtattggg	cagttcttta	tggcagcatg	agaataatac	agatagggtt	34440

aatttcacta	gatattat	tttaatgcc	gaatacaaa	tgactctatc	atgaacaaat	34500
aaaattaaca	taaatagaat	agatttcaatc	atgcaaaaag	tatttttaatg	gtataatata	34560
taaattat	tatatatgca	gtaatctcaa	ttattccct	cactttgata	acaagagatt	34620
atTTTTatga	attctactat	aaacagaaat	tgagtattca	tattggccta	accttcacac	34680
tgaggtggag	aactccattt	tcccatgtag	catgttgtt	cattttcttc	agatatcctg	34740
aaaccaccct	cacaagtata	actcaatttta	gtcccatgtg	cataactttc	ttgtgaagac	34800
ctggatgaat	taatggttcc	gtgttctatc	tgaggtggtt	gtgaacatgg	aattttttct	34860
aaatgaagaa	tgaaaatcaa	agggttaaaa	acaaaataaaa	tacttaaaat	gaaatataaaa	34920
actaaatact	atctcgatt	ttaaagttag	tataatttga	acaaaataaaa	ttattttaaaa	34980
acaaaaacat	attagaaact	cgcaaagata	tattcctcca	ccatatctat	gttaccatcc	35040
tottgttcaa	taatcatctt	cattcatgtc	ttgttcatca	caaggattaa	aatatgcatg	35100
aatggaaatg	ttatctgaca	tttacataat	attccaaaaga	ttttggctgt	atTTTgttca	35160
aaaaactgaa	agagtggtag	ttgattaatg	tgccataggtc	ctaattttatt	ttgtcaggat	35220
aaagtaatag	acacagagaa	agaacttctc	tcttgtttac	acgaagcaca	agagaatatt	35280
aacctcattt	gaaagaatta	tgtaaaacaa	attatacact	actgaccaac	acagagtggg	35340
attgactgcc	atcttccatc	tttgcattgt	atttcttctc	cttcctgaat	tagataaattt	35400
tcttggcaca	gaacagatac	tttttctcca	tcccgataat	tcagtgtggt	tgtcatattg	35460
tgagaattgg	gaatctgagg	tggaggtggg	cataattgta	tttgtgccac	taaaaaatat	35520
taaaaaatata	attaatgtta	taataaaaaa	taaaaaataa	aaatattaaa	attagaattt	35580
ttgatgaaaa	ataatttata	tgattaaaaat	agaataaata	gaaagatcaa	taactgtttc	35640
ataaattatc	acataattaat	tatgatgttt	ttgtatgcaa	atattatact	tttcagctgt	35700
gtaacagtta	cattaaacaa	tagaactttt	ggcttgtatt	ctcatagact	ttctttagt	35760
tttttcatat	attctttgtt	taataaaatt	gcataattta	tgtaaatattg	atTTTaat	35820
ttttgagcct	ttagaatgtt	ttaatggaat	tacacactct	taattacatg	cattaaataa	35880
aaattgatata	ctataatcaa	atgtatcagg	attggattaa	aacactcaca	aattttctgc	35940
caatggaatc	tgattagcca	gaagtagaat	tatatgtagt	taataatcaa	tttggtagt	36000
acacttgacc	aatataagca	ttaaatataa	tcactagtga	tttatagtgt	gctattttaa	36060
acttgaaact	cccctagagc	ttttattttac	tagcttacct	gtactgttta	gggatattta	36120
aatggatggt	atgcacccag	tttaatgcat	tgcacagcct	ggcttttagt	gtataatcac	36180
atataaagac	acctttgtaa	actcacagct	aagctcctgt	taaactgcga	tacatcagaa	36240
atatctcatt	ttttcataat	atgaaaaatga	agcatgtcct	gtttgactga	cgggggagtt	36300
tagaagcatc	tgggagcatt	ctataatccc	ttgattttcc	tttctcctat	catagtgtat	36360
gctctacttc	acctaagct	ttatgtaatc	gtactatagg	aaatcatggc	aatgatttta	36420
agtgctgac	atTTTgttat	caattcaggg	agacgtttgg	atgaacaaaa	cttcattaaa	36480
ggttattgat	aatgtcgagt	tttctttttt	cgcttatgat	aaagtatttc	atattttatca	36540
aaagtatttt	gcttattttct	gttttttcaat	atTTTgacat	gttttttaaca	ttctcatcaa	36600
tttatttttt	ttaagattaa	tgggtcaacta	tttatgcttg	aatgattctt	tccttctatt	36660
tttgttgggt	gtacattcct	gtctaccttc	tagattgtag	tacctgttgc	ttttattttt	36720
ttatttgttt	tttctgatgc	atgttataat	gtcaaataca	tctctgtttc	agctgtatcc	36780
cattgatttt	aatgtgtacc	acaatcatta	ttattttaatt	taaagtattt	gctgatagta	36840
aacaatttaag	aaagagatta	tttaacattt	tgtgacatgg	caaataaatt	tgaagaacat	36900
tgtgacccag	tatagcctaa	ttctacattt	agtgtgtatg	catattttta	tttgtaaata	36960
gaaccgttag	caaggtagac	tatgtgctga	gcaattaaaa	aactgagtgt	ttcaaaatat	37020
tgaaattttc	ccagtattct	ttcacaagag	aattaaatta	gaaaccagca	aaaatcactt	37080
atctagaaaa	aaacaaatat	tttgaaatta	aacaataaac	ttccatataa	ttaatcatct	37140
acagacaaac	cacaagacaa	atgagaaaaat	atTTTcaa	aaataaaaaat	gaactctctc	37200
tctctgtctc	ccgacacata	gaacatacac	acacacacgt	gtgtaacatt	ctgggacaca	37260
gctaaagcag	tgcttaaaaag	aatagagctt	taaagtttta	tatttttcaa	gtatgatagt	37320
ttatgaccat	gttttcat	ttcacccctaa	gattgagaaa	agtgaattta	aaactgaagt	37380
catcagaagg	aagaaaacag	taaaatcagt	gaagaagaga	aaacggacaa	agaaacacag	37440
agaagggaga	aaattagcaa	agctaaaatc	agtaaaacat	aataaaaacta	aaaaatacag	37500
agcaaatgga	gaaaatttta	aggcattaca	attgggtttt	gaaaatatta	ataaaattga	37560
ggacaaagta	aaaacaatga	tcaagatttta	aaaaatgatc	aatattgagg	atgaaagagg	37620
gcagtgcac	cagcacgatg	ccagtatagg	aagccaccac	tctcccttcc	ccccacaggc	37680
acactgattc	aatgacgata	ctggaaacaa	ttccctttat	gagaaatcaa	gaaaccaggt	37740
caaaagcctcc	tgcaaccccc	taaagttaaac	agagaccaat	atatttttgac	tgcttctctcc	37800
tcagagagga	aagataagag	tgaactaagc	atctatcatc	ctagcttttg	ggggagcatc	37860
ctaaagtaca	ggtttctctc	ttgcttgtgt	aggagcactt	aacgatacct	gcaatactct	37920
agtttctctg	gggtaaaata	aagagctagg	cagggagtg	tgtcagcaaa	atggcagaag	37980
tggaagctcc	tgactcttct	tccacccaag	aatgtcctaa	aaaaacatct	attcataaat	38040
gaactcctcc	tgaaagaaaa	tgaaagacca	gtaaagggac	tcctacttaa	caggcaacaa	38100
agacaacatt	cacattgaac	aagtaagaaa	agttgcaaca	caatggagca	tggacccag	38160

ccttggtcac	tgcaccacac	aattagaaaa	ggaatctcaa	aaacccagtt	tctccttggtg	38220
gagaagtttt	tggatctcac	ataaagcatc	ctgtgttttg	gcctttaatt	cactaattttt	38280
ggaagcagag	gagattaaac	acatgagagt	ctctctagat	cacaggaaaa	atgggtggat	38340
gatacaagtg	ctgaagagct	tccagaaact	tcattccctta	atagcagttc	agagaagggg	38400
ctgaaaaaac	agtcccctgt	ttctcccgag	aagttttatg	atataattctt	cctgtgggcta	38460
cttagagggtc	tgaattctaa	aaaacttgca	gtctggattc	taatgaactt	gcacaggga	38520
cttctctagc	cggttcccgt	ggctcaccct	agtgtacat	ccagggtacat	taatcactct	38580
tagaacaagt	ttgtccacac	aaacttgagt	gccctaactt	ttacaacttt	cattcaggga	38640
ctgtattctc	aagctcttag	ttctgggagt	agagggcaca	aaatataatcc	agagtctatc	38700
tagaccactg	aaaaaagaaa	tggcggttta	tatgggtgtg	taagcacttc	caggagcttc	38760
attgcccag	agcagtgcag	agaaaagggt	tttaaaatgc	agctcccctg	tttatcctca	38820
aaaagggttg	tgtcatccat	caagtgtctac	aacctttaca	gttacctcca	aaaggactcc	38880
tcttaaaact	cttaactgtc	acagcagata	ttagaaaaat	accagtctcc	atagatcgta	38940
aagcaaatag	atgggtcttaa	aatgtctatgt	aaaaactcca	ggcgctatgc	caaattggag	39000
cagtgcagaa	aaggaaagag	aaagttcaat	ttccatttct	ctgtcgaaag	ggcttagggc	39060
acatacttcc	actggctact	taatgaactg	gcctctatcg	agcttgacac	gggtatctaa	39120
tgacgcaaac	aaaaaataat	cttcccgcag	ccaaagccaa	agtttggcac	ttcatgagtc	39180
tcgcccgaat	gataaattca	gatttatcca	ttcttctctg	accaagtta	gccatgcatt	39240
caaagggtcat	cacttctata	gctccaactc	aagagatcgt	ctccttaaca	aactcacact	39300
gggagatgat	agagatctgc	attcctgaaa	ggccctacat	cacagaatac	aaaaagctgg	39360
taatacaatg	gactcatttc	aagcagatac	ctcttcagga	tcagagcatg	cagcctgaat	39420
attagtacag	gtattagcca	cagattcttt	acttggtgta	atacagagag	agagtgggag	39480
ataaacacgc	acattcactt	tcactatgaa	aatagaagta	agtaaataca	cagccaagtc	39540
ttcaatatatt	tcagctacat	ctagacctcc	tggctcctaa	cttggttggtc	ccagggtcctg	39600
aaaagatgtg	gcacattcta	acctccaggg	ggccacaaaa	aataagagac	agcagtcgc	39660
acaaagactt	gagaggcaca	tgaaaatctc	tggctggaaa	aattagttag	gtctttctcc	39720
tatatgaagc	cagtctgata	agactgagaa	aggccattgt	cttatctatt	gcatagaaac	39780
actgtgagtt	aaagaaaata	aagaaacaag	atatcataac	tccaaacaaa	agaacaagat	39840
gagtctccag	aaattgacct	gaggggaagt	gatataagtg	ttttactcaa	gaaagaattc	39900
aaaataatgg	tcataaagat	actcactgag	accaagagag	caatgcacaaa	acaaattaac	39960
tacttcaaca	aagaggtaga	aagtattttt	aaaataccaa	acaaaaatca	caaatttgag	40020
aatactataa	ctgaacggaa	aagtttttaa	gaggtattca	tcagcagact	agatgaagga	40080
gaagaaggaa	ttagtgaact	tgaagtcaaa	ttactgaaaa	tcaccaaatc	tgagaaccaa	40140
aataaacaca	taaataaata	aaagtgaaga	tagcttaaga	tccagatgga	atactaccat	40200
gtggaataac	gtatgcatta	tcaccatggt	aaaaacagaa	agaaacacaa	cgatacagaa	40260
aatatattca	aaaaaataat	gacagaaaaac	tttcaacaac	tgggaaagaa	atagaaaccc	40320
acaccagaa	atctcaaagg	aatcaaaata	agtttaatga	aagatagtca	ctttaagaca	40380
taacacaatc	aaattatcaa	ccaagtattg	aaaaaagcca	atgaaaagt	atgaaaagt	40440
aatggttaca	taaaatggaa	tttccacaag	actatcagtg	gattactcaa	cagaaacctt	40500
gcaggccata	aggaagtggg	atgatatact	caaaattctg	aaagaaaaca	actgccaagg	40560
aataattcta	gattccacta	ttctgtctta	aaaacaaagg	agtgtataag	gctttctgag	40620
attgaaaaaa	agctgagaga	gcataaggac	actttcctgc	cttacaagaa	atgttaaagg	40680
gagttcttga	aggtgaaaga	agaggatgct	aattagtaac	atgaagatgt	taaagtataa	40740
aacttactag	taaaagtaag	cacaatatga	aattcaaaca	ctctaatact	gtaatagtga	40800
tgggtaaaata	cagctagcat	aaaggttaaa	aggcaaaagt	ggtaagaaca	gctgaagcta	40860
caaactttgt	taagagatac	gaattattga	aagatgcaaa	gcatgtgatc	aaatagaaaa	40920
catgggagga	gcagagtaaa	atttagatat	tttatatgta	atcaaaattc	agttcctatc	40980
agcttaaaat	acctgtttata	agatatgtta	tgcaggccta	aggataacta	caacttcaaa	41040
tagcctttta	taagggtatgc	tatgcaagcc	taaggatagc	caaaagcaaa	acatctaata	41100
gatacacaaa	agattaaaag	aaaaaatcct	aagcatatgg	ctacagaaaag	tcatacaaac	41160
atgaataaaag	caagcaagaa	agaaacaaaag	aatttttaaaa	acaaccagaa	cacaattaac	41220
aaattaccac	tataaatcct	tacctatcta	aaattacttt	aaatggaaat	ggaatatatt	41280
ctataatcaa	aaggcataga	atgactaaat	aaatcaaaaa	ttaatatcca	attataaact	41340
gcttacaatt	gacttacttc	actgtaacgt	aaattcacag	attgcagtga	aggcatggaa	41400
aaaaacctat	aaaaataaaa	actaaaagag	aacaggggta	gttataactca	tttcagacaa	41460
aatagacaag	ggaaaaattg	tataaaggta	caaagaaagt	tattatataa	tgatagtggg	41520
gtcaatttgt	caagataata	caactattat	aaacctatat	atgcacccaa	catcaaagca	41580
actaaatata	taaaggaaac	atttaggaat	ctgaatggag	atgtggactg	caacacagta	41640
atagtagggg	atatcaatat	tttactttca	acgttgagac	agatcatcca	gacagaatat	41700
caataaggaa	acattaaact	taaacaataa	tttataccaa	atagattgga	cagacatata	41760
aagaacattc	cacataacaa	aaaaacacat	attcttctca	aatgcgcaca	gaatattccc	41820
cagaatatgt	tatatgttag	gccacaaaaac	aagtcttatc	aaattcaaga	agactgaaat	41880

catatcaagt	cacttttctg	acaacaaagg	tatgaaatga	gaaatcaata	ataggaggaa	41940
ctatggaaaa	ttttaaat	ggtgaaaatt	agacaatatg	ctctgaaaca	atcatagggt	42000
caaaccattt	taaataaatt	taaaaatatt	ttcagtaaag	gagaatggaa	acaaaacgta	42060
gcaaaactta	tgggatgcag	caaaagtagt	tctaagatgg	atgttttttag	gaataattgc	42120
ctatatcaag	aaagtggaaa	gaactcaa	aaacagtcta	gtagtacacc	tcaaagaagc	42180
agaaaaacat	gaacaaacta	gtcaattcca	aaattagtag	aaggatggaa	atcataaaga	42240
tcagagtaaa	agtaagtaaa	atagagcccc	caaagcagta	caaaatatca	atgaaaaatag	42300
ttttttttta	gataatcaaa	aattgacaaa	gctttaacca	gaataactaa	aaaagagaga	42360
tacggcttaa	agaaacacaa	gatcggagat	gaaaaggggtg	atattacaac	tgatatcaaa	42420
aaaatacaaa	gtataatgag	agaccgttat	tagcaattat	atgccacaa	attggataac	42480
ctagaagaaa	tggataaatt	tctagacaca	cagcctacga	cgattaattc	agaggaaata	42540
gaaaatctga	acagagta	catgaggcaa	cagattaagt	cagtaataaa	atgtttccca	42600
tcaaagaaaa	tccaagacct	gatggcttca	ttgctgaatt	ataacaacat	tttagaaaagg	42660
actaatacca	attcttctaa	aacgactcca	aaaatttgat	gaggagatca	tttttcta	42720
tcattctagt	ggcccaacat	tactctggaa	ccaaaaccag	acaaggacac	acacgcaaaa	42780
gaaaacacaa	ggcaaaatcc	cctgatgaac	ataggtaaaa	aaccctcaa	cactatacta	42840
ggaaaacaaa	tcctacagca	cattaaaaag	atcattcact	atgatcaaat	gggtttaatc	42900
caagaaatgt	aaaggtcggt	taacataggc	aaattagtaa	aggtgatgca	tcccattaac	42960
agaaaggacg	ataactatac	gatcatttta	ataaatctat	atagaatggc	taaaactata	43020
aaacttcaag	aaaaaactgt	agaacatgta	cacttcactg	catatatata	ttatttgctt	43080
ctttaaggac	tctaaacata	ttgaaatggt	gatagcagat	tagtttttgt	attggttgtc	43140
aatgctttct	gtatatccta	gactggcaga	cattggtaaa	aattattgaag	ttagtggagg	43200
aaggaaaccc	acaattggat	agcaaaatcc	agatatataaa	tatgagaaga	ctggaataaa	43260
acctacacta	ttcaagtga	actgtatgtg	tcaatatgac	taacttttca	agatagatga	43320
acaataaatt	aatagataaa	tagatgatta	ggtagatgaa	caggtagatg	aatagacaga	43380
gagatagatt	aaataaatga	atcaacagaa	atagatatag	atacatacat	acatgcatac	43440
agacatatatac	aaacagatac	atagtagtta	ttggcataga	cagaggata	ggcacaggaa	43500
catttggttga	caagaaaagg	aatgagaagc	actggctctc	caacagtaat	gatgacatgt	43560
agtgcctgggt	ttatgtgtgt	gtgtgtgtgt	gtgtgtgtgc	gtgtgtgtgt	gtgtgtgttt	43620
atactaaagg	taactaatcc	acagggcaca	gttaatatata	ggaacagtgt	tttcattaatc	43680
ttctagttta	ctgccttat	tcagtagcat	ttgtaataat	aaatagctaa	agttttttaa	43740
agacacacat	acctattact	tttccaaatg	agaaatagaa	tacatttctg	aaaacaaaat	43800
aagagcttac	ttgagcagtt	cacttctgga	tcccatcttc	catttatgca	gactgtgtgt	43860
atccatcctt	cttttctctc	acatctgtac	cttatgttag	aattatgatc	gaattccttc	43920
ttgtttttta	aatgttctct	aagtataatt	aaatttgatg	atttgcactt	cttaagttta	43980
tctattgcta	taaaataaat	atatttttat	gaaaattcaa	atgataggaa	tcaaaccaac	44040
tattacataa	aaatagttat	aaagtaaata	gtattagcat	ggtaaaatta	tgacttaatc	44100
attataaaat	tcaccaacca	agttattcct	gacacatttg	catcaaaatg	ctattatgtc	44160
aaaatataag	cctgttatcc	tgtcgtgtaa	atgttagaga	tacctatcag	aagacatttt	44220
attctttggg	aaatacaaaa	tatcattgga	tatttctattg	gataaataag	tatgattgga	44280
cattaggact	cttagaattc	aggacccagg	aaaacttttag	gaaaaatctc	agtttagaga	44340
aaagtgaatg	aggggtcccca	agatcctccc	ggttagtcac	caaagaggca	aaatgatttt	44400
aaagattgta	catctcaagt	cacactgtaa	gtgaatcacc	ttgccttctt	gctgatcaag	44460
acatgagatt	tacagtgtga	agtccgtcaa	tgagattttac	gtcctgactc	agtccttgac	44520
tacctcatgc	cactcagcta	taccactgat	tgtaggggcc	tgtggcccac	caaccctgca	44580
gcacatttca	ttattttggc	tgatatggaa	caaactgaaa	aattatcact	tttggagctt	44640
ttaagagaga	aaagaatcct	atgggagagt	agtaagtagg	tattttgtca	actttgtttc	44700
tttgcttctc	agtgcctaaa	aaggaatacc	atacaataac	aataatattt	atattttata	44760
taaaactgtt	ataatttctc	agtaattagt	actcatattt	aatcatatga	taatttttta	44820
atatttttgt	tttttaaaga	aagagtctta	ctctgttgcc	caggctggaa	tgacacaatag	44880
agctcactgc	aatctcgaat	tcctggcctt	aagcaatcat	tcctcctcag	cctcccaagt	44940
agctggatta	caggcatgca	ccaccacacc	ttactaattt	acaaaatttt	ttttatagag	45000
atgggctttt	gctatatgtc	ccacactagt	gtctacctcc	tggcctcaag	caatcttctt	45060
gccttggcct	cctgaagtgt	tgagggtata	ggcgtgagca	accaccctgg	cctcacatga	45120
caatttttgt	aagtaaaatg	ttgcttcaca	cttttaataa	taaacaatac	tgttatcaga	45180
cgcagaaaaga	ttcataaaat	tataattacta	gctttatttt	ttctttctag	acacatattg	45240
aattataagc	aatatgcaaa	agattgggtct	catattgaag	actggaaatg	ttgaggcata	45300
tctgtaaaat	tcaaaaatat	agttgcaatt	attgttgtta	caataaaaaat	attaaacttt	45360
gttaaatgtt	gatttaagaa	gggtattctc	accacacac	tggggaagt	gggtccatac	45420
tccatgaata	cacgtaattg	atctgtgtcc	aatcattgta	aatgattctg	agcaattgaa	45480
ttccactgaa	tctccatagt	aataaggagg	ggaagaaagc	tgggcccagc	catgtttcaag	45540
ttcagggtata	tctccacagg	tactctctcc	cactatgtaa	attttcaaaa	aaaagtttat	45600

tgtgaaaaca	tgatgtatgt	gttttagata	caaaatacaa	aagttttgac	aagttttaa	45660
attaatattt	tatacattac	caatacacac	tggtaaagtt	gtccactctc	catcaacaca	45720
ttgaatttta	ttaggtccct	tcattagaaa	tctaggattg	caataatatt	ccaccacttc	45780
actgtgtcca	tattcttctt	tcgttttttc	cttaacattc	ccattgagga	gttcaggagg	45840
tggaccacat	gattgtactt	gctctatagt	agaaatacta	tgtaaataat	ggttaaattg	45900
tctgtttttac	aatataaaaa	ttcagtaaaa	tggaaaagatt	ttcttctttt	attcatgtat	45960
tcttcattat	gtaacttatt	atagcatcct	aaacaatcaa	gaatgggtgt	catattgtat	46020
tacttatact	aaattgtcat	attgaaggta	tattaaaatg	ttaaaatatg	ctcagacttc	46080
tagatatctt	aaagatgcaa	gaaaaccaat	tagcaaatgt	ggttatgaaa	atcatgttaa	46140
tttttacatt	tcatggaaac	attttatcat	aacatttttg	aaaaatatca	taactgaggc	46200
aagcatttga	tcaacataaa	gtttgactaa	tcaatacaag	caactgaatt	gaatataagc	46260
tgcttaaata	ttgttttagac	acaccgggtg	aaacttaagt	tgcagcccac	actatataaa	46320
atgtccagaa	tggatgttga	catttcaagc	aaaatgaaaa	ttaacaaaaga	aatccctcca	46380
ttgtcagcca	ctagtatggt	ttaaatgttt	gtcacctcca	accccatggt	gaaacttcca	46440
ccccagtgtt	tcagggtggg	tctaattggga	gatgtttgga	tcatgggtat	ggaacttcca	46500
tgaacagatg	aatgccccct	ctcagggtga	gttctcactc	tattagctcc	tggaagagct	46560
ggttcttaaa	aagagcctgt	cactgcccctg	ctctctctct	tgcttctctc	ctcatcatgt	46620
gttctctgga	cacagtggct	cctcttccct	ttctaccagc	attctgtggc	tctcactgaa	46680
tgcagatgcc	cgatcttgaa	ttttatagtc	atgagtatag	tgagccaaat	aaaacatttt	46740
tacaaatcat	ccagactcag	ttattccttt	atagaaacat	aaacctaaag	tagactaaga	46800
ccgacaacac	ctgtgtgtct	gggaataactt	ccagcacatc	gttcaagaaa	cagtggagat	46860
taacttaagt	gactgaatct	cagggtattca	gtactcaata	catgtccttc	acaggcaaat	46920
atltgactta	atlttagtaga	ttacaggcaa	tgggagccca	aacaaaatta	taaaacaaaa	46980
agttgggtatt	caaagttcta	attcttattt	cagcaattgt	aagataagca	ttcaccttta	47040
catattggga	ggtcaggaga	caatccaaag	tggttagcact	gaacggaatt	aggtccaact	47100
attgtaaatc	ctggtttgca	ggagaatttc	aacacctctc	caactttata	ctggcttttc	47160
ttgcgatcag	gaactaagtg	tacatctatt	ttaggaagtt	cgcattctct	ttcttgaaaa	47220
aggtaaaata	atltcatgag	aatatataat	taatcattgc	caaagttaat	tttacatatg	47280
ccacaataaa	gtgaggttga	tattgggtca	tacagagggg	catcagataa	atccttttcc	47340
ctgtaaaaga	tgctacatat	tatgttttat	atgtgtctta	aattgaaatg	gaactttatt	47400
ataaatgtta	tggatttgaa	atatatctgt	tctaaaattt	aatttgtaaa	ttcaacttat	47460
ttacaatgaa	tctagtttta	atcactgaca	ttaatgaaat	ttaatattac	tttttttact	47520
caaaacatga	aattactctc	tcatattaaa	aaagaaaagt	gcatatagac	cagaattggg	47580
gcttttttgaa	aacaagatga	ctgactaagg	agtttgagca	caagttctcc	tcagaaagaa	47640
gaaccaaagt	tacaggtaaa	tgatcataac	ttgaaaaata	tttaagagag	gggtgcaggag	47700
cgtcatagag	aaaccatgga	gagaagccaa	agcatggaaa	aagacagaag	caagagcctg	47760
acaaagggtg	actaggaccc	tgtgggacct	catagaaaag	gtaggtagga	gtcttctggg	47820
ctccctgcag	ctcaccgtgt	ggatccaagc	catcagagag	ctcttctgtc	ttcgtgaaca	47880
cacacactga	tgtgagtggg	gatttgggaa	cttcttgagg	gcattacacc	aaactactag	47940
ttgaataggg	tcatctgoot	tccccttggg	cctgagctgc	agtggtaggt	ttcatgcctg	48000
cagtgcactc	atgtggggac	tgtttccctac	ccaggaacct	cagccctctg	tcccataaac	48060
accagagccg	cacaaatatt	ccctgtcacc	tgcttgagtg	tggcagtcac	ccatagctgg	48120
ctggacccaa	aggagttaca	gcattcccaa	tagtttaacc	accagggagg	ctattcctaa	48180
tggaaagtgc	aacaaaggaa	cacccttgtt	ggcaaagaag	actgtagcat	tcactttctc	48240
gtgtgcaaga	gcaacctgct	tgtgggctga	aatgactac	gccacttcca	gcagacacgc	48300
agacgcgggt	tttggtctctg	caagggagga	gtatagattc	atcccaggag	cccaatgggtc	48360
ccagcgcttg	ggcacggatg	tagagagggg	aacatgtccc	gtggatccaa	ttctgtgttc	48420
atagctgtgg	tcaactgcaa	aggagactgg	tgtagacaca	ccagaggacg	gacattgtag	48480
gggtattagg	gggtggctac	aactccactg	gtcatgtgcc	caatgaagcc	aggcttgcaa	48540
gaaagacaag	ctacgggtat	ctccccaggg	tcttccccctg	acaccctgtt	cagggctgggt	48600
gcttgtgtctc	atccttggag	catccaaggg	tgagcttagt	ggtacagatc	tatcccgtct	48660
tgtccccagc	tcttcagacc	actgtacctt	tcacagatca	gtccatttct	tggggcaaca	48720
gagagtctct	cataaacagt	gacaagcata	ggctcatctg	cctctgctgc	agctggctct	48780
tacctgtccg	tgccacctac	tgtcctgaat	gttgaactgc	acagcccagt	gcaaaatgct	48840
gacactaggg	catgatgcag	aacaagggtta	gttttctgctg	tagtcctcca	taccagccct	48900
tcaggaggca	gtaagcctcg	tcatacaccc	agtacataac	tactacaacc	agcaattaag	48960
aaagccatca	tacaaaagtt	atctctaacc	aagggtactca	aacagagctc	ttaccactga	49020
aagaacccag	aacctaaacc	aatagccctt	atacaacata	catcgtagtc	atattctcaa	49080
agggaaaaaa	aaaatcctgt	ctgttggaaa	ctggacttaa	aaataagaag	ggatagttca	49140
tctggatgag	aagaaaccac	tgaaacattt	ctggaagtat	gattttaaacc	agcgtattac	49200
aacactcgca	aaggatcaca	ctaactcttc	agcaataagt	cctaaccaaa	ataaaatctt	49260
tgaataacca	aagaatttaa	aatattttatt	ttaaagtagc	taaatggagt	ccaagagaaa	49320

gttgaaaagc	aacacaaaaga	aattagaaaa	aaaactcagc	atatgaatga	aaaatgtact	49380
aaaaatattt	tttaaaaaaac	aaatagaact	tatggaaaatt	aaaaattcat	tgaagaatta	49440
caaaatatag	ttgaaagatt	taattacaga	ttacatcaag	cagaaaaact	tgctctcaga	49500
gcttgaagac	aggtctttcc	aattaaccct	gtcagacaaa	aataaagagc	aaataacatt	49560
ttttaatgag	caaaggtttt	gagaaaaatg	acgttctaaa	aaatgagaaa	acttaagagt	49620
tatagatatt	cttgagggag	aagaaaaagc	taaaaaaac	tttttgagga	aaatttatct	49680
cctcttgccc	tcttgctaga	gacatagaaa	tccttataca	agaggctcag	ataacaccag	49740
gaagatgcat	tgcgagatga	acttctacaa	acatatagtc	atcaggctat	ctaaagtcaa	49800
tgtgaacggg	aaaaattata	aaatcagcaa	gagaaaaagc	tctaatacaac	tataacggaa	49860
atctcgttaag	actaacagt	gacttctcag	cagaaaactgt	acaagccaga	agatattggt	49920
gtcctatattt	caggggttctt	aaagaaagat	tagttcatat	ttattgaaaa	aacatatatt	49980
agagatatat	tttgtatttt	gctaaactaa	acttcataaa	tgaagaatat	ataaagtctt	50040
tcccaaacaa	gctaatacta	aggaagttca	tcaccactag	aatccactt	taggaattca	50100
ccccacaaga	aatgatccag	ggagtcctga	acatggaaat	agatgggtcaa	tactcactat	50160
cataaagaca	tgcaaaagta	caaaactcac	aggtcttatt	aaaaaattac	acagttggga	50220
ctacaaacca	gctaggtaac	aactaacata	atgacaagaa	caaaacctca	catgacaata	50280
ttacttttta	acataaatag	attaaatggt	ccacttaaaa	gatataagatt	tgtggaccaa	50340
atatggaaaa	cagaaaccaa	ccacatgctg	ctcaaaagaa	acccacctaa	cttagagaaa	50400
cctatacaaaa	ctcatggtaa	aggtatggag	acagatattt	tgaacaacag	aaacaaaaag	50460
catttggtat	agttatatatt	atatataaaa	aaagatttca	aatcaacaag	aaaaaaaaaga	50520
caagaagttc	attacacaat	gataaaggaa	gcaagaagat	ataacaattc	taaaatatata	50580
tgcactcaaa	acctcagcac	tcagattcat	aatgaaaatg	ctactagagc	taagtagaaa	50640
gataaacagc	aataataatga	gggcaagcaa	cctccacacc	cccaatgact	atactagaca	50700
gattgcaggg	acaaaaaaat	aaacaaagaa	acctcatact	taaattggac	tgtagaacaa	50760
atggacctaa	cagacatttt	aacgacattc	cacccaacaa	cctcagaata	tatgtttttc	50820
tcacctgtgc	atggaacatt	ctccaaaata	gaccatatgc	taggctacag	ctacaaagca	50880
agttcccaaa	attttaaagg	ttagaaataa	tatcaagtat	cttatcagaa	cttggtgaaa	50940
tataactata	aatcaatatc	ataaagaatt	ttcaaaacta	tccatatata	tgaaaattaa	51000
atgacctgct	tctgggtgat	tgtgaattaa	actaaaaatt	ttcttcacag	caaaggaaat	51060
aataaacaga	gtaaacagac	aacctcagaa	tggaagaaaa	tatttgcaaa	ctatgaatct	51120
gaaaaagggc	taatatccag	gaactgcaaa	gaactgaaac	aacacaacaa	gaaaaaaaaa	51180
taataatccc	atgaaaaagt	ggacaaaagga	tatgaagaga	tatttttgcaa	agaagacat	51240
gaaaatgacc	aagaaatatg	aaataaaaaac	tcaatatcag	taatcatcag	agaaatgcga	51300
attaaaaaaa	tgagttatca	tcttacatta	gacacagtgg	ccactgtcaa	atagtcaaaa	51360
aataataaat	gttggtgaca	gtgaggagaa	agaagaatgc	ttatacgctg	ttggtgggaa	51420
tgtaaattag	tacaacctct	atggaaaaca	gaatggacat	ttcccaaaga	actaaaaaca	51480
gaactaccat	ttcaccacagc	aatcccacta	ctgtgtatct	acccaaagga	aatcaattat	51540
catatcaaaa	tgatacccgag	actcatatgt	ttatagcctc	actactcaca	gtagcaataa	51600
tatggaatca	aactaattgt	ccaccaacag	atgattggat	aaagaatatg	tggtatagat	51660
atatgccata	gaatactact	cagccaaaac	aaaaataaaa	aagaaaaaaa	aagaataaaa	51720
tcatgccttc	agaagcaaca	tgtataaaaac	taaaggccat	tatttttaggt	aaaataattc	51780
agattcagaa	agtaaaatcc	cacatatatt	cacttataag	tgagagctaa	ataatgcgta	51840
catatggaca	gagagtgtcg	agtaacagac	attggagact	cagaaatgtg	gcaggatagc	51900
aggaggggtga	ggaataagaa	attacctaata	gggtgcaatg	ttcagtattt	gggtgatgaa	51960
tacactaaaa	gtacagactt	caccactatg	caatatatcc	atgcaacaaa	actgcatttg	52020
gaccatctaa	acataataaa	catagaattt	aaaattttta	aaataaaaaga	acacatcata	52080
aaacaccatg	gaaatatctt	aagaagttta	atttataata	gaactgggga	ggatcccagag	52140
aataatgatg	gtataatatc	tgtcatttga	gagtcaatga	taactttatt	taactgaaac	52200
taaacacact	caaatgattt	ctggtctcat	catgtttata	attcttgatg	actgacatat	52260
acatcacaaa	aaggtaaatt	ctcatcaaag	atttattagt	gaagatatat	gcactaagaa	52320
attaattaaa	attgggtattt	ttgttttaag	taatcaagga	aaaagaaccc	aaaatagcat	52380
ttctaataata	ttttaagtta	aaaaaaatat	aaaaaacaca	taattaatat	attacaaaata	52440
aagaaaacaa	accaagataa	attttcaagt	tcacatggaa	aggcaaatcc	taggtatcct	52500
gaatatattat	gttaacatat	aacaattttt	gttatatgta	ctatttatat	caatgtttta	52560
taaatgtgat	aattattctg	attcagataa	gaaatgtgta	aaattatctc	ttacatgttt	52620
ataattttta	aaaatcagca	acattactaa	atattatcca	aaatattatt	tttcttattc	52680
agaatcctcc	tttcttgcta	acttagaaaa	gtacaagcta	gaattcataa	attagaatca	52740
tactaaaaag	aaaattaatt	acatcataac	ctcaattatt	aaaatacaat	tacaaaatta	52800
gattttaaacc	tattcttaaa	agtaatgtca	caaaataata	actacaaaaa	tttgcttttg	52860
tgtttgtttt	aatgagtttt	gcagattatt	tgagaaaatc	acacttgaat	gagaatcact	52920
gggattttctc	tcctaaaagt	ctataccaat	cttctacata	gcaattcttt	ttttgtgatg	52980
tgtgtttgtt	caogtatttt	gtgctaattt	tatataaatt	ctgtctgttg	taatattgtg	53040

aaaagcatta	tcttaaaaaag	gaaagttaag	atcttgatta	ttgggtatta	ttcaaagtct	53100
gtattttatat	agaggtaata	acttacaaaa	cgtgatttag	agaagaatgt	gaatggacac	53160
tccatgaatt	agaaatat	ttcttcatct	aaaactcaaa	accctaagtc	ctagtactag	53220
atatgtgaaa	tgtaatatg	aatttttaac	tctgagatac	atactcctta	tttagcttaa	53280
gtgctccata	ataacaattc	tgtggaaacc	tttccacaaa	gaagagacct	cctaggacac	53340
ttgaaatata	ctcagatgtc	tgtcaatcca	catgcagttt	tctgttacat	ggctgagaga	53400
agaatatattg	aaaagaatac	taagctggta	tttcttcggt	taatgtttgg	aggcctgtac	53460
tatactagca	aattcctagt	tatgtgttca	aatgatccta	agtctttgta	caatttgcaa	53520
tagaaagaca	ttttctacat	cagcttctac	tgctatgtcc	gccactccaa	ctttctctcc	53580
tttaggtttt	catttcatgt	ctggtgattg	gaaagactac	tgaagcaata	tattcacaat	53640
tttgtgttct	tttttgaaga	agacccctca	aaattgtaaa	agcttctggc	ttcataaaac	53700
ctaaattttac	ctatcatcac	agaaaagaaa	tttatgagtc	tcttaaatta	agcctcccc	53760
tctcaattag	agcaaaactc	aacctcttta	tgatccatgc	ctactcttcc	aatgttatca	53820
aatgtctctc	tccctcacta	aatccaggat	tcagatttta	tgatctttga	attttattaa	53880
aaaggtcaag	ttcttcgctg	cctcagctgt	tcacataacc	cttctcacta	taacaaaagg	53940
ctttcaacca	ttctttgcat	cgatgacttc	ctatgtaaaa	cagatctcca	gttccttccc	54000
tcttattttc	tatctcaatt	attggatttt	ctatttctct	gtacacagtg	atacataaaa	54060
tatattttaa	atatttttat	tacttgata	tttggcttat	ctctttttag	ttttccactg	54120
tcttatatta	gaataaaatc	tctggataag	tagacctgtg	cttgtgtttt	caccattttc	54180
tctgttcta	tgataggtgt	ttacaacagc	aggaatgagt	caaatttaac	tggacctttg	54240
acactgcctt	tcatctacaa	tgtactcatt	ctctttctca	gctgtgacta	tttcaaaact	54300
tttctattct	acctagtact	cttctctctc	cttcgcccac	acactattca	atctcagatg	54360
accatgtctc	atacttcaaa	acagaatcca	tcagcttcta	ccattttcca	acgttactgc	54420
tcattttctc	tcccatctcc	tgtcacaaaag	ttgtaagcag	tccgtgttgc	acctgtcaca	54480
aggttgtaag	cagtctgtgt	gccaccaaaag	cacaatacct	ccacagtagc	tgtgagtcct	54540
ttccctctgc	attttctcag	ggcaactatg	taagtcattg	gttcagcctt	tgcagctccc	54600
cttttgctgt	atctgtctctg	gtgtcttcca	tcttttttct	tttaattatc	ccttcagtgc	54660
acaactttcc	tcaagcaata	ttctgatctt	cctattagat	tcaaagccag	aatcttgaaa	54720
gagttatgtc	tacagtctgt	attgaatgtc	tagctcatta	tttttattgg	cagattctat	54780
gtagggtctg	tctcttctac	tctattaaaa	tccatttttg	ttacacttgt	ctctggcctg	54840
taccttacct	aatccatcac	aatttctgaa	cagaatataa	taactaaatt	agaaatat	54900
atcactttga	taatgatatt	aaggtaatta	aattacaact	tctttgactt	tattatataa	54960
ggcactatgg	caataaata	ttataaata	tttagtctgc	taactaacac	aatcctttga	55020
aatattagaa	ctgtttgtaa	atatgtgaca	ttttaccaac	aagaaagagt	caacaaagct	55080
tcaaataagac	ttgctgtgtt	ggccaaagat	acatgccag	caagcagtg	aattagaatt	55140
cagacaggat	gacttattaa	gcaatctgtt	acactacctt	ttcattaata	atttccttat	55200
ttttatgtct	atggcaacat	tctagatttt	ttctcctgtt	tctctgggtc	ctcctttttt	55260
ccccattttc	tttactatct	attgctcttc	tgtcttatat	ataaatgtgg	taatgtttca	55320
gggcttcatc	ttgagctctt	tgtcttttcc	attctgtatt	cttatccaat	ttagcgtcat	55380
catttatatg	atgatattcc	gaaatgcata	tctcctctct	agatgcata	ccaactccac	55440
acttcacata	tccagttttg	attttccatt	ggcgactcaa	tcataatgtg	tccaagtcaa	55500
aagttgcaaa	gccctctcaa	aatgcattct	atccagtcag	taccatttta	caaaatgggt	55560
attgccattt	acctacatac	ttgtgagaaa	acaattgaaa	acaaacatgt	gagtccttta	55620
atctcactct	ttttcacacc	caacatttag	taacatcacc	tgtacttttc	atcacctaaa	55680
tgttttccaa	atcagccttc	tgtctgtgac	ctccccatc	atcactctct	ctcagtcctc	55740
acactttctc	acctacactg	gactcatggg	gtcgctctct	gcctacaaaa	agtacagcat	55800
ccaggaaaac	aatccaacaa	aactagaaat	caaattatac	cattcctttt	cttaaaactc	55860
ttttatgggt	tttcattagt	cataaaatga	atccaaatga	tatgatgcct	tgagctgatc	55920
tggataaattg	tttccctgcc	tcccatctag	cctcagcagg	atagactctg	ctttaccacc	55980
ttgaaatata	ttgttttggt	tttacagctt	tgcacatatt	tttctttgcc	ttggaacact	56040
ctgcatatac	ttgttttccc	acagagccaa	tccctctctc	aacctgaaa	aatagatggc	56100
tgattgagaa	acgtaaatga	gattcatgta	atggctttca	gaacttttca	aatttagaaa	56160
ataaagaact	acactcagaa	agtacagaaa	ttaacacaca	agatagaaga	tgtaaagtga	56220
aaattaaaaa	aacaaattag	ctgagggaat	tgtaaccaac	tataattttg	gtaataagtga	56280
ctaggttcta	aataatttga	aagcttttat	ttagggtaac	aaaagcaatt	atattataat	56340
cacaaatctg	gaaggtaggt	ggcccatagg	aagtattaat	ttaatgcact	actttagaga	56400
tattttcaaa	actcccttct	tttcccagtt	tatgtcaaat	caggagatat	cttgatttta	56460
atcaacattc	cttaacaatt	cctctatata	attcaaat	ttaaaattgg	aaaacagatt	56520
tattttcatt	ttgaaaatga	atttctgaaa	aaccagta	taccataaca	tatgggtaaa	56580
tcagaccaac	cattgttaacc	acacactatg	gaaccagtgg	tgcttccagt	attgctttca	56640
taaccatcat	ggcattcata	gtccaatgtg	tcattcagct	taaacatgt	gaagtcattt	56700
ttagttctgg	cattcataaa	tactgggata	tcacaagatt	ctagtgcata	aaaaatttag	56760

aatgtcattt	ctaattgtcat	ctaataaaca	atctgagtat	ttcccattct	aagaagaaaa	56820
agctttattg	attagatcta	ctaataaata	ggtaccgtac	aaaaataatc	tatgactggg	56880
gagaatttgt	tgctgtaaaa	tagttgtcaa	aagtgaaagt	atatctttct	acacaacatt	56940
ttttttcatt	gcttaagccc	caaaatatat	tttaaaaaaca	tttttcttaa	ttcattttata	57000
ctaaagcatt	tatgacaatg	ctagtaataa	aacaggccat	tacagggtata	cattattttt	57060
taaagaaaaat	cataacagaa	ttttgtaaat	taagagtcca	aactaattcg	tagttgagac	57120
atatgtaaaa	aggagaaaaa	gactgaaaat	ataaattcct	atggtatata	agacattttc	57180
tctttaataa	taagaaaatc	ttaaaagaat	aattaataaa	aatttagtat	aaaatttagct	57240
tttttatgag	gactaacatt	ttttgtaaac	tagacctcat	attaagcaca	gacattaaaa	57300
aatgaaaaca	gtatacatga	ataccttatt	cacttcactt	aacatgagta	tattaaatat	57360
tacttcaa	atattactga	gaggcaggag	gatcatttga	gattaagagt	tcgagaccag	57420
cctggctaac	atggcaaaac	cctgtctcta	ttaaaaatac	gaaaattagg	caggcatgat	57480
ggaggggtgcc	tgtaatccca	gctatttcagg	aggctgaggt	aggagaattg	cttgaaaacg	57540
gaaaatggag	gttgacagtga	gccaaagatca	tgccactgca	ctccagcctg	gccgacgaca	57600
gagcaagact	ccatctctct	ctctctctct	ctctctctct	ctctctctct	ctctctctct	57660
ctctatatat	atatatatat	atatatatat	atatatacat	atatacgtat	acacacacac	57720
acacacacac	acacatatata	ctgagtgggt	ttgcaaaaaa	taagacaaat	tgaaccaatt	57780
gttcccagaa	aattttcata	aatatctaga	tagtgtggta	gggaaatctt	cataaatatc	57840
tagatagtgt	ggtagggaaa	tcatacaaca	gagcagaaat	tggtaccatc	taggaatatt	57900
ttgtctctct	actacctaaa	tatttatgaa	aaatttctaa	gaggggaagt	attcagtatt	57960
agacatatcc	tacagtgtca	aatctacaaa	ttatagagtt	taaattattt	tgatgttatg	58020
cactaggcat	ccatatcttc	aataaaaaa	ttgtctttgt	atctaggagt	aaagaatttg	58080
atgtaaaagt	ctaactttat	aaaacagata	tatattaaca	gtcataaagg	tctcagctaa	58140
agcaaaatca	gtttaaacca	gaatacacat	aaagctccct	aacttgtttc	tgtaacacag	58200
aatgcttttag	agtaggaaaa	gctgaatgg	aaagacagac	taatatctga	gtaattaatg	58260
tgaaaaggaa	aaaaaattga	tgtctgcttt	gttcctgcag	gttttttttt	cttatctttt	58320
caaatgaaat	tatatcagcc	cccacaaaaa	gactaaagtt	agtaaacttt	tgtgtatcat	58380
ctggataatc	aatacaaaaca	taataaatta	cttactaatg	cacgtgggtt	gagctgacca	58440
tccatctttc	ccacatgtaa	ttgatcctga	tgtttcacca	tctgctgtta	catatcctag	58500
tttgcaattga	tatttcgctt	tttcttttaa	ggcatatgta	tactgagatt	cagaaataaa	58560
cccattctca	atatctatac	ttgatttggg	acatgtttct	aaaaggggaag	agaataagaa	58620
aaagacaagc	atatgatcaa	taacatttta	taagaattta	agtaatatgt	aaatataaaa	58680
aataatgagt	catttgtaac	tgaaaacctg	gataaccata	agcattcaaa	tacttaagtc	58740
aaggaaaata	agctcagagt	tgccaaagac	attacatcaa	gactcttcat	cactttttta	58800
aacaaggctc	tatttaagac	acttacaatt	atttctaaga	aattattgga	aatctgtttg	58860
tctaattggat	ttggaattct	acagcatgtc	agaactcaat	agacaatgag	tattattttg	58920
taggactttt	taatcttgcc	tattgtagat	ttcttgccaa	ttccaaatct	catttagcca	58980
attggagtag	ctgagatcct	gtgatgatct	tagaaaatct	gccaaaataa	ttttcatagc	59040
ctttggctcc	aagaatttga	aatgtcattc	ttattgtgtg	cttcaaagta	aatggacatg	59100
tggaagtcaa	agaagacgag	gaacagtaac	agattttatt	atcttgaaag	gccaaaatga	59160
tgattcctca	aattatgtag	aacttaactt	gaaagagtgg	aagttactgt	ttctgttaac	59220
tgatgataga	aattactgtc	ggttacatgc	acatgtatgt	ttattgctgc	attattcaca	59280
atagcaaaaga	cttggaacca	acccaaatgt	tcaacaatga	tagactggat	taagaaaaatg	59340
tggcacatat	acaccatgga	atactatgca	gccataaaaa	atgaggagtt	catgtccttt	59400
gtagggacat	ggatgaaatt	ggaaatcatc	attctcagta	aactatcgca	aggacaaaaa	59460
accaaaccac	acatgttctc	actcatagat	gggaactgaa	caatgagaac	acgtggacac	59520
aggaagggga	acatcacact	gtggggactg	ctgtgggggtg	gggggagggg	ggagggatag	59580
cattaggaga	tatacgtaat	gctaaatgac	gagttaattg	gtgcagcaca	ccagcatggc	59640
acatgtatac	atatgttaact	aacctgcaca	ttgtgcacat	gtaccctaaa	acttaaagta	59700
taataataat	aataataata	ataacccaaa	aaaagaaatt	actgtcgttt	actaggttgc	59760
ttcccagaac	tcagcttcat	ttttaaataa	ctcatggata	aggagaaaaat	cagaagagga	59820
aacattaaat	attttgaatt	gaatgataat	aaaaacatat	taaattaaac	ttgggtgagat	59880
gacactcgaa	caatcctcag	agggaaattt	atcattatat	agctataaaa	gaaaagaata	59940
aaaactgaaa	ataaattatt	ttttataata	aattataaca	aagaaaccag	acaaaatcca	60000
gcatgagtat	aaattttgaa	acaaatccaa	atatgagaag	aaaccaaata	gaaaacaatc	60060
agtacagaca	atttaaaaag	gtaaaagacc	aggcaagaat	aatcaagtaa	aacagagttc	60120
ttgccacaaa	taaggaaatg	gaacaaaata	gatgaaaata	acattttcag	acattggaaa	60180
gcaggaagca	cctaattcca	gagaaaaagt	gacaatgaga	tgagttccat	catcaaagtg	60240
actttatgct	gggagaaatt	ttccaaacag	cacatggag	aaggagaatt	cagcagaag	60300
tgccacactt	gctgagtaga	agaaacaaaa	ctcagtgttc	ccaaagaaga	tgagttcact	60360
agaatctgca	ggaaacagag	tgagaaaaga	agaaactatg	gagtgaaagg	gctctacaaa	60420
tttccacagc	aactccctag	attatttggc	tgaatattga	cactctggag	agtagagcaa	60480

31/64

aactcccaa	gaatggacaa	aggataccta	tcagatgaag	aacactacca	gagaacaaaa	60540
aggtaaagga	ttcccagagc	acacacacaa	cacagggaga	catttaaagtg	gaatcaatca	60600
gagtagaaag	actcgtttga	acatctaggt	cacgtagtag	agacatcaga	agcagcttaa	60660
tattctgaac	aaactatctc	tggggttttt	taagcttttt	aaaagcttaa	aaataagcct	60720
tgaaagaact	aagttgaccc	aaaacaaacc	taaacttaaa	aaaaaattaa	aacaagtaat	60780
ccttgggggtc	tcacagatgt	acagacttga	gaagttccaa	agctgcttct	cttagccaaa	60840
atacagaatg	gagttaaaaa	aaaatccaca	ttttggtaat	aataccctct	tcacacctcc	60900
ctccaaaaat	cacagtaaat	cttttatgga	atactcacc	tactccagcc	aaacactgat	60960
tgatatacta	tatatcaaaa	gttgtggaat	ggcactagag	cagtatgaaa	taaattggtg	61020
tcactaaata	cctgggatag	aaaatgacgg	tgttccactt	caataacctt	agcctctacc	61080
attagatatt	agtaaaagta	gaaaaaatta	atctcaaagt	aagcagaaga	aatactacaa	61140
taaagatcag	agatgaaata	ataaagaagt	aaatatgtat	ataaacaagg	aaacccaaag	61200
ccttgttattt	tagatctcta	taattgagaa	accttttagac	agactaaatc	agaaaaata	61260
acacaaattg	cttataacag	caatgacaga	aatgacatca	ttatggtttt	tacatatatt	61320
aaaagaaaaa	taaaaaatat	tctgaataat	gccatgtcaa	taaattcaag	aacttgaatg	61380
aattaaaaaa	ttactgaagc	cacaaactat	catggctctc	tcaagaagga	ttaggtagca	61440
ttaataaatt	ctgtctatta	aacaaattga	atttttcgtt	gatggatgaa	atacaaaata	61500
tttagttata	aatctagtaa	aatacaggat	ctgtatgctt	aaaataaaaa	aaactagggt	61560
aagactgtat	gatcttacta	aatcaaagga	tatataatat	tcattggattg	aaaaatttaa	61620
tactattaca	tatcagttct	ccccagattc	atctgtgaat	gtgtcccagt	tctagtgaat	61680
aaccaagcac	aatgttttgc	acatacgaac	atgtctgattc	taaagtcata	tggaaaggtg	61740
aaggggctaa	aacagctaaa	caattcttca	aaagataaga	gaagttgaaa	aactcacatt	61800
accaaaattt	aagacttaaa	aaaagctaca	gtgagtaaa	gatctcatga	tactggttaa	61860
aggacaaaca	cgtggaagaa	tagaagagaa	aacgggtgtcc	agaaatagac	tcacatgcat	61920
ggatcgatcc	tataaatagc	ttctatttcta	ttttgttata	agactatcag	gttcacatgc	61980
ccactgttta	gcaatagacc	aatacgctga	gacagtaggg	tttgcagcaa	agaaaggcct	62040
taatcaacac	aagggcacca	aacaaggaat	tgggaggatt	ctcaagcccc	agatctgttc	62100
tgagaagggg	ctatgtgcaa	gagaccttaa	ggggatcatg	gagggtgacg	ggctagaaaa	62160
tttgggttgt	caattggtca	gggtaagggg	gatgaagtca	ccaggatgtg	gaacctgcat	62220
tatttctctga	gtcagctttt	tgtctgggct	tttagaccag	ctgatgtgtg	tgtctgtgtg	62280
tctgtgtgtg	tatgtttgtg	tgtgtgtgtg	tgttttgttt	ttgagcaaga	tgatcttgct	62340
ctgttgccca	tctggatttc	agtagcgtga	tcacagctca	ctgcaacttc	tgccctccag	62400
gctcaagtgg	tccctcccacc	tcagatctcc	tgagcagctg	gtactacaga	cctgtgccat	62460
aatgcccggc	taatttttcta	attttttgtg	aaaatgaggt	tttgccttgt	tgaccagtat	62520
gttgctaggt	tttttttttca	tatgcagaac	ctaaaggaga	aactcatgca	gaaagattat	62580
catctcacia	tgtcttagat	tttatctata	gaaaggaaaa	ggacccaaat	gtcttgtgac	62640
aagggtctct	ttatcctagg	gtagtaatca	atgaccagct	acagagaagt	tggaacaaatg	62700
gaaagctgat	ttagtatta	ctgctgattt	tcctgaaatc	atagttgaat	ttttccccct	62760
taatcaattt	tatataactt	tcctagggac	agtttcagtt	ccttccgggc	ttgatccctt	62820
ctcaattctg	aggtgtaaaa	gctaatatgg	tatgaatcgg	gcaatggcca	ttctagcttc	62880
tttttgctga	cacggggcac	agagagagag	tcaggattag	aggaatgaaa	ccgtcttgta	62940
acaacctgca	agctgttata	cccagcttag	ggtgctggat	gaacatgtta	gtacttcagt	63000
ctatggtttt	attgtaatat	ttaattgaat	catgtaaatt	ataatcccta	taaacagaa	63060
tgtgagcttg	aacttcaaga	gtccttgaaa	aatggactgg	aaaacatgga	gtatgcagcg	63120
ggaaagctca	aaaaactatt	cagacatagg	gtctgtggta	gagacatatg	gtctccagcg	63180
agactgctga	aataattttct	ttagtttggg	ttttattttta	ccagaagcat	tgatataagt	63240
acaacagggtg	gtattgatca	ctgtacagac	tccctctctgt	aaagccaaga	gaaaatcaag	63300
tgtagttccg	ttgtcaagaa	ctatctgggc	aagtaaat	gaagagt	ctcagcctca	63360
atgttcttag	cagcctcttt	tgcaattatt	tctgtgggtg	ccaataagtt	tctgatcatg	63420
tcccagtgag	tgtatactcc	atagctagga	ctcgtgatgc	ctagaaggct	ctgccaccag	63480
atataattgat	atatgcctgg	cagtcctctt	tggagtcggt	gggaaaaatg	gcagaatatt	63540
ttgtcattag	gatggactga	gaagtatctc	agtaagttag	agcccttaat	atacaggtta	63600
ttgagacacc	agtgggcttg	ccctaacaga	ggagggtctg	atcctatgcc	acaaataaac	63660
atgtaccaag	ggggcacaca	ggtaagccc	tcaagggtgc	atattattgat	ggattttttt	63720
atggggaata	tagacaaatg	gaattgaact	agggatcttt	ttttacaggc	tccccagaat	63780
ttgtgtgata	ttccccactg	taaatat	tggcatagta	aggagaaact	tttagtttta	63840
tttcccttct	cctagctgcg	tttgtctgcc	cagtatgcc	tgggccatgg	agggcctatg	63900
taatggaaatg	actttccatt	tatgataggc	agagagagat	tgacacatgg	ggtgggtgatt	63960
tcttgggtgta	ctattacttg	gacctggaaa	gtagccatgg	aaagaagctg	gtgcagatag	64020
gtagtcatat	ttggaacatc	cagaaagtca	gtgacaagta	tgactaacag	aaaatgctta	64080
ttttgaatag	tttgggggag	ttactgacag	atccatcatt	ctggtaagtt	tcttccagtg	64140
gcaatacctt	gaaacagttg	aactacagtg	ttgctatgcc	tgtctaggca	ctgtagtaac	64200

aggagaggta	taattagaag	ttttaaaaca	agagtgacca	tttctaaatt	ttagaatgtc	64260
cacataatga	gtggcatgag	actatgttag	catggcatag	aatgtctaga	aaatctataa	64320
gtctaacaat	tgtattgacc	aaggcaatta	tgaagtaatg	tctataaggg	tagcaattgt	64380
aattatctag	gcaattataa	tgaccaagta	aatatatggc	ttaagcattc	agtaaggcag	64440
ggaatagaca	ggaaggatc	tcaccttttt	atataaaaata	attataataa	caaacattcc	64500
tgttatgctc	aaagtaacta	ttgtagttgt	caagaagaca	tatgttttgt	ctaatttcat	64560
taaagttact	tatctgatat	ttttcctcaa	aagatatttg	aggcccatca	aagattttact	64620
tatccattca	gatagggttg	agacagtctc	tgaagttgaa	gtggcctctc	tacattttctt	64680
gataggacaa	gaatctggcg	ggcggggttt	tatatggctg	tggtgaatcc	agggtctaag	64740
tccttcaagc	tgaacagagg	aatgggtcac	cagtcagctc	ttgcatggcc	tctttcactg	64800
tgttttaagt	ggtccccagg	atgtcgactt	ttcctggctc	tgagcagaac	ccagtctctg	64860
ggttggtatg	gatgaaagag	aatgtcagtt	ggataccaca	atctgctgga	accacaaact	64920
cgtgaatagt	agttaaagta	caacctaaag	attgtgtatg	tttgataata	tctaatttat	64980
ttatgtgtat	gttattggca	ttccttagtc	tgagaaggta	acggaagaat	gatctcccat	65040
gtaaaatttt	taaagggtct	aatttaagcc	cacttttagg	gaccaccctt	actctgagca	65100
gggcaatgga	cagaatgtta	ttccagggtg	ttagtttctt	ggcaaactct	agctaaaatt	65160
tgttttgttt	tatatagtat	gatttatctt	ttgagttttt	tcagtagact	tcagtctgca	65220
ggctgtatga	agattccaga	ttatgctgag	ggcctggaat	atatggtgtc	ctaggctaca	65280
gaaattgcac	tatggtcaca	ctggatggag	acaggccacc	taaacctgag	ggtaatcttc	65340
tctaccaagg	ctctcattag	ctcagacatt	ctcttggctc	tgacagcgaa	tgattttgtt	65400
tatcttgaag	atgtatctaa	aaatacaagc	aagtatttaa	aatttcctgc	tacccttggc	65460
atcacggtaa	aatcaatttg	ccagtcctct	aatagccctg	cacctcttgc	ttgaatcctt	65520
ggtactgggg	gtggaggacc	agtccttaaga	ttgttctggg	caccaagtag	gtatttttaa	65580
attatttttt	ggatagtctt	ctttaagtgt	gtcccaaaga	catagtcctg	gatcaattga	65640
agggtggcat	gcctgccata	ctgtgtggta	tcagtgtatg	gtttgatgat	atctgtcaca	65700
agatacttgg	gcaccagaac	cttttcttcc	gtgtcacata	tccactcatt	ttgagtctct	65760
tgattggagt	caaagtctca	atcgaattct	ctctttacat	cttcttccat	taggtaggga	65820
ttttaggctg	aagttttatt	cagggattaa	tggcattagg	aaggcttttg	gcattttttt	65880
ctctgttcac	ctcttttagtg	gcctgctctg	cctagtgtat	ttttttttct	tgctaccaa	65940
ttgtccattc	actgatgtcc	atggtagtgt	attatagcta	ctttcttggg	taccaagact	66000
gccttttagt	aggctaagat	ttcttttagc	tgccttaattg	tttttctttt	ttaatcatca	66060
aagggttaaga	gcccgccttc	tttccaaacg	gccccatgag	catggacaac	aataaaaaaca	66120
tacctggaat	cagagtaatc	ggtgactcag	gagtcctttac	ctagttagga	tgccctgatt	66180
aggactctaa	gttctgcctt	ctgtgccgat	gaaccagag	ggagtgtctc	tgcatctagg	66240
atctgtcaca	gggttacaa	agcatactca	gccttctgtt	gtccgtgggtg	cataaagctg	66300
ctttctctcag	tgaatatattt	taagtccagg	tttttaaagg	gaattttggt	catgtctggt	66360
tgaatagaac	acacttgctc	agtaatttat	atgcaatcat	gtatagggtt	gtatagcagg	66420
atttaaagca	gaaacagctc	tcaaagtaac	actaggatta	tccaggagga	tgacctgata	66480
cctattcagt	cttctagagg	taagtcagta	gctccacttc	tgttccaaca	aatagcatac	66540
acagtatggg	gtgtgtacag	tgctagggtta	acccaaagtg	aactcttctg	cctcctggag	66600
aagatcacaa	gtggtgccag	tggctcagag	ataagaagtc	caaccatca	taacaatgtc	66660
cagctgtttt	gaaaagtagg	ctacaggcct	catgatattc	cccaagtctt	gggttactac	66720
tcctaaaccc	atcccttctc	tctcatgtat	gaacaaatca	aatggctttc	ttagttcagg	66780
gggtctcagt	agccagatcc	attagtaatt	tttacttaat	ggttagaaaag	gccttttgag	66840
attccttgctc	caattctagaa	gtcaaagtgc	tggctttagg	gcttcataga	gacattttgc	66900
tataagccca	aataaagaaa	atgaaatatg	gcaacattca	gccataccta	aaaacccctc	66960
acagctgctg	ccatgtcctg	agtctggcca	ccctgacaag	agcttctctc	cagtcgaaa	67020
gcagattact	ctgctcctga	gaaaattcaa	acctaaaata	tataattgag	tttttcaata	67080
tttgtgattt	ttttcttgga	tactttggat	ccccatccag	acaaaaaaaa	aatgtaaagc	67140
cagtataata	ttctgggtcaa	tttgccatag	ttgtgctggc	ttctaatatg	ccgtcaacat	67200
atataagcaa	agtctcattt	ttcaattgga	ggtcccaaaa	ctccttagca	tgtattttccc	67260
ccggacgggt	agtgagtttt	tgaagccttg	atggagcatc	atccagcaat	actatcattt	67320
agcttttagtg	tcagagtcct	cctattcaaa	ggcaaacact	tcattgggact	ctggactcag	67380
gggaatacag	atgaaggcat	ccttcagatt	caagactgaa	caccagtaca	actcactggt	67440
taaagtcatg	aataatgtat	aagcatcagt	tatcaccaga	taaatggctt	tgaaaatttg	67500
cctagtagcc	ctcaaactct	gtacaaacca	ataatcctca	gttccatgtt	tttgtcctgg	67560
caagacaggt	atgttacatg	agaaacaagg	aattcttctc	gtattgcagg	aaggccatta	67620
gcagaggcta	aatgcattgc	tgtgcctttt	ctctcaaagg	gcgctgcttt	agatttggca	67680
gcgccactcc	tgacacaaac	ttgacttgta	ctggagatgc	agttttttgt	ttccctggcc	67740
tcccatctgc	ccatgtttcc	ggactaacct	tttggagtat	ctcttcaggg	gtgcaggcac	67800
tttcaaggat	ctccagttgt	aataatatgg	cctgcagagc	acatgcttgg	tctgaaggca	67860
cctggatgtc	caatcatctc	agagaaaaag	taatcttagc	atttagtttg	gttaagagta	67920

ctgccctaac	aggacgggag	cagtgggtca	cacctgtaat	cccagctccc	agcacttttg	67980
gaggccaagg	agggcagatt	acctcatgtc	aggagttaa	gacgagccag	gcaaacatgg	68040
tgaaccctg	tctctactaa	aaatataaaa	attagctggc	tgtgggtggca	cacgcctgta	68100
atcccagcta	ctcgggaggc	tgagacagga	aaattgcttt	agctcgtgag	gtggagggtt	68160
cagtgaacca	gaggttgtag	tgagccacaa	tcgtgccacc	acagtccagc	ctgggcgata	68220
gggcaagact	ctgtctcaaa	acaaaacaaa	acaaaacaa	aacaaaaaag	gaagactttc	68280
cccaacaaag	ggataggaca	ttcaaggatg	tatagaaaaa	ctctgtcttt	tttttttttt	68340
tttttttttt	gacagagtct	tgctctgtcc	cccaggctgg	agtgcagtgg	catgatcttg	68400
gctcacttgc	aagctctgcc	tccccgattc	acgccgttct	tctgcctcag	cctcccgagt	68460
agctgggact	acagggtgcc	accaccatgc	ccgactaatt	ttttgtattt	ttagcagaga	68520
cggggtttca	ctgtgttagc	caggatggtc	tcgatctcct	gaccttgtga	tctgcccata	68580
tcagcctccc	aaggtgctgg	cattacagga	gtgagccacc	gcgcccagca	aaaaactgtg	68640
ctttaaatga	tcttactcta	gctgacaatc	caaaatttgg	aggaatgatc	tcatcagcat	68700
tttttctgag	atttcagtca	ccttcattat	ttctgaggaa	agtttagacc	accagatatt	68760
taacaccaaa	tagatggcac	catgtctact	agaaagtcca	gaagctgatt	tctcaccatc	68820
atcaggatct	caagcccat	gtgggaaata	tggagggtgt	tgtctgggtc	aggagaagcc	68880
cctgggtgct	accatttctg	gtctttttct	ttagtatctc	tctcaagctc	cccagctatc	68940
ccaggcattt	gggtgggcaga	aggctgactg	tttaacatca	ggctttgtag	ggcatgagaa	69000
attttccact	cagtgtcccc	cctgttgtag	taagcacact	ggttgggacc	tgcaatggga	69060
tgtccgtttt	tattggcctt	tgggggcccc	ggtggttcta	ccatagatgg	agtgtctgat	69120
gacggccctt	gttgtgggtc	agggactact	agggtcagag	ccacagataa	caagtcagct	69180
tgccattttc	attattcctt	gtgttttatt	ttccactctt	taaacttgtg	atcagtaaat	69240
acattaaaaa	caatcttcac	taattgagac	aaaaacatgt	ccaatgcctc	agctacgttt	69300
tgtaactttc	tctgaatatc	tggggcactt	tggttgataa	acatcatgtt	agctatcatc	69360
aaattttctg	gggtcttctg	gtcaatatcc	atltattctc	tgaagcttc	aaagacttgt	69420
totaagaatt	ccaaagcaac	cctcattagg	cttctgcttg	accatcctgg	accttactga	69480
gactcctttg	cttgggcact	cccttgtaga	ggctgatcaa	aatgcagttt	tgatagtgtt	69540
caaggttaga	tctatctcca	gtgtttatat	tccatcccag	gtcagagggtg	ggaactgcaa	69600
tctgagcagc	tgcccttact	ggattactgg	gagagttagt	gtgaataaga	tcagcctttt	69660
ccttagcttt	ttctaaaacc	attcttttgt	tctctgaagt	caacaaaaata	ttgagcaaat	69720
tgggggtgct	tgctcaggta	gggttctgtg	tggcaaatag	agaggagaat	agattcttca	69780
tatgcttttg	atgttttttt	tttttttttc	aatcctgttc	cttccataaa	ctttagatct	69840
tctcaataaa	taggcataat	atlttttctaa	ttaagtaggt	tggaagtgga	gaacagagaa	69900
taaaccaaga	taaactctat	aggctggcct	gtggcagcaa	cacctcctgt	aagcagttgt	69960
tatggggaaa	ctgcctctca	gaaccagagt	gactccccgg	ctaaatggag	ttccctgttg	70020
ggtataagaa	gtgacaccct	gcctaaatgg	agtcctcctgt	tgggttataa	gaagttagaga	70080
tcatacctgt	tgccccggat	ttgtgacttt	ttgggtgggtg	ggactctgga	gaggcgccag	70140
tagtgctgct	gcagctcccc	cataaagtgg	aggggggtga	gtcatagggt	cttttaactg	70200
aaccatcata	gcatcatctt	tttcttgtaa	atcagtccaa	acagtcttta	atlttcttact	70260
ttatcatgat	tttacctttt	tctacattgt	tgtacttttc	caaagcaaca	taaaacatta	70320
tacatagggt	atltcatctc	atltcctcttc	cttcttacaa	aacaaatcta	gctacaggat	70380
cgtactgtaa	gcatgagaac	catgcagtgg	ccactgttct	ccgaaatcca	gtgggtatta	70440
aggttaaagg	atgttaaaaa	gtaagataat	ctttttttgt	ttcatggaat	gatagacaaa	70500
ggcctttcaa	ttttggaaga	tgagcccat	caggggtgca	ttgtgggtta	ctttgggaga	70560
actaagggac	agcccttagt	tcatgagagc	taagtaagct	gctagggttt	gtctctgggt	70620
ctgtcccagt	ggaaaggggg	cactaggcag	tgagtaaatg	ccctcaaaga	gagtgccttc	70680
gacctggctt	gccacaaata	gttacgagat	tgtcagattt	gtatgcctgc	tgacacagca	70740
cagaacaata	cactgagaca	gtgggggttg	cagcagagaa	agagttaa	aatctcaaag	70800
ccaccagccc	cattgggctg	cctggaggag	ctgaattagc	atltcccat	ctggctggaa	70860
taatacacac	ataacaaaac	agatactagt	caccatactc	aggacccaag	tattgacctg	70920
gcaagactca	aacttggttc	cattggccct	tgtcatcttt	gatccactca	agctggagag	70980
ggatgacctt	cgatcagaag	ttcagagggt	aaagcctggg	aaagattgaa	gagcagatga	71040
ttaccctgag	ttaggcttgc	tgagattcca	ctagcaactc	cttcaggact	aactgaatgt	71100
gactgaccaa	acaagaagag	ttccctgagt	tagtaatttc	ttccactagt	aatttcttca	71160
gggatcccc	ccacaaacat	aaatacatat	aacaagacaa	agacaaaaca	aagacctttc	71220
catataaagt	ttcagattcc	aaaatccaag	accatttctc	ccaagcaatg	ccctctagtc	71280
tttttccatc	tgaagggaga	tctcctcaaa	taagttccta	cctagactta	gggagtgtca	71340
acaagacctc	aaagaggcca	caagacctct	aagacgaaaa	caggcacaca	cacacagaag	71400
gaaatgggg	gccagctgct	ctgagaaaa	tcacctgaga	cttcttctga	gaccagaaat	71460
ggtttctctg	ctgcagacaa	ggttgtgtgc	tgaaagtcag	cactgcccctg	ccaacacaga	71520
aggccccagc	taaggccctt	agttcatcat	aactaagcag	cttcttgagc	ttctctctgg	71580
gtcagcccca	gtggcatggg	ggcactggac	tgtaggtaaa	tgactgcaag	gagagtggct	71640

tgccatgaat	ttttttttct	tttctttttt	tttttttttg	agacggaatc	tcaatctgtc	71700
tcccaggatg	gagtgcagtg	gcacgatctt	ggctcactgc	aacctctgcc	tcccagggtc	71760
aagtgattct	ccagcctcag	cctcccaagt	aactgggatt	acaggcatgt	gccaccatgc	71820
ctgggcaact	tttgtatttc	tagtagagac	agggtttcac	catggtggcc	agcctgggtc	71880
cgagctcctg	acctcaagta	atctgcccct	ctttgcctcc	taaagtgtcg	ggattacagg	71940
tgtgagccat	catgtctggg	tgcttgccat	gaatttttat	aagattgtaa	ggtttgatg	72000
cctgctgtgc	agcaacagaa	tataccaaga	cagtggagtt	tgcaacagag	agtttaccaa	72060
ttgcaaggtc	accaaacaag	gacatgagaa	gaattctcaa	gactcaaac	catttcactg	72120
aagctttctg	ggaaaagaatc	tttgaagggg	gagtggctgg	aaaattgagg	tcatcaattg	72180
attcgggtaa	gggggctgaa	atcatcagga	tatggaaagt	acattcttcc	ctaagttgag	72240
tttcttgtca	agcctttcag	aatggctggc	atcagtagtt	ttgttagtat	gcagaacctc	72300
aaggagaaac	tcaaatggaa	agtttgatcat	ctcatattgt	cttaaatttt	aactaaagaa	72360
cagaaaaaga	acaaagattc	tagtgacaaa	gattatgtta	tcttgacta	gtaatcagtg	72420
accagctata	aggaagtggg	tcaatggaaa	gctagcctaa	tgattaccat	tgattgtcct	72480
acaagcctag	ttgaatttta	cttttccctc	cttaactgtt	tttaaaaatt	ttttgaggat	72540
gtttttcaat	taaaaagga	gcaaaggcaa	ttcaataaag	aaaacatagt	cttttaaaaa	72600
agtgatactg	gaacagtaac	gcatccaaat	gcaaaataat	aacctctctc	atattcctca	72660
tacctatac	aaaaattaac	tcatataact	aagtgtaaaa	tgtaacttcc	tagaactgta	72720
tatggccttg	gtttaggcaa	ggaaatttta	gatgacacaa	agagcgtaat	ctataaatga	72780
aaaatgtgat	aacatcaaaa	ttacatactt	ttgctcatga	aaagagacta	ttagagagaa	72840
aagtaaagct	acagatgcaa	gaaaaatatt	tgcaaaatat	ttactcagtg	aagggttgt	72900
agccacaata	tatcatgtag	tctcaaaatt	ccgtaatgga	agaaacaact	caatggaaa	72960
tgggcaaat	ttagacagtg	ttcaccaaag	gaggtacata	gatggtaaat	aagtacaaa	73020
aagatgctaa	gcagcattag	tcactaggga	atgcaatacc	atcacacaca	tattagaatg	73080
gataatttaa	tggaaaaaaa	aacacattat	ctcaaaggct	ggcaagggtg	cgaacaact	73140
ggatctcaca	tacttgagt	atgtgaaggt	acaatgtatg	atcgctcagg	aaaacagttt	73200
gtctattttc	tataaaaatg	aacacatatt	tagtatgata	tttgctatgg	gtttttaaaa	73260
aatagctctt	ataattttga	gatatgttcc	atcaatacct	agtttattga	gtgtttttac	73320
catgaagggg	tggtgaattt	tattgaaggc	cttttctgca	tctattgagt	taattatgtg	73380
ttttttgtca	ttacatttat	tgatttgtat	atgttgaaac	agccttgcat	cacagagata	73440
atggcgactt	gctcatggtg	aataagcttt	tagatatgct	gctggatttg	ctttgccagt	73500
attttattga	ggattttcgc	attgatgttc	atcagggata	ttagactgaa	attttctttt	73560
tctgttgtgt	ctctgccagg	ttttgggtatc	aggatgatgc	tggtccata	aaatgagtta	73620
aggaggagac	cttctttttc	tattgtttga	aatagtttcc	aaagggaatg	taccaactcc	73680
tcttagtacc	tctggtagaa	tttggctgta	aatccatctg	gtcctgggct	atttttgggt	73740
ggcaggctat	taattactac	cacaatttca	gaacttgtgt	ttggcctatt	cagggttttg	73800
acttctttct	tctgctttag	tgttgggagc	gtgtatgtgt	ccagggaattt	atccatttct	73860
tccagatttt	ctactttatt	tgtgtagagg	tgtttatagt	attctctgat	ggtagtttgt	73920
atttctctgg	gatcagtggt	gataccctct	ttatcatttt	tattgtgtct	atttgattct	73980
tctgtccttt	cttctttatt	agtatggcta	gtagtgtact	ttgttaatct	tttctaaaaa	74040
ccagctcctg	ggtgcattga	ttttttgaag	ggttttcatg	tctctatctc	caggctctgt	74100
ctgatcttag	ttatttcttg	tcttctgcta	gcttttgaat	ttgtttgtct	ttgcttctct	74160
aattcttttt	ttattattat	tatactttta	gttttagggg	acatgtgcac	tacgtgcagg	74220
ttagttacat	atgtatacat	gtgccatggt	ggtgtgtctg	acccattaac	tcttcattta	74280
acattaggtat	tatctcctaa	tgctatccct	ccccctccc	cccacccccc	aacaggcccc	74340
ggtgtgtgat	gttccccttc	ctgtgtccat	gtgttctcat	tgttcaattc	ccacctatga	74400
gtgagagcat	gcgatgcttg	gttttttgct	attgccatag	tttgctgaga	atgatgggtt	74460
ccagcttcat	ccatgtccct	acaaaggaca	tgaactcttc	ttttttatgg	ctgcatagta	74520
ttctatggtg	tatatgtgcc	acattttctt	aatccagttc	atcattgttg	gacatttggt	74580
ttggttccaa	gtcttttgcta	ttgtgaatag	tgccgcaata	aacatacgtg	tacatgtgtc	74640
tttatagcag	catgatttat	aatcctttgt	gtatataccc	agtaatggga	tggctagggtc	74700
aatgggtatt	tctagttata	gatccctgag	gatctagaca	atgacttcca	caatggttga	74760
actagtttac	agttccacca	acagtgtaaa	agtggttcta	tttctccaca	tcctctccgg	74820
cacctgttgt	ttcctgactt	tttaatgata	gccattctaa	ctgggtgtgag	atgggtatctc	74880
attgtgggtt	tgatttgcat	ttctctaatg	accagtgtatg	ctgagcattt	tttcatgtgt	74940
cttttggtcg	cataaatgtc	ttcttttgag	aagtgtctgt	tcatatcctt	caccactttt	75000
ttgatggggg	tgtttggttt	tttcttgtaa	atttggttga	gttcatttga	gattctggat	75060
attagccctt	tgtcagatga	gtagattgca	aaaattttct	cccattctgt	aggttgccctg	75120
ttcactctga	tggtagtttc	ttttgctgtg	cagaagctct	ttagtttaat	tagatcccc	75180
ttgtcagttt	tggtctgtgt	tgccattgct	tttggtattt	tagacatgaa	gtccttgccc	75240
atgcctatgt	cctgaatggt	attgcctagg	tttcttcta	gggtttttat	ggtttttagat	75300
ctaacattta	agtccttaat	ccatcttgaa	ttaatttttag	tataagggtg	aacgaaggga	75360

tccagttttca	gcttttctaca	tatggctagc	ctgtttttccc	agcaccattt	attaaataag	75420
gaatccctttt	cccatttctt	gttttttctca	ggtttgtcaa	agatcagatg	gttgtggata	75480
tgtagcatta	tttctgaagg	ctctgttctg	ttccattggg	ctgcatctct	gttttgggtac	75540
cagtaccatg	ctatttttgg	tactgtgggc	ttgtagtata	gtttgaagtc	aggtagcatg	75600
atgcctccag	ctttgttctt	ttgtcttagg	attgacttgg	caatgcgggc	tctttcttgg	75660
ttccatataa	acttttaaagt	agttttttcc	aattctgtaa	agaaagtcac	tggtagcttg	75720
atggggatgg	catgctgcca	aaggtaattt	atagattcaa	tgccatcccc	atcaagctct	75780
atttctttta	attgaggtgt	taggggtgtca	agtttagatc	tttccacttt	tctgatgtgg	75840
gcattttagt	cgataaaatt	tcctctaaag	actgctttta	ctgtgtccca	gatattctgg	75900
tacattgtgt	ctgtcttctc	attggtttca	aggaacttat	ttacttctgc	cttactttca	75960
atatttactc	agtagtcatt	cagtagcagg	ttgttcagtt	tccatgtagt	tgtgtagttt	76020
tgaatgagtt	tcttaatcct	gatttctaatt	ttgatttcac	tgtggtctga	gagactgttt	76080
gttgtgggtt	ttgttctttt	gcgtttgtctg	gggagtgttt	tacttccaat	tatatggctg	76140
atcttagaat	aagtgtctatg	tagtgccaag	aagaacactt	gacttctggt	ggagagtctt	76200
gtagatgtct	attaggtcca	gttgggtccag	agttgagttc	aaattgggaa	tatctttgtt	76260
aatgttagtt	ctcgttgatc	tgtctaggat	ggacatagta	ttgggagttt	tggaccagac	76320
aatcaggcaa	gagaaagaaa	taaggagtat	tcaaatagga	agagaggaa	tcaaattgtc	76380
tcttttttga	gatgacatga	tggtatatatt	agaaaacccc	actgtctcaa	cccagaaaact	76440
ccttaagctg	ataagtaact	tcaggaaagt	ctcaggatgc	aaaatcaata	tgcaaaaatc	76500
acaagcattc	ctatacatca	gtaatagaca	gaaagccaaa	tcatgagtga	actcccattc	76560
acaattgcca	caaagaaaaat	aaaatacgt	gaaatacaac	ttacaaggga	tgcgaggaa	76620
ctcttcaagg	agaactacaa	accactgtct	agggaaataa	gagagggcca	aaataaatag	76680
aaaaatatct	catcctcatg	gataggaaga	atcaatatca	tgaaaaatgg	catattgccc	76740
aaagtagttg	atacatacaa	tgctattccc	atctagctat	cattatcttt	cttcacagaa	76800
ctaagaaaa	tgcttttaaat	ttcatatgaa	accaaaaaaa	ggtcccattc	agccaagaca	76860
atcctaata	aaaagcacaa	agctgatgca	tcacgctacc	tgatttcaaa	ctatactaca	76920
agactacagt	aaccaaaaca	acatgggtact	tgtaccagaa	cagatatata	ggccaatgga	76980
gcagaacaga	ggcctcagaa	ataacaccac	acatctacaa	ccatttgatc	ttcaacaaac	77040
ctgacaaaaa	caagcaatag	ggaaaaagatt	ccctattgaa	taaatgggtg	agggaaaaatt	77100
ggctagccat	atgcagaaaa	ctgaaaactgg	acccttccct	tacacctaata	ataaaaaatta	77160
actcatgatg	tattaaaggc	ttaaatgtaa	gacctaaaa	cataaaaacc	atagaaaaaa	77220
acctaggcag	taggttattc	aggacatagg	catgggcaaa	gacttcatga	ctaaaacacc	77280
aaaagcaatg	gcaacaaagg	ccaaaattga	caaattggat	ctaattaaac	taaagagctt	77340
ctgcacagca	aaagaaacta	tcacagagat	gaataggcaa	tctacagaat	gggagaaaat	77400
ttttgcaatc	tatccatctg	acagaggtct	aatatcaaga	atctacaagg	aacttaaaaca	77460
aattttataag	aaagaaacaa	acaaccccat	caaaaagtag	gtgaaggata	tgaacagaca	77520
ctttctcaaaa	gaagacattt	atgcagctcag	caaatacatg	aaaacaagct	tattgtcact	77580
ggctattaga	gaaatgcaaa	tcaaaaccac	aatgagaaac	caattcacgc	cagttagaat	77640
gctgatcatt	aaaacatctg	gaaaccacag	gtgctggcga	ggatgcggag	aaataggaaa	77700
gttttactct	gttgggtggga	gtgtaaatta	gttcaaccat	agtggagac	agtgtggcaa	77760
ctcctcaaag	atcaagaacc	agagatacca	tttgaccag	caatcccatt	actgggtata	77820
tacccaaagg	aatataaatc	attctactat	aaaggcacat	gcacacatat	gtttatcaca	77880
gcaccatttg	cagtagcaaa	gattttggaac	caacccaaat	gcccattcaat	gatagactgg	77940
ataaagaaaa	tgtggcacat	atacaccatg	gaatactatg	cagccataaa	ttgaatgagt	78000
tcgtgtcctt	tgcagggaca	tggacgaagc	tggaaccat	catcttcagc	aaactaacac	78060
aggaacagaa	aacaaaacac	cacatattct	cactcataag	tgagagttga	tcaatgagaa	78120
cacatgggaca	tagggagggg	aacatcacac	accggggctt	gttgggggtg	gcgggggaa	78180
gggagagaga	gcacaggagc	aaagagctaa	ttcatgcaag	gcttacaacc	tagatgacgg	78240
gttgatgggt	gcagcaaacc	accatggcac	acgtatactt	atgtaacaaa	cctgcacgtt	78300
ctgcacatat	atcccagaac	ttaaagtata	ataataataa	aacacacaca	cacacacaca	78360
cacacacaca	cacacaccat	ttatctaaca	aaccagctct	tagatatgta	tccatgagga	78420
ataaatttgt	gtttatataa	aaactgcaga	tgaatatattt	tcttaacagc	atgattcaca	78480
aatgccaaaa	acaatgcaaa	tgcccttcaa	cacatgaatg	gattaacaga	ccgtgataca	78540
tgatataatg	gaataatact	tagcaataaa	aaaagggtgt	ctgggtagtg	tgatgaaatc	78600
ctatgccatt	cagccccatt	ctccccagag	cctgaatact	ttcttgtcta	gtgcatccac	78660
agtttatact	acctgctgt	tagtcaacta	gtagtctttg	atgaaatcct	atgccattca	78720
gctccatccc	gccagagca	tgaatcctcc	cttcgtctag	tgtatgcacc	agcctgttag	78780
tcacttagta	gtattccaag	ttatcagggtg	gaaaaacata	gtctacttgg	gtttttatact	78840
attaatcatt	tcggggcattt	actggggagc	ctggaaacata	tcccacatga	ataagaggga	78900
ctagtgcagc	ttttttctct	cacaggtaag	tagagactac	tctgtctatc	ttcagaagaa	78960
tcattcagat	ggcactagta	attcaagttt	tacaagtcaa	gagaaattga	tattctgtga	79020
tttatctggc	aaatttttta	tttaaatgac	tatttttaaag	gaaactacag	ccagtttgca	79080

ttcataaagg	atacactcca	atatatatct	actgtactca	ctcaagtatg	tttaatTTTT	79140
tctgcatatt	ctcacaacat	ggttatgagg	aatttagatt	ttattaaatt	gaaaaacaat	79200
gtgattcact	gacaattgac	tgtacatgaa	aatataacgt	tgatatctca	atctgaagat	79260
gaagctaaga	cttggttaatt	atatgacaac	cgtaaagtag	ctaaataacc	tgactaaagt	79320
acagggctca	gcatgaagag	taaaatagta	acattcttaa	gaataacttg	agccagacaa	79380
acttgggaca	aaaggaaaga	aggaagggaag	gaaggaagga	aggaagggaag	ggagggagggg	79440
agggaggggag	ggaggtgaca	gagggaggga	gggaaggggag	ggaggggaagg	aagaaagaaa	79500
gaaggaaaga	gaaagaaaga	aagaaagaaa	gaaagaaaga	aagaaagaaa	gaaagaaaga	79560
aagaaagaaa	gaaagaaaga	aagaaaaaga	aaggaaggga	aagagaaaga	aagaaagaaa	79620
gaaaaagaaa	ggaagggaaa	gagaaagaaa	gaaagagaaa	aaagaaaaag	aaggagaaac	79680
gtagacaaag	aaaggaagaa	agaaaaaaga	atgaaagaaa	gaaaaagaaa	gaagggaagag	79740
aaggaaagaa	agaaagaaaa	agaaagaaag	aagaaagaaa	gaaaaagaaa	aagaaagaaa	79800
gaaaaaggaa	ggaagggaag	aaagaaagag	aaaaaataag	tagttgattc	tacaatcagc	79860
tccaaaatca	aaccaagagg	cataaacgtt	gattgagttg	tttgatatca	ggagaaattg	79920
catatctaatt	caaggcatat	tattagcctc	aattaatctg	tgaagaaaaa	aataaaagta	79980
atggggaatt	ctgacactga	atgatgagac	aaaaaagaga	ctgatgaagc	aaaaagattt	80040
gggtgaagag	tcctgattag	gggtgaaagt	catatccata	cttattaaaa	acctatatta	80100
attaaaattc	agggagtggg	gggtgcagcg	aggcgagatc	gcgacattgc	actccagcct	80160
gggtgacaga	gtgagattct	atctcaaaat	aaaataaata	aataaaattc	aatagagggg	80220
tactgcaatg	ctgggttaaaa	aattgtttac	taatagtgcg	gaatactcag	agtaatagtt	80280
attgtgtgtg	tgtatacaca	cacaatgtac	aaaatataca	ataaaaaata	tactgtttga	80340
gaaaggtact	ataaaaaattg	ttagggaaat	gttgagttaa	ccatatttca	tttaaactatg	80400
aaatacacgc	attatcatga	ataaaatcaa	cacaaaatat	ttttaaaata	tgaaaagtaa	80460
aggtaacctt	taactttttta	gaataaagaa	tagtatagtg	gctctatggt	tttgaagtat	80520
tcctttaaat	agaaacaaga	aacattcatc	atgaaaaaag	attgactatt	atgtagtaga	80580
atgagcaact	tatgttcata	atgcagaaaa	aaggaaagaa	aaatactagc	cacaaagaga	80640
atacatttgc	attacgtata	attaaaagag	attttatatt	cagaattggt	aagatgattc	80700
caactaataa	taccaaact	ctcaaaaagg	taaataaaga	aatcaaaact	gcatttccaa	80760
agattagaag	cattaaatac	caattaaact	gtgaatatat	attctaaacc	cagttagtgg	80820
taaaagaaat	gcaaattttac	actataatgt	tataacattt	tatagccatt	caatttgtaa	80880
atattaaaaa	gtgacatcac	caatcattaa	catgtaaaaa	aagaagtaac	tggtgatata	80940
aatgtatggt	ggaataaata	ctgtaggaaa	ccttctagag	tagaatatgc	acaagatctc	81000
agaataccca	tttgacttta	catatactag	agaaagtcaa	atagctttac	tgtaaaaatg	81060
tcatatcact	gcttgaatat	atgaattatt	gggtatcatc	gtatttactt	tctattttta	81120
actataattg	tataattatt	ttgagtcaaa	tgattgattc	caatgtacat	attaatattg	81180
atataggagt	tgagaaaaaa	ttgttttaggc	agataatgag	ggtacagcag	tccttgataa	81240
ggtttttctc	tttaatgaaa	ggcagccccc	aaatcatttt	cttttctaac	aagaggagcc	81300
tgtaaaaatcg	aactgcaaac	atagacaagc	aagctggaag	cttgcaagg	gaatgccagc	81360
agttgtgtcc	ataggaagag	gtacacctgg	actaggcatg	ttcatatggc	aggtgcatct	81420
tcctttctct	ttgcagacca	cgtgtacagt	aaggagaaa	caacatggcg	ctggccaggc	81480
aaagatccca	tttgattaat	aagattaggg	tggggcgcc	agcttctctg	catattatgt	81540
aaatgtcaca	cctagtttaa	ccaatctttg	ggccctatgt	aaatcagaca	ctgcttcctc	81600
aagaccgttt	ataaaatcca	gtgcactcca	ccaggggcag	ggattcactt	tcaggtgccg	81660
ctctctctca	caagagagga	agctgttctc	ctttctcttt	cttttgccca	ttaaacctgt	81720
gctcctaacc	tcactccttg	tgtgtgtcca	cgtccttaac	cttcttggtg	tgagataacg	81780
aacctcagat	atttaccag	acaatgatgc	cgcttcaata	cgacttcatt	taaccaacaa	81840
gtattgtggt	caaattcttt	tactgtattc	ttgactaatg	cccattaata	ggagaattta	81900
ttttactatg	tacttatcaa	gaaatttgta	tattcattta	tacacagttg	aaaaaccaa	81960
aactaaatag	gtccattggt	aaaacaaggt	gacataaaca	ttttgccaca	attaatatag	82020
atgagtctta	gaatgtcatc	tatgttactt	agaaagacat	gaacatgcta	ggatttcaga	82080
gtagtgtagt	tactgacacg	gatgcactct	ggagtaggag	accagccatt	ctccatacat	82140
gtaactgtgg	tctgcgcttt	tgggaagagc	tagccaggat	ggcaggcaac	gtctatagat	82200
ttaccctgta	caaactttct	tccatgattt	tgattatata	cattttccaa	ataaggaaaa	82260
taacattttc	ctaaggacca	taacaatgat	aaataaataa	agtaaagtga	aaacataaat	82320
ttgctcaaaa	tagtatatta	caattatttt	tacaatatatt	aaataagatt	gcataaacat	82380
ccaaaaataa	tgtataactg	aagacgaact	aaagttacta	acaaagggtt	gcacaaaaag	82440
aaatatcaat	attcaatatt	acttatcttt	agtttttata	attaatagat	gtataaatta	82500
tatagatatt	ctcataaagt	ccctatatatt	atcttctcct	tgattttcaa	gaagaaaccc	82560
tcataataga	aaagatctat	tttggtcact	ttgcttgaac	aactcttttc	ttggccctat	82620
ttctgttaca	taagacaggt	gtaatcactt	atgtgctctc	ctttcttcga	cttttgaaag	82680
ttttatacat	atatatagca	gttcagaggt	ttacttactg	aggcatggta	ctgctggcga	82740
ccatccatct	tgtgtgcaat	gaatgtgatc	ccagtaactt	cctgacggag	tctcaaaatg	82800

ttcatcacag	taataggagt	aatatTTTTcc	tacagctact	ggaaagtatg	gtctacgcat	82860
attctcatga	tatagacctc	catgtTTtaat	gtctggataa	tcacaagggt	tcacttgcaa	82920
taaaaatttt	aaaaaaagta	taaagaaatt	ttactgtaat	aaacactcat	attagagata	82980
aattttttatc	actgaattat	attctcttct	tagtataaatt	acacattcca	ttagggtttc	83040
taggtcaaaa	caaatgatag	aactcagatg	actgagatat	gtaacaagaa	ggtctttgtt	83100
aatgaagatg	aaattatgtc	ttgtggatca	catgatgcgt	aaatttgtat	gaaggctctc	83160
cagaaagaaa	aatgcacaga	cctattttaat	atatttccct	taaatacaca	taccctatcc	83220
ctgggttaatt	aaataagctt	ttcggttgag	aaatatgccca	atTTTaccgc	ttagctcatg	83280
tatttcttttc	tttcttttct	tctttttttt	ctattctcat	cagtaaacaa	gagccctgca	83340
ttttcttctc	agaacaattc	aatgtaagga	agtagtattt	tgagggattt	aaggttttta	83400
tttgTTTTtag	attgaattca	tgggctgggc	gcagtggctc	acgcctgtaa	tcccagcact	83460
ttggaaggct	gagacaggca	gatcactcgt	aaggagttcg	agaccagctg	ggccaacatg	83520
gtgatactcc	gtctctacta	aaaatacaaa	aaaaattagc	cgggcctggg	ggtgcgcccc	83580
tgtaattcca	gctacttaga	aagcagaggc	aggagaatcg	cttgaaccca	ggaggcagag	83640
gttgcagtga	attgagattg	tgtctttgca	ctccagcatg	ggttacagag	tgagactcca	83700
tctcgaaaaa	tataaataag	taaaataata	aattaggctc	tttcttattt	attgcagaca	83760
acgtaaaaat	atagagaaac	acaaaaattt	ttctttgatg	ataccgcgca	gaaaaataac	83820
atagttaatt	catgcctcaa	acaattcatt	aagccaagtt	ctccagtctg	tatttaacca	83880
gagaaacaga	ctagaaatat	ttcttcatat	ccaaatagtt	aagattttga	ttaacttttt	83940
tgtttattttc	taatttttaat	tggagagaaa	aataattttg	atgtcataaa	atataatttaa	84000
gtaagggtaca	atataattac	atTTTactga	gttattatat	attaattttg	acaaatacat	84060
ttgagtgtca	tcttgTTTTat	tataattaaca	ggtttatatata	tttttcagaa	aatttgctct	84120
tttcatggga	tattttgttag	attatctagt	actttcaata	acaaaatggg	attaatgttt	84180
tccatgaaat	atgtttctat	ttcaataaac	cttatgcaat	aggttaaaaa	gaatttcaat	84240
acacacatac	acacacacac	atataaatat	tcttttacat	ctccatcttt	cttaaattct	84300
gtgattttatt	ttctttttgta	tttgattaga	gaaattttca	tgtagtttct	acatttatta	84360
tgtggattat	aaactgaata	attgtatatc	ttaaatgtat	ttctctaata	aagactagt	84420
aatgatactt	cttttcagtat	agttttcttg	cctacaatcc	atatacttta	taattgatag	84480
atTTTTttcc	ctattttatct	gaagctccca	gtgttgaaat	taaaacattt	acttagtctt	84540
atTTTctttta	agtaacattc	tacatttttc	ctcaccactt	tttaaagatt	tggaatattt	84600
tctattttacc	attggattttt	acaaatttca	tcatgatttg	ttgagacatg	tattatttaa	84660
caataattct	gcattgggaa	agcttgagtc	ttggatttgt	gggagctgtg	ccttaaaggc	84720
ctcaattgaa	tttcacatta	aatggtagag	tagagatttc	aaagcttgtg	gttgatttca	84780
aagcaagtat	gagtatccat	cttattatgg	tatttcccag	aaggtcataa	aataaaattg	84840
tccaccgaga	tttctttcca	aaaggaataa	aaaggaggca	taattaaaaa	catataacat	84900
taccacaggc	tcgagctatt	tagctattct	ctaatttggt	cacattttaca	tctgttttta	84960
tccctttttac	aaattgattc	cttgaagcaa	atattagtac	ccacagagag	tctcatcagc	85020
gctgagaata	gaaggacttc	aaatagcttc	attctacttg	ttacacttct	acaaatgtag	85080
tttttggttt	cacagcattt	atgggtgttt	catcataaag	ttggctcaaa	cagatcttaa	85140
aattgataaa	aatattcact	aatTTTTata	actgctgcta	atataattcat	actgtaattt	85200
atTTgaccca	agtccaggat	cttagagtca	acattgttaa	atTTcatctt	attagattca	85260
gcttagcaca	taagagtctc	tttgaatgct	gaactgccct	aatgcagatt	ccttattatc	85320
atcctctgtg	tcaattccaat	tgtgaatttg	tactgcactt	cccctaaatc	attaaactgt	85380
tcaatgacac	aagtgagtaa	tgaagcaggc	ctgagaataa	agtcatgcgt	ctgataatta	85440
gatatgggtta	tttaatgaaa	ttaaaaactg	ataaaccata	taactcatca	actcctctat	85500
cttggtccatg	agaactccag	atggttcatt	gtcaaacatt	aataattgaa	atccaaatat	85560
agttgggtct	cagttgggtt	agatacattt	gggtggaact	acattgtcat	aagccaacca	85620
taaaatcatt	aaataatttt	ctcataattc	ttatgcacac	tgaatgtttt	catactgata	85680
atagcttctc	ctcttaggga	ttggaattat	gccaggaatt	aaagttgaag	tcattaatca	85740
atcatttgta	tcatattttt	ctttcatgga	atatatagtt	taagtgtagt	acttcttgtc	85800
tatgtactta	tagatagaaa	gaaaagaaat	ttgattgtag	agatagaaaa	aacattaaaa	85860
aggggtaaaag	gagcatccca	gaaataaaat	actctattga	cttgagtggg	atTTtgctac	85920
atgtgatgat	ttttggaaa	tacctccaac	actaggaaat	gactaagact	tggagtcctt	85980
caacctcct	ccctccaaat	agtgggtgct	aattttctct	cccttggaata	tatgctggac	86040
ttagtgtctc	acttcgaaa	aatagatatg	gctgaagtta	acagtgtgtg	agtagataat	86100
tgatatgggt	tggctctgtg	tccccacaca	catctcatgt	tgaattgtaa	ttcccaatgt	86160
tgaggggaggt	gattggatca	tagaggtgga	tctccccctt	gctgttttca	tgatagttag	86220
tgagttctca	tgagacctgg	ttgtttaaaa	gtgtgttagca	ctttccccct	tgtctctctg	86280
ctctcctgct	ctgccatggg	aagatgtgct	tgcctccccct	tcaccttcca	ccatgattgt	86340
aagtttctta	aggcctccca	gccatgcttc	ctgtacaggc	tgtggaactg	tgagtcaatt	86400
taacctcttt	tcttcataaa	ttatccagtc	ctaggtagtt	ctttctagta	gtgtgagaac	86460
acactaatac	atggtattgt	ggcttccctc	attctcagat	tagcagtgtc	ggagaaagct	86520

gccatttatc	aactcatgga	aaggcctatg	tggttaaggac	ctgaggcctc	ctgacaacag	86580
ccatgtgtgt	cagtaatggt	agaagcagat	cctccttccc	agccaagcct	tctgatcact	86640
gtagcctggg	ccatgatcct	gattgcaaca	caagaagaca	gtctgattca	caactactta	86700
tataagccat	tttgagatta	ctgaccgata	gaaactgtaa	gataataaaag	gttagttgtt	86760
ttaagtaaat	atgttttttg	ggatattttgt	tacaatgcaa	taaataacta	atatagtatg	86820
tgtttagatga	cattatTTTT	atctagtgtt	ttaattcaga	tattggaata	atTTtattaat	86880
tagggaaaca	tacattcata	aacacacata	cacattttaa	tttgagtagc	aaaaaatatg	86940
agtttcggca	acttcgaaaa	ctaaagaatg	cctccaacag	ccttactttg	tatatacaat	87000
aagacaaaata	tttggttttta	ttgagtcctt	atTTTTttatg	tgTTTTaaaag	aaatttcaga	87060
attaagaaat	gggtcaagat	atgaatggaa	cttacaggta	catctcggag	caggtatcca	87120
gccagtactt	gtgcattttg	ctgtattttcc	ccgggttgca	ggataaaaaac	catttctaca	87180
ctggtacgtg	atTTcatctc	cagttctgtg	tttaatcctt	aaaggtgagt	agtcaccatt	87240
tggaatataa	ggattatcac	atgattttttc	tgaaaagaaa	aaggatatat	ggataatgca	87300
gaaataagta	tccgttaaaa	ttaatcattt	atataaacat	ttaaaagtgg	gtgttatttta	87360
tttgtcctta	gcataataca	aaatggcatt	aaaatgaaca	tatcatagta	tcctttctgg	87420
tatatcactt	atTTTTcctt	tcactatatt	ctcatctgac	atatttgtac	ctcctgggct	87480
cttaatccct	tcttctccaa	agtcatccca	tacttcatga	ttttccataa	ctggcaatgt	87540
tctcatcaca	tataacttca	attcttactt	tcactttcct	tctattcctt	ggtttctgtg	87600
gttctcataa	ggattgttta	caaataattca	gtgtttcttt	cctctggaca	attgatagga	87660
ctgcgcaacc	cctcctcttt	gaagtaactg	tgcccatgtg	attgcgtagg	agactataat	87720
aaaagtggaa	gtaatatctt	ccacttttaga	gagaagtttt	aaaagccatt	gtgtgaattt	87780
ttatgttctc	tttcccaaag	ataccgcgat	taaagaagga	catgaaaaaa	aatgatgttt	87840
ctgtcacttg	attcttacia	ttaatacaat	gagtaaaagtc	ccttctgac	tacattgaca	87900
gtgaacatga	atgaaaataa	acttcagtc	taatatctta	aacattgaga	tactgcatta	87960
catttttctt	actataatag	gataaaaatag	cagagggttt	ggaaaacctt	ttccgtaaa	88020
ggccagataa	aatgtctctg	ctgcaacaac	tcaactctgc	cattatagta	caaaagtaat	88080
gaaaaacaat	acataaacaa	atgaacttgg	ctgtgtttca	ataaaacttt	gtttacacaa	88140
agggggcaag	ttgtattttta	cctgcagcct	atagtttgcc	atcctttggc	ccagtgtatc	88200
ttaatctata	aggcaccttc	tcactccttt	ccattaactc	tgctatatct	caatatgtga	88260
tccatttgca	aaattcggtt	taagataaaa	tactatgcat	tttaagtatt	gtagaaaaac	88320
tatatgacca	cttctattgg	agtcataatt	tattttggac	taaaaagctg	tggaacaacat	88380
tcagcattgc	ttgaaatcca	tttatatacc	cccaatttat	ttactatttg	atTTcccatg	88440
gtaaatgata	catagtctcc	tctctttttc	caagccacct	gaaacaattg	cctcttcatc	88500
aacagataat	aagtctccat	tcacacaaaa	caattgagac	cagcagtagt	gagtttccta	88560
tacttctttc	cagcactcct	caacattatc	tgtatctata	ctgattttaag	tcttttagttt	88620
agtcttcagt	ggtaaagtgt	tgctttcaaa	ttcagggttag	ctttaattct	ttcattttcc	88680
cctgtatttt	aaaccattgt	ttattccttc	cctcttcttc	accttatcaa	ccacactcct	88740
aaattgatat	ggaagctttt	ccaattttca	gtcccttcac	tcaacccttt	gttcaagttt	88800
agctaagtga	ctacattttc	cctccccctt	aaaacaaaaa	tccttaaaat	accattttat	88860
aattgctgtc	tccactttcc	cgtctcacat	ttattcttta	actcactact	acctagtttc	88920
tgacctctat	tttggttgcca	ttgctctgat	aaaagctacc	aatgagccca	atgtccaaat	88980
tcagaaatgc	tttgcaatttc	acataattcca	gtcactggta	catattatgg	acttcttaat	89040
tatttattga	actgaacaga	taaaaactctg	taatatattga	ctctgtttgat	tacatacttt	89100
ttggtgttct	ccattacctt	atatattttat	gttctcctgc	ttctccttgt	ctttgtctaa	89160
gtgatgcttt	tcttttatat	cttatttatt	tcctttactt	tatatTTTT	gcttctcctc	89220
ttgtacttta	cttaattttt	taatttttgg	gcoctgcata	cctgtcacat	ctcatctcct	89280
gccatttttc	tacttcttct	ctatactacc	accattcctt	tctcataagt	tgtatatttag	89340
tcaaacataa	aatTTtataa	agtTTtaatt	attcattata	tatttctctt	tctcaatacc	89400
atacttccac	tgtgtccatt	cagctcctaa	gtttatactt	cgttctgaca	gaataagctt	89460
taatatatct	ctatagctaa	caggataata	tatttagatt	agcaataatt	atatgagaaa	89520
caatatgtat	gtgacttaat	atacaagttt	taaagcttta	ctatttttaa	atTTtactat	89580
tttatgtaaa	aatatgtctt	cagtgtttga	tgttgacact	aacttcaaat	aagtcctaaa	89640
tgtattcctt	ttttcttttt	ttctgtcact	tcatcttctt	ctatcatatt	ttcatatacc	89700
cattaaagtt	cagtttatgt	atcttcaatt	atTTttcctt	atgatatagc	tcaatttaat	89760
accaattttt	gaagtcaaaa	gctatgagat	gcaaaaaaca	agagtTTaac	taagaaatca	89820
ataaaaataat	atggaacaat	tttgTTaatt	agaatagaa	agacttctgg	tgattatgct	89880
caagcagtag	acataaatcc	tgtgataaac	cttaatttcc	tacactcata	atctttttta	89940
aaatacatca	tgTTattaaa	acattgcccg	aacctgtacc	tttatccaaa	acaatacttg	90000
agactatcca	tattttccta	ctattggaaa	caaccattgg	tcatttgaag	ttagaatact	90060
aattcaaggt	tagcactcta	tgctttgaac	caatagaaaa	tccaatctgt	acaggggaaga	90120
gatagattcg	gatcaaatg	agctttcctt	tagcagttct	tcgtaccttt	gattgtttct	90180
ataaataact	ttctgttaca	gattgtccct	attggacaca	gagaccaaa	ttttgacaat	90240

tcaccttttaa	atcagtcctc	tgacatgtgt	gtgccataga	ccagattgaa	gaaaattaaa	90300
gtattttaaaa	tttaagtaga	ttattttcact	ttaatattat	cttattatitt	aattccaaac	90360
ttctttataga	tttagaagca	acaaagagag	tttgaagtta	cctgattttca	gagaaaatga	90420
tgtgtataga	ttttgaattc	atcttatatc	agcaagtaga	tccttgcttt	gtaccaagaa	90480
aatagtcata	tttatgtctat	attagttggc	atacaaagag	tgggaattcct	ttattaagaa	90540
agactttctct	atatctaadc	agcgtaaagt	atattttcaat	aaaataaaaac	gtgggtgagag	90600
agtgtatgct	taactaattt	gggataaaac	ctcctttatt	tatatcgatt	attagtgaac	90660
tgtctttctga	aaaggagtac	ccaatcccag	tgctttctct	tgggtatctct	tttcctaaag	90720
aaagcaggac	ctgcaagcat	agtattgaat	attcagggttt	tacttgtact	tgtgactgag	90780
aatggaaaaa	aaattataaa	agaaaaatgt	tttataaatg	tagagtcttt	gaggggtgtg	90840
tgtgtgtgtg	tgtgtgtgtg	tgaatcaatt	agtgttcaag	agaagcaaga	atagaaatgc	90900
agtaatacat	ttgggaaaaa	cagatggatc	tctcattgtg	aaaacaaaata	tgtgctaagg	90960
aagagtttta	agtaggtatc	aaagtgaaga	agtaaaagag	acgaaaaaat	cagatgacta	91020
caatgaggta	gtaatgctac	agagtcacat	attcaaataa	aactaaattc	ccagagtctt	91080
attttgaatt	cattgaaagc	tggaaatgatg	gtttattgca	atgtttatct	tcaatacaca	91140
gcaagtcct	gattgaaaaa	aagtggttta	taagttacat	tttgattact	gcatggataa	91200
attcactata	gatttgagag	gggctctgga	aataatatac	ttcaggtaga	agttaatgcc	91260
aaaggacttg	tgcattgact	tcctttgctt	aggaaactacg	aatgccatga	agacaaatag	91320
ttggacccca	cacaccatta	gccaaacatg	gatctgatgt	gggttattac	tgtctcatgt	91380
tcattaatttt	ctttctaaaa	tattctctta	acagtgccta	aaagtagaga	tcacgcaatt	91440
gtgaagaaaa	atatgttttc	caaggagaca	cttgtgggct	caaaccaaaa	tttttttagt	91500
gtataaaaatt	aaacccaaaat	taactattct	tttgtaaaag	aggattacta	aagcacagtt	91560
taaacatgta	tttatgaatc	atgggattta	aagttcagag	ggctcttaag	agttcaactc	91620
ttctttctct	cacagtatgg	cagtatcacc	cttttagatt	tctggaccat	atgtggtaac	91680
actgttcctt	gtttcactaa	ttgcagcaga	cctcatcaaa	agcaaaccce	cttattttat	91740
aaatgtttga	aaatatctca	aaactgttat	caccacacta	tagctgtagc	ttcttactgt	91800
acgtcttatg	gcataatttc	ttaaaagtcc	acaactgtcc	atattctctc	ttcttggcca	91860
tgatagtttg	aaactttccc	gtttaaaatg	aagtaggtta	agtagaacac	tctattccag	91920
atatattttt	tgggtgggcaa	agagcacagt	tgagatgaac	tctttggctc	tgtgtaacat	91980
ccctccataa	tgaaagttga	gaggtttttt	tttttttttt	tggtaatttt	ccaggaccat	92040
catcacggtt	gagtcatact	gggcctgttg	tttaacaaaa	tattcacttc	cttcaactta	92100
attccattgt	cagttgagag	tttcctcacc	tgggtattaat	acaagttact	tttaaagtat	92160
tttaaaaatat	tcatataatt	taaataaatt	ctgggcatta	gtggagcaat	ctacttgttt	92220
gagaatttga	tgttactgag	aattaggaag	tctattatag	tcctcactct	gatccagaca	92280
tggtttttga	tgatagacca	atgacttaat	aagctactga	actttttctgg	ccctgtttat	92340
gtctgttttc	agagtgtgtg	tatcgtacga	agtgtactca	aatgaacct	tgaacacaga	92400
aaatgctata	tgttttttat	aatagtttat	ttacataaat	tagcactcta	cttttgatta	92460
aaataagtgg	attttttaaa	agaatttaatt	aaaatatgtg	ataaatttat	aaagatccag	92520
aaaataaagg	taacattacc	ttcacatgaa	ggcaacggac	gccatccaga	ttcagtgcac	92580
acagcatctc	ctcttttact	gtattcataa	cccatgttac	atttatatgt	aaatcgttca	92640
ttctccttat	aaataatctt	ctgagatata	ggagatccat	ttataacatc	tggggatttg	92700
catgaaattt	ctaaataaaa	gggatttaaat	tccaaaatgt	ttattgcaaa	ttaaaggact	92760
gtgaccagga	cataattata	tgaaaacaga	aatgttgttt	ccatcaggta	aatcagtcaa	92820
ccaaacaaaa	gttctgtttt	gacttgaccg	cttaataaat	gatttatctg	aagaaagtta	92880
aaattctgat	taaaattatg	cttctgtatt	tatttagttt	caggataaat	tagccttctt	92940
gaaataaata	gtgaccagta	acattcatca	actgtataaa	taaaattgat	cataaatata	93000
gttttattgt	gatgttttca	ctgaatgacc	tgcaaaaaat	aacacatctt	ctagtatttg	93060
ataagacagg	aattatcaac	aggacttttt	gtcaaagaca	ttgatttaac	tcattgtcat	93120
tacatctctg	aaaagtaact	gacctgtttt	tgtgtcatca	ctatttagcc	aagatttcct	93180
cagaaaaaaa	aaaaatggcc	atcatctttt	atacctttta	taccacttct	tctcaaacat	93240
ttttacctgg	gatttgtgcca	atcataagta	gtttcccaaa	ctctgttctc	ccactttcta	93300
atccattttc	cttgtgtata	gcttaatgac	ctctcaggta	gacacatcgt	aactccactt	93360
gaaatccttc	attgattccc	aaatcaatct	gaataaaaaga	cgcgttcttc	agcatgggtg	93420
atgcagcacc	tcagcactat	gtattggccc	accttctatt	tatcactgac	tcgttcccta	93480
cttgcacacct	agactaagggt	gcctaggaac	aatggacaag	aatcagtggt	gcttcatgct	93540
ccttaaagcc	tcaactgccc	tccacttccc	tttccctgaa	ctctgggtatg	cttttgctct	93600
cattttcatc	tacaaaatct	cgtttttttt	ctttaagact	taatcgtagg	catcagccat	93660
tccaggaagt	tttcactaac	cacaggaatc	tagttgtaag	gatgtaaatt	ccatccatgt	93720
acttctaaag	tacataatat	ttgctatgct	gaataaaaaat	attagattta	acataaagaa	93780
ctattgttgt	tacaaagtgt	tcttaagaag	agaaatttct	ttatctgtat	ctaagatata	93840
acagacttta	atagtaaaaa	taatttagat	atatttagata	atatttaaat	ataaatatgc	93900
cagaaacttc	tgccaaacaa	ttattggtaa	aatgaacttg	aactatggta	ctactaaaca	93960

aatcaaccac	gatgtttatc	acagaagcca	aaatctttga	ttgggtcatga	tgcaacaggtt	94020
ggcagtatta	tgactaaaaa	aatcctggct	tacagttttac	tataaaactt	tttttaagag	94080
gcaacaat	at	ttctgttcaa	ttcagcaaca	tttatagtaa	acttgcagta	94140
caaataataa	ataggtctgc	ttcctaaaag	tgttattcaa	aaacgaatgt	cattccta	94200
tatctctgga	aatacataat	gaatctttgg	ctttcaaaat	aaaaacaaat	gtctattcca	94260
gaggtcttac	agcttgcagc	agaaatactt	agcattctct	ttcaacctaa	gagacaacta	94320
caatggagtt	atgggttaaag	catggactct	gggtgcagat	aacctacatt	taaatcctaa	94380
cttgactctt	tatgccatga	taatccaggg	catgtgattt	aacttctttg	caccagtctc	94440
ttccattata	aaatgaaa	gatgagtaag	taaatcatgg	agttttttga	aagttaaaa	94500
gaaatgatgc	atgcaaagaa	cttagctcaa	ttacaggcag	atagtaagt	ctcaataaac	94560
attagctatt	gttaatat	ctgataattc	ttagaatgaa	cgatgtttta	aatgtatatt	94620
tacatttaaa	aagctaaaaa	tactaaaaca	gtaagtgtat	cttaccacac	cactttgggt	94680
tctctttact	ccaaaaacca	tcgtctgaac	aatgcatttc	ttcatctcct	tcaatcttgt	94740
agcctgagtt	acatacaaac	cgtactgctt	gtccaaaatg	gtattcccga	tctgggtcca	94800
ttgcactact	gacaattttt	ccattctctg	gtgctgtcac	tggtaaacac	ttcacactg	94860
aagaaaaaac	atgtaatgtt	ttctaattgga	attttaaaag	tttattgtga	aaaatatgtg	94920
tatgtataaa	atcatcctca	ggataagatt	ggaggaaaat	acttaaat	tttttagaag	94980
catttgatat	acctgtttgc	tagagatact	ttcctctaag	aaacaagcaa	atggaatgtt	95040
tattcctgat	tcttttctat	gggagtggac	aatgaaaatt	actactttca	atgctagctt	95100
gtatttttgt	agtaacaaac	tagtattttt	aaataattaa	gaaatataaa	gcttgagata	95160
attaaataca	ttttcattta	tgccctagaa	taatataaca	ctgtgttcct	aaaagatgta	95220
aaagcaaact	ttatgacatt	aacttcaata	gagaaatcat	cgtaattttt	ccatctctct	95280
cgacctaa	gtttaaaata	atttgagtag	tctttttgat	tctactta	attttcca	95340
ttctctaaag	ttgtgggtcaa	actttattgt	actatagaat	gactcaggat	gcttggttaa	95400
ataaaaaatt	tagggctatc	ttcctgcatg	ctcaccccaa	agatactgat	tcagtaggtc	95460
atttttttagt	aaccaaagat	tttagttttt	aacaagcatc	ccagggtgatt	tcaatgtaga	95520
tgttccctag	accattaatc	ttcttcctcc	aattttcata	gatgaaaaaa	tcttccatta	95580
ttttctgtag	ttgacagttt	ttgaatgatt	atcacgtttc	ttctgtatct	ctctccactt	95640
gccactcact	gtggaattag	gaaatactac	tctggttgat	ttcttttatt	tccataatga	95700
ctagagattt	ggattattag	ctcaaaacat	gaaaacagaa	tctacatttt	ctcattttca	95760
ctgtttgctt	tacagaccag	tgagaaataa	cagagctcgc	ccttagttta	ttcctctttt	95820
cagtaaaagt	aagttccacag	gcaacctccc	ttagtgggag	gtctcaatca	cgttctccac	95880
ttcagctgtt	accatagatc	cctgcatttg	gggtggttact	gggtgagttc	ttcttcatta	95940
ataaaaggcaa	aattctgggtc	tttattttagc	taatgatgct	tatatgcgtt	tctagtcatt	96000
agaatccaaa	aggaaataaa	aatcagtttt	agattccctta	atgtcctaata	cttcaattat	96060
tatatcagat	cagggtgcat	tcgttttttg	cttttgaaac	accaagaatg	tagtaataaa	96120
aagactagat	ttccactcta	cattgtatga	gaaaaaaaaa	cattaaataa	aaatattta	96180
tagagacttt	aagatatttt	aatgtaagac	tttttttaaa	tttagatat	ttatttcaat	96240
atacttggta	atacattttt	tgtctacctt	cacatatagg	aatatcattg	gtccatccat	96300
ctgtgtcaca	ttcacggtaa	ttaatctcac	ctagcaattg	atacctgaaa	acaaaaaaat	96360
aacagaacgt	tgacataatg	tgtgttttaca	tgcaagttta	aactcgatgc	cattctgagt	96420
gtccagaaac	tccatattta	ggaaaatgaa	cagcatatgc	attttcttgt	ttcttgtttc	96480
ttgtttgttt	ttccttcctc	cttctcctcc	tccttcactc	tgtcttagat	ttcttaacgt	96540
tctctagaac	attaatcttc	ttcctcta	tttcatagat	gaaaaatctc	ttaacctctc	96600
tctcccttta	tctttctctc	cttcttggtg	catggactga	aaataatcat	aatccttgtg	96660
tcagcacaaa	atcattattg	ttcatacaaa	agtattctta	tttttcattg	aattatctaa	96720
ttagctaaa	tcaataatat	agtaagctcc	atgaactatc	acaaaaacaa	aagctaaaaa	96780
taccatagta	accaacgact	aaccttatgt	ttcctctctc	tccagtctta	gaccgtattt	96840
ctgtcctcca	tgattctgat	attttctgaa	caccttaggg	tttctacata	ataaagatag	96900
tgccagccaa	aagttgttag	tgtgtgattt	actttcagca	cttgccctcca	tctctccatc	96960
tctatcgtag	agattttttc	ctgagaatac	ccagtgaatc	aaatctgctc	atccaagcca	97020
tctaattgtt	aacttaagta	atttttagtaa	cccatcaagc	ctgccccttg	aatctaaaaa	97080
atgctctact	tgaatatgag	ttccctggga	catgtgcata	atgtgcaatc	attgctagag	97140
gcttcagact	tatctcctta	gccaaagtcaa	gaggtgagga	gtgctgaact	taaagagagg	97200
acacaagcct	gtgataaaa	aaatatttca	gaggtgagga	aggtagcaaa	ttaaaaaaat	97260
cagccccagg	atattataac	ctatttggtt	atgtgtgata	agatcagcag	taatgattga	97320
agggctaaaa	atgtattttga	aaaacctccc	tcaggtagtg	actaaggaga	gaataaaattc	97380
ataagaaatt	atacttattt	ggtatctact	atatctcaag	gtctcttcta	agggctgcag	97440
atgtgtgtct	tattttattt	tcctgccaat	ccatgatgca	cataaaatgt	gtctgttttg	97500
taggagagga	aatggtagtg	aagagatata	tttttaaaata	cccataaatg	ttaaagtggta	97560
gagttttgaa	aggcaggctt	actccagtga	ctaagcttta	aactattata	ttttattgct	97620
tcaaattaag	gaaaaaatgg	ggaaataata	atgttatctc	atttgtaata	tttggttaca	97680

tttataattta	tgaagtatac	gattatagtg	atctaatacct	ggttttccca	tacataaatt	97740
tttctccaaa	ataatttttc	atctagcaga	gaataagggg	gataaaataa	cactgaggat	97800
atacagtgat	gattttggca	atgaaaaccc	agtagttggg	tagaaggaa	agagtcaatg	97860
attctgaaag	agtagtattt	ttaatccatg	tggtagaagt	aatttgcaga	cctgggacat	97920
taagtaacct	tagttgtaag	taaaacttat	aagcagggtga	aagtcttgct	ttccttaaat	97980
tttataaaa	ctgtcaaaa	agttaccata	caatataaat	tggttacaat	tcctattgtt	98040
cctgacacat	tgaactccca	tgataactctg	cacaaaatag	aatgtcgtga	agacttgttg	98100
gggtgaatact	tatatatgtg	catactgttt	tcccactctc	ccataattat	actctatcag	98160
agaagttata	cttcattttaa	attttttcaat	gttaaggaga	taatattggt	tccagattta	98220
attattttcca	tcatagttaa	acttttcaggt	acttgtgtat	tactttttta	aatgctcata	98280
gaaaaatata	ataaccttaa	aaatatataa	agtagtagag	ttcctattta	ctatcttaat	98340
tataaacctc	ttttcgtatg	gactacatac	ccctcattac	atgtatacac	agcttttaca	98400
ccatattcaa	acacattttc	tcctgtaagg	gtaaaagtac	caaaaggagt	atctccagga	98460
tgtccacagg	gccttttctaa	aacgaaaaaa	aaagttatga	attagtagtg	aatagcaagg	98520
aatatatttt	atgtaggagt	gggggaacaa	gtatatattga	tattatataa	gaagacagat	98580
tgaatgttaag	gaaaatttaa	catagcaaag	ccattatttc	ataattgaac	ttaaactata	98640
tgcttgcttt	tttaattttg	gaggatgacc	accccttttt	gaaaatgatg	atgtattggc	98700
tgggcacggg	ggctcacgcc	tgtaatccca	gcactttggg	aggctgagg	gggtggatca	98760
cgaggccagg	agttcgagac	cagcctgccc	agcattgggtg	aaaccccatc	tctactaaaa	98820
atacaaaaat	tagccggggc	tggtggcag	tgctatagtg	cccagctact	cgggaagtgt	98880
aggcaggaga	attgcttgaa	ccaggagggc	agaggttgca	gtgagccgaa	atagcggcac	98940
tgcactccag	ccaggcgata	gaggggagact	ccatctcaaa	attgcgccac	tgcaactgcag	99000
cctaggtgac	agagccagac	tccatctcaa	aacaaaaaaa	aaagattatg	tattattttg	99060
tatttgactg	gcaatagtga	tataattcag	gcataattgc	tacaatatta	aatcttaagt	99120
attttttacac	ctagttttca	taaaatttcac	aaatgtatta	agtacttact	ctgacatttc	99180
cttaattggat	taagagcaac	ccattctccc	ttcctgcata	ccattattac	atttccaaga	99240
gatctatatc	cagggcgcca	tttatagata	gcctgggtgc	cttctggata	tgtttgggtca	99300
gaccaggaac	ctgtcagaat	ttctgtattt	cttcttgagg	gaagtccatt	gcaatctaca	99360
aacaataaaa	acaaaataag	tgcataaagt	gtctatttta	atgtacagta	tatttaggta	99420
attgttgctt	ttaaaaatgc	ctagacagtc	acaggtctat	ctaaaattct	ctctctctct	99480
ctctctctoc	taaccccata	tctatggagt	aaacatacat	ttcatgcatg	tagtgtaact	99540
atacattttca	ccttataaaa	tttgtatcta	cataatttta	taagaatgtt	cactgtggaa	99600
aaacaccta	aaaactttgc	aaagcaatag	atataattttg	ttatattact	cttaattgct	99660
ggagagcatt	ctactattct	tccattaat	tgggaaatat	ttattgagca	ctattctaag	99720
ttataaagaa	aaaacaatga	agaaacaaac	tatctgttct	caaagcattt	ccattctatt	99780
aggggaagcca	gttattaagt	aatcaaagag	atgtataata	tgcattacag	gtagaaaaat	99840
tatatattaca	aaaattagca	tgataagtta	atacagaatt	atacaggcac	tccaataaag	99900
atagaatagg	atggaaaaga	acaatgtttc	tactccaaat	tggaaacaac	acaaattgtg	99960
tgtgcatgtg	tatgttcaaa	ggtaagttgt	gggagcaaa	aggattaaat	gaacaaaaca	100020
caagtaggaa	ggacctgttt	caagtaata	tagggctctc	ggccattttt	tacctgggta	100080
tgtttgtcag	ctctggatat	ggattgaaga	tcaggcctct	atttagtctg	aatggaagaa	100140
tggtaatgag	gtaagaaaga	accaaacata	aggaggctat	atctagcatg	agaattctg	100200
aaactttgcc	aaatcagggt	gctttgctag	agtctaggta	gcttcatacg	ggaagactga	100260
ctttcccggt	gtctcataga	aaaaaagtct	caataagaaa	atggatctga	ctcaaataca	100320
caactagtat	tctcatcaaa	acatgccata	tttgaaaagtc	actctggatg	atatttaaga	100380
gcagatgtca	aaacagcaga	aaagctgtat	acatatatat	attattttata	tataataaaa	100440
gctcttatat	atatgttcac	ttttctgctg	tttcattttat	atatgagcat	ttaagattat	100500
atataatata	gaacagagtc	aaaacagcag	aaaagcaaac	atataatata	atggcctttta	100560
ttatatatat	atcatatgct	cacatacata	atataatagt	gttgggcttct	tctatctcaa	100620
aagtctaata	tatgtacaca	catatatagt	atataatata	acacatattt	atattttatgt	100680
atataatagt	gtatatgtat	atactctgtg	tgtgtgtgtg	tgtgtgtgtg	tgtgtgtgtg	100740
tgtgtattag	tcttttgaga	tagaagaaac	caaccagatt	cttgacttta	aaaacccaag	100800
agggtttaat	ctttgagact	agaaaccaga	aatgggactg	actcaaaact	aaagtgttac	100860
ccaggctccct	ctgagttaaa	tttttgagtg	gctcaagaaa	gagcaaaaca	tcttgttgat	100920
gagagtaagt	tatataaaact	tttgtcatta	catgtttttg	tttaaaaata	cgatttttgaa	100980
taaaaattaa	aagatacaca	aaaaagcaaa	aacaactgtg	aacaaaaaga	gaaaataaat	101040
attcagtaga	actagacact	cagattcaga	tgttagaatt	agtgttaggt	ctttataaca	101100
gctatttttag	gaacattaaa	ggaactatag	aaaatataga	aatgaaaatt	taaaaaagat	101160
attcaaaaata	aaattgactc	ataaatcatg	tgctatctta	aaattggatc	aaaaatcaga	101220
aataacaact	tgtcagatgg	ttttaagaat	caaatggaca	cagcacaata	caaacttatt	101280
aaacttagag	gaagtttaat	gtaaaaataa	ccaaaaggaa	atatagaaag	acaaaagtgt	101340
ataaacaaca	acaaacaaaa	cagagtataa	aaaaatgtgt	gggtgagagt	caagttataa	101400

aacatgttta	attggaattc	taacaataga	gaagaaaatg	aacataggca	atattttgaag	101460
aaacaatagc	tcaaaggttt	cmetaatga	tgaagaaat	cagctcacia	aatcaaaatt	101520
tctaaaaacc	ccmetaatgc	tgtataccaa	gaaaacctat	actgatactc	tgctgaaaac	101580
caaagataaa	ggmetaatct	taaaagcaga	ttgtattagt	ccatttttgc	acagctatga	101640
agaaatactc	aagactgggt	aattttataaa	gaaaagagat	ataattgact	cacaattcca	101700
catggttggg	gaggcctcag	gaaagttaca	gtcatgggtg	aaggggaagg	aaagacctct	101760
tcacatgatg	gcaagagaga	agtgcataca	ggggaaatgc	cagatgctta	taaaaccatc	101820
aaacctcatg	agaactcatt	cactatcacg	agaatagcat	aggagaaact	gccccatgat	101880
ccaagcacgt	cccactgggt	ccttccctca	acacacaggg	attatgggtga	ttacaattta	101940
agatgagatt	tgggtagggg	cacagagcct	aacctatatta	ttctgcccct	tgcttttccc	102000
aaatctcatg	tcctcacatt	tcaaaacata	atcatgcctt	cccaacagtc	cccccaagtc	102060
ttactcact	acagcattaa	ccctaaagtc	catgtccaaa	gtctcatctg	agacaaggca	102120
agtcccttcc	acatatgagc	ttgtaaaatc	aaaagaaaat	tagtcatttt	caagatacaa	102180
tgggaatata	ggcattgggt	aaatgctccc	atcccaaag	ggatgaattg	gctaaaaaaa	102240
agggaccaaa	ggctccatga	aagtgcagaaa	tccaataggg	aagtcattaa	aactcaaagt	102300
tccaagacag	tcccctttga	ttccatgtct	cacattcagg	tcacactgat	gcaagagggtg	102360
agctccacac	gccttgggca	gacctgcccc	aatgggtttg	caagggtatgg	ccccctgccc	102420
tggctacttt	cactgctggc	attgagtctc	tgtggctttt	ccaggcacaa	ggtgcaacct	102480
gtcagtgaat	ctaccattct	gggatctgga	ggatctgtgg	ccctcttctc	acagctccat	102540
taggtagtgc	cccactggga	cctctgtgtg	ggggctccaa	tcctacattt	cccttgctca	102600
ttgcocctag	agagggttctc	catgagggtt	cctcccttgc	agcacacctc	tgctgggaca	102660
tctaagcact	tatatacatt	ttctgaatct	aggtggaggt	tttgtattct	gtgtaccac	102720
aggaccaaca	ccatgtggaa	gctgccagg	cctagggctt	tcattatctg	aagcaatggc	102780
ccaagctgta	tgttggcccc	ttttagacat	ggctgcagct	ggtgcagcta	ggatgcaagc	102840
caccaactcc	tgagactgca	tacagcagtg	ggggccaggc	ctgcaaaacc	atttttcctt	102900
ccgaggcaac	caggcctgtg	atgggagagg	ctgccttaaa	gatcactaac	attccctgga	102960
gacatttttc	ccttgtcatg	gtgattaaca	tttggctcct	cattccttac	acagatttct	103020
ccagtgggct	tgcatttttc	ccaagaaaat	tcgggtttta	tttctattgc	atcatcaggc	103080
tgcaaatttt	ccaaactttt	atgctctgct	tcccttttaa	acataagttc	caatttcaga	103140
ccaactttct	caaagtcca	agttccacag	atctctagg	aaggggcaaa	atgttgccaa	103200
tctcttttgc	aaaacacagt	tagagtgcac	tttgatccag	ctcccaataa	gttccttgct	103260
cccatctgag	accacctcag	cctggacttc	atattccaga	tcactatcag	catttttggtc	103320
taaagcattc	aacaagtctc	taggaagttc	caagctttcc	cacatcttcc	tgtcttcttt	103380
tgagacctcc	aaactgttcc	aacctctgcc	cattaccag	ttccaaagtc	acttccacat	103440
tttgagggtat	ctttataata	gtgccctact	accttggtag	caatttactg	tatttagtcca	103500
ttttgcactg	ctataaagaa	ttacctgaga	ctgggtagtt	cataaaaaaa	gaagtttaaa	103560
ctgattcata	ctttcacatg	gttggggagg	cttcaggaaa	cttacaatca	tagtggaagg	103620
tgaagaagaa	gagaggatct	tcttcatatg	gtagcaggag	agagaagtgc	aagttgggga	103680
aatgctcagat	gcttaaacca	ttaaatctca	taagaactca	ctcactatca	tgagaacagc	103740
atgggacaaa	caacccccat	gatccagtca	cctccactg	agttcctccc	ttgacatgtg	103800
atgattatgg	agattataat	ttaagatgag	atttgggtgg	ggacacagag	ccaaaccata	103860
tcacagacag	aggaaacatt	ttttttccag	gagaatagta	aaaataacag	ccaagtctgt	103920
ggaagttaa	actgaagtct	gaatatatat	gtcttagcat	tactaaagtg	ctgaaaatta	103980
aaagtcagca	gagaactcta	taaatggtga	aaatatactt	caaaaatgaa	agcaaataga	104040
aacacattct	taagcaaaca	aaagcagaaa	gaattcaaca	agagcagact	caactataga	104100
aaaatactaa	aaaagttctc	tgggctgaag	gaaactgata	taaaatataa	gcaagaagt	104160
acaaaaagga	ataagcagaa	ctgaagaaaa	taaatagaag	agtaaataaa	aaagctattg	104220
aaacatgata	aaccttatgc	tatgtatatt	ttactcaaat	aaaaaagagc	cttgactgtt	104280
taaatcaata	gaccatgttt	aatagtgttt	ttaataaatt	caagagtata	atatgaaaca	104340
atagttagca	aagtgtcagg	aaaaggtaaa	gaaaataaaa	gtgttgtgat	gttttcccca	104400
tagtcttgat	gtggtaaaaa	tattaatttt	gaataaattg	taataatttt	agcatgtttt	104460
gttgaatttg	ctaagtttag	cactaaacca	ataatattga	gatacataaa	ataactagaa	104520
tacatgatgt	aatgagatag	tcaagactat	ttgattaaaa	taagagaagg	caggaaaaga	104580
agagagaaaa	attgaggcaa	aagtaagtag	caatatgcta	gacttaaaact	gaactgtatc	104640
agtaattaca	ttaaatataa	atggattcat	caccatacta	aacatacaaa	gattgtctga	104700
ctggataaaa	gcataaaaaga	aaactcaaat	atatgatgat	tacttttaat	aaaattgtac	104760
atataaattg	agagtaaatg	ataaaaacca	atatgctaga	aaagtatcaa	ccaaagtaag	104820
aatgatatta	atgtattaat	atcaagcaaa	tgataatttt	agttagaaaag	tattattaga	104880
taaaaagaga	gtcattttcat	attaataaaa	aggctacttt	aacagaaaaga	tgtaataatt	104940
gcaaatgtgt	ctgaacaatg	tttgctggag	ctggctcata	ctgactcata	ggagccaatt	105000
atacacatct	tttgctaata	caatgtctcc	tgatgacacg	ttggtaactt	gaaattgacc	105060
atattgtgag	aattttacacc	atgaaaactca	gcaaatttta	caaatcatgg	ttgttccctt	105120

tccttttaaa	aaatagttgg	ttgtttttaca	tttaccagca	tgccctctttg	cataaaacta	105180
ttaatacatc	ttcaaaatat	aacagaaata	aaagaagtaa	gcaatccacc	atcatagttt	105240
gagattttaag	cacactgttt	ccaatatcca	atagaaaaga	aatagaaaaa	taaggatata	105300
caagatataa	gcaacattat	taaccaaatt	aagtttttta	tattaataaa	acactgtctt	105360
caacaattgc	aagatgcata	ttcattccaa	gcaaatctct	accaatctca	aaaaattaaa	105420
gccactctaa	gtatactccc	tgaccactag	acattgctaa	cagaaaaata	gtggaaaatt	105480
cacaaaaatt	ttgaagttaa	gcaacccttt	tttttttttt	ttttttttga	gacggagtct	105540
cgctctgtcc	cccattgctgg	agtgcccaat	ctcagctcac	cacaacctcc	actcctgggt	105600
tcacgccatt	ctcctgcctc	agccatctga	gtagctggaa	ctacagggtgc	ccgccaccat	105660
gccccgctat	tttttggggt	tttttttctt	gtatttttag	tagaaacggt	gtttcaccgt	105720
gtttagccagg	atgggtctcaa	tctcctgacc	tcggcctccc	aaaagtgatc	cgcccacctc	105780
ggcctcccaa	agtgtcgaga	ttacaggcgt	gagccaccgc	acttggcaag	caacacttat	105840
aaataactca	tgagttaaag	aaaaatataa	tataaatgag	aatatgattt	gaaataaaca	105900
ataatggaaa	tatatgttaa	aattttgtggg	ctgatgctga	agcactgatt	agagagaaaa	105960
aaatataact	cgaatgaatt	agaaataaaa	aactgttggga	aatcaattat	ccaaatttct	106020
aattcaagaa	actagtaaaa	cattaaatga	aatctaaaga	aaatagaaaa	cagcaataaa	106080
tagtgatgat	cacataaata	accctccaag	ttcaagggtga	caactaaagt	atlttaacta	106140
aggataccca	attctgtttgt	taccgggcat	ggatgtgacc	tatactggca	tcaactttca	106200
tccttcatca	gcaaaattat	cctgggtggg	gttaagatat	tagaagctga	gtttcagtgc	106260
ctgaaatctc	catcaagctg	ttcttgtgca	tactgccttt	atccttattc	tgtattttcc	106320
ttcaagccaa	gtaacctttg	caatgggtaa	gtctatcgta	ctgtgtaaac	ttggactacc	106380
tcaaattgaa	actcactctg	gcaggcttgc	aattaaaaatc	cactggggcc	gggtgcggtg	106440
gctcacgcct	atattcccag	cactttggga	ggctgagatg	ggtggatcac	gtgagctcag	106500
gagttcgaga	ctagcccagc	aaacatgtcg	aaaccccgctc	tctactaaaa	atacaaaatt	106560
agccaaactgt	tgtggcacat	gcctgtaatc	ccagctacgt	gggggcgtga	ggcaggagaa	106620
tctcttgaac	ctgagaggcg	gagattgcag	taacccaaga	tcacgccatt	gcactccagc	106680
ctgggcaaca	agagcaaagc	tctgtctcaa	aaaaatataa	taataataaa	taaaaaataa	106740
aacccactgg	aaatgaaatg	ggataaattt	gaatccttac	tttatttgca	cagacacatg	106800
cacacaaatg	ccaggtagac	taaagagtta	ggttttaaca	aatttaaaat	aaatacatat	106860
atgtttcatt	cttttataat	tttttaatta	tctgtatat	atgatgatat	gtcattttta	106920
cttactatta	tcttagtgcc	atctatctat	aattatattt	atltttataa	tatatlttat	106980
aaaaagtatg	aataaatatc	aaaaaaggaa	ggcttaatgc	ataaagcaat	ttgcaaacag	107040
aacatatata	cattaaaact	ttgttaatta	aaaatttat	ttgtgaaaaa	atcatatata	107100
caaaatgtgg	agaaaattta	actgaaaaat	tattcttaac	acaaacactt	cttgacagtaa	107160
caaaagcact	aaacactatc	taaagaaaaa	tgtagagata	ggatagatca	tttacttaag	107220
aacaggcatt	aacgtgacca	ttaccaataa	ttaaaagaga	taaaaattaa	aagaaaatta	107280
ttttttgacc	aatttttaaca	caaaaatgta	aaggagatga	taatcaattt	tgctggaaaa	107340
ttaggtataa	taaatattat	tattaaataa	aactgaaata	taaatgacta	ttactttact	107400
aaaaagcaac	ttagcaataa	agaatcttaa	aagtactcat	acgtaagttg	acaaataatt	107460
tcaatttttt	aaaagtaaca	aataataatt	aaagattttg	tgaaatattt	aggtacagag	107520
tgtttattcc	agcatttttt	ataatggata	taattagaat	atlttatgaa	attgtcaaat	107580
tatgtacac	ccatctgaat	taaaaattgt	ggtttgggta	atattttaatt	atgtgcataa	107640
aattttataat	agtaagaagg	aaagtacagta	tatatlttct	gttatagtga	gatacattag	107700
gtcagggggc	agaaaaactaa	cctgtggggc	aaatccaatc	gctgcttgtt	ttgtaaataa	107760
aatttttagta	gaacacagct	atgctcatat	agttatatat	tgtctatgac	tccttttatg	107820
ttacaataga	agacgtgagt	agcgagacat	tatggctcac	gaagtctaaa	atattttattg	107880
tctggctatt	tcacaaaaaa	tttgagtgc	ttgggattca	ttatttcaga	ttaatcttat	107940
cacttaggac	accttcacaa	taaaaccagg	tgggcagcca	tggtggctca	cacctgtaat	108000
cccaacattt	tgggagggtg	aggtggggaga	atccccttga	gccaggaggt	ctgagaccac	108060
cctgggcaat	atagcaagat	cccatctcta	caaaaaatta	aagaaacaaa	ttagttaccc	108120
atggtggcac	acacttggtg	tcccagctat	gtgagaggct	gggacaggag	ggtctcttga	108180
gcccaggagt	ttaaggatgc	agtgaagctat	gatcatgtca	ccgcactcca	gccgagagac	108240
agggtagagc	cctgtcacaa	aaggggaaaa	aaacaggaaa	acatatgttt	tgaaataaat	108300
actttcatag	aggcatttag	aaagctgacg	agacagtaaa	gaattacat	aacatatctt	108360
ggtataatca	gaacccagaa	aggaaaaacag	gcagccaatt	tttttctgca	ctgtgggcat	108420
tcaccatttg	gggaagacac	aagcttgctt	tttgatagcc	ttattaggct	aaagcaacaa	108480
aattcaaagt	tggaaacctc	aatgaattca	cccacaggat	aagggagaac	tggaggtaaa	108540
ccacactctt	cttacaggaa	cccagctttg	aattgcttag	agcaccaagg	aatttttaag	108600
cacaaatttg	gcttaaggta	gtctcacact	gaaagttctt	ctagccaccc	agaaaagata	108660
agttgtaact	ttaatattgag	gaagattttt	ttcttaagca	ccaaattatt	attacaaatg	108720
tcaaagacat	tatacgggag	aaaaagcacc	tagttaccat	aaacttcata	aggaacaaaa	108780
tagatatttg	atattggaat	aaatatatac	agactataat	caacaatact	aattctgttg	108840

tttaaatgta	agagaaaagt	ttgactaatg	atatctgagg	aaagaaatta	taacaaagta	108900
gtagcagatt	ttaaaaagaa	ccaaatataa	tttctaaaaa	tgaaaaaacc	catttttaatc	108960
atcaatggac	agcttaatag	cagataacac	agttgtaaaa	agaattcgtg	gacaggaggg	109020
caggtcaaaa	gaaataatac	aggatgcaac	atggagacac	acatgtgtgg	aaaatacaca	109080
agatgagcta	agagtcaatg	aggatagaaa	agccagagca	atgttggaag	agaattttta	109140
aaaatgaatg	gaacatacca	attaatatat	ccaagaatta	aaaaattcca	agcagtaaaa	109200
aaacacacct	atatgcatca	taaggaatat	gcagaaaacc	aaagagaaaa	tatcttaacc	109260
ttgttagaga	aaaatattaa	tttaaaagca	gtaatggtta	gatttacaaa	gacttctcaa	109320
tagcaatagc	agacgccacc	aggtattaat	cacttccatt	ttcaggaaga	aataactatc	109380
tatatagaat	tctatataca	gaaataattt	tttgagaata	aagttttgat	tcataaaatt	109440
tatttttatt	tattttttga	caagatctct	attgcccagg	ctggagtgc	gtggtgtgat	109500
tttagctcgc	tgcgaccctg	accccctggg	ctcaagtggg	cccctgcctc	agccccccaa	109560
gtagctgtga	ctacagtcac	aaactacctc	tctcagctaa	tttttgtatt	ttttgtagag	109620
acgagggttt	gccgttttgc	ccaggctggg	ctcaaactcc	tgggctcaag	caatccactc	109680
accttagcct	cccaaaatgc	tgggattgca	ggagtgaacc	accgtgcccg	ggctgattaa	109740
taaaaattga	gagaatttgc	cactataaag	acacattaag	gagagaaaaa	agatatattt	109800
cagaaaaactg	aaactgatcc	taaatataag	gtcttaggat	gaaagaagaa	atgaaaaaca	109860
aagaaaatgg	taaatgttca	agtaaatata	aatgaatact	gactataaaa	taataaaaaat	109920
attaccttac	atgggtttta	atacaaacat	gtatgtgtat	acacccatat	acataaaaca	109980
catgacaata	gtaggtaaac	tgtgagaagg	attaataaaa	ttaatgtctt	ttaagttctt	110040
cacagtgtcc	agaaaaacag	aaaggattta	atgagctgtg	acagttttct	taataagtca	110100
tcttgcttaa	gtcagcattc	ccagttattg	agtcaaacta	atctaaatgt	tggtgagaaa	110160
atatgttgcc	agatacactc	ccaatcagtt	gacttttaac	aagctgatca	ttctaggtaa	110220
tctagatagg	ccagatcaaa	tcatttgaaa	ggctctgaaac	atagggctga	ggctcctctg	110280
aaaaagagag	ggaattctgt	ggaaagcagc	ttcctttcct	gtgagttcca	tcctgtctgt	110340
aatcttcctt	ttctgactac	ctgccctgtg	gatttcagac	ttgcttatct	catgctcaca	110400
attccttgag	gcaattttatt	taaaaaaca	aacaaaaca	aacaaacaaa	acaaaacctc	110460
tttttaagta	ggtagatagg	agattgggat	gtcaatcaat	taattgactg	atagataggt	110520
aatcttctac	ttctacttaa	gcttcccgc	ttgaatcctg	agtgataaat	tattattaga	110580
ctttagtaag	ttaagaaggc	atatgctatg	ctctgaatac	atgcaacctc	cccacaacct	110640
ccaatttata	tgttttaaac	taattaccaa	tgtgatagta	ttaggaggtg	gggactctgg	110700
gaagtgttta	ggtcgtgaag	gtggagctgt	catgatattg	gatgtgtgcc	tttatagaag	110760
aggcaccaca	gagctgcctt	gtccctttca	tcattggagg	acacagccaa	aaggcactgt	110820
ctatgaacca	gagagcagac	ctcaccaaac	actgaatctg	ctggtactat	cttgctgtta	110880
gactttctag	cattcagaag	tgtaagaaat	acattcctgt	tgtttataag	ctaggcagtt	110940
aataatattt	tgttgtagca	gccccaaaga	aaaagtttta	gaagtgccca	ttaacatggg	111000
ggaacaaatc	catatgaaaa	catttttgcaa	tatttcataa	gaaagaaaaa	accatataaa	111060
atttatattt	acaaaataat	gtgaaagttt	ttatgggcac	taatttttccc	ttgacctttt	111120
tgcaaatttg	attagtga	ctcatataat	attgtgattc	acattgcact	atttcgatgt	111180
ttataattta	agtaaacata	ttctactcca	ctagatgggtg	ctaatactct	atcataacaa	111240
cacaatcccc	ggcccccttc	gcacaaaagg	aaaactgatt	aattacaagc	tgatatgttt	111300
gtttttcact	ttcaaaattt	agatccattt	gatgatgttc	aggttattgg	aaaaaataaa	111360
taagtaaagt	aatccattaa	cacaaaaaaa	gttttagccc	ctcacttcct	agtgagaagt	111420
aaatgctttc	ccttctgggt	attattatat	ttccagggtga	tacgtttgtg	cccctaattc	111480
ttgattttcca	aatatagtct	attgctttta	acaaccagat	gtagaaaaca	ggatacatc	111540
tcttccacaa	aatcttccca	ccaacttctc	acaatattta	ctctgtgaat	atgtttacta	111600
tatataaaga	attatcatat	tgattacott	ttctcttcaa	atagtactta	aaattctggg	111660
gctttttcca	tcagtgttaa	atggcatott	ttgattctgc	ttgtaagaaa	aagatatgac	111720
cgccccgtgt	ctattttccc	ttgctcctac	taccatcttc	aaaatcttag	ttcagatcat	111780
catctgtcac	tttgggtcatg	aaacttgcc	gctaactagc	ctccagtcct	ctactctcct	111840
gttacttcag	tctattcaca	gagtgacaag	tgattcttgc	aaatctgggt	atgtcattcc	111900
tgtgattaaa	attcttttat	gacttcaact	tttactttat	cagcatttgt	aactcctttc	111960
cttggttttg	gaacccttta	tctggctctt	gccactttct	cggatctcat	catgttaaat	112020
ctcccactga	tttactgtgc	aaagtcacgc	tgattttatt	gtttatatatt	tgttgagcat	112080
ttcaaaactta	ttttttcctt	agatccttta	cacgggttat	ttcctcctct	tagaataatt	112140
ttacgacaga	tttctgatga	ctggccttgt	ctcatctttc	aggcctctac	tcaaatgttc	112200
tgtcctcaaa	gtgatccact	cattctagtc	cccaagacca	agcccaccta	atgtctctac	112260
atactaccat	ccccatctct	atcttctctt	aggccctact	ttacctcctt	cacaaaattt	112320
ttcacaatgc	tataactatt	tttgttccatt	agggttttcta	tctatctccc	cacatcaaaa	112380
tgtaagctcc	ccacaattga	agaacaatgt	ttttcatagt	tcgtggaaga	atcttcatta	112440
atgtctaggt	cttctcactt	cagatacact	ttcctgtctg	cttttgttct	aaccattatt	112500
gtattgagta	ttattgagat	aggagatggg	acttggacac	tggaccaaat	tgaggattat	112560

cacaaacagg	tctgagtggg	agccccctccc	tgtaagacac	acagaccagt	gtgctatgac	112620
agttttaccat	taccatggca	acacccagaa	gttacaggcc	ctttccacag	caatgaccca	112680
acaaccggaa	gttaccatcc	tcctcctggc	aatttcagca	ttaactacct	cttaatttcc	112740
atataattaa	aagtgcata	aaatatgagt	gcagaactgc	ctctgagctg	ctactgtggg	112800
cacactgcct	atgggtagcc	ctgcttagca	aggagagggtg	cctctgaggc	tgctatacac	112860
tgccacttca	acaaaaattg	ctgtttaaca	ccacaggctc	acccttgaat	tctttactgg	112920
acaaaaccaa	gaaccttccc	aggctaagac	ccaatttggg	ggcttgctgt	cctacatcat	112980
tatcaactca	tgccatagca	aaagtattta	aggtaattgat	tcactgcact	gagttcta	113040
aataattagg	tatatcttgt	gacataactt	ttatttgcct	gaattgacta	acaatcgaat	113100
gttcaagctc	agttgaacca	ccttcaagta	gacaacaaac	ggttattttg	gccccagtag	113160
tcaaactctc	agcatgtatg	tacaacgggc	ttattaaata	ggatgcatac	aaattgaaag	113220
gcacagaaac	atTTTTTTTga	gatgtgattt	atcttaaaac	taaaagaaat	agccatctca	113280
tttttctcat	tctagattaa	tgagtagact	aagccatcat	atctaagtat	ttgagtttaa	113340
acaatgaata	cttcatctta	cgtttacaag	tcatttaatt	gccagttaat	tttgtttaca	113400
aaacactaca	ttgggtgaagc	tttaattcat	ttggctttat	tttacaattt	aaaattagtt	113460
ttagtctgga	tgcatgtggg	catgcttata	atcccagcac	tttgacatgc	caagtcaaga	113520
ggatcaatag	accccaggag	ttcaagacca	gcctgggcaa	cgtggtgaaa	ccctgtctct	113580
acaaaaaatt	ttaaaaatta	cctgagcagg	ccgggcgcgg	tggtctcatgc	ctgtaatccc	113640
agcacttttg	gaggccaagg	ccggcagatc	accagatcac	gaggtcagga	gatccagacc	113700
atcctgacta	acactaacac	ggtgaaactc	cgtctctact	acaaatacaa	aaaaatagcc	113760
gggcttggtg	gtgggtgcct	gtagtcccag	ctactcggga	ggctgaggca	ggagaatggc	113820
gtgaacccgg	gaggcggagc	ttgcagttag	ccgagatagc	gacactgcac	tccagcctgg	113880
gcgacagagc	aagactccat	ctcaaaaaaa	aaaaaaataa	aaaaattacc	tgagcaaggt	113940
ggctgtaatc	cctgtacttt	gggatgctta	gggtgggagga	ctgcttgagc	ccaggagggtc	114000
gaggctgcag	tgagccatga	ttgcaccagt	acgctgcagc	ctgggtgaca	aagtgatcc	114060
ctgtctcaaa	aaagtaagaa	taataactaaa	caaaatcaag	ttttttttta	gccccatgaat	114120
taagagtgtg	aatacgttta	actactggta	aagagttagga	atgtttttac	tataatttga	114180
ggaaaatagt	tatataattt	tggtcaaagc	taaaaatcaa	tattacttaa	tatttttaata	114240
atcttaattt	acctaatttt	ttcacttttca	aattttaagg	gggcattatt	gacatacaaa	114300
caccaagcta	attacttatt	attgacatac	aaacataagaa	ctaattactt	attttcaatg	114360
tcaatatatc	ttttaactgt	tagttgaaaa	gtgtttttat	tcaaataaaa	taaatcatga	114420
taaaattata	tatttgggaa	atccttaatc	aaatttgtgc	tagattgttt	tggtagacta	114480
aagttggtct	ctttgttcaa	ttattctatt	tttctaaaat	tattttgtgc	ataaaaaaca	114540
gtagatattha	tttttttaaa	agcctacttc	taaacttagt	aggtatcaga	atataattata	114600
aagcaaagtt	acaaaatcaa	tttggaaaaa	aataaaagcaa	atgaacaaaa	cagaaatagc	114660
aaaaataggt	attttgcatt	aaatttcttt	cttatcttct	cactgatcta	tagtaatact	114720
atttattcaa	taatcctttg	gcttttggtat	acacagggga	tatatatttc	aggactcccc	114780
cacaggccaa	aatctgcaca	tactttaaatt	ctacatttgg	ctctctggaa	accgcatgta	114840
cgaaaagtca	gtttttccta	tgcttaagtt	ttgcaaccca	ccaatactgt	atttttgacc	114900
caggtttagt	tgaacaaaat	tcacatagta	agcagacccc	tgaagttcaa	gcacatattg	114960
gtcaagggtc	aattctatat	gcataatatac	gatatgatct	aattagcttt	tcaaaaataag	115020
aaatattcaa	attattttat	aaataacatg	agaataaaga	tcatttcaga	agtaacatat	115080
atacctttgt	aaacagagta	aagaattggt	taaagaaaca	aactctagag	acaaagcaga	115140
atagagatta	tgtcacactt	aataggcatt	tgagaaagaa	aaagaaaaaa	gaaaaagaaa	115200
aaatttagct	aggtgtggga	ggctgaggca	ggaggttgc	ttgagcccag	gtgttggaag	115260
ctgcaagtga	ctatgatcgc	accactgcac	tccagcgtgg	gcactccagc	ctcaggcaac	115320
aaagcgagat	cctgtctcaa	aacaaacaaa	caaacaacaa	aacaacttaa	cagtgaagag	115380
agcaagaaga	aaattccaga	accataaaaa	gcagatagga	gaatagacga	tagtcacatg	115440
aagttggata	gaataacaag	tatgtcataa	ttagagataa	aacaagatac	tatcagaaca	115500
tggtttgaaa	ttccacaact	ttcttgaaat	gtgtatttga	atagctaatt	tctaattgcca	115560
gttattgttc	cagtcacaaa	aaacgaactc	agccacaaag	agacagtaca	attaggaccc	115620
tgaaaataga	gaaaaaaaaa	aaaaaacgca	acacacattg	taccaagtat	tactaagttag	115680
tacttgttga	agttaaaagt	atggaaaaat	gaatgagcga	aagaacagat	gagtaacaat	115740
gaaactatct	ggaagccttt	ccattatatac	tgtagattat	ggacagcctg	tggaagaaagc	115800
gtagtagaca	gtagtgacta	gaaaaatataa	gagaagacaa	ggtgataact	gttttagtgca	115860
cttaaaactc	tggtgcaaga	acccaggaaa	ctctaacttt	tgtaattcca	ttgtacatct	115920
gacctatgtg	tctaagcttt	aaatttatgt	tacagttcag	gagtttctga	agaatatttg	115980
ctttttcctt	ttctttcttt	ctttctttct	tttttttttt	tttctttttg	agatggaatc	116040
tccctctgtc	gcccagctg	aagggcaatg	gcattgatctc	agctcactgc	aacctccgcc	116100
tccctgatcc	aagcaattct	cctgcctcag	cctcctgagt	agctgagatt	acaggcacgc	116160
gccaccacgc	ctggctaatt	tttgatattt	tagtagagat	ggggtttcac	catttttggtc	116220
aggctggtct	cgaactcctg	acatgggtgat	ccaccacct	gggcctccca	aagtgttggg	116280

attacaggtg	tgagccacca	tgcccggcct	ggaagaataa	tcacttttct	atctattaca	116340
tttccagtta	acaaggttta	tgaaaaactt	ggctaagtta	aaatgtcaga	agaaataaaa	116400
gtgtttctgc	aaatgttttt	tcttttcctt	ttattgtttc	atTTTTtgat	gttcagttac	116460
tttatttcct	ctgagctatc	tttttatgac	tccttataat	tttaagctaa	aatgcaatac	116520
ttttttgtca	attacatcat	cccctttcca	tgtactatgg	ttttgtgaag	aaatgggtaa	116580
agtacacgtt	agttaactga	gcacggggata	gattgggtgg	cagaatctca	aaggcctagg	116640
caggtggggg	atgggtgtgtg	tggggaggag	gagaaggcat	aactgggaag	aatgaaaagt	116700
ggcaaaagac	tgacagaataa	acaatcgagg	attaagcaaa	taaaagtggg	tcaatgtaga	116760
ctgggtcaga	tcttagaaac	caaaggccac	acatgaagaa	cattttacca	tctgtctttg	116820
aacttatatt	tgggaactta	cttctaccta	agaataattt	tagttagcaa	tacttagata	116880
tttcattttt	agtttaaatt	atatgttaggc	aaaagagtag	catatgcatt	cccaggatat	116940
gcctaaat	aaaataagca	aagcttgcct	tggcagacgt	ctcaggctcg	tgccatttct	117000
gtgggcattt	tctctacccc	ttctcttata	gcactcacta	tagcacttca	accagcagat	117060
ctgtcctacc	tgggaaaacc	ccatcttcca	gaactcattt	gttctattct	tatcctcctc	117120
aacatccatt	tctaccctcc	cccgccact	gaaattgttt	caggggaagt	gtcagatgat	117180
aataattcaa	agtaaattat	gaataatact	aaattttaact	atcctaaaat	atgtattcag	117240
tgtatttgtc	attccatgta	aatgacagat	tgggtgaaat	tatagtaata	ttaatatcaa	117300
cacgtaaagt	atTTtaggag	gagatgagat	attgaagcca	attgggccat	cgcacaat	117360
aaatcacacc	atatagataa	atacacatac	tactatctct	gaaaatatgg	gggtttgggg	117420
gagcaaaggg	gaattcttat	ttatcacact	gaaattcaaa	catacaattt	aggatttttag	117480
accactattc	tcttttctct	gactgtaatg	gaatccatca	atctctgatc	tataaagtct	117540
tctgggacct	gaaaataacgt	ttctgcactc	taaatctcca	ggattaaaaa	acatgtctcc	117600
caaacaacac	agccagtatt	tacttgaaca	tgtttcagta	gagttttaat	ttattcactt	117660
taatcatctt	ggaatttctg	ggctgtggcc	taatttcata	tagtacacaa	ttgttagacc	117720
ctaaatctaa	aaaatctgct	tggtcataat	atattcaaaa	ccttgggtcat	actatatttc	117780
aaaaaggtga	aattaggtgg	tacgattgag	aaactgttat	tttaaaactt	gtcctgtaaa	117840
tctgacccaa	ttcttagtag	cctgcagtga	ccccctgagc	cagactgtta	aaacaaggag	117900
gcaattaacg	ttcctacaca	attggaaatg	ttattgtaga	caatatattg	cattagaaag	117960
gttctatgta	gtacccaata	tattaaaaaa	agaaaacaaa	tagaaagctg	aaattacaaa	118020
ttatttcctgc	tggctataat	tctttcttag	taatgaatag	tgTTTTTTTT	gaagaaagt	118080
cactcttaac	agagcagaag	taatgctaaa	atgttatgct	gttgaataaa	gcagattgtg	118140
atagtattca	aactatcttc	tcaatttggg	attcagtat	caatgtggaa	aatataaaca	118200
gaagcaaata	ttgaaatata	tgtgagtatt	tttcatgatc	aaagctactc	tgtaaagtaa	118260
aaatttttta	gatatggtag	attaatagaa	ctgatggaca	tctcgaacta	gttttagttc	118320
agagagtatt	tgggaaacaa	ggaataaatt	aggagtctga	tatccactga	aaattcatgt	118380
agtttttctc	cattggcttt	tgcattacat	gtgcttttat	gaaaattatg	aggctggcct	118440
aagcattgct	ttaaatacaa	agttgtgctt	atcttttag	gaaataatca	gatttatatc	118500
attttcacca	taacataatat	agtgccgatg	ttcaattcac	cagtagaaac	tgataccaca	118560
tttaaacaca	cattgatgaa	aaataaaata	aaagtgaac	aagtcagcaa	taatcaatta	118620
tgtaaataag	atgttttaaat	cactattgtt	taattatcac	atatactttg	atgtactcta	118680
ttttaataat	atttcaaatt	caacttttta	ataacttaaa	ctgttttatta	aacttgccat	118740
tgattcctga	ttttaaagat	tagaaataaa	acaaatctcc	cttatatgac	aaatgggtatc	118800
tatgtaaaac	tggagcaaac	agtatgtagg	tatgaaacgt	tagaaacatt	cccataaatt	118860
tagtaagaaa	agacagaaat	atttacacaa	agaaacagaa	aaagatgtct	tttacaatag	118920
gtaatatga	cattgtttctg	gaactgtttg	taaatacaaa	aaggtttcat	tttaaaatac	118980
taattataat	atTTtatatgt	acaaggaaat	aattgttttc	ttcattttaa	aagtggctac	119040
atataaagtt	tacaagccaa	agaacaagca	ataacattag	aaaatataac	tgaaaataat	119100
tcaacctttc	aaaaggtatt	aaacataatt	gaatatTTTT	taaattacca	aagtgtataa	119160
ctataagaat	atatctgctt	ttattttcta	gattggaaga	ctgaaacaga	gatttgtatt	119220
atTTgcta	attcttcagt	tcctagaggc	tatgtaatgg	tcactcaatc	aaaatttctt	119280
tactaagtga	aaagattttta	gaaattatga	ataatatgta	attcattcag	tttaaaaaatg	119340
tttaccaaat	atctatcaca	taactgggtta	cctatcaaaa	actaggaag	caaacctcct	119400
ccaagaataa	gctttttta	ctatcaagaa	gcagtgat	aatttaaatt	tattatgaat	119460
ccagaaattg	tcttactgag	gtcagaaaaa	aactcctaca	ttcatattca	ctactccaaa	119520
agactgctct	tcaagaatat	atgttatata	caactacagg	aaaaaaatct	ctattgaaca	119580
acttaactgt	tacaaatatt	gtatattcaa	ttgggtttca	aatttatata	atatttttat	119640
tctgataata	caagtaatac	ttgtctacaa	gaattctaag	gtcatgacaa	tatcagttgt	119700
aaatgataaa	tgaattttta	tttaggaaga	gttaaaatca	tatttgaaat	aaatctaata	119760
attatgattt	gatggctttt	attgactatg	tatatctaca	tccttcttaa	tgctttcaca	119820
taatacattt	tggttatact	cctaagcaaa	aaagtaaaat	acattttatg	ataattacaa	119880
gggaaatgat	tattccagat	catagttttt	cagaaatgtt	tattaaaaa	ttttattcta	119940
ttttatatta	aatataatta	tgatgaatat	ttagatatac	cattcaata	aggttcttac	120000

atTTTTTaaa	ctcaacaatg	tcaaaagcca	ctcaattgtc	aagttacaga	atacttaagc	120060
acatttttcta	aatcaaattt	ttattactcc	tgtgaaaagc	atcattagca	aatgttttcat	120120
aatacagttt	tcagaaaaga	gtctctttta	atcttacctt	ctgctacaca	aatagcccat	120180
aacataaggc	aaataatctt	tgctagaagt	ctcatttttt	ggatctttta	agaggacatt	120240
taccagctaa	ctctgttcac	aacgtccagt	tctcctcttc	caagaattgt	gattagtgc	120300
ggaaagaact	tgctgcaaaa	ggaagttgaa	actagatgct	ccgcctatca	gaaacttttg	120360
caaagtaaat	aaaaaatcaa	ccacaagcca	caagcccaga	aatgccagaa	gttaaacccta	120420
attctcactg	cactcccact	aaatgttaat	gctgtgaccg	gctcttggac	tttttcttat	120480
taagctaggg	aaattctccg	ttggaaaatg	ttcatgttct	tggtatgtgc	aaatcagcag	120540
ctggtgatat	cctctggatt	tcataaaccc	ttcaattatt	caaactctat	tcgggtctat	120600
tgtgtataaa	cctcagaaca	ggaaataaga	gaaactttta	aagaaatcac	atacaaaaact	120660
ttgggttagg	caatgttttc	acaatcagca	cccagacaat	gtgtacaaac	tttgccaaga	120720
atgcagtgct	tgatgaattt	gggggtctgc	ttttctagca	atztatgaaa	ttagttttct	120780
aaatactttt	tgtatatgtg	tatgaagcaa	ctggctcact	ctcatttgac	gtaaatagg	120840
ttaataatct	aaaaatcaac	aaattgaaat	gctgattttt	aaaactttgt	attgtagtgt	120900
aatatgtata	aggaaaacat	aaatcatatg	ctggatattg	agaaggtaaa	gatacctgtg	120960
aaaccaccac	caaggtcaaa	acactgaaca	ttattacatc	ccagaaaacc	ccagtactcc	121020
ttttcagtc	atacgctct	caaccctctc	ccacaccccc	cacacacaga	gaccacgatt	121080
ctgatcttca	agaacatgga	atatattttg	ctggcttttg	tactttgtat	aatgaaaaag	121140
aagcagttta	ttcttatgtt	tagagttttt	cacaaaaaat	tgtgttttga	ccattcaaac	121200
acattgttag	atgtagttac	agatagttca	ttcttattgc	gatttaatac	tccacttttt	121260
gaatagttca	catttttatt	atctgtgtgc	ctgttagtga	gcatttgagc	agatttttag	121320
ttggagctgg	tatgaatagt	gctgctatgg	gccttatatt	atgaggtttt	tggtaaacac	121380
aatccacatt	tctggttaagt	gcatacttgg	tagtgaaaca	ctgggacata	atztatgttt	121440
aggtgtaatg	gataaaatta	gacaattttc	caaattggatt	ataacacttg	acatcacttg	121500
acattttctat	cagcagtgct	caagttgtct	cataccctca	gagatacttg	gtaattttta	121560
tccttgtaat	tttagctttt	ctggtaaac	aaagcaataa	ttctccgtgg	ttataatatg	121620
aatttttctg	atgactaatt	gaaatgtgag	agatccctga	ttcccttga	aggacatgca	121680
acaggtgtgc	ggcttgccag	ttaggtcgcc	ctgcagctca	aaccctttac	ggggaggggg	121740
agcacacaga	tgccacgggtg	cggaacccg	agtgagcgct	ttcgggctct	ggcctcacag	121800
cagcatctag	gggtgggtgt	ctgcgatttc	cgaagcccaa	gtgggctgat	gttacagtgt	121860
gctccttttag	ctttgccatc	tgcaaatggt	ttatgtgtta	atcagctcaa	caaaccctct	121920
tccttatctc	atgggtagtg	ggacagtga	atagccctct	atatccccag	ctgttgccca	121980
gtgtcccaaa	agaatcggat	cacacggggg	ctcgagggat	gagggcaact	ttttatttag	122040
tggtggagg	ggctgtcagc	aagatggagt	gggaagggtga	ccttcgccca	gtgtcaggcc	122100
tcccagtggc	cagactcttc	tccacccgtc	cctggccaaa	ctccctcgg	agtcagatg	122160
tccctcctct	ctttctctgc	tgtgtcattc	tgccatcgca	ggcctgtttg	tcggcttgcc	122220
tctccgtctc	ggctctgtga	ggtctcttct	ggagcttgga	gtttgggatt	tatatggggg	122280
tacgacagcg	gggcatggcg	ggccaaaagg	caactttttg	ggtgtgaaac	ctgaaatgcc	122340
tgtcctcatt	tagggccaca	ggtcttcagg	cttgagggtg	gggcctttgc	ttggggacca	122400
ccctcttcta	cccagtattt	ccctgtctcc	tgcccttaac	atgaagtga	gaaactttcc	122460
tgtggtaact	ggtcatttag	ataccctctt	tggtaaagg	tctattcaaa	tcctttgcat	122520
atTTTTTct	tattgagttg	tttgtctttg	acttatttga	gtgtaggaac	tgtttatata	122580
taattactta	tatatcttag	atatgaaaa	aatcttatta	atatgtatta	taaatacctt	122640
cttccagttc	gtgggttttc	tttctattca	gtattacatg	tcttttataa	taataaaaaag	122700
aattccctta	ttttaaaata	gagcaaat	tcaatttttt	tctatgacta	gtgcattatg	122760
tgtcctat	aatgaaagct	tgccatagtc	tagaacacaa	tgcttttctt	ctaaaagaat	122820
tatttttatct	ttcacattta	agacctttag	aacaactgta	attgtctttt	gtgtatagca	122880
taataaaaaag	ctccagatgc	atTTTTTaaa	tagagatatc	caattgttat	agcattatct	122940
aacgaaagta	tcattctttc	ctctgtactg	acatgctttc	acctttgtca	taagtcagg	123000
gctggatatg	tgtgggtcta	tatcaccaag	ctcttcttac	tgtaatagtt	tattttttaa	123060
acttttctaa	agtgtaaatt	tctgggaact	ttggctttct	agttatcttt	taaattgatt	123120
tcttttttaa	tttcatattc	ttaaataatta	cactgtttta	aaatttgatg	agtctttctt	123180
tatggcccat	tatagtcaaa	attctaccta	tgtcagtagg	tcaagtttgt	aatttgttaa	123240
aatcttttgt	atTTTTTatta	tgtttttgtc	tgattattcc	atcagatatt	gaaaggggtg	123300
attacatctc	ccattataaa	tgtggatttg	tgtatttccc	tgtttaatgc	tgtgaatctt	123360
tatatatttt	agggtctatga	tgatgcttgc	atacgtat	agaattgtga	tatccttctt	123420
ttgcattgg	cattttctca	tattaaatgg	cccaccctaa	ctctaatttt	gcttccaatg	123480
tgaattttac	atTTTTTattt	atTTTTTattt	ttatttttgt	aataaaaaata	tgaaggaata	123540
gagttagact	tagtcatttg	ttctgagaaa	aataagaaat	aaaatagcat	ggatatatga	123600
ataatcaagc	aaattcgaat	tctgaactat	cattctgaag	tttaatttga	tttaactgat	123660
aacacatatg	ttgacatact	agatcattta	aacttcttct	ttatttcttc	cttagtttta	123720

tctgtttgag	tatgaatcca	aacatttttac	ctgggggctta	aattttccaat	agtgggtttct	123780
attctaatag	caatattatc	acttggagag	tattccagaa	acttactaag	attaatatta	123840
ttgagtgtta	attatatacc	aggcacagat	ctaagcacat	ttattcaata	cttaatgcaa	123900
cacaatgaaa	tgggagacta	ttactctttc	aaagggtatag	atgactgaac	tgaaccacag	123960
aacatttttag	caactccctt	aaggtcacaa	gacattgctg	gagccaggta	tcaaataccag	124020
tgggtctgtgt	ttaaaaatag	tgtttaaaaa	tatagtaaaa	tattcacata	tgtactctag	124080
tgtatgcttc	acattttattt	atttttacaat	tatgcatata	ctgtaaaaagt	attgaaggta	124140
cacacacaca	tatatatggt	tgtggataat	ttaaagtaca	tacaggaatg	attttgctat	124200
acaaatcttc	acctaatttg	caattgttga	atgtaaaaatg	ccactctact	atccaagtag	124260
aaataatcct	cttgaattaa	tttcaacaaa	tatcttttcag	atgtattatt	tttactattt	124320
tttcttttatc	ctacctttttt	tcaaagactg	atggctaacg	tcaattgagt	gtttttgttt	124380
ccctttttttc	atcaatactt	ttcaaaaacta	caaaagtcta	ttataaagaa	attcagaaca	124440
taagaaaatt	agcaacatat	tatgccttaa	actcataaaa	ttattatgta	gtattagatt	124500
accattagaa	agaccagata	gtaaatagtt	aactattaat	actaagatta	aacatgaaat	124560
ggatccaatt	tatttttcaat	attcatgttg	gcacattctc	agcaaataca	tactatgtat	124620
atttggacat	taaaaaattta	gaagagtaag	gatataaatt	tgtattagag	aaaaatccat	124680
atttaaaaaaa	ttagaatatag	ttaatatcta	tgctaagtaa	caaatgactg	ttatgattaa	124740
aatttttcgaa	ggaagttttac	aagaaagaga	aattactgaa	cactgggtttt	gatcagggat	124800
gatttttaaga	acacttggat	attacactgt	agtttaaggg	aagagtacca	ctgagactgt	124860
gaagaatagg	aaagtgtggg	gactaatcta	gaattaatga	gaagactcac	attggagcag	124920
tggtttttgca	caaggaaaatt	gtggaagaag	taaaaggagc	tttaaagtga	gaatgggtttg	124980
aattccagat	caaaaaacttg	caaattattt	tacaggcaat	aaagaatcct	tgatagatct	125040
aattgaggaa	gaaatgtaag	tcattgcatta	tttaagtaat	ggtgcttttg	cggttgtatt	125100
aaaatagatg	gaggaaaaaag	gactcagaga	aatgacaaat	taaataaatt	actgaatgaa	125160
ttcataatac	aactattaca	cagcatctca	atgtaaagaa	aaagggtaaa	aactaatatt	125220
tataacagag	cttgatttttt	ctatgaagct	aatgaagtct	aagcttcagg	gctccctaatt	125280
tgaacagaca	ccatcaagga	cctgagctgg	cccttaataa	cgtttctgca	tggctcatcta	125340
tttttgtaaa	aaattgaaga	gaattaatct	cttaattgca	agagaatgaa	cggctgtctc	125400
tottatttcta	tgtctgatttc	cccttcattg	catttccact	gattcagttg	acattacagt	125460
ttcaggcatt	tgaaggatgc	aagaaaaagt	tacacataga	atgctatttag	tttgagattt	125520
atgtggtata	ttttcagctc	tcaattaaat	ataatttgat	aaactgatgg	cctccaagtg	125580
taagaatggc	ttccaggaat	actcctacca	cccctgtgcc	aaatcaattt	gcatcataac	125640
acaaaacttc	agtgtctgaa	gacagcacat	atgaatatgc	ccgacaccag	aagtctatgt	125700
gtagtgaagg	agaaacaaga	ttaaaaagta	taaagactat	gatcagctgt	gtaaaaattt	125760
aagtggatga	ttccattctc	attgattctt	ctcctagtaa	aaatgaaaac	ttgctcaagt	125820
cattcacaaat	atattggcat	caataacaat	accataaaat	ttacaacgca	cctttgaaat	125880
gaagacattg	agggtcaaaat	agtttttcaat	gttttcaattt	aaagaacatt	taataattaat	125940
tatatcatta	gaactctttt	aatgtcctga	aaccttggag	cttattatgt	cagggaaatc	126000
tgacaggatt	ttttccgaaa	tttgatgaca	atcttaaaaa	tgttttagaca	taagtgggtga	126060
acttgaaaatg	acttcaaata	tttccacata	acaagaaaca	aatttaaatc	aaacatacta	126120
aaagaaagac	tgaattattt	tttctatttt	atgtacactg	aaaatattat	aaaatgggtg	126180
catatgaagg	aaaagtcaaa	aaagtattca	acaaaaacgt	agaaattcaa	ggtaacaaag	126240
actttatcac	acaatgacta	tacctactat	atttttgtgt	tctatgatat	ttcattgtgg	126300
ttttaatttg	catttcccta	atagttattg	atgttgagta	tttttttcat	gaacctgcta	126360
gttattttgta	tgtttttctt	tgagaaatgt	cttagcagtt	cctttgcccc	tttttaaat	126420
atgttattttg	ttttcttgct	attgagttgt	ttagagttcc	ttatatattt	tggacattaa	126480
ctccttatca	agtgtatgg	ttacaaatgt	tttctcccat	tccataggct	ttctcttcat	126540
tctgttattt	gtttccatag	ctgtacagaa	gctcttttagt	ttgatgaaat	cccatttgtc	126600
tatttttcaat	tttggtgcct	gtgcttttcag	agacactaaa	aaaataaaaa	taaaaataaa	126660
ttgcaatatt	gtggagattt	taactcattt	cttctagtaa	ttttacagtt	ttttgtcttt	126720
aatccatttt	gagttgattt	ttgtatctag	tgtaagataa	agatccaatt	taatccttct	126780
gcatacagat	acccaatttt	cccaatacaa	tttggttgatg	agtctgtcct	ttcttcattg	126840
tgtgttcttg	gcacctttat	tgaaaatcaa	ttggccgtaa	atgcatgggt	ttatttctgg	126900
gctttctatc	ttgttttcgt	gataaatatg	tttgtttcta	tgccagcacc	atgttgtttt	126960
gattacaata	gtttttataat	aaattttgaa	atcaaggagt	atgatgcctc	cacctttatt	127020
ttttctatcc	aaaattgttt	tgattattttg	ggaactttttg	tgtttccata	tgaattactc	127080
tgggcttgct	atatatgggtg	cttattgtgt	tgagggtacat	ttcttctata	cttagtcggg	127140
tgggaattttt	atcatgaaaa	gatattgaat	tttgtcagat	agtttttctg	tattttattga	127200
gatgatcatc	tgggtttttgt	ccttcattct	gttatatttg	tatatcagac	gtactgattt	127260
gcataatggtg	caacatcctt	gcaccccaga	gataaatccc	acttgatcat	gggtggatgat	127320
tctttcaatg	tgttggttgaa	ttcagtttgc	taatatattg	ttgaggggtt	tcgtgcctat	127380
gtgatgagag	atactggcct	gtaatttttca	tttctttag	tgtctttggc	tgggttttgg	127440

atcaaaaataa	tattgacttc	atagaatgat	gttagaagta	cttcttccac	ttcaattctt	127500
ttaaaaagtt	taagaaagat	cgatattagt	tcttcttaaa	agtttggtag	aatttagctg	127560
taaaaccata	cagcttttgg	cttttctttg	acaggaaact	ttttttgatt	caatcatttt	127620
atttgttatt	gatctattca	gatttctatt	atttaaatgat	tcagggttgg	tagattgtat	127680
atgtctaggt	tgcattgtga	tgtgtcttga	tatgttgtat	gtgtatgcat	gtagaaattt	127740
atacatttct	tctagggttaa	ccaaattatt	ggtgtatgat	tcttcatagt	tgtctcacia	127800
ctttttattt	ctgtggtatc	aattgtagg	tctcctcttt	catttatgat	tttattttatt	127860
tcattctcct	ttttaaatgt	agctaaatat	tattatcttt	tcaaaaaatc	aacttttttca	127920
ttgatttttt	ctgactattt	tatttttctg	ctctgttctt	tgttattttcc	ttccttttgc	127980
taggtttgaa	ctttgttctt	ctctcagttc	cttgaatttt	acatagttca	tttgagatct	128040
ttttttaata	tagacatttg	ttgttatata	ttttctatga	agaacttttcc	acttataact	128100
tttttcgctg	catcccgtga	gttttgcaat	gtagtttttt	cattttttatc	ctgtattttt	128160
tatttttcatt	ttgattttctt	ctctgacaca	ttgttgaaga	gcatggtgat	taattcccac	128220
atatttgtaa	atttttcatg	atttctcttg	ttattgat	ctagtttcat	gttactgtga	128280
ttggaaaaga	ttgttatgat	ttcaattccc	ttaaacccta	acttattttca	tggtcctaagc	128340
tacgatctat	cctggaggat	gttccttacg	tgtttgaaaa	gaatgtgcat	tctgttgctg	128400
ttggttagaa	tctttggtat	atatctgttg	ggtctatttg	gtctaaagtg	taattcaagt	128460
ccatttttatt	ttttattgat	tttctgtcta	gatgatttgt	tcattgttga	aaatggggtt	128520
ttgaagtcct	ttgctatggt	tatgtttcat	tctatctttc	ccttcagatt	gcttagccat	128580
tctcctgttt	gacccaagaa	tactagctgg	tggtcattgt	gactgcagca	tttaccctcaa	128640
gatgactttt	cattgaaata	tcttgggtgt	actattattt	ttacattgct	ctagtatatc	128700
aacttttgaa	acaaaagacg	tcattctatt	tatagcattc	tgttttttagt	agtgatattt	128760
tcgtttacaa	aatatggtaa	tccttgatca	ctgaaaatgt	caaactcctag	aaaacgtagc	128820
attcctacat	gttacgttaa	catagttctc	gaacagatgt	tggtctgaaga	ttcatttgat	128880
gaatctgatt	gttctcaaat	agatgattct	gatgtccatt	ctgttttagaa	ataactccaa	128940
gaaactttca	tattttattt	tcacattgaa	aatcagtcac	atttgcttca	acctcaaaga	129000
ctttgtttat	gtaaaatcaa	gtgaatgttg	gcagcaagct	ttactttttt	ttcctaaatg	129060
ggaaaagagt	taataactgc	tttatatatt	taggtgtctc	gatgttgagt	gcatatata	129120
ttacaattgt	tatattatct	tgatgaattg	accactttat	cattacacag	tgaccttctt	129180
tgtttctttt	tacactttac	tacttaaagt	ctattttgtc	tgatacaagt	gaagctacct	129240
ctgctctctt	ctgattttca	ttttgctggg	agtatccttt	tctatcccag	cagtctctgt	129300
gtgtctctaa	aggtgaattg	agtttcttgt	taacatagta	tacttggatc	ttgttattgt	129360
ttttaaaaaa	tattcatcct	gccactcttg	atctttgaat	tacagaagtt	aattcattta	129420
catttaaggt	aattattgat	aagtagggac	ttgctactgc	tactttgtaa	tttgttttct	129480
ggctttctat	ttctgccttc	ctctcttgc	gtctttattt	gtggtttgat	aattttctct	129540
ggtggtatct	ttttaatcct	ttcttttttg	ttcttttgca	tcaactatag	gtttctgcct	129600
tgtggttagt	taccatgagg	aatacataaa	acatcttaaa	catttaaatc	aattaaacat	129660
tttaaatcac	ttcatcagtc	tcactagtca	catttcaaat	actcaatagc	cacatatagg	129720
taatggctat	tacagagcat	tttcatcatc	atagaaattt	tcataagata	gtgctaagtg	129780
atatggtagt	ccaaatcagg	tgccatttat	gctcagaaaa	aggatggaaa	ggaaatgagt	129840
attttccata	tggtgatctt	gatataatatt	caaaagagca	ggatattaaa	catcatgaat	129900
tattaataat	aaaactacta	gttacatctg	attggtaaacc	caattttaatt	tttttttttt	129960
aagacagagt	ctcgtctctgt	caccagagct	ggagtgcagt	ggtgctatct	tggtctcactg	130020
caacctctgc	ctcccagttt	ccagtgatct	tcttgccctc	gcctcccag	tagctgggag	130080
cacaggcgca	caccaccact	tccggctgat	tttttggtag	agacgggggt	ctgcctcagc	130140
tcactgtgtt	gcccagctg	gtctcaaat	cctgagctca	agcaatccac	attttttaata	130200
ctcccaaatt	gctgggatta	caggcatgag	ccactgcacc	cggccaattt	actcagctctg	130260
atcacaaata	taagtgttat	aattcacatg	tgaagattca	gtcatcaatt	cacacaacca	130320
tgtttttatt	ttttcagttg	tcatggtttg	ggcttttctg	tctgtaccct	aagttacaaa	130380
ccagcacttt	gaaagtatat	ctagtacaaa	ttaaagcaca	acacaaatta	tcattgatcag	130440
aaagaagaga	attgtgcaga	gtccattgtc	ctttctctaa	tttaattcaaa	ttactgactc	130500
cttgtcattt	tcttttcaact	ttcctgattt	gaaatcaaat	tttctctccc	aaaagtgtcc	130560
agacatatat	tggtctcctt	tctctcccaa	aaaagagttt	taaaatcctg	ttatgtgctt	130620
ttgttatatt	tcccttttaa	ttgcaggaaa	aaaataatgc	cccaataccc	tttttcattg	130680
atatgcattg	cctaagataa	aggctacctt	tatgatttat	ttttagaacat	cttcttttcta	130740
catgaagaag	ccctaacatt	caaagtttcc	tttcccaact	agtagcttta	tgacttttaga	130800
aaaggacact	gctagcacaa	ttcaataatt	tggaacaaaag	tgaagaatga	ttatatattat	130860
ttttgtttta	ttttagtgtg	aagggaagtga	aaacacacat	gatcctacat	aataatttaa	130920
tgcaattatt	ttattaggtg	cattattaaa	gctagattgc	aagctcttca	agtcacttaa	130980
ccatctgaag	gtaaaaggaaa	aaaaaatacc	atatccttgg	caacttcttc	cttccactata	131040
aatcgcatgc	aaaatctttt	aaaatcttca	gagaaaattg	attttccctcc	cagggtacaa	131100
ccagctgcct	cttttaattgt	tctctttccc	aggttccag	gcatttatcc		131160

cacacaacac	aactgcaa	ttctgtcttt	taaatggcat	attagaaatc	tgtgagcaaa	131220
gtcacttttt	tgcccagca	ctggcactgc	atcaactttc	caagctctac	tgactcaatt	131280
ttaattgcta	tgtaatgatt	aattttatat	tgtcaggtgc	tgtattaaat	gcattatcta	131340
atttaattca	ctcaaaaact	ttataatata	cttttatcat	tgccgttttc	tgccataggga	131400
atctgaattc	cagagagggt	aaaatgactt	gcttaagtta	gtagtgaact	tgagatttga	131460
tccctggctg	tctggttcct	caattgagca	tgtacacaa	agtctcgctg	cctttttgac	131520
tccaagtgtg	ttttattcca	aagcttttgt	atcaattttg	gttttggaca	gagggaaactc	131580
ttagagctga	tattctccag	tctctaata	agattcatag	agacataatt	taatacgttg	131640
tgtaatgatc	atacttaagt	agagtgtatt	tgctttctgt	aagttaattt	tccaagatat	131700
ctaacaatt	atgtactgct	acatatcaga	tagaagtaat	catttcttgg	gaaaaataaa	131760
accagtctta	cctatgatgt	ataattagta	aatgactgaa	agtagatggt	taattgtcat	131820
ttattagttg	taagtaaata	atttataaacc	cagttaatat	aactaattag	attagcttat	131880
acatatcatt	taaatgaaat	tcaaattcaa	aatgatgcct	gagaattcat	atatgtttac	131940
attttgatag	ttattatgct	atctctattc	ccccccaga	aaaaatctat	tccttaacc	132000
taattaattt	ttaaatcaac	agcaaaaaaa	aaaatgtaaa	aattaatctg	ggtacatgac	132060
caacttttga	tagatttgat	aaaatatttt	attgatatat	cagaaaaaaa	cataattact	132120
gctagtttca	ttgttaagtt	tttaattctaa	taagaaatcc	tattttattaa	tcattaaaca	132180
ttacattact	aataatatct	atatttaatg	tcactactaa	attaacaaaa	cagcatttga	132240
ttgtaaaaga	gaaacttttt	tccattagat	attcccaggg	aataaaagttc	cactcacaaa	132300
gtattcctca	aaagtgtatt	taaagtaatc	tttaaggtaa	tcccaaattc	tcaatagcac	132360
ataaaagcat	gcatttttta	aaagtaatca	ataaaacaaa	aaagatgaag	taaactatta	132420
attccctggg	agattttctta	atgggtatata	agtgtttatt	tttctctgtc	agggtgaatta	132480
ttagaaaata	atttgaatgc	caagggtgatg	aagattcctt	ttgattacat	atgaaaaacct	132540
tctttaaaaa	ttactcacag	ataaaaaattt	tcacttctcc	atgggtttcag	tgccagggtta	132600
ttatatacaa	aaatggttaa	actgctaaat	aaaatatgca	attctaggtg	tcttatttgt	132660
aatccttagt	cctgttttcag	cagttgtcca	aggtcaggct	aattgtaatg	atcacttttg	132720
tagaacacaa	tggttaaggat	gactttttgt	tggtgtgtgt	taagatggag	cctccctctg	132780
tcaccagggc	tggtgtgtatg	tggtgtgtatc	tcagctccct	ggaacctctg	cctcctgggc	132840
tcaaacaatt	ctctcgtctc	agcctcccga	gtagctggaa	ttacaggcat	gcgccaccac	132900
agccctgcta	acttttgtat	tttcagtaga	cacgggtgtt	caccatgttg	accaggctag	132960
tctcaaatct	ctgacctcaa	gtgatccacc	gacctcgcc	tcccaaagt	ctgggattac	133020
aggcataagc	cactgtgccc	agctgagggt	gactattttt	ataatggcat	cttaaaatga	133080
ttaaactatt	taaatttaaa	aggtcattaa	tagtgtgaaa	aatttccact	gaagtaattt	133140
ccacttctac	agtgaagattt	gtaatagatg	ccttctttgt	tcttaaaaaat	gagttgtata	133200
cattaaatat	gtacagtttt	atgtgttaat	catacatcaa	taaaatgatt	tgaaaaacaa	133260
tgttcaaagt	cagttgaaac	ctattcttaa	gggaataatg	gtagtgacta	ggtgtgttaa	133320
accccgtagt	accagtatct	aactaatagc	caacacaata	tggtgttcag	ggctagttgg	133380
agccagatag	aagcattttc	ctggcctttg	tgttatttta	agattgaact	acataattgac	133440
cttcataaca	tggaatgaaa	tggtatcctg	attcctttgca	catagaactg	gctgcaaaga	133500
aaagctgagt	tagattacac	agcaggga	taaaagaaag	agaaaaagta	cctcttactt	133560
tcatttgaat	gtaactgtga	aaatggatgt	atgtaatat	ggctaaaaata	cgcttaggaa	133620
gggaatttct	aaaatgagaa	tacatttgca	aagccacaga	tgctatgaat	ttttatgttt	133680
caagacatta	caaattgttg	tccaagaatg	ttatccta	tcccaaactc	ccaattgcac	133740
ataaaggcag	gtattttttc	acagccttgc	aaaattgctt	aatataaaaac	ttttacgtta	133800
ctgttaatgt	aagtga	gcataatata	ttctgtttt	gatcacttca	gacatttttg	133860
gaagaatggt	ttatgactat	gatattaatt	tattaattac	tcacataact	cctagctatt	133920
tgctatttga	tttgtctctc	actgtttttc	taaaactatt	atcttgacac	atccctgggt	133980
cagctcctta	atcatttagt	ccttttcttt	tctttttatt	ttctttcttt	ctttctttct	134040
ttctttcttt	tttttttttt	tttttttttt	tttgacacgg	tttcgctctt	ggtgcccagg	134100
ttggagttag	gtggcatgat	cctggctcat	tacaacctct	gcctcccggg	ttcaagtgat	134160
tctcctgcct	cagcctccc	agtagctagg	attacaggca	tgccaccaca	cgccagcta	134220
attttgtatt	tttgatagag	acagggtttc	tccatgttgg	ttaggctggt	ctcgaactcc	134280
cgatctcagg	tgatccacc	acctcggcac	cccaaagtgg	tggtgattaca	agcgtgagcc	134340
actgtgccc	gccatagtcc	ttttcaacgt	attagtttcc	cagggtgct	atcacaaatt	134400
accactaact	gggtggttaa	aaatacattt	tatcactttc	tggtggttag	aaatattaa	134460
tcaagggtgc	agcagggcca	cgctacctcc	agagatgcc	gagaagaatc	cttctagcat	134520
aagggtgattg	ctgtcaattc	ttgttaattc	tcggctttca	gttgcatcac	tctaatactc	134580
gcattcatca	tcacatagac	tttttcattg	cgtgtctctc	tgcttctgtg	tgtaaatctc	134640
cctcttcttt	ctcataaaat	caccaaata	gtatgacctg	atgttaactt	gattatatct	134700
gcaaagactc	tattttccaaa	taagtcacat	tcataattag	tggtggttag	ggtagtcagc	134760
acataattggc	aaccacatat	atttatgttt	ggtgggcatt	gattgtgtgg	agaaaagtta	134820
agtataatca	tcgacttaga	gaacttaaa	tagaacaag	aggcacatat	aaatatgcc	134880

ataagtgcag	aactgagtag	aaaagaaata	caggtaaatgg	aaggagaaag	cagtcaagct	134940
agagaagaca	ctcaaaactgg	attttgataa	aattagtaag	tggtcgacag	gccagctttg	135000
tgaatttctg	ctctgctatt	ttttctcttg	gtgggaaggt	tttaatcatg	aagtgtattt	135060
ctttaataga	tataaaatat	tcatatttta	atttctgttt	gtgttaacct	tttaataaac	135120
tttttatttt	agtatagttt	tcaattttata	gaactgttga	aaatagaata	cagagaatcc	135180
tgaataacct	atatagaact	tcccttatca	ttaatatctt	atattactat	ggtacatttg	135240
tcacaacaaa	tgaagcaata	ttgccacatt	ataattcatt	aaaattcoatg	gtttacaatt	135300
atttccttat	ttttaccaa	atcttcgttc	tggtgccacga	tccatttggg	gatataacct	135360
atttagtcac	catgtctcct	gtggctcatc	tagactgaca	gtttcttaca	cttaccttgt	135420
ttccttgaaa	aatttgagga	gaactggtta	ggtatttgaa	ataacatctc	tcagttggag	135480
ttggtctgaa	gttttcctca	tgattaaata	aggggtatgg	gtttttggag	gaagatcact	135540
cacatgaagt	gtcattttca	ttacatccca	tcaagggtac	atgataccaa	catacatcac	135600
tgattatgtt	aacctgaatc	acttggctgg	agtagtgttt	gtcaggttta	tacagtgttt	135660
atttaactta	tttccctatt	tccataccgt	gtttatttgg	aagagcatta	ctaagcacac	135720
cttatattca	aggggtagga	cattaagctt	cactcctttg	aaaggggaat	actacatata	135780
ttctttgtaa	ttcttttagtg	ctggaaactt	gtttcttccc	tccattaat	ttatgcattc	135840
aatcatttat	gtatataaat	atggactcat	ggatgttttag	tttacatttt	gggttatgat	135900
ccaaaactat	attattttatt	ttgtctttca	aattattcca	gattaggcca	ttgggagacc	135960
tttcagattg	actcttgat	gcttttgaca	tgaccccatc	attttatttt	tttcagtgtc	136020
tccttatttc	tgacactaca	ggataatcta	gtttcatctt	gtatattccc	tgctcagtc	136080
ctagaatcag	ccctttctgc	aagtaacaag	ccctttctgc	ttgtttccgt	ctattggagg	136140
atagttctag	aaacgaagat	ctgggtgctg	agtgggtttg	ttgtcttgct	ggtactgagg	136200
tgttattttc	cataggtcct	ctcagcaaat	aatagagcta	ggaaatgtac	ctatgtatac	136260
taatctatgc	atgcacatat	ttataataat	ttccatttgt	acctatccat	atattaagct	136320
agcatgagtt	cagactagtg	tctctgactc	taaccagtg	ctacagggtt	tattctagat	136380
ttcctcctgt	ttgatgtaac	ctccccctcc	aacagtgaga	agctggctcc	taccatgtaa	136440
catctattta	cttttggtta	atcacagtac	acatgtatag	aattttgaga	attattcatc	136500
cacaccacaca	tgagacataa	ctttgccagc	tagaatagta	cttacgtact	gttccttttg	136560
ccttcagact	tacagtttcc	aataatcatc	aaagttactt	agataagcaa	cttttccctt	136620
cttctttaag	tgaggtgata	acatacatct	aatagagtta	atttttataa	tctgaattcc	136680
acccagagat	ccatcatctt	cctacttgct	tatttttaaa	tttgataaca	tcaatattta	136740
ctctttgtgc	tatgaagttt	tataaatttt	tgctgaaagc	gtaatgtccc	atattcacca	136800
ctatagtaac	atatggtact	gccagcttat	agagttgatc	aattacaaat	aagagaaata	136860
gaataattttc	ctttaccttc	atttttttct	tctccaacat	tattttcttt	atgtagggtcc	136920
aagtttctga	cctagatcat	cttccttctg	cctgaaataa	atcttttaac	atttcatgca	136980
ggtctactgg	tgatgaattc	cttcgttttt	taattttctc	ttcatttttg	taggataatt	137040
tttctggata	tagaattcta	tggtgataga	tcattctttc	aatacttggt	gtattttact	137100
ccactctgtt	cttgcttttg	tgacttctt	gtacttctt	atccttgatt	ctctaattggg	137160
taaggtgttt	ttttcttctg	gattctttta	gattttcttc	ttgttttgct	tttggttttc	137220
ttaaatttga	ataaaatatt	aggagtactt	tttcagtatt	tattctggtt	ggtgttgtct	137280
aatcttctcg	gaactgtggt	ttgggtctgt	cgtaattttt	tcaatgttct	tggctgttag	137340
taattcaaat	tttcttctgc	tcccttctct	gttttttctt	cttctaatat	tcaaattata	137400
catagtcact	ccagttgaat	tttttccaga	gttcttaaa	gttctgact	gagctttttt	137460
tgtttttctt	tactttatat	ttttctcctt	aaatttaagt	ttggaaagt	tctattgacc	137520
tctctacagg	ctcagtgatg	ctttccttag	cctattccgg	tctactgatg	agcttaccta	137580
aagtaatctc	cgtttctgtt	acagtgtttt	tggttcttag	cacttctttt	atattctttc	137640
tcaaaatttc	tatttctgct	tacattatcc	atctgttctt	gcatgttgct	tattttttcc	137700
actagaaccc	ttaacatatt	aattatagtt	atttttaaat	attctgtctg	ataagtccaa	137760
gacttgtgtc	atataagtgt	ggtaagtgtg	gttctgatat	ttgttttctc	tcttcaaaact	137820
gtcttttttg	tttccctttg	gtgtaccttg	taattttttg	tcaaacacca	aacatgttat	137880
atcagatcat	aggaactgag	gtaaatagag	ttctactgtg	aagatttatg	ttctgattag	137940
aaactgaatt	ttattttaatg	cttgctgcag	ctatggatat	caaagaattc	atattcctct	138000
agtgtccttg	actttccctc	cttgactttg	ggcattcccta	agtatttttt	tctcaagagt	138060
ctgtgtcttg	cagttctttc	atctgtaatc	aacaagagct	ctgttgattt	gatggtaagg	138120
tggttagggg	gggggtgttt	tgtaatcatt	caattaaatc	taattgtggg	gtggggggct	138180
gtatatttgg	cctgtgatct	tcacaagtgt	tttttctcat	attttttttg	ttttgttttg	138240
tttttaatta	ttcttcccaa	ggtgagacag	aaagagtaga	agaggctgga	gtgataagaa	138300
tacccttctc	catggctctg	ggacaatgct	ctgttaagtt	ttctccctgg	agagttggga	138360
tttgttatgg	gaaaggttct	tggcatattt	cacaaggatt	actcttccaa	ttcctcatgc	138420
cagaagaagg	tgtttcttgg	ttcttcattt	tgagaacctg	gtgctatttc	tggaggtaaa	138480
gcatacaaaa	gtgtgtgtat	actaggggtt	gtgggtctct	gttaagtctg	tggaccctgg	138540
agtttctcat	tctcattcta	ttccacactt	agtccttaga	aatttgtcaa	aattatcatt	138600

taattcttat	tagtttatgg	cttcagctac	ttttgcttga	aataagcaga	cctgggctgt	138660
gactctctga	atttacttct	ccagatttca	gggtgggtgg	ttgcctgcaa	aatcaattct	138720
ttgttgggct	caagaaaagt	cactgatttc	taatttatcc	atcttttcct	tgttgtaaga	138780
ataggagtgc	ctgcttctta	gattttgaca	tatgagagct	gaaagtcctt	tatattattg	138840
acatgaatgt	ctcagttgct	caaatgcatg	ggtatctcta	ttgggttata	gtcatcatga	138900
tctttgtctt	tggcatctaa	aaaagctaga	ggaaggcatg	acagaatggt	ccaaacctaa	138960
tatgcttgcc	tagcttgcac	aattgaagca	atgtttcaga	ccaggagaag	aaatagtgtt	139020
tggctctctc	acagaagagt	taatataagt	aggggctcta	tcccagggtta	cttccaagtt	139080
taacagtcct	gacaagacag	tataagccac	tgaagactac	agaggcttag	ataagaaagg	139140
gtcatgttct	caaactgaca	tagaaatgac	aaaatgtggc	cctggtagtg	tgtcttaaac	139200
attgcaagt	ctttttaaaa	ataaccctct	aaaggaaaac	caagtcatgc	taatattgta	139260
atgacaaatc	atcagtga	ttattgacaa	atcatcaata	aattctagga	caatattgtc	139320
aaattttattg	gcaaattcatc	aataaattct	agaacaatat	aaactcttga	tgcattgtca	139380
gattctgtta	caatgatgat	ttttgataat	ggcttctact	gagaaaactg	cctattgtatc	139440
acattgcata	ccatcctagc	acaactgaca	aaaacagggt	gactttgaat	atagccaaaa	139500
tccaaggcat	gacaaagggt	accttggttg	gaactatttg	gaccataatt	caaagaaatt	139560
gtaagatga	gctgttgatt	catcagccat	taagtacaaa	aaaggagcct	caacacttga	139620
ctgattgttt	tggatattgc	agatagcaca	taccacaatt	aaaaattgta	ctacagcctc	139680
tagactaatc	aaacagacta	ccagcttaat	atctacagct	catggctttg	aatcaagcc	139740
aaatattagt	aactcaaggc	ctgaagctca	tatctccttc	agactccatg	acattacaaa	139800
tgtttctagc	cacagggttg	attgaaacct	atggcaaaaag	accatgagta	ctcctcagcc	139860
tctaggattc	atactcaagg	actttctcct	gctacagaga	aatgctccta	ccatttctct	139920
tacagattta	gattatcgca	cctcaaaaaa	tgtcgttact	ccttagcaga	gcccccaaat	139980
agaagctaga	actggtcctt	gagaccttag	ccaggctacc	aattccacct	ttacacaaaag	140040
atatcatggc	tgtctataaa	atagtctgca	tacagagaaa	acaaaatcag	tgcaaaagag	140100
cagccttcca	acataataat	agattgccaa	taatttatgt	cgttgattgc	tcttcggaat	140160
gagttgcaca	tcaaattggtg	ttcctagaca	tcccaatatt	aacaaattta	cctttacaca	140220
gacttctggg	ccaacactaa	tagcctgaaa	atatacgtac	tcaggactgt	ggttggtgta	140280
tagcatagga	aacacctggc	ccactaggaa	tgcattgagtc	ttggagtggg	gaatgataaa	140340
attttgagaa	ggaacagtat	ccctcccttc	ttttaataac	agtattgtta	aatatatgtg	140400
ccatctctct	tttctttttt	tttgtgccta	ccatgacctc	tgaagatata	tagaattttt	140460
tagatgcttt	tttaaaacttc	aatatgtgaa	aggaaagatt	atattgttca	acgtaaggat	140520
aattgagcag	acatgaactt	ggacattgac	tttgctcaaa	gtggttttac	acacccccgc	140580
ttctgcccc	atggactgct	catgaaaata	atatggtgac	ttgtttccct	gtgaaactca	140640
ccatcctgga	gaaagaacat	tcagtctgtc	tcagtcccaa	gagggaatgt	aaactttgat	140700
tgggtgggtg	taaactaccc	aactctgaga	gatggatggg	agggtgagaa	ctcataaata	140760
attttgtctt	ttgctattac	acatatgtaa	aaataacctg	aaatactctt	ttacaaaatt	140820
tttgggcaat	gtcttgtgat	ataaatcctg	tacaaatttg	gatattgttac	attccactgg	140880
atccagcttg	tgttttctca	ctgatgctcc	attctcagaa	aatactgtgt	aacctctctt	140940
actcccagac	atactgtgaa	accactatg	agtttgtgtc	aatcagagct	aaattactta	141000
cacttaatga	gtgccccag	gggatgagag	aaaattatga	atggtttgga	ggctcatctc	141060
cttctctctc	tttttttttt	tttttttttt	tttttttttt	tggtagtata	gcaaggatct	141120
ggcccagctt	gagccaatct	ggggagaaaac	aaggctcttg	gctgacatca	gcattcttgt	141180
cattcaaagt	ctttccaagt	gcacttactt	tgcagacctt	ggctgtaagt	atgcctagtc	141240
cctgggtattg	ctcctgagat	tccttgaaac	attttttatt	aattaaatta	tgcatttcta	141300
tattcatcct	aagctaactt	aaatatttgt	aacaagaaga	taggacatat	tctctttttt	141360
tgtgattctc	atttccacat	ccatcctgta	caggtaggct	tctgcctgat	ggaatattgg	141420
taatgggtcca	catagacatt	caatgttttg	cctgtactgt	gaaatgagtg	ttcagggtat	141480
tgtttggaat	cagggttttaa	gtcttacctg	aagaccgaat	gtcttttagta	gttgtagtac	141540
tcttcagatt	ttctatctct	cttttaataca	gttttctcaa	cttctaattt	ttctagaaat	141600
ttgcctatct	catatgcatt	ttcaaatata	ttggcattaa	tttgttcata	attgtctcat	141660
tgttttaatc	ttaatattat	ttaatctgtt	ctgttctctt	tttagttctc	cttaacttta	141720
atcttatctg	agggtttacct	attttattag	taatttcaaa	aaaatcaatt	cttggtatcg	141780
ttagttaact	agggttttca	attttctttt	tttttctttt	attattttccc	tccctccact	141840
cttggtggat	ttatatcatt	gttatatttt	taattccatg	agatagctgt	ttagctcatt	141900
gatttttaaca	ctattttttt	ctaattgtaag	aatttttaggc	tatccattta	tctctatatg	141960
ttcttttaat	ttaacactct	attatgatac	atagtattta	agttattctc	attttccaaa	142020
ttttgcctaa	tttccttagt	gctttttcct	gtgattcacg	agttgtatgc	tttttcttgt	142080
atttacaagt	atagttttat	tctagtcata	ttttgttatt	attccttaat	tgtgtcatca	142140
tctcatgaag	ttactgtgtt	agcaactatt	tgaaaatttt	aaaaactaac	ttgatgactt	142200
ggcacactat	cacttttcat	aaatattcta	tatgtgcata	aaaatgcata	ttcttgtaatt	142260
gttatggtac	actatttgat	atatattatt	acttttaggtt	tagtaatggt	gttgataaaa	142320

ttctctaaat	tgtttctggt	ttataaaaat	ttattttat	tactaaccac	taagagaggt	142380
atgataaaat	aacacagaat	gttgatagat	ttgtcaatat	ctctttgtag	atgtgtgaat	142440
tattttcactc	tcttttctcc	ctcctctttt	tctttgtctc	tctctccctt	cctttcttct	142500
ttctccctc	tcctgtctcc	tatgttctta	gatagataaa	attgtaaaac	tgttacagat	142560
tgagaaggga	acattttacc	attatgcact	gatcctcttt	aatttaataa	cattttgtaa	142620
tctagtggat	tttttttagtt	taatttgaca	atttttatctt	ttcactgcag	agtttagccc	142680
aattagtgc	attgtgattt	tcaattgttt	taatcatttt	cctgtcatct	tacaattatt	142740
tcctctttta	cactttttac	ttttctcctt	taatgacctt	ttttttatcg	ttcctattcc	142800
atttttcatt	tttattttta	ttgtttaaat	cattatctta	aaatgcactt	aattgtataa	142860
aataaatcca	tatttcaatg	acccttcaaa	caataagaaa	ttataatact	tgtctgttta	142920
tgactttccc	aatttacatg	atcttatttt	ttcgtatctt	aatcctgccc	tttcttttaa	142980
caccactaac	taaaaattat	gattattaat	ttttaaggaa	ataatattta	cttaaattta	143040
cctcaaaatt	gtctctttga	ctatccctct	gttgtcattt	atgaaagcac	aacttctaga	143100
agcttctttc	tttcttttct	ctttcttttt	ttttttatat	gggtttcttg	ctctgtcacc	143160
caggctggca	tgcatgtggc	tgataatggc	tgactacaat	ctcaaattct	tgggttcagg	143220
gtgttggaac	tgtttgttcc	ccagtgcctc	aaagaaatag	cattcgaaca	taaaactaat	143280
tctctcagca	aggcagtttt	tactttctgc	agaaaggggtg	ctctctgcag	atatacaagg	143340
ggatcctctt	gcctcagcct	ccctagtagc	tggaacttca	ggcattcatc	atcacacttg	143400
gctaattttt	tcttattttt	tgtagatgct	gcctctcatc	atgttactca	ggctagtctt	143460
gaattcctgg	cctcaagcga	tcttcttctt	tcctcctccc	aaagtgcctga	gattaaaggc	143520
atgagccgcc	acaccctgct	aaaagcttct	ttaacaaagt	ctgtgtttta	taattattag	143580
cttttttata	caaaattttt	cttcaaagag	agttttcctg	agtactccat	tggaaagctga	143640
ttttttattt	ctcttgacaa	tgtgaagaga	ctatttctact	atctcatagc	ttccatcttg	143700
gcttaaaaagg	cttcttacag	tgtagcagtc	tttgttttgt	tgggtgagctt	tcttttttct	143760
ctgcttctct	taggatcttc	ttcttgtctt	tagtgttctt	catttttact	aatgtatgcc	143820
taggtatgca	tttctgttta	cttgtttaca	acccttctgt	actcattgct	tcctatctat	143880
tttttatttg	ttctgaaaaa	tcctcagaca	tgatctcctc	aaatgttttc	tcttttcttt	143940
tatatattct	ttttctggga	ctcagaggta	tacgataccc	tcgcttatag	cctctgtttc	144000
tctttcatgt	gattttgtct	gttttatatt	tggggctatg	tcttcagatt	tatatatttc	144060
tttttatatt	tgtgcctgat	aattttacta	tctaattgtt	gtgtcattgt	aaatttttag	144120
gtctcatttt	ttctgactcc	cactcttgaa	gacaaggttc	tctgtgtgtt	cagtgatctg	144180
tgtttgtcaa	ttcacatttt	cttctctatg	gggaacatat	gaacatatga	gggcctatta	144240
tttttcataa	gaaagaggaa	attttcattt	ggttctgcc	ggttccagaa	gtcagcagtg	144300
agccatgcaa	catttttagat	agctccaagc	atcccactaa	ctaaagtgg	agtaataaaa	144360
acactcagaa	tctcagtggt	ttaaaatgag	tttttatttg	tttttatatg	taaaaacaca	144420
aatgcataaa	atataataat	atacaaaaata	ttgcattttg	tgtgtataat	atacaacata	144480
ttgtgtttgt	atgtacaata	tacaaaaata	caaataattt	taaacagatt	ttggtttaga	144540
catattttta	tagaacactc	tttaatat	gtttattcta	tttctcactc	atgctgcttg	144600
tttttaagg	cccccatgg	actgacagta	catgtttttc	tcaccctgag	atcaatatga	144660
gatctcagtc	tgagatctag	gctatctgaa	cgctatcagt	cacgaagaga	aaggaagaaa	144720
tctggtaaat	tgtacactgt	ttcttaaagc	ttctgattag	agatcatata	aatcaatata	144780
actctcattt	aattgtccta	agaggggtcc	atgggtgtat	ttagtatcaa	aactatgaag	144840
tacagtctta	ctgttagtct	caaatactct	catttccattg	tttctctattt	ttgttaggtt	144900
taacatttat	tctgagtttc	caaccttaca	ttcaatttca	tacttaattt	ttcaattttc	144960
ttcaaactct	agtttttggt	ctaagtggat	ttattttttg	ccgcgaatct	ttccaaatgt	145020
ggctcttctg	ttatttgagat	cttaattttg	attcatcttt	tttctccctg	tatttcatca	145080
tcaaattttt	aggataagct	gttgttggac	tctatttctt	gatttctctg	acattcataa	145140
atttattttt	tttatactaa	aatgtcaact	tgactaaata	taaaaagtat	tgagtcacac	145200
ttcttttttc	taaggacttt	ataaatatta	ttgcactcat	ttttagtctg	tgattacgtg	145260
caagagtcat	tcagattttt	ctcctttctg	tgactttctc	tgaataccta	taggggtactt	145320
tttactttgt	aaccaatttt	aatttaattt	cattttacatt	gttaaaatca	caaaataaga	145380
tatactgttt	taccaagtca	ggtaacaccg	agatatagaa	aagaaaatat	cagtagtatt	145440
tatataccct	ctccttaagc	tagttttttc	ccttttttaa	tataaatatt	tattgtttac	145500
aacacagtta	gagaaaatgt	ggaaatcgta	tgtctaggat	gaattactat	tttaaatgta	145560
aatacaacca	tgtaagtaac	atgcagatta	agaaacacta	caagagtagt	agcattccag	145620
aagttcctgc	atgccccctt	ccattagctt	gagtaaccgt	taacttgact	actaacagct	145680
aaaatagttt	tgtttatctt	ttttttgaat	aaaaaaacaa	gaagtttttt	gcaaaattta	145740
aatacacata	gtcagaaata	taaatgggat	ataatattgt	ttatatattt	tattaatgaa	145800
agcattgtat	acagatagtg	tagcatcaca	caaaaaggta	tgtgtatatt	cttaataata	145860
atatttgaat	taaattttgt	gagctatgtg	aagggaggct	aaatttttat	atctgcaggt	145920
atcaacgggt	gtacttatgt	gaaatcgtgg	gcatttgaaa	agatttggag	aaaccagaaa	145980
ttttgtatat	tgctaattgaa	aacgaacatt	ggtacaatta	ctttaaagaa	ctctgtagcg	146040

gaatctacca	aatttgaaaa	tatccacatg	ttgcagtctg	tcagttctat	tcctaggtat	146100
atacttaaaa	aattttataga	catgttcacc	gacagacatg	atatgtatta	aaattccaat	146160
atctcttacg	atggaattgg	tgccctttcta	agaagagatc	caaaagagtc	ttctttcttt	146220
caatctctct	ctctccccct	ttctctttct	ctctctctct	cactctttcc	ccaccacatg	146280
aggatattac	aagagagcag	ccatctgtga	acctaaaaaga	aggcactcac	caaaacccag	146340
accattctga	catcttgatc	ttagacttca	aaccttcaga	actgtgagaa	ttaaatggtt	146400
gttattttaag	ccacacaatt	tttggtattc	tatttttagca	gccccaaattg	tcaaggaaaa	146460
taattacctc	aaactacaat	gcattattac	cactcaccca	caaagaaaaa	aaaaaagcta	146520
aaatgaaaaa	aatcacatca	taagggctcc	agccccaggc	ccatgacctc	attacctccc	146580
aaaggccccg	tgtgctaaag	taattccatt	gcagggtagg	ctttcaacat	gaatttcgtg	146640
ggacacaatc	atacagtcca	tagcacttat	ttaacagttt	tatatctctc	tacagctttt	146700
cttctatggt	catatataaa	gatatacaga	tgattttttt	ctactttatc	ttcatttggt	146760
atttaacatt	taatcatgca	aataattatt	tataacatgt	ataaggactt	actgtaaaat	146820
aaacctacct	ctgcttaaga	aatggaatgt	tatctttgca	gaattcttga	tctatctttg	146880
aaattcaata	ttttcaaaag	aattggtttt	tgcttttatt	taaccatcat	tttaaattta	146940
ttattaattt	ttcatthaatt	cggctccaga	agcagtga	tgagataatc	atactcttta	147000
gttcaaaagc	accttagttg	tttcatttta	ttttcatatc	ctctcttatc	gccactccct	147060
ctctgatttt	tctttctctc	tactaactgc	caaacacatt	aaaatatttg	atgcataaac	147120
atgtgtgtgc	atgttcttcc	aaaacatatg	tttcactttt	tcatagaaat	tatttttctt	147180
acacatctta	tactaggtct	taaatttttt	attctgtatt	atattttaaa	tacctatcgt	147240
gtttatatat	atatattgct	gcatagtttt	cataatgtac	accaatcaca	gatgactttt	147300
ctatccccct	agtgcacagtc	actttaactg	ctccaacttc	tttctatccc	aacaataatg	147360
caatgcatac	ctttgtacat	gtgtctttat	gggtgattgt	gaagacatct	cgggggtatag	147420
cttttgagct	gtattctctt	tccaaaaagt	ttatgtatcc	taaatacgat	tttataccaa	147480
ctaattgctc	tctggaatgt	ctacatcagt	ctatattaca	atacagtata	caaaggctct	147540
tatatcctta	tatctcacta	ttgtttttaa	atgtgtatat	ctctagttac	taatctaggt	147600
aaacattttct	tcttaaaactt	cagatgggta	ttagctttta	tttcttttct	gtaaaaattcc	147660
tcttcatatc	cttttctatg	agaagccata	cttttaaat	attgatataa	ttgatatgca	147720
tacattttct	atatatttct	tacttattct	caactaaccc	ctaattgatt	ttatatattg	147780
taaaagtcag	atatttccaa	tctgtcattg	ttttggtttg	ttacttttaa	cagttgttct	147840
tttggtcaga	aaaggcattg	attttgtaag	tttattttgt	atccagcaat	ctttatgcac	147900
tctatgcact	cttttttttt	tttttctgtg	accaagtctc	gccctatcac	caggctggag	147960
tgcagtgaag	agatctccgc	taactgcaac	ctctgcctcc	tgggttcagg	cgattcttct	148020
gccttagcct	cctgagtagc	tgggattgca	gggtgtgcac	accatgccca	gctatttttt	148080
gtatttttag	tagacacggg	gtttccaccat	gttggccagg	atgggtcacta	tctcttgacc	148140
togtgatccg	cccgcctcgg	cctcccaaag	tgctgggatt	accagcgtga	gccactacac	148200
ctggccttca	tgcgctcttt	tattatttgt	aattagttgt	caatgaattc	agctcctcca	148260
gtgtttttct	tagtttttatt	gttctagatt	gttttcttag	aatacaatat	gctgtcttaa	148320
cctataaata	aaggattctc	ttcagaaaaa	aacagtaaat	ttttgaattt	ttaaaatata	148380
ttttctatta	tcatatattg	attacataat	tgttttttcc	tcatactcag	taacagcaat	148440
tatgcgtata	ttgtatttgt	cttttatatc	tataattaga	tctctaattc	gctttattta	148500
tcatttttaa	gaattccatg	ttgattctct	caagtttttc	tttcatgtcc	taaaatatag	148560
aacaggggata	aatgtgtgtg	tgtgtgtgag	tgtgtccatg	gtgggggttt	atgtatgtgt	148620
atatgcacac	aatgctgcta	atgttgcttt	tatttctgta	tttggtttgt	ttctctcttt	148680
tatcttttaag	tgagctctgt	gaacttactt	ttcatttctg	gtcttataat	tgggtttatgt	148740
tttcttttaag	tcttttgaac	tcaagaagat	ttgattagaa	actataattt	gggttttggt	148800
aattgttcta	gtgggtattt	taacctctct	ttatttctta	tattgctttt	ttcttactta	148860
tttaattttt	aatctacgag	tatgtcatcc	atgcttggtt	ctttctgatt	cttacttatt	148920
ttgaatggga	tgcacatatc	tagtttaaat	atctgctgaa	ataaaaattaa	aggtgagaga	148980
tgtgagctaa	agcagtgaac	acttaggaca	tatctcatc	atctttgttt	tgtcatctcc	149040
ttggtaataa	tctccactct	ttattttacgt	ttctcatgtc	tgctgagcag	aaaatctttg	149100
gagttttcat	ttccacagta	aagtcctatg	ctccaggtgt	ctgtgacatt	tttagaatct	149160
attaatttat	ctttgtctgg	ctttgattag	ctgtcaccaa	gggtgattggg	gtgtatgtac	149220
tctcatcttg	actgatttct	gaaaagatgg	catatatatg	tggcttctta	ttcagccttt	149280
ctacactcct	caatcttgct	ttataaacac	tgtattgtat	tcacatcttc	catgtaagat	149340
atctttgatc	ctttcagagc	tgtgctatat	attttgaaga	acctctgcac	tattttaaaat	149400
atctgtaagt	gtttgcactt	actcttgaca	ctttttccca	ttttggtccc	aataaaatttt	149460
ttcttttatt	tggagtttgt	gattttaaatt	gtggttgtct	cctgggtccc	atgatgacac	149520
agcagtccat	atctctttta	tacttggtgg	ttgttttcagt	tggcaatata	gaaggagatg	149580
aataaaattg	caaaagtga	gaatgctcaa	tctatgcagt	taaaaatgat	gtaaaagttaa	149640
tatattaaaa	ttaggtaaaa	tattgggttaa	aatttttttt	ctttgttcaa	aacagagtct	149700
cacctgttg	ctcagcctgg	agtgcagtgg	tgtgatctca	gttccactgca	acctctgact	149760

55/64

```

cctggggttca agccattctc ctacctcagc cccctagtag ctgagattac aggcattgca 149820
caccacattg gctaattttt gtattttctag cagagacaag ttttcaccat gttggccagg 149880
atggtctcaa actcctgacc tcaagcgatc caccaacttc ggcctcccaa agtgctggga 149940
ttacaggcat gagccaccgt tccagcctgg ttaaaatatt ttttaattgct tatctttgaa 150000
agtctgctat tattgtgaaa ttgatttttc tatgggatca gatggactga tgctttgtgg 150060
tgggtgtgta atcactgcag aagaaaattt gggaaactgaa cctggaatgt tagtccatgc 150120
caattatttg aaaatttagca tccaaaaagc aataaaaattt gttgagaaaa attgaaagtt 150180
attacactac ctagttttac taggaaaaga ttctggcatt gggccaatga tgactgataa 150240
ttattcatag cactattgaa gagattgatg tattttacta ggaatttttc aggtgtgagt 150300
gatagaaatt cagctctctt aagcaaaaag ataacttatt gattcctatg actgggtact 150360
ctaggagtgg tgcttgcttt agtcatagcc agatccagaa gattaanaat aaatcttgtg 150420
ttgctgcaaa gtttaggtat tttcggacca ttcacaatat ggacagacat agcccctagt 150480
tagaaatcta gcagaacaag aatttttgtc tcctgatact catacatgaa atattccttg 150540
tcaccattgc ccatactctt tgaaccacat tagattatat gcccatgcaa gtatatagaa 150600
aggggtagta gaatgccacc atgac 150626

```

<210> 10
 <211> 23
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Forward promoter primer for CFH gene

<400> 10
 agaatcgtgg tctctgtgtg tgg 23

<210> 11
 <211> 22
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Reverse promoter primer for CFH gene

<400> 11
 agcagctggg gatatactct gg 22

<210> 12
 <211> 23
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Forward promoter primer for CFH gene

<400> 12
 tcaaagaga gtgagccagt tgc 23

<210> 13
 <211> 23
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Reverse promoter primer for CFH gene

<400> 13
 ctgttcacaa cgtccagttc tcc 23

56/64

<210> 14
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Forward exon 1 primer for CFH gene

<400> 14
gtgggagtg agtgagaatt gg 22

<210> 15
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Reverse exon 1 primer for CFH gene

<400> 15
aactcaacaa tgtcaaaagc c 21

<210> 16
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Forward exon 2 primer for CFH gene

<400> 16
gatagacctg tgactgtcta ggc 23

<210> 17
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Reverse exon 2 primer for CFH gene

<400> 17
ggcaatagtg atataattca ggc 23

<210> 18
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Forward exon 3 primer for CFH gene

<400> 18
acctcagcct cccaaagtgc 20

<210> 19
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Reverse exon 3 primer for CFH gene

57/64

<400> 19
tgcataactgt tttcccactc tcc 23

<210> 20
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Forward exon 4 primer for CFH gene

<400> 20
aaggaggagg agaaggagga agg 23

<210> 21
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Reverse exon 4 primer for CFH gene

<400> 21
caggctgcat tcgttttttg 20

<210> 22
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Forward exon 5 primer for CFH gene

<400> 22
ccactcccat agaaaagaat cagg 24

<210> 23
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Reverse exon 5 primer for CFH gene

<400> 23
acttctttgc accagtctct tcc 23

<210> 24
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Forward exon 6 primer for CFH gene

<400> 24
gataaatcat ttattaagcg g 21

<210> 25
<211> 22
<212> DNA
<213> Artificial Sequence

58/64

<220>
<223> Reverse exon 6 primer for CFH gene

<400> 25
gaaccttgaa cacagaaaat gc 22

<210> 26
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Forward exon 7 primer for CFH gene

<400> 26
ggatgacttt ggagaagaag g 21

<210> 27
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Reverse exon 7 primer for CFH gene

<400> 27
tatgagtttc ggcaacttcg 20

<210> 28
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Forward exon 8 primer for CFH gene

<400> 28
tcattcttcac taacaaagac c 21

<210> 29
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Reverse exon 8 primer for CFH gene

<400> 29
agatctattt tggtcacttt gc 22

<210> 30
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Forward exon 9 primer for CFH gene

<400> 30
ctttgtagt aacttttagt cg 22

<210> 31

59/64

<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Reverse exon 9 primer for CFH gene

<400> 31
ttatacacag ttgaaaaacc 20

<210> 32
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Forward exon 10 primer for CFH gene

<400> 32
ggcaactctg agcttat tttt cc 22

<210> 33
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Reverse exon 10 primer for CFH gene

<400> 33
agagtaggaa aagcctgaat gg 22

<210> 34
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Forward exon 11 primer for CFH gene

<400> 34
catagattat ttttgtacgg 20

<210> 35
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Reverse exon 11 primer for CFH gene

<400> 35
caaaactccc ttcttttccc 20

<210> 36
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Forward exon 12 primer for CFH gene

60/64

<400> 36
atctgatgcc cctctgtatg acc 23

<210> 37
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Reverse exon 12 primer for CFH gene

<400> 37
attcagtact caatacatgt cc 22

<210> 38
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Forward exon 13 primer for CFH gene

<400> 38
caccattctt gattgttttag g 21

<210> 39
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Reverse exon 13 primer for CFH gene

<400> 39
gaatctccat agtaataagg 20

<210> 40
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Forward exon 14 primer for CFH gene

<400> 40
caatgtgttg atggagagtg g 21

<210> 41
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Reverse exon 14 primer for CFH gene

<400> 41
attgaattat aagcaatatg c 21

<210> 42
<211> 22
<212> DNA
<213> Artificial Sequence

61/64

<220>
<223> Forward exon 15 primer for CFH gene

<400> 42
catttcagcg acagaataca gg 22

<210> 43
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Reverse exon 15 primer for CFH gene

<400> 43
gtgtgtgtgt gtgtgtgtgc 20

<210> 44
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Forward intron 15 primer for CFH gene

<400> 44
aaggcaggaa agtgtcctta tgc 23

<210> 45
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Reverse intron 15 primer for CFH gene

<400> 45
gtcaaattac tgaaaatcac c 21

<210> 46
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Forward exon 16 primer for CFH gene

<400> 46
aactgttaca cagctgaaaa g 21

<210> 47
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Reverse exon 16 primer for CFH gene

<400> 47
gtggtgattg attaatgtgc 20

<210> 48

62/64

<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Forward exon 17 primer for CFH gene

<400> 48
ggtggaggaa tatatctttg c 21

<210> 49
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Reverse exon 17 primer for CFH gene

<400> 49
atagaataga ttcaatcatg c 21

<210> 50
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Forward exon 18 primer for CFH gene

<400> 50
cgatagacag acagacacca gaagg 25

<210> 51
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Reverse exon 18 primer for CFH gene

<400> 51
cagctataat ttcccacagc agtcc 25

<210> 52
<211> 26
<212> DNA
<213> Artificial Sequence

<220>
<223> Forward exon 19 primer for CFH gene

<400> 52
gtgtaatctc aattgctacg gctacc 26

<210> 53
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Reverse exon 19 primer for CFH gene

63/64

<400> 53
caagtagctg ggacttcaga tgc 23

<210> 54
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Forward exon 20 primer for CFH gene

<400> 54
tagtttcatg tcttttcctc 20

<210> 55
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Reverse exon 20 primer for CFH gene

<400> 55
gaattttaag caccatcagt c 21

<210> 56
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Forward exon 21 primer for CFH gene

<400> 56
ccaggactca tttctttcac c 21

<210> 57
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Reverse exon 21 primer for CFH gene

<400> 57
ctttctgaca gaaatatttg g 21

<210> 58
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Forward exon 22 primer for CFH gene

<400> 58
tgatgtttct acatagttgg 20

<210> 59
<211> 25
<212> DNA
<213> Artificial Sequence

64/64

<220>

<223> Reverse exon 22 primer for CFH gene

<400> 59

ggagtaaaac aatacataaa aaatg

25